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Determinants of Clinical Phenotype in Myeloproliferative Neoplasms 
Dr Jacob Grinfeld 
Background: Myeloproliferative neoplasms, (MPNs) such as polycythemia vera, essential 
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied 
progression rates. The genomic characterization of patients with myeloproliferative 
neoplasms offers the potential for personalized diagnosis, risk stratification, and treatment. 
Methods:  We sequenced coding exons from 69 myeloid cancer genes, common to two 
separate bait sets,  in patients with myeloproliferative neoplasms, comprehensively 
annotating driver mutations and copy-number changes or copy. We developed a genomic 
classification for myeloproliferative neoplasms and multistage prognostic models for 
predicting outcomes in individual patients. Classification and prognostic models were 
validated in an external cohort. Cytokine profiles of over 400 patients were also analysed 
to determine the contribution of the inflammatory microenvironment to phenotype and 
progression risk. 
Results: A total of 2035 patients were included in the analysis. 33 genes had driver 
mutations in at least 5 patients, with mutations in JAK2, CALR, or MPL being the sole 
abnormality in 45% of the patients. The numbers of driver mutations increased with age 
and advanced disease. Driver mutations, germline polymorphisms, and demographic 
variables independently predicted whether patients received a diagnosis of essential 
thrombocythemia as compared with polycythemia vera or a diagnosis of chronic-phase 
disease as compared with myelofibrosis. In particular a set of mutations that included 
ASXL1, SRSF2, U2AF1 and EZH2 was enriched in myelofibrosis and associated with 
poor outcomes. The JAK2 46/1 haplotype strongly correlated with the presence of 9pUPD 
and independently with a PV phenotype, demonstrating that the underlying germline 
background can play a role in determining somatic events and can affect the patient’s 
phenotype in its own right. 
We defined eight subgroups based solely on clustering of genomic data that showed 
distinct clinical phenotypes, including blood counts, risk of leukemic transformation, and 
overall survival. These included a sub-group defined  by mutations the same set of 
chromatin and splicesome component genes described above, and a subgroup enriched for 
TP53 mutations and chromosomal changes, which carried a significant risk of AML 
transformation. Patients with no detectable mutations had very low rates of progression or 
death. By integrating 63 clinical, demographic and genomic variables, we created 
prognostic models capable of generating personally tailored predictions of clinical 
outcomes in patients with chronic-phase myeloproliferative neoplasms and myelofibrosis. 
The predicted and observed outcomes correlated well in internal cross-validation of a 
training cohort and in an independent external cohort.  The prognostic model performed as 
well as or better than a number of existing risk scores including the high molecular risk 
genetic score and international prognostic scoring systems and even within individual 
categories of existing prognostic schemas, our models substantially improved predictive 
accuracy. 
Cytokine profiles varied significantly across MPN subtypes, with high levels of TNF-
alpha and IP-10 seen in myelofibrosis, and to a lesser extent in polycythemia vera. 
Patients with essential thrombocytosis however, were found to have high levels of GRO-
alpha and EGF, and levels of these at single time points or when measured longitudinally 
were predictive for the risk of progression to myelofibrosis. 
Conclusions: Comprehensive genomic characterization identified distinct genetic 
subgroups and provided a classification of myeloproliferative neoplasms on the basis of 
causal biologic mechanisms. Integration of genomic data with clinical variables enabled 
the personalized predictions of patients’ outcomes and may support the treatment of 
patients with myeloproliferative neoplasms.  
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1. Introduction 
1.1 Philadelphia-negative Myeloproliferative neoplasms 
The three classical Philadelphia-negative myeloproliferative neoplasms (MPNs) are 
characterised by clonal expansion of haematopoietic progenitors, hypersensitivity to, or 
independence from, cytokines, and overproduction of mature erythroid and myeloid 
progeny. Common to them are the clinical features of bone marrow hypercellularity, and 
an increased risk of thrombosis, haemorrhage and transformation to acute myeloid 
leukaemia. Since these are chronic conditions that normally manifest well in advance of 
leukemic transformation they offer an invaluable model for studying the process of 
leukaemogenesis and advancing our understanding of stem cell function and cell fate 
decisions. A better understanding of the processes that determine the progression to acute 
leukaemia are of particular importance in the context of MPNs as these leukaemias are 
invariably not amenable to standard chemotherapy. 
Current diagnostic criteria separate the classical Philadelphia-negative MPNs into three 
distinct disease entities: polycythaemia vera – characterised by a raised red cell mass; 
essential thrombocytosis – characterised by an isolated increase in platelet count; and 
idiopathic/primary myelofibrosis – in which the haematopoietic compartment is gradually 
replaced with collagen fibres, leading to bone marrow failure and extramedullary 
haematopoiesis, and which is often associated with constitutional symptoms1. 
1.2 Evidence for clonality 
Support for the clonal, and therefore neoplastic, nature of these conditions came from 
studies in the 1970s that found skewing of lyonisation at the G6PD locus (on the X 
chromosome) in women with PV2 and ET3. Additionally, a number of clonal markers were 
found. These included deletions of chromosome 20q in a small number of MPN cases 
(predominantly PV), as well as in other myeloid malignancies4,5, gains of chromosomes 8 
and 9 and deletions of chromosomes 5, 7 and 136. More striking was the discovery of 
frequent (~33% in early studies) copy-number neutral loss of heterozygosity on 
chromosome 9p, identified using microsatellite polymerase chain reaction (PCR) and 
missed on standard cytogenetic analyses7. 
1.3 JAK2 mutations 
1.3.1 Discovery and characterisation of JAK2 mutations 
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In 1951, William Dameshek hypothesised that rather than these being “pure” 
proliferations, the three myeloproliferative phenotypes may represent differing 
manifestations of a single underlying process8. This was shown to be the case when 
mutations in components of cytokine signalling pathways were detected across different 
MPN phenotypes. The commonest of these is the valine to phenylalanine substitution at 
codon 617 (V617F, due to a G>T substitution), of the Janus kinase 2 (JAK2) gene on 
chromosome 9p (and located in the region of previously identified LOH) which is found 
in 95% of patients with PV and 50-60% of those with ET and PMF9–12. JAK2 is a 
cytoplasmic tyrosine kinase, required for signal transduction from a number of cytokine 
receptors, including those for thrombopoietin (Tpo), erythropoietin (Epo) and granulocyte 
colony stimulating factor (G-CSF), and which therefore plays a vital role in 
haematopoiesis. 
1.3.2 Effect on molecular function 
The V617F mutation occurs in the JH2 (janus homology 2 or “pseudokinase”) domain and 
results in a constitutive increase in the activity of the JH1 kinase domain. The mechanism 
by which this occurs is not entirely clear, but it is thought that the mutation may reduce the 
autoinhibitory function of the JH2 domain via changes in JH2 conformation13, ATP 
binding14 and its own inhibitory kinase activity15. Although expression of JAK2V617F has 
been shown to allow for JAK2 signalling in the absence of receptor ligation10,11, the 
expression of cytokine receptors16 and a functional FERM domain (required for receptor 
binding)17 are still required for JAK2 signalling and cytokine independent growth. 
Furthermore, there is also evidence that the V617F mutation allows escape from negative 
regulation by suppressor of cytokine signalling 3 (SOCS3)18. This increased JAK2 
signalling recapitulates that seen in the physiological response to cytokine binding, 
namely the increased activation of signal transducer and activator of transcription (STAT) 
5 and 3, mitogen associated protein (MAP) kinase and Phosphoinositide 3-kinase (PI3k) 
pathways10,12. STAT5 in particular is thought to have a critical role in the pathogenesis of 
PV, as its deletion abrogated a PV phenotype in a JAK2V617F-knockin mouse model19.  
Transcriptional changes seen in JAK2-mutated cells include upregulation of polycythemia 
rubra vera-1 (PRV-1)20,21, the function of which has been associated with increased 
signalling in response to Tpo and interleukin-3 (IL-3), and of nuclear factor erythroid-2 
(NFE2), a transcription factor implicated in erythropoiesis and megakaryopoiesis22. Over-
expression of NFE2 even in cells lacking JAK2 mutations has been associated with 
erythropoietin-independent erythroid maturation and red cell overproduction23,24, and can 
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induce a myeloproliferative phenotype, with thrombocytosis and leucocytosis, in mouse 
models25. 
 
Mutations in exon 12 of JAK2 are also seen in a small proportion of patients and are 
located between F533 and F547, in the linker region between the SH2 and JH2 
domains26,27. These mutations also induce increased constitutive signalling to a greater 
degree than JAK2V617F, with greater JAK2 and extracellular regulated kinases 1 and 2 
(erk1 and erk2)26, and cytokine independent growth. The mechanism by which these 
mutations act is less well understood. 
 
In addition to its in cytoplasmic signalling, a number of non-canonical roles have been 
described for JAK2, including histone phosphorylation28, which may be perturbed by 
pathogenic mutations and may provide alternative pathways for dysregulation of 
transcription and stem cell function. JAK2V617F expression has also been associated with 
an increase in reactive oxygen species, activation of DNA-repair mechanisms, disruption 
of cell-cycle checkpoint responses and impaired apoptotic response to DNA damage, and 
accordingly with a greater rate of double-strand breaks homologous recombination29–31. 
Therefore JAK2 mutations appear to be able induce a mutator phenotype, which may be 
one mechanism underlying progression of disease to MF, MDS or AML. 
 
1.3.3 Effect on cell biology 
A number of studies have demonstrated that JAK2 mutation can be found in the 
haematopoietic stem cell and progenitor (HSPC) compartment32–34. Xenograft models 
suggest that JAK2 mutations do not however result in a self-renewal advantage34 and this 
is recapitulated in some knock-in mouse models, where JAK2 positive HSPC are skewed 
towards symmetrical differentiation and expansion of the progenitor pool rather than self-
renewal, and demonstrate a lack of an advantage in competitive transplantation 
experiments35,36. This also is consistent with the absence of significant clonal expansion 
over time or development of overt MPN in cases with a transplanted JAK2-mutant clone37 
or in a subset of cases in the general population that have developed a detectable JAK2-
mutant clone38 (see later discussion). These findings have lead to the suggestion that the 
JAK2 mutations alone are insufficient to lead to persistent disease and that additional 
mutations, or other factors, are required to overcome the lack of a competitive advantage. 
It is also possible however expansion of the progenitor pool alone is sufficient to establish 
and sustain disease, and that a stem cell advantage is not required at all. This is consistent 
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with the finding that adult haematopoiesis is predominantly sustained by a pool of long-
term multipotent progenitors39. 
1.3.4 Acquired 9pUPD and JAK2 homozygosity 
As noted above, acquired uniparental disomy/loss of heterozygosity of chromosome 9p 
had been found to be a recurrent abnormality in patients with PV even before the 
discovery of JAK2V617F mutations. It is now evident that this genetic lesion is found 
almost exclusively in the context of JAK2 mutations, and results in their homozygosity. 
Using fluorescence microsatellite PCR JAK2 homozygous subclones were identified in up 
to 80% of PV patients and around 50% of JAK2-mutated ET patients, although the ratio of 
homozygous to heterozygous clones tended to be much higher in PV cases, with 
homozygous clone sizes generally <10% in patients with ET40. A link therefore exists 
between JAK2V617F dosage and the degree of erythrocytosis and this is supported by the 
finding of higher haemoglobin concentrations (as well as leucocyte counts) in JAK2-
homozygous patients with ET41,42. This hypothesis is additionally supported by a number 
of experimental models where the ratio of wild-type to mutant alleles correlates with 
increasing independence from Epo and increasing erythropoiesis36,43,44. Similarly, JAK2 
exon 12 mutations, associated with greater JAK2 and erk1/2 phosphorylation, are always 
associated with erythrocytosis and do not appear to result in thrombocytosis.  
However, the presence of homozygosity does not account for the differences seen between 
patients with ET and PV alone, since, as noted here, not all patients with PV have 
homozygous clones, while conversely a number of patients with ET do. Furthermore, 
transcriptional differences are seen in erythroid colonies from ET and PV patients when 
analysis is restricted to heterozygous colonies alone45. 
1.4 Other intracellular signalling pathway mutations 
1.4.1 MPL mutations 
Missense mutations at codon 515 of MPL (which encodes myeloproliferative leukaemia 
protein, the thrombopoietin receptor itself), including M515L and M515K, are also seen 
and are associated with increased STAT-3, STAT-5, ERK and AKT signalling46,47.  Less 
frequently, other activating mutations of MPL, such as S505N, which is also found as a 
germ-line variant in familial ET, and S204P are also seen and are associated with 
thrombopoietin hypersensitivity or independence48–50. Given MPL is involved in 
thrombopoietin signal transduction and megakaryocytic differentiation, it is not surprising 
that these mutations are seen almost exclusively in patients with ET and MF (roughly 8-
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10% of JAK2 unmutated cases), and not found in those with PV. 
1.4.2 CALR mutations 
More recently mutations in calreticulin (CALR) have been identified in patients with ET 
and MF. These have consistently found to be insertions or deletions (most commonly a 
52bp deletion or 5bp insertion) in its final exon resulting in a 1bp shift in the reading 
frame and a common novel C-terminal sequence51,52.  This was an unexpected and unusual 
result, since, unlike JAK2 or MPL, CALR is not known to have a direct role in 
megakaryopoiesis or regulation of haematopoietic stem cells. Rather, it is known to be 
involved in the regulation of calcium uptake and release by the endoplasmic reticulum 
(ER), and acts as a chaperone, regulating folding and quality control of newly synthesised 
glycoproteins in the ER53,54. However, the restriction of CALR mutations to patients with 
ET and MF, mutual exclusivity for JAK2 and MPL mutations, its preferential expression 
in megakaryocytes (as determined immunohistochemically)55 and increased JAK-STAT 
signalling in CALR mutant cells51,56, pointed towards a similar mechanism to MPL 
mutations. 
  
Subsequently it was demonstrated that CALR mutations can impart TPO-independence in 
cell lines57–59, retroviral and transgenic mouse models60–62 in a MPL- and JAK2-dependent 
manner, mimicking the effect of activating MPL mutations and recapitulating their 
phenotype in vivo. This has been shown to be mediated by direct binding of MPL by the N 
domain of CALR, a phenomenon that uniquely occurs in the presence of the mutated C-
terminus, leading to autocrine activation of MPL, JAK2 dimerization and downstream 
STAT5 and ERK phosphorylation59–61. 
 
Other mechanisms may still be in play, beyond aberrant MPL binding and activation. The 
loss of the KDEL (lysine, aspartic acid, glutamic acid, leucine) signal from the C-terminus 
may lead to mislocalisation of the protein and therefore to other aberrant functions. It has 
also been shown that type 1 (52 bp deletion), or type-1 like, and type 2 (5 bp deletions), 
and type 2-like, mutations are associated with different clinical phenotypes: Type 1-like 
mutations are associated more with MF and a higher rate of MF transformation when 
found in ET but a more favourable risk for patients with MF63,64, while Type 2-like 
mutations associate more with ET and higher platelet counts65. This has associated with 
differences in calcium binding, with the most aberrant ER-dependent calcium shifts seen 
in with Type 1/type 1-like mutants, which are associated with loss of a greater number of 
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calcium binding sites65. 
1.4.3 Mutations in regulators of cytokine signalling (CBL, SH2B3, SOCS) 
Compared to other malignancies, the MPNs have relatively few mutational events with the 
majority carrying mutations in JAK2, CALR or MPL (Figure 1A). However, a number of 
additional genes have been found to be mutated in up to 10-20% of cases (Figure 1B). 
These have been investigated both in smaller studies sequencing individual genes across 
myeloid malignancies as discussed in the following sections, or as part of wider targeted66–
69 or whole exome sequencing studies52,70. 
As might be expected from the role of receptor signalling pathways in the pathogenesis of 
MPNs, loss of function mutations in negative regulators of receptor tyrosine kinases are 
seen, as well as mutations in down-stream pathways. 
Figure 1: (A) Frequencies of JAK2, CALR and MPL mutations across MPNs. TN denotes 
“triple negative” (B) Frequencies of additional mutations, with counts normalised to 
MPN subtype frequency52,66,95. 
 
LNK (lymphocyte specific adaptor protein, or SH2B3) is an adaptor protein that binds 
both MPL and JAK2 to act as a negative regulator of JAK-STAT signalling. LNK deficient 
mice display an MPN-like phenotype with megakaryocytic hyperplasia, cytokine 
hypersensitivity and splenomegaly71. LNK exon 2 mutations, affecting the plekstrin-
binding domain, are found in a small number of MPN patients, more often seen in 
advanced phase disease, and can also be found in patients with an erythrocytosis lacking a 
JAK2 mutation, suggesting they may be sufficient to initiate disease72–74. 
 
Another negative regulator of cytokine signalling, Casitas B-cell lymphoma oncogene 
(CBL) is an E3-ubiquitin ligase, which is specifically involved in the ubiquitination (and 
resultant degradation) of a number of receptor tyrosine kinases, as well as having a role in 
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signal transduction itself. Its targets include PDGFR, c-KIT, FLT3 and MPL75. Mutations 
in its RING-domain (responsible for ligase activity) have been described in MPNs, 
particularly in MF, atypical chronic myeloid leukaemia (aCML) and chronic 
myelomonocytic leukaemia (CMML)76,77. Mutations in the SOCS proteins, which also 
suppress JAK2 signalling, are rarely seen in MPNs78 but their down regulation has been 
observed79. 
1.4.4 Ras pathway: NRAS, KRAS, NF1, PTPN11 
Mutations increasing RAS pathway signalling are also observed, but, as with CBL and 
LNK mutations, tend to be seen more in myelofibrosis, advanced/transformed disease or 
myeloproliferative neoplasm/myelodysplasia (MPN/MDS) overlap conditions80.  In mouse 
models NRAS mutations are sufficient to initiate a CMML-like disease characterised by 
myeloid bias and increased self-renewal, but with a propensity for proliferative 
exhaustion81. KRAS mutations as well as those in negative regulators of RAS, such as 
NF1 and PTPN11, have also been found in some MPN patients66,67,82. 
1.5 Mutations in epigenetic regulators 
1.5.1 TET2 mutations 
Mutations in epigenetic regulators are the commonest mutations seen in addition to those 
affecting JAK2, CALR and MPL. In some cases, these mutations are enriched in patients 
with MF or MPN/MDS overlap conditions, but often are found across the spectrum of 
MPNs. Of these, loss-of-function mutations of ten-eleven translocation family member 2 
(TET2) are the most common and are detected in approximately 10% of MPNs83,84. TET2 
hydroxylates 5-methylcytosine to 5-hydroxymethylcytosine (5-hmc), a process which is 
thought to be particularly important for transcriptional regulation in stem cells and in 
embryonic development. A reduction in 5-hmc is observed in TET2 mutated patients, and 
is associated with increased self-renewal capacity and myeloid bias85–87. The HOXA 
cluster, implicated in cell fate decisions, is known to be regulated by TET2, and therefore 
its dysregulation in the context of TET2 mutations may be one mechanism underlying the 
stem cell expansion seen with these mutations88. 
1.5.2 DNMT3A mutations 
Loss-of-function mutations (including dominant negative missense mutations at codon 
882) in DNA methyltransferase 3a (DNMT3a), a protein responsible for de novo 
methylation of CpG dinucleotides, are found across MPN subtypes89. As with TET2 
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mutations, their exact role in MPN pathogenesis is not yet fully understood, but it is 
thought that the resultant epigenetic deregulation (both hypo- and hypermethylation are 
seen) results in upregulation of “HSC fingerprint” genes such as GATA3 and RUNX1 and 
downregulation of differentiation factors such as Ikaros (IKZF1), resulting in a 
differentiation block and HSC expansion90,91. 
1.5.3 IDH mutations 
Hotspot mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are described in 
<5% of cases66,92 These enzymes catalyze the conversion of isocitrate to alpha-
ketoglutarate, but these mutations result in the production of 2-hydroxyglutarate, which 
inhibits Jumonji-C domain histone demethylases. This leads to histone hypermethylation 
and also inhibits TET2 activity, which in turn results in a differentiation block93,94. In 
contrast to TET2 mutations, which not appear to be associated with particular MPN 
subtypes (while being associated, in one study, with poorer overall survival and increased 
progression to AML95), IDH mutations are more commonly found in MF or transformed 
disease92,96. 
1.5.4 Mutations in polycomb repressor complex components 
Mutations of genes involved in histone methylation are over-represented in 
myelofibrosis/transformed disease. EZH2 (PcG Enhancer of Zeste Homolog 2) is the 
catalytic component of the polycomb repressive complex 2 (PRC2) and, together with 
EED and SUZ12 acts to trimethylate histone H3 lysine 27 (H3K27) causing repression of 
transcription. In contrast to EZH2 mutations seen in lymphoma, those in MPNs tend to be 
loss-of-function mutations97,98 that result in de-repression of a number of genes (including 
putative oncogenes such as LMO1 and HOXA9) and increased HSC self-renewal99,100. 
 
Mutations of Additional sex combs like 1 (ASXL1) are also relatively common in 
MF66,101. ASXL1, a component of PRC1, is also known to regulate PRC2 and to have a 
role in the regulation of HOX genes. ASXL1 mutations accordingly are associated with 
HOXA upregulation and reduction in H3K27 methylation, which were linked with 
impaired recruitment of EZH2102. 
1.5.5 Mutations in spliceosomal proteins 
Mutations in components of the spliceosome including splicing factor 3B subunit 1 
(SF3B1), splicing factor arginine/serine-rich 2 (SRSF2), U2 small nuclear RNA auxiliary 
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factor 1 (U2AF1) and zinc finger RNA-Binding Motif And serine/arginine rich 2 (ZRSR2) 
as well as other much rarer mutations, are also seen in MPNs, again more frequently in 
patients with MF of MPN/MDS overlap syndromes, and are often associated with poorer 
outcomes66,103–105. 
 
The effects of hotspot mutations of codon 95 of SRSF2, codon 34 mutations of U2AF1 
and codon 700 of SF3B1 are perhaps the best explored, as knock-in mouse models have 
been made for each106–108. SRSF2 mutations appear to result specifically in skewed motif 
recognition (rather than loss of function) with alterations in exon usage in a number of 
genes, which include EZH2 (leading to reduced expression), and bcl-6 co-repressor 
(BCOR), which is also known to be mutated in myeloid malignancies106. Mutations in 
U2AF1 alter its 3' splice acceptor preferences leading to mis-splicing of a set of genes that 
includes BCOR and SRSF2107. EZH2 expression was also found to be reduced in 63% of 
U2AF1/SRSF2-mutated primary specimens (with a greater amounts of unspliced than 
spliced transcripts), and this was associated with decreased H3K27 trimethylation100. 
 
Spliceosomal mutations are common in MDS. Mutations of SF3B1 in particular have been 
associated with the presence of ring sideroblasts, with the specific syndrome of MDS with 
ring sideroblasts and thrombocytosis (RARS-T) and with a much better prognosis than 
other spliceosome component mutations, as well as being found in a proportion of patients 
with chronic lymphocytic leukaemia109,110. These mutations are particularly associated 
with the use of cryptic 3’ splice sites and lead to the mis-splicing of a number of genes 
including those involved in mitochondrial metabolism and iron homeostasis, as well as 
ASXL1 and CBL, resulting in defective erythropoiesis108,111,112.  
1.5.6 Mutations in other transcriptional regulators 
Protein truncating insertion/deletion mutations have been reported in NFE2113. These 
mutations were predominantly restricted to patients with PV or post-PV MF, and were 
associated with both higher NFE2 mRNA levels and increased protein stability. As noted 
above, NFE2 is thought to be a critical regulator of megakaryopoiesis and erythropoiesis, 
with roles in the regulation of haem and β-globin synthesis, and its over-expression has 
been reported across MPN phenotypes, as well as in other conditions associated with 
erythropoietin hypersensitivity and erythrocytosis114,115. Mutations in RUNX1  which also 
plays an important role in the transcriptional regulation of stem cell fate decisions have 
also been reported in MPN, but associate more with leukaemic transformation of the 
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disease116, while GATA1 mutations are seen in the context of transient myeloproliferative 
disorder117. IKZF1, which is commonly mutated in acute lymphoid leukaemia, are found 
to be deleted in a small number of MPN cases transformed to acute leukamia118. 
Finally, mutations in the cohesin complex components (including STAG2), which has 
roles in sister chromatin adhesion, transcriptional regulation and DNA repair, have been 
found in a small number of  MDS/MPN overlap cases119,120. 
1.6 The impact of mutation acquisition order 
While JAK2, CALR and MPL mutations are almost always mutually exclusive, the further 
mutations discussed above are normally found in combination with a phenotypic driver, 
and in combination with each other. There is increasing evidence that not only can the 
specific combinations present in an individual influence their disease phenotype and 
natural history, but the specific clonal architecture, including the order in which the 
mutations were acquired, and relative clone sizes present for each may do as well. This 
may in part explain the clinical heterogeneity across even patients with the same mutations 
or combinations of mutations121. 
 
While CALR mutations are shown in most cases to occur in the dominant clone, 
differences in the order of mutation acquisition have been demonstrated in JAK2-mutated 
MPNs harbouring concurrent TET2 or DNMT3A mutations, where mutation order has 
been shown to have an impact on disease phenotype, thrombotic risk, age of presentation 
and response to treatment122,123. Patients in whom the JAK2 mutation occurred first have 
larger “double mutant” subclones (harbouring both JAK2 and either TET2 or DNMT3A 
mutations), as well as larger JAK2-mutated homozygous clones. In JAK2-first TET2-
second cases, there is expansion of erythoid progenitors, and patients present at a younger 
age and are at greater risk of thrombosis.  
 
In contrast, TET2-first or DNMT3A-first patients are characterised by a dominant “single 
positive” subclone (i.e. harbouring the TET2/DNMT3A mutation only) in keeping with 
the greater self-renewal capacity seen with TET2/DNMT3A mutations compared to those 
in JAK2. These patients were more likely to have ET, which may in part be related to 
constraints on the expansion of the JAK2-mutated clone and on the development of 
homozygosity. Therefore, it is likely that the order in which mutations occur will influence 
the composition of the stem cell niche in which later sub-clones will arise and reside, 
potentially introducing constraints on their potential to expand. However, it is also feasible 
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that separate clones may act cooperatively. This has been shown in solid tumors such as 
glioblastoma, where cytokine secretion by a relatively minor subclone can drive the 
expansion of a more dominant tumor clone124. 
 
Beyond determining clonal hierarchical structure, there is also evidence to suggest that the 
order that mutations occur  can have cell-intrinsic differences in terms of transcription and 
clonogenic potential. For example, acquisition of a JAK2 mutation on a wild-type 
background was shown to be associated with a proliferative advantage, but this was not 
the case on the background of an earlier TET2 mutation. Furthermore, TET2 and JAK2-
mutated (double mutant) HSCs/progenitors from JAK2-first patients were able to generate 
more progenitors than those from TET2-first patients, and this was reflected in differences 
in gene expression122. 
1.7 Additional Chromosomal changes 
As discussed above, numerous recurrent cytogenetic abnormalities have been found in 
MPN patients through the use of conventional cytogenetic methods. Further studies have 
investigated their occurrence more systematically using high resolution single nucleotide 
polymorphism (SNP) microarrays or next generation sequencing (NGS) across MPN 
phenotypes in both chronic and transformed disease states, and enabling the identification 
of CN-LOH125–128. 
 
CN-LOH/UPD of chromosomes 1p and 9p (associated with and leading to homozygosity 
of MPL and JAK2 respectively) are commonly seen, and associated with progression to 
myelofibrosis125,126. UPD of 4q, 7q, 11q, 14q and more rarely 8q are also seen. In some 
cases, these are known to be associated with mutated genes at these loci, leading to 
homozygosity for the mutant allele (including TET2 on 4q, CUX1 and EZH2 on 7q and 
CBL on 11q). However, this is not the case for all regions affected by UPD and it has been 
hypothesised that UPD serves to cause homozygosity for germline variants, for example 
FANCM R658X (located on chromosome 14q), acquired homozygosity of which was 
associated with transformation to leukaemia129. 
 
1.8 Impact of germ-line variation 
 
The effect of inherited genetic variation on myeloproliferative phenotype forms a 
spectrum, from hereditary erythrocytosis or thrombocytosis, non-neoplastic conditions 
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where germline variants are sufficient give rise to myeloproliferation in all cases, to 
variants that increase an individual’s risk of acquiring an MPN though the acquisition of 
classical MPN-associated variants or those that do not necessarily alter the risk of MPN 
development but may influence its phenotype. Additionally, genome wide association 
studies (GWAS) have identified a number of loci that are associated with haematological 
parameters such as haemoglobin concentration or platelet count130, which may therefore 
influence the phenotype or presentation of an underlying MPN.   
1.8.1 Hereditary erythrocytosis/thrombocytosis 
The hereditary erythrocytoses/thrombocytoses are highly penetrant, monogenic disorders 
with Mendelian inheritance. Secondary hereditary erythrocytoses are driven either by 
mutations that give rise to high oxygen affinity haemoglobin variants, or mutations in 
oxygen sensing machinery, and are therefore associated with normal or high erythropoietin 
levels, while primary erythrocytoses are caused predominantly by Epo-receptor truncating 
mutations. Hereditary thrombocytoses are driven by mutations in the thrombopoietin gene 
itself (THPO), causing an increase in circulating levels, and in MPL as well as JAK2. 
While these hereditary conditions are not MPNs, since the driving genomic variant is not 
somatically acquired and is present in all cells with polyclonal haematopoiesis, an 
understanding of the genetic basis for these conditions may still inform our understanding 
of MPNs. Furthermore, patients presenting with an apparent MPN may in fact have one of 
these conditions, and progression to bone marrow fibrosis and even AML is reported in 
cases with germ-line MPL mutations131,132. Additionally, the inherited variants seen here 
may also occur somatically, giving rise to an MPN. Examples of this include MPL S505N 
and JAK2 V617I mutations48,133, but somatic mutations in other genes affected in these 
hereditary conditions may also have the potential to cause MPNs and should be considered 
in patients not found to have canonical JAK2, CALR or MPL mutations (triple negative 
cases). 
 
The germ-line mutations of JAK2 are of particular interest, since they appear to give rise 
to over-production of a single lineage, for example isolated thrombocytosis is seen with 
JAK2 V617I134 and erythrocytosis with  E846D and R1063H135, and secondly they do not 
appear to be associated with disease progression to bone marrow fibrosis or AML, 
highlighting important biological differences between these mutations and JAK2 V617F. 
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1.8.2 Familial MPN and germ-line predisposition 
There are several reports of familial clustering of MPNs (where two or more family 
members are affected by MPNs), and there is a tendency (in approximately 60% of 
familial cases) for family members to present with the same MPN phenotypes. In fact, the 
relative risk of acquiring ET has been estimated to be approximately 12 times higher in 
first-degree relatives of MPN patients136. 
 
Causes of familial MPNs include germ-line mutations of RBBP6137, and a high penetrance 
duplication of 14q32.2, which has been associated with overexpression of ATG2B, a 
mediator of autophagy, and GSKIP, a regulator of the WNT/β-catenin pathway138. It 
appears that these changes operate via independent pathways: RBBP6 mutations affect the 
p53 pathway and thereby influence the response to apoptotic stimuli and the risk of 
developing further mutations, while ATG2B and GSKIP overexpression promote 
megakaryopoiesis via increased thrombopoietin sensitivity. 
A number of more common, but lower penetrance germ-line variants have been associated 
with MPN development, including single nucleotide polymorphisms (SNPs) present in, or 
close to, telomerase reverse transcriptase (TERT)139 and “MDS1 and EVI1 complex locus” 
(MECOM)140. Two JAK2 haplotypes (46 and 1) are found to be in linkage disequilibrium 
(with the exception of one SNP). Whilst the combined haplotype (termed 46/1, or GGCC 
in reference to the defining alleles) is found in 24% of the population, it is found in up to 
56% of patients with MPNs, with an odds ratio of 3 to 4141–143. Together with TERT and 
MECOM-associated SNPs, the 46/1 haplotype is estimated to account for 55% of the 
population attributable risk of developing an MPN140. 
 
Not only are JAK2 mutations more prevalent in patients with the 46/1 haplotype, the 
JAK2 mutation preferentially occurs on that allele in 46/1 heterozygotes, One possibility 
for this association is that the 46/1 haplotype is more prone to mutation and therefore more 
likely to give rise to JAK2V617F and exon 12 mutations. However, perhaps a more likely 
possibility is that the occurrence of mutant JAK2 in the context of the JAK2 46/1 
haplotype confers an additional clonal or phenotypic advantage – the ‘fertile ground’ 
hypothesis. Further support for a clonal advantage for JAK2 46/1 is the fact that JAK2 
allele burden rises more rapidly in patients carrying this also haplotype144,145 but also that 
an association appears to exist between 46/1 haplotype and MPL mutations146. 
 
One other SNP, in the inter-genic region between HBS1L and MYB (rs9376092) has been 
 22 
found to be enriched in MPL- and CALR-mutated MPNs, and more frequently in JAK2-
mutated ET patients140. Together with the 14q32.2 duplication mentioned above, which 
was found to be predominantly associated with an ET phenotype, the HBS1L-MYB SNP 
appears to be one of the few germ-line variants that is associated with a particular MPN 
phenotype. Other reported genomic variants that may predispose more towards PV include 
SNPs within JAK2 itself147 and affecting the glucocorticoid receptor (GR)148,149 , although 
the latter association was not validated in a subsequent study150. 
 
Finally, it is worth noting that gender also appears to have an effect on the risk of MPN 
development and MPN subtype, with female predominance in ET and in younger patients 
with PV, but worse outcomes in male patients, although it is unclear to what extent this 
associated with intrinsic differences in tumour cell biology, or whether this relates to cell 
extrinsic factors such as levels of sex-related hormones, inflammatory cytokines or iron 
stores, or other potentially confounding factors151. 
 
1.9 Age-related clonal haematopoiesis 
There has been increasing recognition that a proportion of individuals who do not have 
evidence of a myeloid malignancy still carry mutations in genes that are recurrently 
mutated in MDS, AML and MPNs. 
Two early studies demonstrated that JAK2 V617F mutations were detectable in a 
proportion of healthy individuals: 5 of 57 healthy volunteers, and 36 of 3,935 patients in 
an unselected hospital population, roughly 10% in each case, although not necessarily 
representative of the wider population152,153. This was later confirmed, although at a lower 
rate, in a large study of the general population in Denmark where JAK2 mutations were 
found in 68 of 49,488 cases (0.1%), of whom 30 were already diagnosed with a 
myeloproliferative neoplasm. Of the remaining 33 cases, 18 developed an MPN within the 
subsequent 4 to 9 years38. Conversely, of a population of patients with a known MPN with 
previously stored samples, JAK2 mutations were present up to 15 years prior to the 
diagnosis of an overt MPN145. 
 
A set of recent studies have identified “clonal haematopoiesis” (i.e. a detectable clone 
carrying a mutation in a known recurrently mutated gene) as a common event in otherwise 
apparently healthy individuals, as has been labelled age-related clonal haematopoiesis or 
clonal haematopoiesis of indeterminate potential (ARCH or CHIP)154–157. The prevalence 
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of this phenomenon increases with age, with up to 10% of individuals over 60 carrying a 
detectable clone, which rose to over 20% in patients over 90. However, this was estimated 
at as high as 95% in one subsequent study of 50-60 year olds using more sensitive 
detection methods to detect clones with variant allele frequencies of as low as 0.0003158. 
The range of mutations detected was similar to that seen in MDS, AML and MPNs, with 
DNMT3A, TET2, JAK2, and ASXL1 mutated most frequently, but mutations in SF3B1, 
SRSF2, PPM1D, KRAS, NRAS, TP53, GNAS, CBL, GNB1, and STAG2 also seen154–158. 
Interestingly, mutations in spliceosome components were seen only in patients over 70156 
and mutations in CALR and MPL were not seen at all (although a number of these studies 
were geared towards only detecting single nucleotide substitutions and would therefore 
miss CALR mutations). The risk of subsequent progression to haematological malignancy 
was assessed in two of these studies. Although it was increased relative to the population 
without clonal haematopoiesis (hazards ratio 12.9 in one study), the rates of progression 
were less than 5-6% over the 6-10 year periods assessed154,155. 
 
Overall, these findings suggest that JAK2 mutations, among other MPN-related mutations, 
occur frequently in the general population without progression, in most cases, to an overt 
MPN, and when they do progress can do so after a long latent period. Possible 
explanations for this observation may include the requirement for subsequent, or pre-
existing, somatic mutations or chromosomal changes, or an influence of the constitutional 
genomic background on which the JAK2 mutation occurs. However, previous sequencing 
studies suggest JAK2 mutations can often occur in isolation in MPN cases52,66,95, and 
germ-line variants associated with JAK2 mutations in the context of MPNs appear to be 
widely similar to those predisposing for JAK2 mutation in the context of clonal 
haematopoiesis alone159,160. 
 
However, the competitive advantage for a potential clone depends not just on the 
mutation(s) that it carries and the germ-line background on which they occur, but also on 
the make-up of their competitors and on the environment in which they are competing. 
This is suggested by the finding of spliceosome complex mutations only in patients >70 
years old, where it appears likely that they carry more of a competitive advantage in the 
context of the ageing marrow. This may be because of a loss of proliferative capacity in 
the wild-type stem cells present in the bone marrow, or differential responsiveness to 
micro-environmental signals such as increased IL-6 or IL-1beta or reduced CXCL-12 that 
may occur normally with age, or may be driven directly by the aberrant clone161. 
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1.10 Role of microenvironment in MPN 
A role for the bone marrow microenvironment in supporting the development of an MPN 
is evidenced by mouse models in which the deletion of Mib1 (causing dysregulated Notch 
signalling)162 or of retinoic acid receptor-γ163 solely in non-hematopoetic cells was 
sufficient to induce a myeloproliferative phenotype, suggesting that in some cases the 
clonal composition of the bone marrow itself may not be as important as the bone marrow 
environment. 
 
Tumor necrosis factor α (TNFα), interleukin-6 (IL-6), fibroblast growth factor (FGF), 
interferon-γ inducible protein 10 (IP-10) and TGF-beta (TGF-β) production by bone 
marrow stroma, and potentially by the tumour clone itself, has been shown to promote the 
growth of MPN clones, while, in some cases inhibiting the growth of wild-type 
clones164,165,7. Tumour cells can also subvert their microenvironment. Clonal 
megakaryocytes and monocytes themselves (in mouse models, and from patients with 
myelofibrosis) secrete a number of cytokines, which include FGF, interleukin-8, TGF-β 
and vascular endothelial growth factor, that stimulate angiogenesis and drive fibroblast 
differentiation and recruitment, leading to bone marrow fibrosis166,167. In mouse models, 
JAK2-mutated clones have also been found to secrete lipocalin-2, which has been shown 
to suppress normal hematopoiesis via paracrine oxidative DNA damage, and may also 
drive the development of additional mutations in the tumor clone168. In addition, there is 
also evidence that, through direct cell-cell interactions and the secretion of soluble 
mediators such as TPO, C-C ligand 3 (CCL3) and interleukin-1β, the mutant clone can 
remodel the bone marrow niche to create an environment more permissive for its 
expansion, via depletion of sympathetic nerve fibres and nestin-positive mesenchymal 
cells169 and expansion of osteoblast lineage cells170. 
 
However, despite an abundance of literature positing a role for micro-environmental 
inflammatory signals in the development of MPNs (including mathematical modelling)171–
174, and the in vitro work and mouse models mentioned above, data from patients with 
MPN are limited and occasionally contradictory, in part because the cytokines measured, 
methodology and choice of MPN subtypes vary considerably between studies. 
 
Pro-inflammatory cytokines are consistently shown to be increased in MF175–177, including 
IL-2, IL-6, IL-8, TNF-alpha, TIMP1, MIB-1b. However, the cytokine profile of patients 
with ET and PV is less well established and some studies showing greater increases in pro-
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inflammatory cytokines in ET than PV178, PV than ET179 or showing no clear increase in 
ET180. It remains to be seen, therefore, to what extent cytokines contribute to the 
development and maintenance of MPNs, and whether differences between patients reflect 
differences in MPN phenotype. 
 
1.11 Prognostic modelling in MPNs 
 
While current practice aims predominantly to reduce the risk of thrombosis in patients 
with ET or PV, patients with myelofibrosis deemed to have a poor prognosis (in terms of 
overall survival or risk of leukemic transformation), can be treated with allogeneic bone 
marrow transplantation, which offers a potential cure. This decision currently is based on 
the use of prognostic scoring systems which, for the most part, utilise clinical parameters 
such as age, the presence of constitutional symptoms and blood counts. However, these 
scoring systems only offer categorisation into reasonably broad risk groups, and may be 
biased towards older patients with more advanced disease, who may be less fit to undergo 
transplantation. 
 
Paired analyses have demonstrated the acquisition of a number of mutations or 
chromosomal changes, among others affecting TP53, IDH1/2, TET2, EZH2, CUX1 and 
IKZF1, suggesting a tumour suppressor role in the transformation process for these 
genes94,104,125. An association has also been shown between a number of mutations 
identified earlier in the natural history of the myelofibrosis, and subsequent shortened 
survival or leukaemic transformation, including mutations of ASXL1, EZH2, IDH1/2 and 
SRSF269,96,98,103. Conversely, mutations in CALR have been associated with improved 
prognosis63-65. As a result, recent studies (discussed further in sections 5.1-5.2) have 
started to integrate these genomic variables into the prognostic scoring systems used in 
MF. This may therefore improve our ability to better identify candidates who will benefit 
from bone marrow transplantation and offer the potential to do so earlier on the course of 
the disease.  
 
Literature on predictive genomic factors in ET and PV is more sparse but the adverse 
factors identified show some overlap with those identified in myelofibrosis68.  If predictive 
genomic factors can also be identified in patients with chronic phase disease, they may 
may identify high risk individuals within this patient group who might also benefit from 
transplantation or novel targeted therapies. 
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1.12 Questions 
A number of questions still remain unanswered in this field. 
•! Are the phenotypic driver mutations sufficient to initiate and sustain disease, 
given that they do not appear to provide a stem cell advantage? If not, which 
additional factors (additional mutations, chromosomal events or micro-
environmental factors) permit clonal expansion and disease maintenance? 
•! Do genomic changes underlie the ET or MF phenotypes seen in triple negative 
(TN) patients? If so, are these in known recurrently mutated genes or are novel 
genes affected? 
•! Are there distinct patterns of co-mutation and mutual exclusivity for genomic 
events, and from this can genomically defined diagnostic entities be 
determined? 
•! To what extent do additional mutations/chromosomal changes (beyond those 
affecting the phenotypic driver genes) determine phenotype? Are there 
additional factors determining phenotype (e.g. ET vs PV in JAK2 mutated 
patients)? 
•! To what extent can a wider and more comprehensive genomic characterisation 
of MPNs improve out ability to understand the mechanisms underlying disease 
progression and generate predictive models? Can these models be used 
successfully for chronic phase patients as well as those with myelofibrosis? 
•! What is the role of micro-environmental signals in determining disease 
phenotype and risk of disease progression? 
1.13 Aims 
•! To comprehensively identify somatic variants and chromosomal changes and 
genotype SNPs associated with MPN pathogenesis or haematological parameters 
across a large MPN cohort to identify phenotypic correlates and genomic 
subgroups. 
•! To use demographic, clinical and genomic data to generate predictive models in 
order to identify those variables most likely to contribute to disease progression or 
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poor outcomes in MPN and to create clinically applicable prognostic models. 
•! To comprehensively measure cytokine levels in patients with MPNs and healthy 
controls to determine which cytokines might play a role in MPN pathogenesis and 
in determining phenotype and risk of disease progression. 
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2.  Methods 
2.1 Patient selection and sample processing 
2.1.1  Patient cohorts 
Peripheral blood samples from 1103 patients entered into the PT-1 trial were obtained. PT-
1 is a multi-centre international trial where both newly diagnosed and previously treated 
patients with ET, aged 18 years or over, were recruited into one of three studies depending 
on their risk of vascular complications181,182. High-risk patients were randomised to 
receive either hydroxycarbamide plus aspirin or anagrelide plus aspirin181, patients aged 
40-60 years without previous thrombosis or cardiovascular risk factors entered the 
intermediate-risk study wherein they received either hydroxycarbamide plus aspirin or 
aspirin alone182, and patients aged 40 years or under with no vascular risk factors entered 
the low-risk observational study and received aspirin only. All centres had appropriate 
research and ethical approval and patients gave their written informed consent. Clinical 
and laboratory details at and preceding diagnosis were obtained at trial entry, and patients 
were followed-up annually for treatment received, clinical events and blood counts. 
Patients fulfilled the current British Committee for Standards in Haematology (BCSH) 
criteria for ET183. 
 
Samples were additionally acquired from 21 ET, 33 PV, 16 MF, 2 MPNu patients enrolled 
in two phase II trials assessing the use of vorinostat184,185, and from clinics at 
Addenbrooke’s Hospital, Cambridge (n=231), Guys and St Thomas’ Hospital, London 
(n=136) and  Universita` di Firenze, Florence (n=366). The acquisition, storage and 
analysis of these samples was covered under the clauses of the ‘Causes of Clonal 
Haematological Disorders Project’ which had regional ethical approval from the Eastern 
Multi-region Ethics Committee (MREC 02/5/22 and 07/MRE05/44) and local research 
and ethical approval at participating UK hospitals. 
2.1.2 Clinical data acquisition and curation 
All patients in the study had their diagnoses made locally following the integration and 
review of clinical, laboratory and histopathological information at a multidisciplinary 
team, comprising the clinicians, specialist haemato-oncology histopathologists, and the 
laboratory molecular diagnostic team. Diagnostic criteria recommended by the British 
Committee of Standards in Haematology183,186–188 and WHO1 were followed for UK and 
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Italian patients respectively. PT-1 study patients met older Polycythemia Vera Study 
Group criteria for ET and despite criteria for ET having been revised multiple times over 
the course of the trial, central pathology review demonstrated high levels of concordance 
with current diagnostic criteria. The diagnostic review process for patients enrolled in the 
Vorinostat clinical study were as previously published184,185. Overall, this cohort comprises 
a mix of patients diagnosed in keeping with real-world best clinical practice. 
Clinical and laboratory details at and preceding diagnosis were obtained in addition to 
follow up information on adverse events. These included age at diagnosis and date of 
diagnosis, sex, MPN subtype, prior history of thrombosis, treatment (where available), 
diagnostic blood counts (haemoglobin, white cell count, platelets), date of transformation 
to myelofibrosis, AML or death, presence of splenomegaly, and cytogenetics and/or 
reticulin grade (for patients who underwent bone marrow examination). These data were 
obtained from a number of sources including patient paper and electronic records (on 
EPIC, eMR and Meditech systems at Addenbrooke’s Hospital), databases maintained by 
Cambridge Blood and Stem Cell Biobank (CBSB, Cambridge), the PT-1 trials database or 
directly from collaborators. Anonymised databases (containing unique patient identifiers) 
containing this data were maintained, and data formats standardised to enable further 
analysis. 
Median follow-up was 107, 78 and 53 months for patients with a diagnosis of ET, PV and 
MF from the time of sampling respectively. The median time between diagnosis and 
sample acquisition was 55 days. In addition, 42% of patients were sampled within a month 
of diagnosis and 69% of patients were sampled within the first year from diagnosis. 
Clinical and genomic data from an external cohort of 515 patients from the University of 
Florence Careggi Hospital were obtained. Diagnoses were again built up as part of an 
integrated clinical/laboratory/histopathology process, and each diagnosis was seen and 
discussed by 3 clinicians, lab biologists and the reference histopathologist, and if needed 
the histopathologist performed a second round of histological evaluation based on the 
clinical updated information. 
2.1.3 Isolation of mononuclear cells from peripheral blood 
40-60ml of venous blood was obtained by venepuncture and collected into lithium 
heparinized tubes and diluted 1:1 volume with phosphate buffered saline (PBS) at room 
temperature. The sample was then layered over an equal volume of a sodium 
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diatrizoate/polysaccharide density gradient (Lymphoprep; Axis-Shield, Dundee, UK) 
using a pipette on the lowest speed setting. Tubes were centrifuged at 800g at room 
temperature with no active deceleration. Mononuclear cells (MNC) were collected from 
the Lymphoprep/plasma interface using a pipette and washed twice in PBS. MNCs 
underwent red cell lysis if they were visibly contaminated with red cells - cells were 
incubated with 10ml of red cell lysis buffer (0.15 M NH4CL, 10mM NaHCO3, 0.1 mM 
EDTA in water) on ice for 5 minutes followed by addition of 10ml PBS and centrifugation 
at 300 g for 5 minutes to wash the cells of lysis buffer and lysed red cells. Cell pellets 
were resuspended in 1 ml of PBS and a cell count performed on a Woodley VetABC blood 
counter (Woodley, Bolton, UK) following the manufacturers instructions. 
2.1.4 DNA extraction 
20µl of RLT was mixed with double the volume of isopropanol and left for 15 minutes at 
room temperature before being centrifuged at 3600rpm for 45 minutes.  The supernatant 
was removed by plate inversion and then washed with 25µl of 70% ethanol followed by 
centrifugation at 4500rpm for 10 minutes. The supernatant was then removed and the plate 
spun for <30 seconds to dry. DNA was then reconstituted in 40µl of dH2O. 
2.2 DNA sequencing 
2.2.1  Sanger sequencing 
Primers for JAK2, CALR, PPM1D(A+B) and TET2 (specific for patient AQ31) were 
already available in the laboratory. PPM1D C+D primer sets were designed (using Primer 
3 software) as the A+B primer sets were found to inadequately cover the area of interest. 
Primers were designed to be 18-22 base-pairs (bp) in length, have an annealing 
temperature of 60°C, and generate amplicons of 150-220bp in length.  Primer sequences 
are shown in Table 1. 
The PCR reactions used 6µl KAPA2G Fast ReddyMix TDS (Kapa Biosystems, MA, 
USA), 3.88µl water, 0.06µl 10nM forward primer, 0.06µl 10nM reverse primer and 2µl 
DNA to make a 12µl reaction volume. PCR conditions were as follows: 15 minutes at 
95°C, followed by 32 cycles of 30 seconds at 95°C (denaturation step), 30 seconds at 56-
62°C (annealing step) and 1 minute at 72°C (extension step), followed by a final extension 
step for 15 minutes at 72°C. PCR bands were visualized on an ethidium bromide 
containing 1.5% agarose gel. 
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Table 1: Primers used for Sanger sequencing 
Primer Name Forward primer sequence Reverse primer sequence 
JAK2V617F TTTCCTTAGTCTTTCTTTG
AAGCAGC 
TAGTTTACACTGACACCTAGCTGTG
ATCC CALR CCTGCAGGCAGCAGAGA
AAC 
ACAGAGACATTATTTGGCGCG 
PPM1D_A TGCCATCCTACTAGCTTCA
TAAGAAG 
TTGGTCCATGACAGTGTTTGTTG 
PPM1D_B TTCCATTGGCCTTGTGCCT
A 
AAAAAAGTTCAACATCGGCACCA 
PPM1D_C AATTAGTGAATGCATACCC
CG 
CAGAGTTCTTTCGCTGTGAGG 
PPM1D_D TGGCCTTTGTGCCTACTAC
TAATTC 
TTTGATTTCTTTAAACATTTAGCCC 
TET2(AQ31) AATCCCATGAACCCTTAC
CC 
GGGTCTTGGCTTGGATACCT 
The PCR reaction was first cleaned of excess dNTPs and oligonucleotides by mixing 5µl 
of PCR product with 0.08µl of exonuclease I (USB, CA, USA), 0.3µl of shrimp alkaline 
phosphatase (New England Biolabs, MA, USA), and 1.62µl of water. This mixture was 
heated at 30°C for 30 minutes  then at 80°C for 15 minutes. Next, 2µl of the reaction 
product was mixed with 2.5µl of BDT buffer, 1µl of BDT, 1µl of 10nM primer and 3.5µl 
of water for a final reaction volume of 10µl. PCR cycling conditions were as follows: 1 
minute at 96°C followed by 35 cycles of 10 seconds at 95°C, 5 seconds at 50°C and 4 
minutes at 60°C. The PCR was run using both forward and reverse primers as separate 
reactions. Clean-up of the sequencing product was performed using by centrifuging using 
Cephadex gel. The supernatant was removed once again and the plate air-dried. 10µl 
formamide (Applied Biosystems, CA, USA) was added to each well prior to undergoing 
Sanger sequencing on a 3730xl DNA analyser (Applied Biosystems, CA, USA). PCRs 
performed at the Cancer Genome Project (CGP) laboratory utilised the same primers as 
above, however, reaction reagents and PCR conditions were different and followed CGP 
in-house protocols. 
2.2.2 RNA bait set design 
Two custom capture RNA bait libraries (Agilent SureSelect) were designed for targeted 
gene sequencing by Dr Jyoti Nangalia and Dr Elli Papaemmanuil and are here referred to 
as TGS1 and TGS2. These were chosen to provide coverage for genes known to be 
mutated in myeloid malignancies189, as well as genes that were found to be recurrently 
mutated in a previous whole exome sequencing study in MPN52. The genes targeted by the 
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TGS1 bait set are show in Table 2, and by the TGS2 bait set in Table 3. In addition, 1966 
SNPs were targeted in order to (a) cover SNPs that were known to be associated with an 
increased risk of MPN acquisition or had been reported in previous genome wide 
association studies (GWAS) to be associated with red cell or platelet indices in the normal 
population and (b) enable identification of genome-wide chromosomal changes. 
Sequencing data from these SNPs were not available for the 151 patients whose samples 
underwent exome sequencing rather than panel sequencing. 
Table 2: Genes targeted by the RNA bait set for TGS1. Overlap with TGS2 in bold. 
ABCC9 
CEACAM
6 
EPHA7 IFNGR1 MSH4 PTPN4 SYNE2 
AC010872.
2 
CEBPA ERVWE1 IL12B NCL PTPRA TCF4 
ADAM18 CELF1 ETV6 IL12RB1 NF1 PTPRB TET2 
AHNAK CHEK2 EYA2 IL31RA NFE2 PTPRC TG 
AHNAK2 CMYA5 EZH2 IL6ST NFKB2 PTPRR TP53 
AKAP9 COL1A1 FAM47C IRF1 NOTCH2 PTPRT TRA2B 
ARHGAP32 COL21A1 FANCA ITPR1 NPM1 RAD21 TRPM4 
ASPM COL22A1 FARS2 JAK2 NR3C1 RAD51 TYRO3 
ASXL1 CREBBP FAT2 KCNMA1 NRAS RB1 U2AF1 
ASXL3 CSMD1 FAT4 KDM6A NRD1 RBM14 U2AF2 
ATM CSMD3 FLT3 
KIAA132
4 
OCA2 RP1L1 VPS72 
ATRX CTNNA1 GABRB3 
KIAA137
7 
OTOP1 RUNX1 WT1 
BCLAF1 CTNNA2 GATA2 
KIAA154
9 
PCDH15 SARDH WWOX 
BCOR CTNND2 GNAS KIF1B PCDH7 SEZ6L2 ZBP1 
BRAF CUX1 GPR112 KIT PDZRN4 SF3B1 ZBTB33 
BRD1 DICER1 GPR116 KRAS PHF6 SRSF2 ZEB2 
BRD9 DNAH10 GRIN2A KSR2 PPM1D SGK2 ZFHX4 
BTNL8 DNAH9 GRIN2B 
L3MBTL
1 PRAGMIN 
SH2B3 ZNF717 
C2orf39 DNMT3A HNRNPCL1 MBD1 PRKACB SH3RF3 ZNF75D 
CACNA1G DNMT3B HUWE1 ME1 PTEN SLC12A1 ZRSR2 
CACNA2D
3 
DST HYDIN2 MLL PTPN11 SPAG9 
  
CADM2 DTNA IDH1 MLL2 PTPN14 SRRM2   
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CALR ELF1 IDH2 MLL3 PTPN2 SSPO   
CBL EP300 IFNA10 MLL5 PTPN21 STAG2   
CDKN2A EPHA2 IFNAR1 MPL PTPN3 SVEP1   
 
Table 3: Genes targeted by the RNA bait set for TGS2. Overlap with TGS1 in bold. 
ASXL1 CHEK2 FAM47C IRF1 NCL PRKACB SPTA1 
ASXL2 CREBBP FARS2 JAK2 NF1 PTEN STAG2 
ASXL3 CSF2RB FBXW7 KDM6A NFE2 PTPN11 SUZ12 
ATRX CSF3R FLT3 KIT NOTCH1 RAD21 TET2 
BCOR CTCF GABR3 KRAS NOTCH2 RAD51 TP53 
BRAF CUX1 GATA1 KSR2 NPM1 RB1 U2AF1 
C22ORF3
0 
DNMT1 GATA2 MBD1 NRAS RUNX1 WT1 
C2ORF39 
DNMT3
A 
GNAS MLL OLFM4 SARDH WWOX 
CACNA2D
3 
DNMT3
B 
GNB1 MLL2 PCDH15 SETBP1 ZRSR2 
CALR EED GRIN2B MLL3 PHF6 SF3B1  
CBFB ELF1 HNRNPK MLL5 PHF8 SRSF2  
CBL EP300 HRAS MPL PHIP SH2B3  
CDKN2A ETV6 IDH1 MYB PIK3CA SLC7A8  
CEBPA EZH2 IDH2 MYC PPM1D SMC1A  
2.2.3 DNA sequencing libraries and Next generation sequencing 
DNA samples underwent library preparation at the Wellcome Trust Sanger Institute, 
Cambridge, UK. Granulocyte derived DNA samples (n=1033) underwent whole genome 
amplification prior to library preparation (the TGS1 cohort). Sequencing libraries were 
generated in a 96-well format, with each sample carrying a unique DNA barcode. Pools of 
16 libraries were made and hybridized to RNA baits. Pools of 96 cases were sequenced on 
two lanes of an Illumina HiSeq2500 machine using 75bp paired-end sequencing. 
Sequencing data were mapped to the GRCh37/hg19 reference genome using the BWA  
(Burrows-Wheeler Alignment) algorithm190 
 on default settings as part of the Cancer Genome Project pipeline. Median depth of 
sequencing was 198x at identified variants – this represents the median coverage across 
variants after removing PCR duplicates, and so represents the number of unique DNA 
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molecules sequenced. Table 4 shows values for coverage at important hotspot loci. 
Table 4: Average coverage at hotspot loci 
"
Gene$ Protein$
Mean$cover.
age$
SD$ Median$ 25%$centile$ 75%$centile$ Chr$ Pos$
JAK2% V617F" 156" 59" 153" 130" 177" 9" 5073770"
DNMT3A% R882" 238" 131" 267" 165.5" 314" 2" 25457242"
DNMT3A% R882" 235" 129" 263" 163.5" 309" 2" 25457243"
ASXL1% E635" 275" 186" 338" 53" 400" 20" 31022403"
MPL% W515" 275" 163" 322" 103" 381" 1" 43815008"
MPL% W515" 274" 162" 321" 102" 379.5" 1" 43815009"
U2AF1% Q157" 245" 151" 283" 88" 340" 21" 44514777"
SRSF2% P95H" 255" 181" 310" 32" 378" 17" 74732959"
IDH2% R140Q" 201" 118" 230" 101" 273" 15" 90631934"
SF3B1% K700E" 256" 93" 254" 210" 297" 2" 198266834"
SF3B1% K666N" 204" 92" 213" 138" 252" 2" 198267359"
IDH1% R132" 182" 127" 182" 151" 214" 2" 209113112"
IDH1% R132" 186" 129" 187" 155" 218" 2" 209113113"
 
As part of clinical trials or diagnostic work-up elsewhere, samples additionally underwent 
screening for CALR mutations by both exon 9 bi-directional Sanger sequencing 
(sensitivity of >10%)52 and exon 9 fragment-size analysis PCR (sensitivity >2%)191, for 
JAK2V617F by allele-specific PCR192 
, and MPL mutations by PCR (W515 and S505)193 
2.3 Identification of variants 
2.3.1 Single nucleotide substitutions – Caveman 
The Cancer Variants Through Expectation Maximisation (CaVEMan) algorithm, 
developed at CGP and run on the Welcome Trust Sanger Institute farm, was used for 
detection of single nucleotide substitution variants194. As paired constitutional samples 
were not available, a single designated normal sample was used as comparator. This 
algorithm uses as its input sorted and indexed binary alignment/mapped (BAM) files with 
a FASTA reference genome. The algorithm proceeds by (1) splitting the file, (2) iteratively 
assessing the base pair calls at each genomic locus (maximisation step) (3) merging these 
analyses to form a complete genome and (4) iteratively assigning a probability to each 
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possible genotype at each position. If these probabilities are above a threshold they are 
called as somatic mutations and the output is written to a VCF (variant call format) file. 
2.3.2 Small insertions/deletions – Pindel 
For insertions and deletions, the pindel algorithm195 (with in-house modifications) was 
used, again on the CGP farm using the existing pipeline. The pindel algorithm uses an 
anchor sequence (i.e. the part of the read mapped to the reference genome) to initiate a 
search for nearby sequences to which the unmapped portion of the read can be mapped, 
and in doing so reduces the search space for the unmapped sequence. In-house 
enhancements of the original algorithm include the exclusion of nonspecific anchors, and 
the use of average read quality to clip poor quality sequence and improve mapping. These 
enhancements reduce the false positive rates and enable detection of smaller indels. The 
output of this algorithm is also written to VCF format. 
2.3.3 Filtering of CaVeMan- and Pindel-called variants 
CaVEMan and Pindel results were merged into two files, one containing the total set of 
variants detected, and another including only those that had passed the preset filters 
carried out by post-processing as part of the CaVEMan/pindel pipeline. 
In summary, filters for exclusion by CaVEMan that were called in this dataset included: 
   <1/3 of alleles with mutant base have base quality >25 
   <8 mutant reads and these are all located in the last third of the read 
 Presence of the allele in more than 5% of reads from unmatched normal 
samples 
    Mutant alleles fall within a simple or centromeric repeat 
   Mean mapping quality <21 
   Mutant allele matches a known dbSNP germ-line variant 
   >10% of reads covering this position contain an indel 
   Mutant reads were restricted to one strand direction 
 Filters for exclusion used for pindel in this dataset included: 
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   Events of >4bp also found in wildetype reads 
   Events must be in >= 3 in a single strand, or >2 in both 
   Event must be in  >=8% of reads if depth <200, or >=4% if >= 200 
   Events of <=4bp are discarded in repetitive region (>9 repeats) 
   WT depth must be >5 and >=8% of total depth. 
 30637 CaVEMan calls and 128583 pindel calls met these criteria and were carried 
forward to further post-processing (see Section 2.4). 
Reads that contain insertions/deletions may fail mapping due to the resulting discrepancies 
in the sequence. This may lead to under-estimation of the number of reads carrying the 
mutation, and therefore of its variant allele frequency. Using in-house algorithms that 
utilised BLAST (Basic Local Alignment Search Tool) in order to screen unmapped reads 
for the presence of the mutation, the variant allele fractions of mutations found using 
pindel were corrected. 
2.4 Filtering of variants 
Given that matched constitutional samples were not sequenced for the majority of patients, 
extensive filtering was required to eliminate potential artefactual calls and germ-line SNPs 
as listed below, in order to enrich for high confidence driver mutations. The filtering 
methodology used here was adapted from that used in previous studies189,196 
2.4.1 Removal of germ-line SNPs 
Variants were annotated for their presence in the 1000 genome project197, NHLBI Exome 
Sequencing Project198, Wellcome Trust internal 500 exome sequencing dataset, the 
Ensembl dbSNP database199, the Exome Aggregation Consortium dataset (MacArthur lab, 
Broad Institute)200 and the Catalogue of Somatic Mutations in Cancer (COSMIC) 
dataset201–203, and specifically whether they were found to be somatic, the tissues they 
were found in, and whether any other COSMIC variants were reported affecting the same 
genomic or amino-acid positions or were within 3 amino-acids of it (the latter criterion 
was later revised). Variants that matched entries in COSMIC describing somatically 
acquired mutations at the same genomic or amino-acid position were retained. Some 
single-nucleotide variants (SNVs) matched a variant in COSMIC by either genomic 
position or amino-acid position, however, if these variants were not reported as somatic 
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mutations in COSMIC and had a VAF>40% then they were removed. SNVs prevalent 
across SNP databases were filtered out. SNVs that were not prevalent in SNP databases, 
did not match (by exact mutation, genomic location or amino-acid position) to a variant in 
COSMIC and had a VAF>40% were removed to reduce potential contamination by rare 
and private germ-line SNPs. SNVs that were not reported in any SNP database, but were 
within 3 amino-acids of a somatic variant reported in COSMIC were retained if their VAF 
was less than 40% due to the possibility that these mutations could represent previously 
unreported somatic events. 
2.4.2 Identification of high-confidence somatic calls 
Further filtering was carried out as follow: 
•! Off target calls (including inter-genic or intronic calls) and synonymous mutations 
were removed. 
•! CaVEMan variants occurring within regions of germ-line indels and variants 
located only on one strand (where read depth was >5 on both strands) were also 
removed. 
•! Variants <1% allele fraction were removed. 
•! Variants were further filtered against a panel of 455 samples (blood from patients 
without known haematological malignancy) that had undergone sequencing on the 
same platform to remove sequencing artefacts. 
•! Insertions or deletions that were removed if they were only detected in 
unidirectional sequencing reads, were located in homopolymer tracts, or were 
present in sequencing files of a panel of normal samples. 
•! In parallel to this, known hotspots within myeloid driver genes were screened for 
low burden canonical mutations. Loss-of-function mutations (as caused by 
nonsense, frameshift or splice site mutations) in the genes ASXL1, BCOR, CUX1, 
DNMT3A, TET2, PPM1D, EZH2, GATA2, MBD1, RB1, RUNX1, SH2B3, 
NFE2, NF1, TP53, CBL, MLL3, and ZRSR2 were also retained provided they 
were not detected as artefacts of sequencing when compared to the normal panel. 
The filtering strategy above was further refined by taking samples that had undergone 
variant calling using a matched constitutional germ-line sample, and interrogating 
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differences in variants that would have been called if one were to perform variant calling 
without the matched constitutional germ-line sample. While this filtering strategy above 
might still not remove all germ-line variants, the variants included likely reflect those that 
might be identified from real world diagnostic practice where routine practice involves 
sequencing of tumour DNA only and not a matched constitutional analysis. 
2.4.3 Genotyping of germ-line variants of interest 
Using SAMtools mpileup204 at loci for a pre-specified list of SNPs (chosen for their 
association with haematological parameters and/or MPN predisposition130,140,149,159,205–209), 
allele fractions for each allele were determined and therefore each patient was allocated a 
genotype. SNPs which were not adequately covered for the entire cohort were not 
included in further analysis. 
The final list of SNPs is shown in Appendix 1, together with their chromosomal location, 
phenotypic correlates and references. 
2.5 Identification of chromosomal losses/gains/uniparental disomy 
Dominant allele fractions were calculated for SNPs across the genome using SAMtools 
mpileup at loci derived from 1000 genomes project197 (using Ensembl biomart210). B-
allele frequency plots for each sample were assessed to determine whether regions of 
deviation from 50% allele frequency for heterozygous SNPs could be identified. 
Normalised coverage plots were then assessed in these cases to classify chromosomal 
changes into gains, losses or copy-neutral loss-of-heterozygosity (CN-LOH) events. These 
were plots of individual base-pairs for each locus within targeted regions, normalised 
against the median values for that locus for cohort as a whole (independently for TGS1 
and TGS2). 
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Figure 2: Detection of chromosomal abnormalities. Dominant allele fractions (top) and 
normalised coverage (bottom) are show for examples of chromosomal loss on 5q, 
chromosomal gain (trisomy 8) and CN-LOH of 9p. 
Recurrent abnormalities were detected across chromosomes 4, 5, 7, 8, 9, 11, 12, 13, 14, 
17, 18, 19 and 20. Traditional cytogenetic analyses, either from FISH or karyotyping, were 
available for only 20% of the cohort. In these patients, 88% concordance was present 
between copy number changes detected by FISH/karyotype and their detection in data 
from NGS. However, it was not possible to identify chromosomal translocations. 
2.6 Single cell derived colonies 
5.5mL aliquots of MethoCult H4435 Optimum (StemCell Technologies, Vancouver, 
Canada) at room temperature were prepared. MNCs were diluted in PBS to a 
concentration of 6-7x106 cells/ml, and 200µl aliquots of the cell suspension were added to 
each 5.5ml aliquot of MethoCult. For cytokine experiments recombinant human TGF-a or 
GRO-a/CXCL1 (R&D Systems, Abingdon, UK) were added to a final concentration of 50, 
25 and 10mmol/l, together with an untreated control. Samples were vortexed for 30 
seconds. Each MethoCult aliquot was then divided across 3 wells of a 6-well plate at 
1.5ml per well, using a 5mL syringe and an 18-gauge needle. 
 Sterile water/PBS was dispensed between the wells and the and 6-well plates were 
incubated at 37°C with 5% CO2 and high humidity for 14-15 days. Following in vitro 
culture, plates were visualized under a dissecting microscope. Single erythroid (BFU-E) or 
granulocyte-monocyte/macrophage (CFU-GM) colonies were recognized by their 
morphological characteristics and individual colonies were aspirated and lysed in 50µl of 
RLT lysis buffer (Qiagen, Maryland, USA) and stored at -80°C. 
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2.7 Measurement of serum cytokine concentrations 
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel Immunology 
Multiplex Assay (Millipore, HCYTOMAG-60K) was selected to measure levels of 38 
cytokines. This method utilises Luminex xMAP® technology, which uses antibody-
coated, colour-coded magnetic microspheres each specific to a different analyte. After 
incubation with the sample these are treated with a biotinylated detector antibody and a 
Streptavidin-PE conjugate reporter conjugate which is then visualised using a Luminex 
xMAP flow cytometer.  Absolute concentrations are then calculated from MFI using a 
standard curve for each analyte. The use of specific, independently identifiable beads 
means that multiple analytes can be measured in a single well. 
This work was done together with Dr David Kent, Dr Nina Friesgaard Oebro, Miriam 
Belmonte and Olivia Harris. The cytokines measured were: Vascular endothelial growth 
factor (VEGF), soluble CD40 ligand (sCD40L), epidermal growth factor (EGF), Eotaxin, 
fibroblast growth factor 2 (FGF-2), Flt-3 ligand, Fractalkine, granulocyte-colony 
stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-
CSF), growth-regulated oncogene (GRO/CXCL1), interferon alpha 2 and gamma (IFN-α2 
and IFN-γ), interleukins (IL) IL1α, IL-1β, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, 
IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15 and IL-17, interferon gamma induced 
protein 10 (IP-10), monocyte chemotactic proteins 1 and 3 (MCP1 and MCP3), 
macrophage-derived chemokine (MDC /CCL22), macrophage inflammatory protein 1 
alpha (MIP1α), MIP1β, transforming growth factor alpha (TGF-α), tumour necrosis factor 
alpha (TNF-α) and TNF-β. 
 The kit was run according to manufacturers instructions; briefly, 200µL assay buffer was 
pipetted into each well of the 96-well plate and left to stand for 10 minutes at room 
temperature, followed removal of the assay buffer by tapping out. 25µL of assay buffer 
was added to each well followed by 25µL of standard or control to the appropriate wells. 
25µL matrix solution was added to the background, standard, and control wells. Patient 
serum samples were thawed and brought to room temperature and 25µL of each sample 
added to appropriate wells. After mixing, 25µL pre-sonicated beads were added, and the 
plate was incubated overnight at 4°C with agitation. The plate contents were tipped out 
whilst on a magnet and the plate was washed twice. 25µL detection antibodies were added 
to each well and the plate was incubated for a further 1 hour at room temperature with 
shaking. After this, 25µL streptavidin--phycoerythrin was added to each well and the plate 
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was incubated for another 1 hour at room temperature with shaking. The well contents 
were then tapped out and the plate washed, and finally 150µL sheath fluid was added. 
After re-suspension for 5 min, the plate was run on Luminex xMAP (Luminex Corp., 
Austin, TX). Cytokine concentrations were then determined by xPONENT software 
(Luminex) on the basis of the fit of a standard curve for MFI versus pg/mL, using values 
derived from the known reference concentrations supplied by the manufacturer. 
2.8 Statistical analysis 
The code for most statistical analyses performed is provided in Appendix 2. 
2.8.1 Tests of significance and multiple hypothesis testing 
Testing for difference in means for continuous variables was performed using student’s t 
test, or Mann-Whitney/Wilcoxon test for non-normally distributed data (t.test() and 
wilcox.test() in R). Testing for differences in proportions was performed using chi-squared 
or Fisher’s exact test (chisq.test() or fisher.test() in R). 
For specific correlative analyses, the Benjamini-Hochberg method was used to adjust p 
values for multiple hypothesis testing (using p.adjust()). The adjusted values quoted in the 
manuscript therefore represent q values (that is, the false discovery rate, FDR). This 
approach was in particular applied to analyses of associations among driver mutations, 
germ-line variants and MPN subtype at diagnosis. 
Where possible however, the tests of association between variables were performed using 
multivariate analysis to correct for the confounding effects of other variables. Fitting of 
generalised linear models and logistic regression were performed using glm(), and of 
linear mixed effects models using lmer() from lme4 v1.1-12. 
For the multivariate survival analyses, overfitting was controlled by L2 regularisation 
through the random effects model (discussed in more detail in Section 5.7). Additionally 
model validation was performed using leave-one-out cross-validation, and through the use 
of external datasets. 
2.8.2 Bayesian network analysis 
The Bayesian network (BN) was constructed by first creating a binary matrix indicating 
presence/absence of genomic features of interest, with each row in this matrix 
corresponding to a single patient, and columns to genomic features. A data value of 1 
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indicates the presence of the feature in the specific patient. The Gobnilp software was then 
used with default parameters to learn the structure of the network211. The parameters 
included a maximum of 3 parents for each node.  The algorithm finds the globally optimal 
BN within the constraints set, by treating the learning of the BN structure as a linear 
optimisation problem. This is then solved using integer linear programming via the SCIP 
Optimization suite 3.2. For the resulting BN we used in-house code written in SWI-
Prolog212 that finds the logic gate combination which maximizes the Fisher exact test p-
value when regressing the parents against the child. For a child, its input vector is 
computed by performing the logic gate operations on its parents' value vectors. 
2.8.3 Determination of clone sizes and mutation acquisition order 
The proportions of cells carrying each mutation were calculated using the variant allele 
fractions corrected for any copy number change at the site of the variant, and comparisons 
were made for each pair of mutations in each patient to determine the order of acquisition 
as described previously122,213. Here, the terms ‘early’ and ‘late’ for describing driver 
mutations are used to denote relative timing. That is, we cannot know when in 
chronological time an event occurred; rather we can sometimes infer the relative order in 
which two events occurred. This then generates data analogous to scenarios that arise in 
sports statistics, where a league of teams play one another in a series of pairwise 
encounters, and we are interested in inferring from this series of pairwise events an overall 
ranking of teams in the league. We adopted methods from sports statistics to generate a 
relative ranking of driver mutations about whether they occur typically ‘early’ or ‘late’ 
during disease evolution relative to other driver mutations. R packages BradleyTerry2 
(version 1.0-8) was used to generate estimates of relative mutation timing with quasi-
variances generated using qvcalc (version 0.9-1). 
2.8.4 Bayesian clustering algorithm 
We performed clustering on the genomic data alone using a Bayesian approach previously 
applied to genomic data from patients with AML214. In brief, the number of clusters was 
learned by using a Markov Chain Monte Carlo (MCMC) method to sample from an 
underlying Dirichlet process, utilising an implementation of the Dirichlet process mixture 
model (https://github.com/nicolaroberts/hdp, hdp package v0.1.0). The MCMC was run 
with an initial 500 iterations, which were discarded (“burn-in iterations”), followed by 
1000 iterations sampled at intervals of 20.  The optimal number of clusters using our 
dataset of 2035 patients and 54 genomic changes was found to be 7. This number of 
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categories was unchanged, when the cohort was combined with 536 genomically 
characterized patients with MDS. From this model, each patient had a probability of being 
assigned to each of the seven classes, and from these probabilities, a simplified set of rules 
was generated to allow for patients to be categorised into the group for which they had the 
initial maximum probability. We included an additional group of patients who were found 
to have no genomic changes (and who were therefore assigned equal probabilities of 
belonging to each class). 
2.8.5 Survival analyses 
The process by which survival models were fitted and integrated is documented in more 
detail in Chapter 5. Simple Cox proportional hazards models were fitted and Kaplan-
Meier analyses performed and plotted using the survival 2.4-1 and rms 5.1.0 packages. 
Receiver-operator curve sensitivity/specificity analyses were performed using the 
survivalROC 1.0.3 package. Variable selection was performed using Akaike’s information 
criterion using k=log(n) using the stepAIC function from MASS v7.3-45. Mixed 
proportional hazards models were fitted using the CoxHD() package (v0.061)215 
The variables included in the modelling were as follows: 
•! Demographic: age at diagnosis (continuous variable), gender (male/female) 
•! Clinical (at diagnosis): history of prior thrombosis (present/absent), splenomegaly 
(present/absent), haemoglobin concentration (continuous variable), white cell 
count (continuous variable), platelet count (continuous variable), PV versus ET 
(for chronic phase patients). 
•! Genetic: Presence (>1% VAF) /absence of mutations in 33 genes (individual 
variables) - JAK2 (V617F or exon 12), CALR, MPL (S204/S505/W515 hotpots), 
ASXL1, BCOR, CBL, CUX1, DNMT3A, EZH2, GATA2, GNAS, GNB1, IDH1, 
IDH2, KIT, KRAS, MLL3, NFE2, NF1, NRAS, PHF6, PPM1D, PTPN11, RB1, 
RUNX1, SF3B1, SH2B3, SRSF2, STAG2, TET2, TP53, U2AF1, ZRSR2.   
•! Cytogenetic: Presence/absence of copy number changes or copy number neutral 
loss of heterozygosity in 16 regions (individual variables) - Chromosome 1 (1p CN 
LOH or 1q gain), 4, 5, 7, 8, 9 (9p CN LOH or trisomy 9), 11, 12, 13, 14, 17, 18, 
19, 20. 
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 Cohort: Original cohort of patient (e.g. PT-1 cohort, Italian cohort, UK centres) 
Individual models were created for transitions from (i) Chronic phase (CP, namely ET, PV 
and MPNu patients) to death (censored at AML or MF transformation), (ii) MF to death 
(censored at AML transformation), (iii) CP to MF (censored at death or AML 
transformation) and (iv) CP or MF to AML (censored at death; transformation from CP to 
MF was treated as a time-dependent variable). Time 0 was taken to be the time of 
diagnosis, but for cases of secondary MF where a patient was sampled in CP (data used for 
modelling the survival fits in (ii) and (iv)), the time of transformation was taken as time 0.  
Data was right-censored at the end of follow-up.  The median time between diagnosis and 
sample acquisition was 55 days. In addition, 42% of patients were sampled within a month 
of diagnosis and 69% of patients were sampled within the first year from diagnosis. This is 
an important consideration when building prognostic models as a mutation that is present 
from the time of the sample may not have been present prior to sampling. Therefore, our 
model left-censors from time-of-diagnosis to time-of-sample for survival analyses. This 
ensures that the risk associated with any detected mutations is only applied to the period 
following sampling (since the presence/absence of the mutation is unknown up until that 
point) and thus, reduces any potential lead-time bias that could be introduced from any 
patients sampled later in disease. 
 Proportionality was checked using scaled Schonfeld residuals, both by plotting these 
against time and testing formally for non-proportionality. For each variable, in each of the 
individual fits used in the multi-state model, there was no evidence that the proportionality 
assumption was violated. 
The individual transition models are then integrated into a single multistate model, using 
the principles described previously215. Death but also transformation to AML were treated 
as terminal events. A “leave one out” method was used for internal cross-validation, that 
is, predictions for each patient were generated using a multi-state model built on data from 
the remaining patients. External validation was also carried out using a cohort of 417 
patients from Italy, for whom a subset of genomic information was available (58% for MF 
patients and 47% for CP patients). The performance of the model was assessed for each 
individual transition (CP to death, MF to death, CP to MF, CP to AML and MF to AML) 
and for overall event-free survival (EFS). 
Random effects Cox proportional hazards models were created using the  CoxHD package 
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(v0.0.61) and integration into multistage models using msSurv (v.1.2.2) and rcpp 
(v0.12.11). 
2.8.6 Methods for prognostic model evaluation 
Numerous methods for evaluation of prognostic model performance exist, each with their 
own advantages and disadvantages, and the choice of comparator will also depend on the 
clinical question being asked. In order to fully characterise a model, and compare it to 
other possible prognostic models, a number of metrics were calculated, namely: Harrell’s 
c-statistic, Uno’s C, the Brier score and absolute prediction error. 
Harrell’s c-statistic is defined as the probability that a given pair of patients is correctly 
ranked according to the prognostic model, and therefore evaluates all comparable pairs of 
patients216. A value of 100% represents a fully accurate ranking, while that of 50% would 
be equivalent to chance. Generally speaking, values of 60-70% are seen in survival 
analyses.  
 
One limitation of this method is that it only determines whether the model correctly ranks 
patients by risk, but not the accuracy of the prediction for a given patient. Secondly, if a 
pair of patients includes a patient right-censored prior to the time of an event in the second 
patient, these patients cannot be compared, and therefore the c-statistic is subject to the 
censoring distribution of the individual study. Therefore a modification of the c-statistic, 
which is independent of censoring, is also included217. However, since the comparisons 
presented in this thesis are of multiple models applied to one single cohort (and one 
external validation cohort), one would expect this second limitation to be less crucial for 
the analyses reported here. 
 
 The use of the Brier score and absolute prediction error addresses the first limitation of 
concordance measures mentioned above. The absolute prediction error is defined as the 
mean difference between predicted and actual outcomes while the Brier score is defined as 
the mean of the squared difference between the predicted and actual outcome218. 
Therefore, a Brier score of 0 would represent a fully accurate set of predictions, while a 
score of 0.25 would be equivalent to a coin-toss (in the context of binary outcome). The 
survival state for censored patients is extrapolated from their last time-point.  
 
From these, briar skill scores can be calculated, defined as the ratio of the briar score to 
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the “baseline” briar score where the prediction is taken as the baseline frequency of the 
event in all cases219. The accuracy of a prediction depends in part on the frequency of the 
event (f) being predicted, or more specifically underlying uncertainty (defined as f(1-f) 
and ranging from 0 to 0.5). Because better (i.e. lower) Brier scores are seen where the 
uncertainty is lower it is not possible to directly compare scores across outcomes or time-
points with different levels of uncertainty. For this reason, the uncertainty for each 
prediction was also calculated for reference. 
2.8.7 Decision tree/Recursive partitioning and Random forest classifications 
Creation of alternative classifications for overall or progression-free survival were 
performed using decision tree algorithms implemented in party v.1.1-2 and rpart v.4.1.10. 
Random forest analyses were performed using randomForest (v.4.6-12) for classification, 
and randomForestSRC v.2.4.1 for survival analyses. These algorithms were also used to 
identify candidate cytokines that were best able to categorise patients by MPN subtype. 
2.8.8 Other analyses and statistical packages 
The following functions and packages in R (v.3.2.2) were additionally used for data 
processing and visualisation: lsr v0.5, data.table v1.1, DT v0.2, tidyr v0.6.1, Hmisc v4.0-2, 
ggplot2 v2.2.1, hilbertVis v1.26, lattice v0.20-34. The arules package (v. 1.5-0) was used 
for frequent pattern mining. 
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3. Genomics of Myeloproliferative Neoplasms 
3.1 Introduction 
Myeloproliferative neoplasms are generally considered genomically simple, with many 
fewer detected mutations per patient than solid malignancies and most other 
haematological malignancies. Furthermore the set of genes mutated is also generally 
small, in that most cases have mutations in one of the phenotypic driver mutations, JAK2, 
CALR or MPL, without mutations of other affected genes52,66,95. 
Despite this, however, the associations between the additional mutations and chromosomal 
abnormalities, and between these genomic changes and phenotype and outcome are not 
well characterised. This is because most genomic studies in MPNs have either focussed on 
myelofibrosis alone, have small sample sizes, have been restricted to a small number of 
genes and/or have focussed on mutations alone without assessing the presence of 
chromosomal changes. An understanding of these questions would inform our knowledge 
of how genomic changes interact and give rise to particular phenotypes, inform our ability 
to accurately define and classify disease entities and improve our ability to prognosticate 
and therefore make management decisions. 
Table 5: Number of patients with ET, PV, MF or other MPN diagnoses sequenced, with associated 
demographic and clinical parameters, and frequencies of JAK2, CALR and MPL mutations, or 
absence of JAK2, CALR or MPL (“triple negative”). MPNu=MPN undefined. 
Diagnosis ET PV MF MPNu Other* 
Number of patients 1321 356 309 14 35 
Median age (years) 54 62 63 54.5 57 
Female (%) 59.1 45.2 35.6 50 34.3 
Median Hemoglobin concentration (g/l) 140 179 116 123 128 
Median white cell count (x10^9/l) 9.1 10.6 9.4 7.35 7.95 
Median Platelet count (x10^9/l) 862 480 329 356 218 
JAK2V617F mutated (%) 54.7 99.7 70.2 64.3 17.1 
JAK2 exon 12 mutated (%) 0 0.02 0 0 0 
CALR (52bp deletion/Type 1-like) mutated (%) 16.2 0 13.6 21.4 0 
CALR (5bp insertion/Type 2-like) mutated (%) 10.8 0 4.9 7.1 0 
MPL mutated (%) 4.5 0 4.5 0 0 
Triple negative (JAK2/CALR/MPL unmutated) 15 0 8.1 14.3 82.9 
* Comprised systemic mastocycosis (n=7), refractory anemia with ringed sideroblasts (n=2), post-
PV acute myeloid leukemia (n=1), myelodysplasia/MPN/SM overlap (n=1), idiopathic 
erythrocytosis (n=11), Hypereosinophilic syndrome (n=2), chronic myelomonocytic leukemia 
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(n=6), chronic eosinophilic leukemia (n=1), atypical chronic myeloid leukemia (n=1), and 2 
patients with unspecified MPN diagnoses. 
We therefore utilised a large cohort, with representation of patients with both chronic 
phase (ET and PV) and myelofibrosis and used a relatively unbiased targeting approach 
that included not only genes known to be mutated in myeloid malignancies, but also a 
number of putative drivers identified in previous studies. The cohort of 2035 patients 
comprised 1326, 355 and 310 patients with ET, PV and MF respectively and 50 patients 
with other MPN diagnoses. Clinical characteristics and diagnoses are detailed in Table 5. 
3.2 Mutations and chromosomal aberrations in MPNs 
3.2.1 High confidence mutation and chromosomal aberration calls 
As discussed above (Section 2.4), a number of criteria were used to define a variant called 
by Caveman (for substitutions) or Pindel (for insertions/deletions) as a probable somatic 
driver mutation. As the somatic nature of these mutations could not be determined 
definitively, as a matched constitutional sample was not available (and genotyping of 
single cell colony derived colonies, done in some cases, was not feasible) for the vast 
majority of cases, filtering against publically available SNP databases was used to exclude 
known germ-line variants. 
The COSMIC database was also used to identify those mutations that had previously been 
shown to be somatic, and the recurrent nature of these mutations was used as an indicator 
that they acted as oncogenic drivers (rather than functionally inert passengers), in the 
absence of a functional assay. For genes known to be affected by protein truncating or loss 
of function mutations (e.g. TET2, ASXL1, EZH2, NFE2), any nonsense/frameshift/splice-
site mutation was included regardless of COSMIC matches. Initially, missense mutations 
were required to be within 3 amino acids of a recurrent COSMIC match, previously shown 
to be somatic.  However, subsequent examination of the cohort that had undergone whole 
exome sequencing, for whom matched constitutional samples were available revealed a 
high proportion of germ-line variants even using this criterion. Therefore, for missense 
mutations, only those at the same amino acid site of a COSMIC match, previously 
demonstrated to be somatic, were included. One caveat in the discussion that follows 
therefore is that this dataset may still include rare germ-line events because of these 
limitations. 
Only those mutations that were mutated in at least 5 patients in our cohort (0.25%) were 
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taken forward for further analysis, as genes mutated below this threshold were unlikely to 
play a significant role in MPN pathogenesis and would be insufficiently powered to draw 
conclusions about genotypic or phenotypic correlations.  The variants detected are found 
in Appendix 3. We found 33 genes to be mutated in at least 5 patients. Only JAK2, CALR, 
TET2, ASXL1 and DNMT3A were mutated in >5% of patients (Figure 1A). As expected, 
JAK2V617F and MPLW515 mutations represented the vast majority of JAK2 and MPL 
mutations, while all CALR mutations were +1 base pair frame shift mutations in exon 9. 
Figure 3: Frequencies of recurrent somatic mutations and chromosomal changes. *In 
some cases it was not possible to confidently distinguish copy number neutral loss of 
heterozygosity from chromosomal loss, and therefore the the term loss of heterozygosity is 
used to denote both. 
Other mutated genes included those involved in cell surface receptor signalling (MPL, 
KIT, SH2B3, CBL, GNAS, GNB1), epigenetic regulators (EZH2, IDH1, IDH2, MBD1, 
MLL3, PHF6, STAG2), spliceosomal components (SRSF2, SF3B1, U2AF1, ZRSR2), 
members and regulators of the RAS pathway (NRAS, KRAS, PTPN11, NF1), 
transcription factors (NFE2, GATA2, RUNX1) and regulators of cell cycling and 
apoptosis (TP53, PPM1D, RB1, BCOR). 
The commonest chromosomal changes in MPN patients were (i) uniparental disomy 
(UPD) of chromosome 9p (16.1% of patients), (ii) gain or UPD of chromosome 1 (1.4% 
of patients) and (iii) loss of 20q (1.4% of patients) (Figure 3). 
3.2.2 Mutation burden 
Including phenotypic driver mutations, there were a mean of 1.3, 1.5 and 2.1 mutations 
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detected in patients with ET, PV and MF respectively, a trend consistent with previous 
observations. Chromosomal aberrations were detected in 8, 55 and 45% of patients 
respectively. 
Heterozygous JAK2V617F occurred as the only detectable driver mutation in 58%, 33% 
and 14% of patients with JAK2-mutated ET, PV and MF. Similarly, heterozygous CALR 
or MPL mutations were found in isolation in 56% and 30% of CALR/MPL-mutated ET 
and MF patients respectively. Excluding loss of heterozygosity (LOH) for JAK2V617F, 
33.6, 56.1 and 20.3% of JAK2-mutated ET, PV and MF patients respectively had no 
additional somatic drivers. LOH at CALR/MPL loci (chromosomes 19p and 1p 
respectively) was comparatively infrequent. 
Overall therefore, mutation burdens across ET, PV and MF are relatively low and, in a 
large number of cases, heterozygous or homozygous mutations of a phenotypic driver 
gene do not appear to require cooperating (coding) mutations to give rise to a disease 
phenotype, even in cases of accelerated phase disease (MF). 
3.2.3 Hotspot mutations and comparisons to other malignancies 
As noted above the vast majority of JAK2 mutations affected the V617 hotspot (V617I in 
one case and V617F in the remainder) and those of MPL largely affected the 515 hotspot. 
MPL W515 mutations were most commonly W515L or W515K (68 and 17% of cases 
respectively) but substitutions to W515R, A, G and S are were also seen. Non-canonical 
mutations of JAK2 and MPL are discussed in section 3.2.4. 
NRAS, IDH1 and 2, SRSF2, SF3B1 and GNB1 were also exclusively or highly enriched 
for hotspot mutations with those affecting IDH1, IDH2, SRSF2 and GNB1 restricted to 
single hotspots previously reported in myeloid malignancies (R132, R140, P95 and K57 
respectively). Additionally DNMT3A R882H/C mutations constituted 26% of the 
mutations of this gene. 
As has previously been reported in AML and MDS, as well as malignant melanoma, 
NRAS mutations predominantly affect either G12/13 or Q61. Data from the COSMIC 
database203 (restricted to these hotspot regions) reveal that G12/13 mutations predominate 
in AML, MDS, JMML and MPN/MDS-overlap cases (73-93% of samples, n=1586). 
Interestingly, the converse is true in malignant melanoma (n=1838) and plasma cell 
myeloma (n=184) where Q61 hotspot mutations predominate (88 and 78% respectively). 
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In contrast, no cases of Q61 mutations were seen in this cohort, although two cases had 
mutations affecting A59 and G60 (mutations affecting these amino acids were observed in 
approximately 6% of MPN/MDS-overlap cases from the COSMIC database but were seen 
in <1% in the other conditions assessed) while all remaining cases had G12D mutations. 
SF3B1 mutations were also almost entirely restricted to two hotspots – K700 (K700E in 
13 cases) and K666 (K666N/Q/R/T in 20 cases). Data from the COSMIC database reveal 
that cases with MDS (whether with ringed sideroblasts or not, n=560) and CLL (n=180) 
predominantly carry mutations at the K700 rather than the K666 hotspot (approximately in 
a ratio of 80:20), whereas the ratios seen in AML (52 vs. 56 cases) and in this cohort are 
skewed more towards the K666 hotspot. 
These finding of mutations at known hotspots in these genes serves to validate the 
sequencing and variant filtering methodology used here, but also suggests that mutation at 
different hotspots of NRAS and SF3B1 may have different phenotypic consequences 
across myeloid and other malignancies. 
3.2.4 Non-canonical JAK2 and MPL mutations 
Complete coding sequence analysis of JAK2 and c-MPL identified non-canonical variants 
in 67 cases, affecting 18 amino acids in JAK2 and 12 in MPL, of which 6 and 4 sites 
respectively had recurrent mutations. Although the somatic and oncogenic nature of these 
variants was not necessarily clear for a number of these cases, a number of variants appear 
to be of potential interest (Figure 4): 
(i)! JAK2 R683G and E627A were identified as the sole detectable mutation in two ET 
patients, one of whom presented in childhood. Both have been reported in acute 
lymphoblastic leukemia (ALL) where they result in JAK2 constitutive activation. 
(ii)!  JAK2R867Q/W was identified in 2 ET patients, again in the absence of any other 
phenotypic driver mutation, and has previously been associated with familial 
thrombocytosis23. Variant allele frequencies did not allow differentiation between 
germ-line or somatic acquisition in these cases. 
(iii)! MPL S505N and MPL S204P were identified in 5 and 6 ET patients respectively 
and have been reported previously as somatic phenotypic driver events in ET48-50. 
In 9 of these 11 cases, there were no other phenotypic driver mutations. 
Additionally, MPL S204P co-occurred with UPD affecting chromosome 1p in two 
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cases, further suggesting an oncogenic role for this variant. 
(iv)! JAK2 N1108S (found in 12 cases), R340Q (5), R564L (3), MPLY591D (3) and 
R592Q (3) have been reported in JAK2/MPL-unmutated MPNs49. However, in this 
cohort these variants more commonly occurred alongside canonical phenotypic 
driver mutations. 
(v)! JAK2 I951T (found in 6 cases) has not previously been reported as a somatic or 
germ-line variant. 5/6 cases carried JAK2 V617F mutations, and 4/6 cases had a 
PV phenotype. As this variant was restricted to the Florence cohort, this raised the 
possibility that I951T was a rare SNP, potentially enriched in Tuscany, and further 
analysis was carried out by Dr Guglielmelli on these patients, suggesting this was 
indeed a germ-line variant. 
Because of the unclear somatic and/or oncogenic nature of a number of these non-
canonical mutations, only patients with MPL W515/S505/S204 or JAK2V617F/Exon12 
mutations were classified as MPL- and JAK2-mutated respectively for subsequent 
analysis. 
Figure 4: Locations of non-canonical mutations of non-canonical variants found in JAK2 
and MPL. Marker shapes denote the phenotype of the patient the mutation was found in, 
and colours denote the presence of additional JAK2, CALR or MPL mutations. 
3.2.5 Novel mutations in PPM1D and MLL3 
Protein phosphatase Mg2+/Mn2+ dependent 1δ (PPM1D), also known as wild-type p53 
induced phosphatase (WIP1), is a serine/threonine protease that acts as a regulator of the 
DNA damage response. Frame-shift and nonsense mutations in the terminal exon of 
PPM1D have been detected in tumours of the central nervous system, as well as in blood 
from both patients with breast/ovarian tumors220,221 and healthy ageing individuals with 
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clonal hematopoiesis222,223. Some reports have suggested that these mutations may be 
germ-line. Protein truncating exon 6 mutations have been found to confer a longer half life 
to the protein, pheno-copying TP53 mutation, with lack of cell-cycle arrest in response to 
DNA damage. 
We identified PPM1D mutations in 38 patients (1.9%) with a similar distribution to those 
reported in solid malignancies (Figure 5), and where possible these were confirmed on 
Sanger sequencing. Genotyping of single-cell derived colonies (Figure 5A), as well as 
mutation timing analysis (discussed in 3.4.1) demonstrates that PPM1D can occur 
secondary to JAK2. 
In 10 patients, PPM1D mutations were identified in a later sample post trial entry and 
were not present at the earlier time point. All these patients had intervening exposure to 
hydroxycarbamide. Of 17 patients where PPM1D mutations were detectable in the earliest 
sample available, the time between diagnosis and sampling was significantly longer than 
in patients without PPM1D mutations. 12 of the 17 patients had received 
hydroxycarbamide before the earliest sample was obtained. However, PPM1D mutations 
were also detected at, or within a month of, diagnosis in 20 cases, and in one case in a 
sample that was taken 7 years after diagnosis with no hydroxycarbamide exposure.   
Figure 5: Mutations detected in PPM1D. Figure A shows their restriction to the terminal 
exon. Marker shapes denote the phenotype of the patient the mutation was found in, and 
colours denote the presence of additional JAK2, CALR or MPL mutations. B and C show 
examples of clonal hierarchies, where PPM1D mutations were found as the sole mutation, 
together with a wild type clone, or were found subclonal to JAK2 mutations. 
Mutations in MLL3 (Figures 1A and Table S3) were detected in 20 patients (1.0%, of 
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whom six had ‘triple-negative’ MPN), and were exclusively nonsense or frame-shift 
mutations, as have been reported in AML224. Unlike PPM1D mutations, these were 
distributed throughout the length of the gene 
3.2.6 “Triple negative” patients 
Triple negative (TN) ET and MF are entities of particular interest, since it is often unclear 
in these cases what is driving the disease phenotype. Therefore genomic analysis has the 
potential to reveal novel phenotypic drivers in these patients. Conversely, comprehensive 
genomic analysis may fail to demonstrate a clonal marker, raising the possibility that, for 
that patient, the myeloproliferative phenotype is not driven by a clonal process. Instead 
myeloproliferation still may be cell-intrinsic, e.g. due to germ-line variation (as in the 
familial thrombocytoses/erythrocytoses or high affinity haemoglobin variants) or cell-
extrinsic, e.g. due to inflammation, Tpo or Epo hypersecretion, or other micro-
environmental changes. 
The majority (82%) of triple negative cases of ET had no detectable coding mutations in 
the set of 33 recurrently mutated genes, and most (67%) of the remaining patients were 
found to have only one mutation. 3 had non-canonical mutations of MPL (in one case 
associated with Chromosome 1p UPD), and 6 had non-canonical mutations of JAK2. 
MLL3 was the most frequently mutated gene of those with a clonal marker (n=6). PPM1D 
(n=4), TET2 (n=3) DNMT3A (n=3), and 20q- (n=2) were also seen. Of these however, 
mutations of MLL3 are over-represented in TN ET cases (OR 3.0, 95% CI 0.95-8.5, p-
value 0.03), in contrast to TET2 and DNMT3A where they are under-represented in TN 
disease relative to JAK2/CALR/MPL-mutated ET cases (p-values <0.0001 and 0.006 
respectively). This raises the possibility that MLL3 mutations may themselves be 
sufficient to drive a clonal proliferation, rather than simply being bystander markers of 
clonal expansion due to another cause. 
Conversely, TN MF cases had an average of 1.5 mutations per patient (although 42% still 
had no detectable mutations), and the majority of those with a clonal marker had multiple 
mutations, most commonly ASXL1, NRAS, CBL, EZH2 and TET2. NRAS, in fact, 
appeared to be over-represented in TN MF cases compared to JAK2/CALR/MPL-mutated 
cases (OR 8.7, 95% CI: 1.69-40.4, p-value=0.005). Isolated SF3B1 was found in 2 cases. 
3.2.7 Putative drivers from targeted genome sequencing. 
31 additional genes were sequenced as part of the overlap of the TGS1 and TGS2 RNA 
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bait sets and were found to be recurrently mutated. These data were further interrogated in 
order to determine whether any putative drivers could be identified, retaining only 
missense/inframe mutations if present, and shown to be somatic, at the same site in the 
COSMIC database. A summary of a number of recurrently mutated genes is shown in 
Figure 6. By definition, the evidence for recurrent oncogenic mutations in these genes was 
more limited compared to the 33 analysed above, and there was a predominance of splice 
site mutations of uncertain significance. With the exception of ATRX, PTEN, EP300, 
BRAF, MLL5, DNMT3B, NOTCH2 and MLL, the VAFs of the variants found in these 
genes were predominantly >40%, suggesting a large number of private SNPs are still 
contained within this dataset. 
ATRX mutations, seen in 19 patients here, have been reported in patients with MDS who 
have acquired alpha-thalassaemia/HbH disease, however none of the variants here overlap 
with those seen in MDS225. EP300 and CREBBP mutations are also reported in 
haematological malignancy226, but again no overlap is seen with previously reported 
mutations, and the significance of these mutations is unclear. Overall, none of the genes 
shown in Figure 6 showed a convincing pattern of mutation or significant overlap with 
other myeloid malignancies. However this set may still include genes that it would be 
worth screening for in future sequencing studies. 
 
Figure 6: Candidate driver genes not included in analysis, showing the frequency of each, 
the proportion of missense, nonsense (*including frameshift mutations) and splice site 
mutations detected, whether they co-occurred with JAK2, CALR or MPL (J/C/M) or other 
mutations (“No mutations” signifies the mutation in this gene was the sole mutation 
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identified for that patient, whereas “TN” denotes triple-negativity but with other detected 
mutations), and the number of variants that had matches in the COSMIC database at the 
same amino acid or base pair. 
3.2.8 Putative drivers from whole genome sequencing. 
Samples from at least two time points, together with constitutional samples for 35 patients 
were submitted for whole genome sequencing by Dr Jyoti Nangalia and analysed using 
pipelines at the Wellcome Trust Sanger Institute. 
Initial analysis of this data was carried out as part of this study, but further analysis by Dr 
Nangalia is ongoing. Firstly, 4 patients were excluded from analysis as pile-up of hotspot 
loci demonstrated evidence of contamination of constitutional controls. Then, the VAFs of 
each mutation were compared between each sample and the respective constitutional 
control using Fisher’s exact testing and only those that were significantly higher were kept 
for further analysis. 39,990 mutations were detected that met this criterion, 15,577 
corresponding to a set of 3444 genes. Genes were then ranked according to number of 
mutations, the recurrence of specific variants, number of mutations relative to gene size, 
and relative VAF by patient. JAK2 and IDH2 mutations ranked highly according to these 
criteria. 
Other ranking genes included IKZF2, NKD2, ZNF733P and ARSD. A recurrent non-
coding mutation in IKZF2 was observed in two patients with VAFs of 6-28%. IKZF2 
encodes Helios, a member of the Ikaros zinc-finger protein family. While IKZF1 (Ikaros) 
mutations are reported in myeloid and lymphoid malignancies118, Helios mutations have 
not been described.  ZNF733P is a zinc-finger protein pseudogene, mutations of which are 
not previously reported in malignancy. Nkd2 is a regulator of the WNT-pathway that 
regulates TGF-alpha secretion (in epithelial cells) and has previously been shown to be 
dys-regulated in a number of malignancies, including AML227,228. NKD2 was mutated in 4 
patients with VAFs of 14-46%. 
3.3 Patterns of co-mutation 
3.3.1 Frequent pattern mining 
Identifying recurrent combinations of drivers is of potential interest as it may allow us to 
pinpoint cooperating events and potentially identify genetically-defined entities. In 
sections 3.3.1-3.3.3 we discuss sequential refinement of the assessment of patterns of co-
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mutations. 
Considerable patient-to-patient variability in driver mutations was evident, with 336 
different combinations of driver mutations and/or chromosomal events observed, of which 
only 33 combinations were recurrent in at least 5 cases.  Most commonly JAK2 mutations 
were an isolated event (n=614), CALR mutations were an isolated event (n=258), no 
mutations were detected (n=192), or JAK2 mutations were found in combination with 9p 
UPD or trisomy 9 (n=168). These four simple findings made up 61% of the examined 
cases. Heterozygous JAK2 mutations in combination with TET2 or DNMT3A mutations 
were the next most common findings (74 and 40 cases respectively). 
However, crude enumeration of the combinations of genomic events seen misses recurrent 
patterns. For example, JAK2+ASXL1+EZH2 (n=2), is counted separately to 
ASXL1+EZH2+7q- (n=1), when in fact the combination of ASXL1+EZH2 occurs 16 
times in the cohort (and is over-represented beyond the frequency expected by chance). 
For this reason, frequent pattern finding algorithms were used (implemented in the R 
package arules). The most frequent combinations of 2, 3 and 4 events are shown in Table 
6. 
This analysis provides a set of “rules” connecting the left-hand side (LHS) and right-hand 
side (RHS) expressions and a number of metrics describing them. These include (i) 
support (the proportion of all cases where the LHS gene combination occurs with the RHS 
expression), (ii) confidence (the proportion of times the LHS occurs with the RHS; 
namely the positive predictive value) and (iii) lift (the ratio of the observed support against 
the support expected by chance, i.e. if LHS and RHS are independent events). For 
example, in 3/5 cases of TP53 mutation and 5q-, 17p- is also seen. Namely the support is 
0.0015 (3 of the 2035) total cases and confidence 0.6, an association that occurs 
significantly more often than expected by chance (lift 64.3). 
Table 6: Most frequent and highest confidence combinations of 2, 3 or 4 co-mutations, 
with support, confidence and lift for associative rules between left-hand side (LHS) and 
right-hand side (RHS) expressions. 
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There are only 10 rules that have a support of at least 10 patients and confidence of >0.8. 6 
of these indicated the strong association of 9pUPD/trisomy 9 (alone or in combination 
with other mutations) with JAK2 mutations. A strong association between 1p UPD and 
MPL mutations is also highlighted, with a lift >20. The only other common (n>=10, 
confidence>50%) associations that do not include co-mutation with JAK2 are those 
between NFE2 mutations and 9pUPD/trisomy 9 (23 cases, confidence 0.56, lift 3.3), 20q- 
and CALR (17 cases, confidence 0.61, lift 3.0), and 17pUPD and TP53 mutations (11 
cases, confidence 0.58, lift 31.8). 
The frequencies of individual mutations and combinations of two mutations is available in 
an interactive format at https://cancer.sanger.ac.uk/mpn-multistage together with an online 
implementation of the prognostic modelling developed as part of this study (see Section 
4.4.10) 
3.3.2 Odds ratios, significance-based and Bayesian network analysis 
In order to quantify the strength of associations and their statistical significance, as well as 
account for negative associations, odds ratios and chi-squared/Fisher’s exact testing was 
used. Given there are 50 mutation and chromosomal events examined, there are 
50x50/2=1250 pairwise comparisons. Correction for multiple hypothesis testing was 
therefore performed, using Benjamini-Hochberg’s method to generate values for the false 
discovery rate (FDR). This identified 47 associations between genomic events with a FDR 
of <0.05, 8 of which were negative associations. These are shown in Figure 7A. 
LHS RHS Support*(n) Confidence Lift
9pUPD JAK2 0.169*(n=344) 0.99 1.54
TET2 JAK2 0.094*(n=191) 0.76 1.19
ASXL1 JAK2 0.045*(n=91) 0.71 1.10
DNMT3A JAK2 0.041*(n=83) 0.73 1.14
TET2 9pUPD 0.033*(n=68) 0.27 1.6
TET2 CALR 0.021*(n=42) 0.17 0.82
ASXL1 TET2 0.017*(n=34) 0.26 2.15
NFE2 JAK2 0.015*(n=31) 0.76 1.17
SF3B1 JAK2 0.015*(n=30) 0.70 1.08
JAK2,*TET2 9pUPD 0.033*(n=67) 0.35 2.06
JAK2,*ASXL1 TET2 0.012*(n=25) 0.27 2.24
JAK2,*NFE2 9pUPD 0.011*(n=22) 0.71 4.17
ASXL1,*9pUPD JAK2 0.011*(n=22) 1.00 1.55
DNMT3A,*9pUPD JAK2 0.008*(n=17) 1.00 1.55
JAK2,*DNMT3A TET2 0.007*(n=14) 0.17 1.37
JAK2,*EZH2 9pUPD 0.005*(n=11) 0.44 2.59
JAK2,*ASXL1 U2AF1 0.005*(n=10) 0.11 6.04
JAK2,*ASXL1 SRSF2 0.005*(n=10) 0.11 5.88
JAK2,*SRSF2 TET2 0.005*(n=10) 0.37 3.01
JAK2,*EZH2 ASXL1 0.005*(n=10) 0.40 6.31
JAK2,*TET2,*SRSF2 ASXL1 0.003*(n=6) 0.60 9.47
JAK2,*EZH2,*9pUPD ASXL1 0.003*(n=6) 0.55 8.60
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Independently, Bayesian network analysis was performed from this dataset by Nicos 
Angelopolous. This method allows the creation of a directed, acyclic graph representing 
the conditional dependencies between the 50 genomic variables (namely how the presence 
of a given mutation, or combination of mutations affects the probability of another 
mutation being present). This complemented the more basic analysis described above in 
that it allows “pruning” of the network. For example, JAK2 mutations were negatively 
correlated with 19pUPD, but this is likely to be solely due to the strong negative 
correlation between JAK2 and CALR mutations, and the strong association between 
CALR mutations and 19pUPD rather an independent association in its own right. Figure 
7B shows a network pruned utilising the dependencies derived from Bayesian network 
analysis. 
 
Figure 7: Networks of co-mutation or mutual exclusivity (A) Naïve model showing all 
significant associations found in pairwise comparisons, (B) Simplified network, 
encorporating the results of Bayesian network analysis. Co-mutation above frequency 
expected by chance in blue, below expected frequency in orange. 
This analysis identified several patterns: 
(i)! JAK2, CALR and MPL mutations were mutually exclusive (with only rare 
cases of co-occurrence), confirming the functional redundancy in their 
pathological mechanisms. 
(ii)! Multiple genes were strongly associated with LOH at their respective loci, 
including JAK2, CALR, MPL, TET2, EZH2 and CBL, suggesting that their 
A B
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increased mutant allele burden conferred a selective advantage. 
(iii)! Both truncating mutations in NFE2 and TET2 mutations significantly co-
occurred with LOH for JAK2V617F (9pUPD and trisomy 9), RUNX1 with 7q-
, and CALR mutations with 20q, suggesting that chromosomal deletions/UPD 
can confer an advantage in combination with other mutations via mechanisms 
other than increased allele burden/LOH. 
(iv)! ASXL1 mutations were commonly co-mutated with a variety of additional 
driver mutations in CBL, EZH2, SRSF2, U2AF1 and NRAS. Within the group 
of ASXL1-mutated patients, there was mutual exclusivity for SRSF2, EZH2 
and U2AF1. 
(v)! TP53 mutations co-occurred not only with 17p UPD/del but also 5q-. (17p with 
5q- occurs in all 3 cases with TP53 with lift 55 and p-value <0.0001, and 5q- 
occurs with TP53 mutations in 5/9 cases with lift 30.5, p-value <0.0001) 
(vi)! While the co-occurrence of TET2 with ASXL1 mutations (OR 2.8) and with 
9pUPD (OR 2.1) were seen significantly more frequently than expected by 
chance (p-value<0.0001), the finding of ASXL1 mutation with 9pUPD was 
rare in TET2-mutated patients (OR 0.24, p-value=0.01). 
3.3.3 Bayesian Dirichlet process based approach 
Although a number of patterns of clustering have been demonstrated in the above analysis, 
it remains unclear whether distinct genomic entities/classes exist within this data, into 
which patients can be classified, and if so how many such classes exist. 
To address this question, a Bayesian clustering algorithm, previously utilised in an AML 
cohort214, was used to identify possible genomically defined clusters. Since the number 
and size of any underlying genomic classes is not known a priori, potential solutions for 
the underlying distributions are “learned” by iterative random sampling (using a Monte 
Carlo Markov Chain method) from an underlying distribution of possible probability 
distributions (a Dirichlet distribution). The end result is a set of probabilities for the 
presence/absence of each mutation defined for each class, from which the probability for 
each patient belonging to each class (i.e. that their individual combination of mutations 
arising from each classes’ probability distribution) can be derived. 
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Figure 8: Individual patient probabilities for allocation to each of the 7 possible classes. 
Each vertical coloured line represents each of the 2035 patients as is coloured according 
to the probability of allocation to each class. Patients with no mutations (left) are shown 
as having an equal probability of being assigned to each class. 
This method consistently identified 6-7 classes. Unsurprising, patients with CALR and 
MPL mutations separate out into two classes, distinct from those with JAK2 mutations, 
and JAK2-mutated patients can be separated into those with homozygosity or not. Further 
classes were predominantly defined by either the presence of TP53 mutations, or two 
classes by the presence of mutations in spliceosomal or chromatin regulator genes, but in 
most cases additionally had mutations of JAK2, CALR or MPL. Finally, there remain a 
subset of patients with no detectable genomic changes (“myeloproliferation with no 
known driver mutation”), and those with changes not specific to a single class 
(“myeloproliferation with other driver mutation”). Figure 8 shows the probabilities 
allocated to each patient for belong in each of the 7 classes and Figure 9 shows the groups 
of mutations most specific for each group, together with their frequencies and associated 
odds ratios for co-mutation. 
As is evident from figures 8 and 9, classes are not entirely mutually exclusive and an 
individual patient’s allocation was not always clear-cut. This contrasts with a similar 
analysis carried out for patients with AML, where there were greater numbers of mutually 
exclusive lesions. In order to allow patient classification, we therefore devised a simple 
hierarchical classification system which prioritised the TP53-aneuploidy and splicing-
chromatin defined categories (which were less common, defined by specific sets of rarer 
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genomic events and potentially clinically relevant but were more likely to overlap with 
other categories) over the broader, less overlapping JAK2/CALR/MPL-defined groups. 
Figure 9: Heatmap showing frequencies of mutation/chromosomal change co-occurrence 
(top-left triangle) and odds ratios (bottom right). Black squares represent the sets of 
genomic events most correlated with the 7 genomically-defined classes. FDR – false 
discovery rate, FWER – familywise error rate. 
The classes were therefore defined as follows: 
•! MPN with TP53 disruption/aneuploidy – defined as the presence of TP53 
mutation, 17p del/UPD and/or 5q-.  (2.5% of patients) 
•! MPN with chromatin/spliceosome mutation – in some iterations this class was 
separated into two classes defined predominantly by {SRSF2, U2AF1, NRAS, 
CBL, GNAS, IDH1/2, STAG2, CUX1, BCOR, RUNX1, PHF6} and {EZH2, 
KRAS, ZRSR2, 4qUPD, 7qUPD/del, ASXL1}, which appears to be related to the 
mutual exclusivity of EZH2 and SRSF2, seen both in this and other datasets. 
However, ASXL1, 7qUPD/del and ZRSR2 were not infrequently present in 
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patients categorised into the {SRSF2, U2AF1 etc.} subgroup (see also figure 9). 
For simplicity, therefore we have combined this into one group. (14.2%) 
•! MPN with CALR mutation – defined as the presence of CALR mutation (and 
therefore enriched for 19pUPD), and/or 20q-. (17.2%) 
•! MPN with MPL mutation - defined as the presence of MPL mutation, and 
enriched for 1pUPD. (2.6%) 
•! MPN with homozygous JAK2 or NFE2 mutation – defined as the presence of 
JAK2 mutation in conjunction with 9pUPD or trisomy 9 and/or NFE2 mutation. 
This group was additionally enriched for TET2 and PTPN11 mutations and 
trisomy 8. (13.5%) 
•! MPN with heterozygous JAK2 mutation. This was the commonest class – 
38.4% 
•! Myeloproliferation with no known driver mutation (9.4%) or 
Myeloproliferation with other driver mutation/unclassifiable (2.2%). 
3.4 Relative timing of individual mutations 
We determined order of mutation acquisition for 271/671 patients harbouring multiple 
mutations using variant allele fractions corrected for copy-number change. Mutations in 
MPL, CALR, SF3B1 and DNMT3A were more frequently early events, while NRAS, 
KRAS, NFE2, PPM1D and TP53 were typically late events (Figure 10). Mutations in 
JAK2 were more variable, coming first in a given pair in 34% of cases. 
We also assessed 330 patients at multiple disease time-points (median interval 7.7 years). 
Late acquired mutations were identified in 29 patients, suggesting in general the number 
of oncogenic mutations remains relatively stable following presentation. These 29 late-
acquisition mutations involved PPM1D (n=10), TP53 (n=3), TET2 (n=7) and NFE2 (n=2), 
corroborating results from the single time-point analysis (Figure S3). Furthermore, 
patients with NFE2, TP53, KRAS, NRAS, ZRSR2, U2AF1, SRSF2 presented with these 
mutations over the age of 60 in 58, 59, 71, 72, 80, 82 and 89% of cases respectively, in 
contrast with only 33% of CALR-mutated patients. 
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Figure 10: Bradley–Terry model derived estimates of the overall timing of mutation 
acquisition. The horizontal axis shows the log odds of a gene occurring second in a gene 
pair. For example, as compared with JAK2(V617F), PPM1D mutations have a log odds of 
1.45 and therefore are e1.45=4.3 times more likely to occur second in the pair. Any pair of 
genes can be assessed in this manner by calculating the exponential of the difference in 
log odds for gene A and gene B. The error bars indicate quasivariances. 
3.5 Associations between germ-line variants and somatic variations 
3.5.1 JAK2 46/1 haplotype 
62 germ-line SNPs known to be associated with variation in haematological parameters 
and/or with risk of acquiring MPN or MPN-associated mutations (and were adequately 
covered across the entire cohort) were genotyped. Testing for associations between these 
SNPs and either somatic mutations or phenotype (discussed later) was carried out in a 
similar method to that described above. This data however carries the caveat that in some 
cases heterozygosity for an allele may erroneously be called as a homozygosity due to 
UPD, since for the vast majority of cases only tumour (full blood/granulocytes, rather than 
constitutional) samples were available. For this reason, only associations that held for 
presence/absence for an allele overall were investigated further, and, where possible the 
precise genotype was interrogated using adjacent heterozygous SNPs (which would 
similarly be expected to be affected by the presence of UPD). 
Pile-up of the 46/1 tag SNP rs12340895 demonstrated the presence of the G allele in 70% 
of JAK2-mutated cases, 66% of MPL-mutated cases, 54% of CALR-mutated cases and 
42% of triple-negative cases, in comparison to a prevalence of 42% in the general 
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population. Relative to the allelic distribution for 1000 genome patients (n=2504 in total, 
503 from European cohorts), therefore, the G allele was enriched not only for JAK2-
mutated cases (p-value<0.0001), but also for MPL- and CALR-mutated cases (p-values 
0.005 and 0.02 respectively in comparison to European controls)197,210. Associations 
between JAK2 or MPL mutations and JAK2 46/1 haplotype have been previously reported 
but one study failed to show an association for CALR229. However, this study only 
included 22 sporadic CALR-mutated cases and 270 controls and therefore may have been 
insufficiently powered to detect an association. 
 
Figure 11: Proportions of patients with GG/CG/CC genotypes of rs12340895 
(corresponding to 46/1 haplotype) in this cohort (subdivided by phenotypic driver 
mutation) and control populations. 1000g=1000 genomes project197. 
 
Further analysis restricted to JAK2-mutated cases additionally reveals a strong association 
between JAK2 haplotype and 9pUPD with prevalences of 15, 25-27 and 41-48% for cases 
with CC, CG and GG genotypes respectively (CG/GG genotypes cannot be definitely 
determined for 25 cases, which have complete loss of heterozygosity for 9p, since 
genotyping is carried out on blood samples alone). OR for 9pUPD and the presence of the 
G allele is 2.52 (95% CI: 1.8-3.6, p-value <0.0001) and 9pUPD occurs on the G allele 
chromosome in 92% of heterozygous (CG) cases. This result raises the possibility that 9p 
carrying the JAK2 46/1 haplotype has an increased likelihood of undergoing mitotic 
recombination resulting in loss of heterozygosity230, that acquired homozygosity for a 
JAK2 mutation specifically in the context of the 46/1 haplotype provides an additional 
clonal advantage, or that homozygosity for the JAK2 haplotype itself provides an 
advantage in a JAK2-mutated context. However, no correlation was found between the 
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length of 9p affected by LOH or the size of the homozygous clone, and presence of the 
46/1 haplotype. It should be noted that the association demonstrated here is not explained 
by independent bi-allelic acquisition of JAK2 in JAK2 46/1 homozygotes, although this 
occurrence is theoretically possible. 
Collectively therefore, these results argue against hypermutability of the JAK2 46/1 
haplotype (increasing the probability of JAK2V617F/exon 12 mutations) as the sole 
mechanism underlying its association with MPN susceptibility, suggesting that presence of 
the haplotype may increase the incidence of 9p LOH or affect its frequency, and provide a 
clonal advantage to, or indirectly influence the risk of development of, CALR- or MPL-
mutated clones. 
3.5.2 Other germ-line-somatic associations 
A number of loci on chromosome 9p, beyond those defining the 46/1 haplotype, have been 
associated with haematological parameters, and therefore were genotyped in this study. 
Some of those assessed, including rs10974900, have high linkage disequilibrium with 
46/1-defining SNPs and therefore share similar associations. 
rs409801(T/C), an inter-genic variant telomeric to JAK2, has been correlated with platelet 
counts, with higher counts seen with the C allele206.  The frequency of 9pUPD in JAK2-
mutated patients was found to be positively correlated with the presence of the TT 
genotype (OR: 1.9, 95% CI: 1.4-2.5, p-value<0.0001), a correlation that remained 
significant after correction for JAK2 haplotype and diagnosis, and 9pUPD more 
commonly occurred on the T allele in heterozygous (CT) cases (59%). 
 
rs741959(C/G), an inter-genic SNP located on chromosome 1p adjacent to TAL1205, was 
found to correlate with the presence of 1pUPD. The GG genotype was present in 63% 
(12/19) of MPL mutated cases with 1pUPD, compared to 33% of MPL unmutated-cases or 
heterozygous MPL-mutated cases, as well as in the 2 MPL-unmutated cases displaying 
1pUPD (in one case in the presence of the MPL R592Q variant). However, this association 
may still be spurious, since the observed fractions of both CC and GG genotypes are 
increased in cases of 1pUPD. 
As with the case of the 46/1 haplotype, these cases hint at a clonal advantage arising from 
homozygosity for particular germ-line variants, or towards an influence of these variants 
on the risk of phenotypic driver mutation or mitotic recombination leading to LOH 
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occurring. 
3.6 Discussion and Future work  
This large-scale sequencing study demonstrates recurrent mutations in a set of 33 genes, as 
well as chromosomal gains, losses and copy-number neutral loss of heterozygosity across 
14 chromosomes. The frequencies of these mutations and chromosomal changes, when 
ranked, fall rapidly such that only 4 genes were recurrently mutated in more than 5% and 
over half are seen in <1% of cases. This long tail of mutations reflects previous 
sequencing studies seen in MPN (Figure 12A) other myeloid malignancies, and well as 
other cancers, and in fact follows a distribution similar to that described by Zipf’s law231 
(Figure 12B). Although the data only approximate to a power law, it is intriguing to note 
that the curve for MPNs falls more steeply than other malignancies, a relationship that is 
held across this dataset and data from COSMIC203, with a similarly steep slope seen with 
CML. 
Figure 12: Frequency of mutations plotted against mutation rank (by frequency) plotted 
on log-log scale, for different MPN subtypes as well as for other haematological and solid 
organ malignancies. 
This likely reflects the fact that MPNs can be driven by a small pool of phenotypic driver 
mutations (predominantly JAK2 and CALR) that are found in the majority of cases, and 
that for a given individual only a small number of mutations are detected (a median of 1-
2). This argues against the requirement for additional mutations to counteract the lack of a 
stem cell advantage of a JAK2- or CALR-mutated clone in order to sustain disease; just 
over 50% of patients in this cohort were found to have an isolated JAK2, CALR or MPL 
mutation. However, the mutational burden of JAK2-homozygous cases is greater than that 
of JAK2-heterozygotes, with enrichment for TET2 and NFE2 mutations, suggesting this 
 68 
hypothesis may still hold in the case of homozygous JAK2. Despite this, it does not appear 
that the development of an MPN, as opposed, for example, to JAK2-mutant CHIP, is 
determined simply by the presence/absence of additional (exonic) mutations. Further 
population-wide studies are required to determine genomic or environmental factors that 
differentiate JAK2-mutant CHIP from isolated JAK2-mutant MPN. While the presence of 
the JAK2 46/1 haplotype was shown to correlate strongly with the presence of JAK2 
mutations, and also homozygosity for these lesions. 
This sequencing study has not revealed any clear novel phenotypic driver mutations that 
serve a similar role to JAK2, CALR or MPL in that they are frequently shown to be the 
sole molecular abnormality associated with clonal expansion and a disease phenotype. 
While SH2B3 is often reported as a phenotypic driver, sufficient in its own right to induce 
disease72, it was only seen in the absence of JAK2, CALR or MPL in one patient with ET, 
where it was found together with an MLL3 mutation. MLL3 and PPM1D are often found 
in conjunction with JAK2, CALR or MPL mutations, but were found in their absence in 
10 patients (and in isolation in 8), suggesting they may be sufficient to drive clonal 
expansion and result in an MPN phenotype. Validation of these findings is required in an 
independent cohort of MPN patients, and if confirmed to be recurrent, functional studies 
are needed to investigate the effects of MLL3 mutations on cell biology, in particular on 
stem cell expansion and differentiation. Further analysis of other sequenced genes (those 
only sequenced in either TGS1 or TGS2) and of the results of the whole genome 
sequencing data may also reveal further candidate driver mutations which, together with 
the candidates mentioned in Sections 3.2.7 and 3.2.8 (including ATRX, EP300, CREBBP, 
IKZF2 and NRD2) could be sequenced in future MPN patient cohorts. Unfortunately, 
Ikaros (IKZF1) was not well covered by either TGS1 or TGS2 panels, and should be 
included on further sequencing bait sets to determine whether mutations or microdeletions 
are present. 
 
Mutations in the panel of 33 genes analysed display distinct patterns of acquisition. Firstly, 
certain mutations tend to occur more often as initiating events, being present in the 
dominant clone in most cases. These include MPL and CALR, confirming previous 
results52,232. Others, including NRAS, NFE2, TP53 and PPM1D occur most often as 
secondary events. Furthermore, distinct patterns of co-mutation, clustering or mutual 
exclusivity were identified. JAK2, CALR and MPL were shown to be mutually exclusive 
(in all but a very small number of cases), reflecting both their sufficiency for generating a 
disease phenotype and functional redundancy. 
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Mutual exclusivity was also observed for EZH2, SRSF2 and U2AF1 (even though each of 
these mutations independently was enriched in ASXL1 mutated patients), a finding also 
seen in patients with AML and MDS106,189,214. This hints at functional redundancy again, 
and this is supported their similarities in co-mutated genes and by studies reporting 
reduced EZH2 expression in SRSF2-mutated cases, and demonstrated reduced H3K27 
methylation not only as a logical consequence of EZH2 mutation, but also in SRSF2- and 
U2AF1-mutated cases100,106. The phenotypic correlates of these mutations are discussed in 
a subsequent section, but work further exploring the overlap in epigenetic and 
transcriptional changes as a result of these lesions and their effects on cell biology, as well 
as the potential for functional synergy with ASXL1 mutations would be informative, 
particularly given their co-occurrence across MPNs, MDS and AML. 
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4. Impact of genomic variation on MPN phenotype 
4.1 Introduction 
Alterations in cytokine signalling pathways play a crucial role in the development and 
phenotype of myeloproliferative neoplasms. MPL and CALR mutations are understood to 
predominantly disrupt the thrombopoietin pathway and for this reason are found almost 
exclusively in patients with ET or MF, rather than PV47,52,51. In contrast, patients with PV 
exclusively carry mutations in JAK2, disrupting erythropoietin, as well as thrombopoietin 
and G-CSF, signalling pathways, and patients with PV are more likely to have mutations 
in exon 12, harbour a dominant JAK2 homozygous subclone and/or to have the JAK2 
mutation preceding a TET2/DNMT3A mutation26,40,122,123. A handful of mutations 
(including SRSF2, ASXL1 and EZH2) have been found more commonly in MF, and are 
associated with a poorer prognosis69,233,234. Beyond this however, clinical heterogeneity 
remains poorly explained, both in terms of presenting diagnosis (ET, PV or PMF) and, 
particularly in chronic phase disease, the risk of subsequent transformation to MF or 
AML. The comprehensive genomic analysis performed on this large cohort enables to 
further explore the associations between somatic and germ-line factors and diagnostic 
classification and transformation risk. 
More broadly speaking, the diagnostic categories of ET, PV and MF, are defined according 
to clinical, histological and genomic factors, but it is recognised that several of these 
features overlap across the three as well as with MDS/MPN overlap syndromes, MDS and 
AML. Therefore, an unbiased classification approach may offer novel methods for disease 
classification, potentially with reduced reliance on subjective criteria and greater 
reproducibility.   
4.2 Phenotypic associations of genomic variables 
4.2.1 Associations between mutations and subtype – MF vs. CP disease 
Using frequent pattern mining, pairwise odds ratios and significance testing, as described 
in sections 3.3.1-3.3.2 a number of somatic genomic changes were found to correlate with 
myelofibrosis rather than chronic phase disease (ET or PV) at the time of sampling. As 
expected, mutations of chromatin regulators and spliceosomal components, as well a 
number affecting signalling pathways (CBL, GNAS, NRAS, and 9p and 1p UPD leading 
to LOH for JAK2 and MPL mutations) were strongly enriched in patients with MF. 
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However, as noted above, a number of these mutations are commonly co-mutated, but are 
also more common in older patients. Logistic regression was therefore carried out to 
determine which variables, including germ-line variants, independently predicted for MF 
phenotype once age and gender are also taken into account. The results of this analysis are 
show in Figure 13A and confirm that the majority of these mutations retain independent 
associations with MF, together with increasing age, male sex and a small number of tested 
germ-line variants. 
 
Figure 13: Odds ratios associated with each variable for (A) myelofibrosis compared to 
chronic phase disease across whole cohort, and (B) PV compared to ET for JAK2 mutated 
chronic phase patients. P-values supplied derived from logistic regression modelling using 
all candidate predictors (including age as continuous variable). 
 
rs11104870(C/T) is an inter-genic SNP on chromosome located upstream of KITLG, 
which encodes KIT-ligand or stem cell factor (SCF), and shown to affect its expression, 
has been correlated with red blood and platelet counts in genome-wide association 
studies205. Presence of the T allele was associated with an MF phenotype (Figure 14A, OR 
2.0, 95% CI 1.1-4.0 for CT genotype, OR 2.9 95% CI 1.6-5.6 for TT genotype, p-
value=0.008 in multivariate analysis). The role of genomic variables in determining the 
risk of transition between disease states is addressed more comprehensively in Section 4.4, 
but intriguingly, rs11104870 genotype alone correlated with rates of myelofibrotic 
transformation from ET or PV, an association that remained significant after adjusting for 
age and gender (Figure 14B, HR for number of T alleles 2.13, 95% confidence interval: 
1.25- 3.63, p-value=0.005). As noted above, it is possible that this association is 
confounded by LOH at this locus, however only 4 cases of 12qLOH were identified in this 
cohort (1 genotyped as CT, 3 as TT). 
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rs13219787(A/G) is located on chromosome 6p within the histone 1 cluster and is shown 
to correlate with haemoglobin and mean cell volume205. Presence of the A allele was less 
common in patients with MF, with the GG genotype having an odds ratio of 3.9 for MF 
(95% CI: 2.1-8.0, p-value<0.0001 in multivariate analysis, Figure 14C), and was 
associated with an average increase in haemoglobin of 2.8g/l in linear regression analysis 
(p-value=0.04). 
Figure 14: Correlation of germ-line SNPs and MF phenotype. (A) rs11104870 genotype 
and MF phenotype at time of sample, (B) rs11104870 and MF transformation from 
chronic phase, (C) rs13219787 genotype and MF phenotype at time of sample. 
4.2.2 Associations between mutations and subtype – ET vs. PV 
Arguably more intriguing are the mechanisms underlying the manifestation of a PV rather 
than an ET phenotype in JAK2V617F-mutated patients. A similar analysis to that 
described in 4.2.1 was performed, with analysis restricted to JAK2V617F-mutated patients 
with either PV of ET (Figures 13B and 15). Unsurprisingly, as reported in previous 
studies, both JAK2V617F clone size (arbitrarily dichotomised at >50%, giving OR 8.1, 
95% CI: 5.9-11.3) and the presence of 9pLOH (OR 18.6, 95% CI: 12.6-28.1) correlated 
independently with a PV phenotype.  
Figure 15: Allele frequencies for rs12340895, rs11042125, rs9376092 and rs6198 across 
patients with PV or JAK2-mutated ET. 
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The 46/1 haplotype also correlated with the PV phenotype (p-value<0.0001); an 
association independent of 9pLOH in multivariate analysis and as such was maintained 
when analysis was restricted to patients without detectable 9pLOH (p-value=0.005), but 
not observed in those with 9pLOH (p-value=0.48). This further supports a role for the 46/1 
haplotype in MPN pathogenesis beyond its association with the presence of JAK2V617F 
alone. It is also worth noting that although numbers of JAK2-homozygous patients with 
ET are limited (n=44), and the resolution of the assessment of 9pLOH is also low, the 
length of chromosome involved (as determined by allele frequencies along 9p) appears to 
be shorter in ET than in PV or MF, but appeared to independent of JAK2 46/1 status 
(Figure 16). 
All six STAG2- and JAK2V617F-mutated patients had a PV phenotype, but this 
association did not reach statistical significance after correction for multiple hypothesis 
testing. NFE2 mutations and rs409801(T/C) also were enriched in patients with PV, but 
these associations did not reach significance in multivariate analysis, likely reflecting the 
co-occurrence of these variables with 9pLOH. rs11042125(T/A) however strongly 
correlated with phenotype205. This SNP is located on Chr11p and has been associated with 
a number of genes (AKIP1, C11orf16, NRIP3, ST5). The T allele has been correlated with 
lower haemoglobin concentrations in GWA studies, and in keeping with this is less 
frequently seen in patients with PV, with the TT genotype seen in in 21% of ET but only 
8% of PV cases (p-value <0.001 for the T allele). The T allele was associated with, on 
average, an increase in platelet count of 51x109/l and decrease in haemoglobin of 3g/l in 
linear regression analysis within this cohort (p-value=0.001). 
 74 
 
Figure 16: Density plot showing lengths (in base pairs) involved by 9pLOH, estimated 
using heterozygous SNP allele fractions in 44 ET, 174 PV and 92 MF cases. A denotes 
JAK2, B: CD274 (PD-L1), C: NFIB, D: interferon cluster. 
 
Previous studies have highlighted two other SNPs as potentially playing a role in 
determining PV vs. ET phenotype (Figure 15). Variants in the HBS1L-MYB inter-genic 
region have been correlated with MYB expression and with a number of haematological 
variables. One of these, rs9376092, was found to significantly correlate with an ET 
phenotype in JAK2-mutated patients140. In this analysis, the number of A alleles correlated 
with the probability of having an ET phenotype (p-value=0.0019), but did not remain a 
significant predictor in logistic regression including the other variables mentioned above. 
 
Finally, SNPs in the glucocorticoid receptor (GR) have previously linked to steroid 
responsiveness as well as alterations in the regulation of erythropoiesis. They therefore 
present attractive targets as a germ-line predictors for PV, and have been shown in some 
studies to play a role in this148,149. In this cohort, rs6198, associated with expression of a 
dominant negative isoform of GR-β, did associate with phenotype (p-value=0.019), but 
this did not reach statistical significance after correction for multiple hypothesis testing, or 
in logistic regression analysis. However, these findings do not preclude a role for these 
variants in certain contexts. 
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4.2.3 Associations with haematological parameters 
Linear regression analysis was performed to determine which variables were the greatest 
determinants of haematological parameters, taking into account age and gender. Increasing 
age was associated with a decline in haemoglobin concentrations and rise in white cell 
counts, while male sex was associated with higher haemoglobin and lower platelet counts.  
Mutations associated with an MF phenotype (in ASXL1, NRAS and components of the 
spliceosome), as expected, were associated with lower haemoglobin concentrations, but 
also in some cases also with lower platelet counts (NRAS and U2AF1) or raised white 
counts (SRSF2). TET2 mutations were associated with higher white cell counts, but 
particularly in cases of TET2 homozygosity. These findings illustrate that even for a given 
MPN subtype , the individual combination of demographic and genomic variables can 
fine-tune and individual’s phenotype. 
Table 7: Estimated change in haemoglobin (g/l), white cell count (x109/l) and platelet 
count (x109/l) associated with each variable, derived from linear regression modelling. 
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4.2.4 Phenotypic correlates of genomically defined sub-groups 
As would be expected from the above analysis, certain genomically-defined groups (as 
defined in 3.3.3) show enrichment for different phenotypes (Figure 17). In particular, the 
homozygous JAK2 or NFE2 mutation group is enriched for patients with PV, while the 
chromatin/spliceosome mutation group is enriched for patients with MF and the 
heterozygous JAK2 mutation group is more commonly associated with chronic phase 
disease rather than myelofibrosis (p-values <0.0001 in all cases). 
However, beyond this, genomically-defined groups have a number of features that 
transcend MPN subtype, suggesting that this genomic classification is able to pick out 
groups of patients with phenotypic similarities. 
The chromatin/spliceosome mutation group is associated with poorer overall survival, 
whether patients are classified as having myelofibrosis (p-value=0.004, with JAK2-
heterozygous group as comparator for all analyses) or chronic phase disease (p-
value<0.0001), and additionally picks out a subset of patients with chronic phase disease 
with higher risk of myelofibrotic or AML transformation (HR 5.4, p-value<0.0001 for 
each outcome). These findings are confirmed in an independent cohort of 151 CP patients 
(with sufficient genomic data to allow classification) and 190 MF patients: p-values=0.02 
for transformation from CP and <0.0001 for event-free survival in MF) 
Figure 17: Proportions of each genomically defined subgroup in patients with Essential 
thrombocytosis, Polycythemia vera and myelofibrosis 
The TP53 disruption/aneuploidy group is significantly associated with progression to 
AML regardless of MPN subtype (HR 10.4, p-value <0.0001 for chronic phase disease, 
HR 15.8, p-value=0.0006 in myelofibrosis), and highlights a subset of patients with 
myelofibrosis with poorer overall survival (HR 2.6, p-value=0.002). This was confirmed 
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in MF for the external validation cohort (p-value=0.002), but there were insufficient CP 
patients tested for and found to have a TP53 mutation in the external cohort to evaluate 
this association. 
In contrast, the group with no known driver mutation, appeared to carry a low risk of 
disease transformation or death, with only 2 AML and 1 MF transformation event 
observed during the follow-up of 183 patients in this group (p-values 0.0004 and 0.0023 in 
univariate analysis). However, these patients were significantly younger (median age 41.5 
years, compared to 58 years in the remaining groups, p-value<0.0001), and tended to be 
female (70.3% compared to 51.8% in the remaining groups, p-value<0.0001), and this 
prognostic association was not independent of age and sex. Despite this, this group 
appears to highlight a subset of patients with a more benign phenotype. Although in all 
cases there was convincing histological evidence for an MPN, a non-clonal cause for the 
MPN-like phenotype in these patients cannot be entirely ruled out in the absence of further 
clonality studies. 
It is also worth noting that Cox proportional hazards models using the Bayesian classes 
defined above alone, are as effective (in terms of correctly ranking patients by risk, i.e. 
their concordance, as discussed in more detail in Sections 2.8.6 and 5.9) as models that 
categorise patients according to MPN subtype (ET/PV/MF), with concordances of 64% 
respectively, and are superior in their ability to predict AML transformation (79 vs 75%). 
4.3 Clinical correlates of mutation order and clonal composition 
4.3.1 Phenotypic driver acquisition order and phenotype 
The above analysis addresses the correlates of specific mutations (as well as chromosomal 
changes and germ-line SNPs) and combinations thereof. However beyond the 
presence/absence of mutations, it is recognised that the order in which the mutations occur 
in can play a role in influencing disease phenotype, adding an extra layer of complexity 
into the association between genotype and phenotype. The presence of 2 mutations may 
correspond to 3 different orderings/clonal structures, of only 3 mutations to 16 possible 
orderings and of 4 to 125 possible orderings235. As the number of mutations increases the 
number of possible clonal structures increases super-exponentially (figure 18), which may 
in part explain how clinical heterogeneity outpaces genomic heterogeneity. Therefore, 
although MPNs are generally genomically simple, since only ~40% have 2 or more 
mutations, the order of these mutations may still play a significant role in determining 
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phenotype. 
Figure 18: Possible clonal structures in cases where 1, 2 and 3 mutations are detected for 
mutations denoted A, B and C. 
As noted above (sections 3.4.1-3.4.2), CALR and MPL tended to be the earliest 
mutational events when present in combination. In patients with multiple mutations, the 
timing of JAK2V617F acquisition was more variable. As mutation order of JAK2V617F 
relative to DNMT3A and TET2 mutations has been shown to correlate with MPN 
phenotype122,123, we assessed the effect of timing of acquisition of JAK2V617F globally. 
Of 480 JAK2V617F-mutated patients (as the sole phenotypic driver) with additional 
driver mutations, order could be evaluated in 140 (29.2%). JAK2V617F was preceded by 
at least one other mutation, most commonly in DNMT3A, TET2, ASXL1 or SF3B1, in the 
majority of patients with ET (74.4% - figure 19A). In contrast, JAK2V617F mutations 
were the earliest detectable event in most patients with PV or MF (70.5 and 62.3% 
respectively). 
9pUPD was detectable in 62.7% of JAK2-first cases but only in 18.5% of JAK2 second 
cases (p-value<0.0001). However, the association between JAK2-first cases and JAK2-
homozygosity does not appear to be the sole mechanism underlying the phenotypic 
differences: when analysis is restricted to cases without 9pUPD there is still a trend 
towards JAK2-second status in ET (Figure 19B, p-value=0.006). 
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Figure 19: Associations of phenotype (ET, PV, MF) with order of JAK2 mutation 
acquisition relative to partner mutations. (A) All JAK2-mutated patients with multiple 
mutations for whom order could be determined, (B) Subset of A without detectable 
9pUPD. (C) Subset of A with detectable9pUPD. 
This analysis includes relatively few patients but suggests some further potentially 
interesting associations between not only phenotype and the relative timing of JAK2 
mutations, but also with the specific additional mutated gene. 
Firstly, correlation of JAK2-first and PV and JAK2-second with ET appears to hold 
regardless of partner mutation, and this confirms previous reports regarding JAK2 vs. 
TET2 or DNMT3A, but also expands it to other partner mutations (Figure  20A and B). 
However, this does not appear to be the case for patients with MF, for whom there appears 
to be enrichment for JAK2 mutation-first, ASXL/EZH2 mutation-second status (Figure 
20C), while the timing of JAK2 relative to TET2/DNMT3A mutations follows a similar 
pattern to patients with ET. 
Secondly, the clonal hierarchy of JAK2 mutation acquisition following a DNMT3A or 
SF3B1 mutation appears to be have high specificity for ET: JAK2 was preceded by 
DNMT3A or SF3B1 in 23.3% ET cases in this subgroup analysis (making up 31.2% of all 
JAK2-second ET cases), compared to 3.7% of MF and 0% of PV. Together, these analysis 
suggest that whether JAK2 occurs as a primary or secondary event is not the only feature 
determining phenotype, but that the phenotypic associations also vary depending on 
partner mutation. 
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Figure 20: A. JAK2 patients with multiple mutations, compared to non-TET2 or DNMT3A 
mutations. B. TET2 and DNMT3A mutated cases only. C. EZH2 and ASXL1 mutated cases 
only. 
4.3.2 Clonal composition and phenotype 
One limitation of the above analysis is that it is restricted to patients with sufficiently high 
clonal fractions for each of the two mutations being compared and requires a significant 
difference in these fractions. It therefore does not include approximately 70% of the 
patients with multiple mutations who have either too low clonal burdens or similar 
fractions for each of the two mutations, or both. 
We therefore extended our analysis of JAK2-mutated patients more broadly by classifying 
patients into those where (a) the JAK2V617F is in the largest/dominant clone and the 
clone carrying the partner mutation is significantly smaller (red in figure 21), (b) 
JAK2V617F and the partner mutation are both in the dominant clone but no significant 
difference in clone sizes can be determined and therefore order of acquisition is 
undetermined (dark red) (c) JAK2V617F and the partner mutation are found in the same 
clone, but JAK2V617F is subclonal (dark blue), (d) the clone sizes of JAK2V617F and the 
partner mutation are such that biclonality cannot be excluded (light blue). 
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Figure 21: Clonal composition for (A) All JAK2 mutated patients (B) JAK2 relative to 
TET2, (C) JAK2 relative to DNMT3A, (D) JAK2 relative to ASXL1/EZH2. Colouring as 
documented in text. 
The results of this analysis largely confirmed those of the previous one. JAK2V617F was 
most frequently sub-clonal in ET (59.7%), but this included a much higher proportion of 
cases (27.3%) where both clones were small, order could not be determined and bi-
clonality could not be excluded. JAK2V617F occurred in the dominant clone (either with 
or without additional mutations) more commonly in PV and MF (81.2 and 73.3% 
respectively, p<0.0001) 
The ordering of JAK2 mutation acquisition relative to specific partner mutations was 
again confirmed as correlating with phenotype in this wider analysis. Specifically, 
subclonal JAK2 in the context of TET2 or DNMT3A mutations was much more common 
in ET than PV (p-values 0.0002 and 0.003 respectively), and ASXL1 and EZH2 were 
more frequently shown to be sub-clonal events in JAK2-mutated MF than ET or PV (55 vs 
21%, p-value 0.0005). 
4.4 Discussion and Future work 
Despite the relative genomic simplicity of MPNs, somatic mutations are here shown to 
significantly contribute to disease phenotype and natural history, and themselves 
demarcate distinct entities within the MPNs. These genomic entities show clear 
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phenotypic differences, and while not fully accounting for phenotypic heterogeneity 
across the MPNs, genomic classification offers a number of advantages over the 
traditional division into ET, PV and MF. In particular, genomic criteria are objective and 
reproducible, and to some extent reflect underlying disease biology, a feature that not only 
has the potential to further our understanding of disease mechanisms but may also 
facilitate the development or delivery of targeted therapeutic agents. 
Here we show that the phenotypic differences between chronic phase disease (ET/PV) and 
MF are strongly associated with: 
(a)! Mutations in a cluster of genes that correspond to the genomic group 
referred to above as the “chromatin/spliceosome” group and which 
include ASXL1 and EZH2, SRSF2, U2AF1 and ZRSR2. As discussed 
previously, there is some evidence that several of these mutations affect 
PRC2 function and H3K27 methylation and affect stem cell function100. 
Further work is required to elucidate the effects of these mutations on 
down-steam transcription and cell biology. 
(b)! Mutations or chromosomal changes associated with increased cytokine 
receptor pathway signalling, namely 1pUPD (in the context of MPL 
mutations), 9pUPD (in the context of JAK2 mutations), larger JAK2 
clones, CBL and NRAS mutations. 
(c)! Germ-line differences, including sex and a number of SNPs, including 
one associated with KIT ligand. 
The mechanisms underlying these associations remain unclear. One possibility is that the 
characteristic processes underlying the myelofibrotic phenotype, namely bone marrow 
fibrosis with resultant bone marrow failure, cytopenias and extra-medullary 
haematopoiesis, are natural consequences of myeloproliferation in the marrow, due for 
example, to increased secretion of pro-inflammatory, pro-fibrotic and pro-angiogenic 
signals, increase reactive oxygen species and bone marrow remodelling. This is in keeping 
with the correlation of myelofibrosis with increasing age. In this scenario, this process is 
occurring at different rates in different patients (with ET or PV, or in the absence of a 
clinically apparent MPN), and the presence of the factors described above (in a-c) either 
serves to accelerate the process or leads to an earlier presentation of MF due to more rapid 
development of cytopenias. Specifically, the set of mutations described in (a) are shown 
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here to be associated with anaemia, and in some cases with thrombocytopenia, and this 
may due to a direct haematopoietic defect, a hypothesis supported by their prevalence in 
MDS. 
A second (although not mutually exclusive) possibility is that these mutations (or germ-
line factors) are directly responsible for alterations in tumour biology that result in novel 
behaviour, which may include alterations in secretions of soluble mediators, that in turn 
drive fibrosis or angiogenesis. This in turn is what leads to the cytopenias seen with these 
mutations rather than a direct effect of the mutations on haematopoiesis. In order to test 
this hypothesis, more work is needed to determine which soluble factors correlate with the 
development/presence of fibrosis, and whether their secretion is correlated with particular 
patterns of mutation. This is further explored in chapter 6. 
We also explore the phenomenon wherein patients with the same point mutation in JAK2 
can have either an ET or PV phenotype. As is previously reported, PV is strongly 
correlated with the presence of a JAK2-homozygous clone. NFE2 mutations appear to be 
enriched in patients with homozygous JAK2, and therefore in PV, suggesting a possible 
synergy between the two. This is in keeping with the association of NFE2 overexpression 
with erythropoietin independence and increased erythropoiesis114. In addition to 
correlating with the presence of JAK2V617F, the 46/1 haplotype correlated with the 
presence of 9pUPD and independently with PV. Whether the presence of 46/1 haplotype 
itself increases the risk of developing 9pUPD or 9pUPD causing homozygosity for the 
haplotype has an additional advantageous role for the clone (or both) remains to be seen. 
Also intriguing are the findings that the length of 9pUPD, where present, appears to 
correlate with ET vs PV phenotype (discussed later), and the genotypes of germ-line SNPs 
(outside of 9p and correlated with blood counts in wider studies) also appear to influence 
the overall MPN phenotype. These findings also require confirmation in further studies, 
both in terms of larger scale, more comprehensive identification of germ-line variation 
(with particular focus on 9p), but also the functional consequences of these variants. 
This study also confirms, on a larger scale, the finding that patients with ET are more 
likely to have acquired JAK2 as a secondary event (for example, as a subclonal event 
within a TET2- or DNMT3A- mutated clone). A number of potential mechanisms may 
underlie these phenotypic associations, including cell-intrinsic differences in double-
mutant clones depending on mutation order, and alterations in the microenvironment 
induced by the first clone. Furthermore, in JAK2-first patients, the JAK2 mutation will be 
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present in all mutant cells, and (except in some cases with >2 mutations) will not be in 
competition with other mutant cells (e.g. a single TET2-mutated clone in a “TET2-first” 
case). A larger JAK2 clone size may itself be more likely to give rise to a PV phenotype, 
but also is likely to increase the chances of JAK2 homozygosity arising. This association 
is demonstrated in our data, with a greater prevalence of 9pUPD in “JAK2-first” cases. 
However, phenotypic differences are seen even in cases without 9pUPD, suggesting other 
mechanisms still may be implicated. 
These analyses still remain limited however, and do not allow us to fully explore the im-
pact of clonal composition on disease phenotype, since they only fully determine mutation 
order in a subset of patients and do not explicate the whole clonal structure. As shown in 
Figure 18 there is potentially a great deal of complexity in even patients with 2 or 3 muta-
tions. Ideally, this would be explored using single cell or single-derived colony approaches 
to determine (a) the true frequencies of each mutation order and the frequency of bi-
clonality, (b) the impact of this on phenotype, and (c) the effect of differing clonal propor-
tions (e.g. double vs single mutants). 
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5 Modelling of clinical outcomes in MPNs 
5.1 Introduction 
Broadly speaking, the aims of creating prognostic models are two-fold. Firstly, most 
modelling methods will provide an estimate for the effect an individual variable has on a 
patient’s risk of developing a particular outcome (death, disease progression or treatment 
failure, for example). This can provide important information regarding causality and 
therefore inform a better understanding of biological mechanisms underpinning disease 
processes. In the context of MPNs, two important outcomes are transformation of chronic 
phase disease to myelofibrosis, and AML transformation. While a number of studies have 
examined paired chronic phase and post-leukaemic transformation samples, and have 
examined the risk factors for AML transformation from MF, few have comprehensively 
examined genomic factors present pre-transformation in patients with ET or PV that may 
have a causal role in subsequent transformation to MF or AML. 
Secondly, prognostic models are clinically useful in that they allow us to estimate an 
individual’s risk which may then inform treatment decisions. For example, patients with 
MF are typically risk-stratified using the dynamic international prognostic scoring system 
(DIPSS)236 and the decision whether to treat conservatively or proceed to stem cell 
transplantation may hinge on this risk score. An important distinction here however is that 
variables may be present that provide useful predictive power without actually indicating a 
causal association – for example, anaemia is shown to be a predictor of poor overall or 
progression-free survival, but it is likely that this is because it is acting as a surrogate 
marker, for example for the degree of marrow failure or dysplasia. In this chapter, we 
examine a number of models and modelling methods in an attempt to both identify a set of 
variables that are likely to have a causative role in MPN disease progression, but also to 
build models that can best predict an individual patient’s risk. 
5.2 Evaluation of previously reported prognostic scoring systems 
1875 patients had clinical follow-up (median 7.8 years, range 1 month to 43.6 years, total 
>16000 patient years) and therefore the impact of genomic variables on overall survival, 
myelofibrosis- and AML-progression free survival could be assessed for these patients. 
For patients with myelofibrosis, a number of scoring systems have been developed to 
identify poor risk patients. The most commonly used of these are the international 
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prognostic scoring system (IPSS)237, dynamic IPSS (DIPSS)236 and DIPPS-plus238. More 
recently the Mutation-Enhanced International Prognostic Score System (MIPSS) has been 
developed239. Of these, only the latter two encorporate genomic variables, specifically the 
presence/absence of adverse cytogenetics and CALR and “high molecular risk” (HMR) 
mutations234. Unfortunately, it was not possible to compute these scores for the majority of 
the patients in this cohort, as data regarding blast percentage and constitutional symptoms 
were not available for the majority. IPSS and DIPSS were available for patients with MF 
from an external validation cohort, which is discussed later, allowing comparisons to still 
be made with these scoring systems. Two purely genomic classifications for patients with 
myelofibrosis have also been defined, one using only the CALR and ASXL1 mutation 
status240, the other using the number of HMR mutations (ASXL1, EZH2, IDH1/2, 
SRSF2), each dividing patients into 3 risk groups234.  More recently, the GIPSS 
(genetically inspired international scoring system) has also been proposed which includes 
CALR mutation type, ASXL1, SRSF2 and U2AF1 mutations and very unfavourable or 
unfavourable karyotypes, but this score was not addressed in this study241. 
 
Figure 22: Stratification of patients into high, intermediate or low risk groups according 
to (A) high molecular risk, (B) CALR/ASXL1 and (C) IPSET scores, as defined in the 
figure. Outcomes (overall survival, AML transformation and myelofibrosis transformation, 
for CP patients) are shown according to risk group. 
Figure 22 shows the survival curves for patients according to these two scores for patients 
with MF, demonstrating significant differences across these three groups using both HMR 
HMR$score
LOW * No$mutations
INT* One$mutation
HIGH * Two$or$more$
mutations
(ASXL1,$EZH2,$
IDH1/2,$SRSF2)
O
ve
ra
ll$s
ur
vi
va
l
M
F$
fre
e$
su
rv
iv
al
AM
L$
fre
e$
su
rv
iv
al
Time$from$CP$diagnosis$ (years) Time$from$MF$diagnosis$ (years)
p*value
=0.002
p*value
<0.0001
p*value
<0.0001
p*value
<0.0001
p*value
<0.0001
CALR/ASXL1
LOW:$CALR+$ASXL1*
INT:$CALR+$ASXL1+
Or
CALR* ASXL1*
HIGH:$CALR* ASXL1+
Time$from$MF$diagnosis$ (years)
p*value
=0.01
p*value
<0.0001
IPSET$score
2 points$ for:Age>=60
1$point$ for:
* White$count$>=11
* Prior$ thrombosis
LOW:0,$INT:1*2,$
HIGH:$3*4
Time$from$ET$diagnosis$ (years) Time$from$MF$diagnosis$ (years)
p*value
=0.1
p*value
=0.04
p*value
=0.003
p*value
<0.0001
p*value
<0.0001
LOW
INT
HIGH
LOW
INTHIGH
LOW
INT
HIGH
LOW
HIGH
LOW
INT
HIGH
HIGH
INT
LOW
LOW
INTHIGH
HIGH
INT
LOW
HIGH
LOW
INT
INT
LOWHIGH
HIGH
LOW
INT
LOW
INT
HIGH
INT
Chronic$Phase Myelofibrosis Myelofibrosis MyelofibrosisEssential$thrombocytosis
A B C
 87 
or CALR/ASXL1 for stratification for both overall survival and AML-progression free 
survival. Additionally, HMR stratification was a significant predictor of overall, AML- as 
well as MF-progression free survival for chronic phase patients, while CALR/ASXL1 
stratification was not informative (data not shown). 
There are few prognostic systems proposed for chronic phase, with most classifications 
geared towards prediction of thrombotic risk. The international prognostic score for ET 
(IPSET) has been proposed, and also stratifies patients into three risk groups, based on 
age, white cell count and history of prior thrombosis242. When used to stratify patients 
with ET in this cohort, significant differences in overall survival are seen, but IPSET 
poorly correlated with risk of MF or AML transformation. IPSET additionally 
significantly correlated with overall survival, as well as AML transformation risk in 
patients with MF, in keeping with the observation that age and white count are predictors 
of outcome in MF, and are sufficient to provide reasonable discrimination. 
These analyses serve to validate a number of pre-existing prognostic scores and suggest 
outcomes in this cohort are not strikingly dissimilar to those in other studies. The 
discriminatory ability for the HMR score in chronic phase patients, in addition to those 
with myelofibrosis, is an indicator that genomic variables may be of value in these patients 
as well, and may play a role in predicting not only survival but also disease transformation 
risk. 
However, while these existing models have clear utility and are both easy to understand 
and implement they have a number of limitations (discussed below). In order to address 
these issues as much as possible, we retained a large number of variables, without 
dichotomisation of continuous variable (where possible), and fitted models for each 
disease state transition. 
5.3 Assessment of relevance of clonal versus sub-clonal mutations 
 Since genomic variables are incorporated into our genomic classification as either 
‘present’ or ‘absent’ regardless of clone size, patients may be classified into a TP53 group, 
for example, with only a small TP53 clone. This may be problematic when exploring the 
prognostic impact of these mutations, since a small clone is treated the same as a large one 
despite potentially having different clinical consequences 
To assess the importance of clone size for clinical outcomes (and therefore whether to 
include this information in the multistate models), we modelled the impact on survival and 
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disease progression of mutation clone size (measured as a proportion of total tumour clone 
size in the sample), taking into account age, sex and MPN subtype. Of ASXL1, TET2, 
EZH2, CBL, SRSF2 and TP53, significant differences were only seen with ASXL1, with 
differences in overall survival (p-value 0.003), and AML transformation risk (p-value 
0.01). 
This observation that would require further validation given the relatively weak strength 
of association and the multiple hypothesis testing. 
5.4 Univariate analyses 
Across the MPNs different disease transitions are possible and we sought to model each 
separately. These were as follows: 
•! Death from chronic phase disease (with censoring at transformation to MF/AML) 
•! Death from myelofibrotic phase disease (with censoring at transformation to AML) 
•! Transformation from chronic phase disease to myelofibrosis (with censoring at 
transformation to AML or death from another cause) 
•! Transformation from chronic phase disease to AML (with censoring at 
transformation to MF or death from another cause) 
•! Transformation from myelofibrotic phase disease to AML (with censoring at death 
from another cause) 
ET/PV/MF status was used as a time dependent variable, which could therefore change if 
a patient transformed to MF, which also allowed these transformed patients to be 
encorporated in the models used for MF overall survival or AML transformation risk. As 
an initial overview, table 8 shows the hazards ratios (restricted to those >2) for genomic 
variables significantly (alpha=0.05) associated with each outcome in univariate analysis. 
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Table 8: Hazards ratios for significant covariates in univariate analyses for overall 
survival in CP, CP to MF transformation. CP to AML transformation, overall survival in 
MF and MF to AML transformation 
This superficial analysis suggests a number of new candidate prognostic markers. In 
particular, NRAS, CBL and TET2 appear to be strongly associated with poor outcomes 
generally, and TP53 with AML transformation. Furthermore it suggests that different 
variables may be important in different disease states or for different disease transitions. 
5.5 Stepwise variable selection 
Proportionality was tested for each continuous variable and there was no evidence of 
violation of the proportionality assumption. Therefore Cox proportional hazards modelling 
was used to fit models for each disease status transition.  
One danger of this approach, given the large number of variables, is of over-fitting. One 
suggested approach is that of variable selection, which has the further utility of 
simplifying the model and making it more parsimonious and easier to implement in 
clinical practice. This was performed using backward variable selection using the 
Bayesian Information Criterion (BIC)243 at each variable selection step as the criterion for 
whether removal of a variable improved/worsened the model. The minimal model in each 
case was required to include age, to avoid confounding for age. Table 9 shows the 
 90 
variables selected for each model. 
 
Table 9: Variables retained in variant selection modelling using Bayesian information 
criterion at each selection step for outcomes shown in Table 8. 
These data support poor risk associated with increasing age, leucocytosis and SRSF2, as 
well as NRAS and TP53, regardless of whether the patient is in chronic phase or not. 
Thrombocytosis, leucocytosis, splenomegaly, TET2, NFE2 and PHF6 mutations and 
14qUPD are additionally identified as candidate predictors for myelofibrotic 
transformation. 
Even restricting risk stratification to whether any of these high-risk mutations are present 
or not provides good discrimination for both MF and AML transformation from chronic 
phase with HRs of 5.0 (95% CI: 3.0-8.2) and 5.7 (95% CI: 4.7-8.7) respectively, 
confirming that genomic-based risk stratification outside of the context of myelofibrosis is 
possible. 
5.6 Random effects Cox proportional hazards modelling and variance contributions 
Variable selection however, is thought by many to be a flawed statistical method since it 
results in loss of information available in a fully-fitted model and to an over-estimation of 
effect sizes and under-estimation of p-values, among other reasons244. 
 To better fit a model and reduce over-fitting, an alternative to variable selection is using 
“shrinkage” methods, which impose restrictions on effect sizes to ensure they are not over-
estimated. Methods include lasso and ridge regression.  The method used in this analysis, 
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using random effects, is similar to a ridge regression and was developed by Dr Moritz 
Gerstung. Implementation was carried out by Drs Moritz Gerstung, Rob Cantrill and 
Jacob Grinfeld. 
The methodology of random effects Cox proportional hazards models has previously been 
reported in the context of AML215. In brief, these hierarchical models require the 
partitioning of co-variates into groups (in this case: genetic, cytogenetic, clinical, 
demographic and nuisance/cohort), and assume a normal distribution for the parameters in 
each group. This results in a ridge-type regularisation reducing the bias that would result 
from using a large number of covariates. 
 
Using ET/PV/MF as time-dependent variables, and after standardisation of continuous 
variables (so that coefficients can be more directly comparable), individual fits were again 
created for each disease transition. Cross-validation (described later) suggested over-
fitting particularly for the MF to AML fit (only 31 transformation events), and therefore a 
combined model for both CP and MF patients was ultimately used (86 transformation 
events). Alternative models were also made that included gene-gene interactions, and 
dichotomisation of JAK2, CALR, ASXL1, TET2 and DNMT3A into high and low allele 
fractions, but these did not show significant improvement in prognostic accuracy. 
 
Figure 23 shows the four disease transitions modelled and the contributions of each 
variable to the overall variance of the calculated risk for each model. This calculation 
accounts not only for the model co-efficient (hazards ratio) for a given mutation, but also 
for the frequency of that mutation. This is particularly useful for the creation of a 
prognostic system, as there maybe strongly significant variables, only found very rarely in 
a cohort, and conversely other variables only associated with a small increased risk may 
still be important to test for if they occur commonly (TET2 and DNMT3A may be 
examples of this). 
 92 
 
Figure 23: Individual fits for disease state transitions. Pie charts show variance 
contributions for each variable. Variables in blue are associated with hazards ratios >2. 
 
This analysis suggests that genomic variables have a minimal contribution to predicting 
non-progression related mortality risk in myelofibrosis once age, sex and blood counts are 
taken into account (although ASXL1, NRAS, TET2, CALR mutations may contribute), 
and that they have even less of a role for non-progression mortality prediction in chronic 
phase. However, genomic variables strongly contribute to AML transformation risk for CP 
and MF phase patients and for MF transformation from CP. Confirming the results of 
previous analyses from this cohort and previously proposed prognostic models, ASXL1, 
EZH2, IDH2, SRSF2 and U2AF1 are associated with poor prognosis/disease 
transformation. Additionally, prognostic roles for NRAS, TP53, TET2, DNMT3A, CBL, 
NFE2, RUNX1 and GNAS are identified and the presence of either CALR or MPL was 
shown to be predictive for MF transformation in ET (HR 2.4, 95% CI 1.4- 4.3, p-
value=0.002). 
5.7 Generation of multi-state model 
In isolation, these models can therefore provide information on the contribution of each 
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variable to the risk of each disease state transition. In clinical practice however, it would 
not be practicable to calculate 2 or 3 individual predictions for each patient and it is not 
evident how these predictions should be integrated. We therefore derived an integrated 
multi-state prediction model using the schema shown in Figure 23. At each time point 
(selected as roughly every 15 days, 1/25th of a year), a patient’s risk of transitioning into 
another disease state is calculated and this process is carried out iteratively over a 25 year 
period. Patients are either defined either as (a) starting in chronic phase, and therefore at 
each point have a certain probability (defined according to their individual risk calculated 
from the individual random effects Cox proportional hazards models) of transitioning to 
death or AML (terminal states) or to MF, from where they can also transition to death of 
post-MF AML or (b) start directly in MF and can transition to death or AML. AML itself 
was a terminal state - in other words the risk of further transition from AML to death was 
not calculated, both because of the limited data available to do so, but also because this 
was not felt to be essential from a clinical perspective. (This algorithm was developed by 
Dr Moritz Gerstung with implementation by Dr Rob Cantrill, and further modification and 
downstream data processing by Dr Jacob Grinfeld). 
This algorithm thus generates a 366x5 (for patients starting in CP) or 366x2 matrix (for 
MF) for each patient, where 366 corresponds to 1/25th year “snapshots” over a 25 year 
period from diagnosis together the probability of being in the following states: Death from 
CP, Death from Post CP-MF, Death from Post-CP AML, Death from AML from post-CP 
MF, Alive in Post-CP MF (for CP) or Death from MF (as starting state) or Death from 
post-MF AML (for MF). The probability of being alive without transformation at an 
individual timepoint is therefore calculated as 1 minus the sum of these (5, or 2, depending 
on starting diagnosis) probabilities. Predictions generated are presented using leave-one 
out cross-validation (i.e. for each patient, the model was built on the remaining patients to 
avoid over-fitting). 
Examples of predictions generated in this manner are shown in Figure 24. Figure 25 
shows predictions of event free survival for equally-sized subsets of patients with either 
CP or MF, compared to the overall outcomes of these groups. This method has a number 
of advantages – it integrates the information from the 4 individual predictive models into 
one set of predictions; it provides patient specific predictions using the full dataset 
(without dichotomisation of continuous variables); and it allows predictions to be obtained 
for     individual outcomes for specific time-points. 
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Figure 24: Personalised predictions of patient outcome. Each of the tiles represents the 
personalised predicted outcome of an individual patient. Two tiles (A) and (B) have been 
enlarged for illustrative purposes. The top left panel (A) depicts the predicted outcomes of 
a 79 year old female patient who presented with ET with haemoglobin 104g/l, white cell 
count 8.4x109/l and platelet count of 2300x109/l, mutations in CALR, SRSF2, IDH2 and 
18q LOH. The varying probabilities of each of these transitions can be judged from the 
vertical axis and their respective Kaplan-Meiers over a 25 year time period shown along 
the horizontal axis. The labelled black curve shows the predicted Kaplan-Meier curve of 
overall survival. The patient in (A) transformed to myelofibrosis (MF) and died within 5 
years, as indicated by the line and circle in the bottom left.  Panel B shows the predicted 
and actual outcome of a 57 year old male patient diagnosed with MF with Hb 125g/l, 
WCC 27x109/l and Plt 119 x109/l, mutated TET2, ASXL1, CBL and BCOR along with 
chr7q- and 11q-. This patient died in MF within 2 years. The remaining tiles show the 
predictions and outcomes for 40 patients in CP and 40 patients in MF selected at equal 
intervals when ranked by increasing risk for progression or death (top left to bottom right 
for each set). 
Post%CP'AML
Death&in&CP
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Figure 25: Predictions for equally sized subsets of each cohort, ranked according to their 
predicted risk according to the multi-stage model. Predicted event free survival (x-axis) is 
plotted against observed outcomes for each group as a whole (y-axis), for chronic phase 
(top two panels) and myelofibrosis patients (bottom two panels). These predictions 
generally follow the dotted line (where predictions are equivalent to actual outcomes) 
even in external validation cohorts with limited genomic data. 10 year predictions (brown) 
and 15 year predictions (red) are shown. 
Both Figures 24 and 25 demonstrate that this modelling method can generate continuous, 
accurate predictions. An additional advantage of this approach is that, since the predictions 
are continuous variables and can be provided for any time-point, the use of the model, in 
theory, can be tailored to the clinical need (e.g. maximisation of specificity or of 
sensitivity, stratification into an number of risk groups, identifying the x% of 
highest/lowest risk patients etc).  
Figures 26 and 27 show examples of stratification into two groups using cut-off points (for 
10 year predictions) that maximise sensitivity and specificity using a Receiver-operator 
characteristic analysis. 
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A more comprehensive evaluation of model performance relative to other proposed 
models is provided in Section 5.10.  
 
Figure 26: Predictions at 10 years for overall survival, MF transformation and AML 
transformation in chronic phase are used in each case to generate (left) receiver operator 
characteristic curves, (middle) curves of true positives-false positives in order to find cut-
offs maximising sensitivity and specificity, and (right) Kaplan-Meier curves using this cut-
off to divide patients into high and low risk groups. 
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Figure 27: Predictions at 10 years for overall survival and AML transformation in 
myelofibrosis are used in each case to generate (left) receiver operator characteristic 
curves, (middle) curves of true positives-false positives in order to find cut-offs maximising 
sensitivity and specificity, and (right) Kaplan-Meier curves using this cut-off to divide 
patients into high and low risk groups. 
5.8 Alternative modelling prognostic classifications 
5.8.1 Decision trees / Recursive partitioning 
In order to validate these results and generate a potentially superior predictive model, a 
number of alternative modelling approaches were also attempted. Decision tree analyses 
recursively partition the predictor variables to create a branching tree structure, attempting 
to determine which variable (and its cut point for non-binary variables) will give the most 
informative split between the patients categorised into each of the resulting branches 
(defined using statistical comparisons between the two branches or measures of 
impurity/dissimilarity). Once the algorithm has determined the optimal decision tree, this 
effectively provides a flow diagram, with decisions at each node, allowing each patient to 
be classified into different risk groups.  
These approaches have a number of advantages: they are non-parametric approaches that 
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do not depend on the distributions of continuous variables (and therefore 
transformations/splines are not required), offer a method for dichotomisation of variables, 
are easy to interpret and apply by just using the resulting flow diagram and inherently 
allow for interactions between variables to be shown (e.g. a variable may only be 
predictive in a certain subset of patients, i.e. down one branch). As an example of the latter 
point, the predictive model for AML transformation from CP classifies the highest risk 
groups as TP53/SRSF2/U2AF1-mutated patients over 48, or patients over 72, suggesting 
(providing this model is correct and validates) testing for these mutations is not helpful in 
the under the age of 48 (where haemoglobin is a better predictor) or over the age of 72 
(since further splitting did not improve the model). 
 
Figure 28: Results of decision tree and random forest analyses. (A) Kaplan Meier curves 
classifying patients into 3 groups according to predicted risk from rpart analysis of the 
training cohort. (B) The rankings of the top ranked variables according to Random forest 
variable importance analysis. 
From Figure 28A it can be seen that these models are very successful when re-applied to 
the training data. However, they are very prone to over-fitting, and are greedy algorithms, 
so that early splitting may lead to suboptimal solutions. Part of the success of these models 
on the training data is that disparate, seemingly arbitrary groups can be ranked together as 
being high or low risk, e.g. for OS in MF, female patients under 62 without 9pUPD but 
with white counts>6.7, form a higher risk node, as do patients over 62 with platelet counts 
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over 190 and under 250, which strongly suggests a model that is over-fitted and clinically 
implausible. In most cases therefore, “pruning” of the trees and cross-validation are 
required. However, these models still may be helpful in terms of highlighting a list of 
important predictive variables. As can be seen from Figure 28, the variables selected do 
overlap with many highlighted by other analyses. 
The ctree algorithm (which uses a different splitting criterion) was also used but gives far 
fewer branches. However, these analyses also highlight a prognostic role for age, sex, 
haemoglobin, white cell count, platelet count, TP53, SRSF2, U2AF1 and 1pUPD. 
5.8.2 Random forests 
The use of random forests avoids the main pitfalls of decision tree algorithms. Random 
forests are created by “growing” a large number (e.g. 500) of individual decision trees, 
each time using a random subset of patients and a random subset of the available 
variables. The random selection of variables and patients for each independent tree 
reduces the chance of over-fitting the model, and the fact that for each iteration there are 
“out of bag” patients that the model can be tested on, means that cross-validation and 
estimation of the model’s error can automatically performed along with the creation of the 
model. 
The performance of random forest models is discussed in section 5.9, but an additional 
benefit of this process is that the importance of each variable can also be computed by this 
process, essentially by assessing by how much the model’s error changes when the 
variable is not used. Figure 28B shows the rank for each variable according to this 
analysis, for each outcome assessed, again emphasising the prognostic role for age, sex, 
blood counts, and mutations in epigenetic regulators, spliceosomal and cytokine signal 
transduction components, NRAS and TP53. 
5.9 Evaluation of model performance and model comparisons 
A number of measures were used to evaluate and compare the prognostic models 
discussed above, including measures of concordance and Brier scores. These are discussed 
in detail in Section 2.8.6. 
The aim of these analyses is to compare (a) the different methods for modelling clinical 
outcomes (e.g. the full multistage model using random effects Cox proportional hazards 
modelling relative to simplified models using variable selection methods), (b) the effect of 
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different variables (e.g. to determine whether an extended genomic characterisation 
improves accuracy of prediction relative to simpler models) and (c) to compare the models 
proposed in this study with existing prognostic models, such as the HMR score.  
 
Figure 29: Concordances (Harrell’s c-statistic) for different models assessed. (A) and (B) 
show comparisons between individual Random effects Cox proportional hazards models 
against those derived using random forest, recursive partitioning and variable selection 
using BIC, for each outcome assessed for CP and MF patients respectively. Paler bars 
represent the results of applying these models to the external dataset. Figures (C, chronic 
phase) and (D, myelofibrosis) show comparisons of the full cross-validated multi-stage 
model (leave-one-out approach) with equivalent models that limited the genomic variables 
to JAK2, CALR or MPL, or removed the distinction between ET and PV, as well as HMR, 
IPSET, models with age and prior thrombosis or CALR and ASXL1, IPSS and DIPSS. 
Comparisons of concordance are shown in Figure 29 and Appendix 4. A number of 
conclusions can be drawn from these 
i)! Random effects Cox proportional hazards modelling performs better overall (in 
terms of concordance and degree of over-fitting for individual models) than 
other methods used, including Cox proportional hazards models with variable 
reduction, decision trees and random forests, although in some cases these 
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differences are negligible. Random forests also perform well, however. 
ii)! The inclusion of extended genomic characterisation improves the performance 
of multi-stage Cox proportional hazards models in the prediction of MF or 
AML transformation from CP, AML transformation from MF and, to a lesser 
extent of OS in MF. 
iii)! The distinction between ET and PV in CP patients does not appear to 
significantly affect the performance of multi-stage models when other variables 
(including blood counts, age and splenomegaly) are taken into account. 
iv)! Predictions for overall survival in CP and MF tend to be more accurate than 
predictions of AML or MF transformation. 
v)! The time-point chosen for multi-stage predictions in order to rank/classify 
patients does not appear to be important as the ranking appears to stay 
relatively constant. However, the accuracy of predictions appears to be greatest 
at earlier time points, which is likely to relate to the fact that the uncertainty 
inherent to the prediction is lower then (i.e. fewer events are expected to 
happen). 
vi)! Predictions derived from Mixed effects multi-stage modelling show better risk 
stratification than the HMR score, and models that use age>60 and thrombosis 
alone, CALR and ASXL1 alone, IPSET, IPSS and DIPSS. However, 
comparisons with IPSS and DIPSS could only be made in the external 
validation cohort, which was not only smaller, but had more limited genomic 
characterisation. 
It is reasonable to assume that the performance of the multi-stage model is 
actual under-estimated here (and therefore that the improvement relative to 
DIPSS/IPSS would be greater) if full genomic information was available, and 
this appears to be the case when performance in this cohort is compared to 
results of cross-validation in the training cohort. 
Regarding point (vi) it is worth noting that the multi-stage model provides continuous 
predictions and therefore it is rare to have predictions tied across different patients. 
However this is not the case for scores such as IPSS/DIPSS for which comparisons can 
only be made for patients across different risk groups. While this is a potential benefit for 
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the multi-stage model, this may result in a flawed comparison between groups. Therefore, 
direct comparisons were made between HMR, IPSS and DIPSS and discrete groups 
defined by ranking patients by their multi-stage predictions and splitting them in the same 
proportions as HMR/IPSS/DIPSS. The results of this are as follows: 
•! Multi-state (stratified into 3 groups, n=158/75/45) compared with HMR (3 groups) 
assigns 65% of patients to the same risk group (with 17% risk group increased, 
18% risk group decreased). Concordance for overall survival improves from 67.1 
to 78.2%. Concordance for AML-transformation improves from 66.6 to 76.6%. 
•! Multi-state (stratified into 4 groups, n= 85/94/63/56) compared with IPSS (4 
groups) assigns 58% of patients to the same risk group (with 22% risk group 
increased, 20% risk group decreased). Concordance for overall survival improves 
from 77.4 to 80.0%. Concordance for AML-transformation improves marginally 
from 77.1 to 78.5%. 
•! Multi-state (stratified into 4 groups, n= 43/89/109/57) compared with DIPSS (4 
groups) assigns only 44% to concordant risk groups (with 30% risk group 
increased, 27% risk group decreased). Concordance for overall survival improves 
from 69.2 to 78.1%. Concordance for AML-transformation worsens very 
marginally from 76.0 to 75.9%. 
This confirms the results of the earlier analysis showing that personalised multi-stage 
predictions provide, in almost all cases, superior risk stratification than the existing 
prognostic models assessed. 
5.10 Implementation of individualised patient prediction calculator 
So that the multi-stage predictions could be available as an alternative or adjunct to 
current scoring systems and its use could be trialled prospectively, an implementation of 
the model was made using the R package shiny, which can be run in a browser at 
https://cancer.sanger.ac.uk/mpn-multistage. 
This package utilises two files, server.R, which determines how user-inputted data is 
processed, and ui.R, which determines how the input (and which is then passed to 
server.R) and output (where the results from server.R are displayed) are displayed and 
associated with variables in server.R. In this case, users can input patient-specific data 
(e.g. age, presence/absence of mutations), which are then entered into the multi-stage 
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model and probabilities for each time point are generated.  From this, predicted survival 
curves are drawn and presented to the user, along with estimates for median event free 
survival, and probabilities for each outcome at 5, 10 and 20 years. Additionally the 
(anonymised) predictions for patients in the training set are available, together with their 
actual outcomes can be viewed. 
5.11 Discussion and Future work 
In this chapter we examined the variables that most strongly determine the risk of death, 
MF and AML transformation in MPNs. A variety of different modelling methods are used 
and compared. Common to the majority of the prognostic systems examined is the 
confirmed predictive role for Age, sex, blood counts, chromatin-regulator/spliceosome 
mutations (ASXL1, SRSF2, U2AF1, EZH2), NRAS, CBL and TP53. Although carrying a 
substantial increase in risk, these mutations are relatively uncommon, particularly in 
chronic phase. 
There is clearly significant overlap between mutations found in the chromatin/spliceosome 
group (defined purely using the genomic data alone), mutations associated with an MF 
phenotype at disease presentation (or time of earliest available sample where not 
available), and the mutations shown here to predict MF transformation from CP, AML 
transformation from CP or MF, and, to a lesser extent death in MF. As discussed 
previously, the mechanisms by which these mutations may lead to disease progression 
need to be explored further, but may include acceleration of the myeloproliferative 
phenotype itself, or alteration in the underlying phenotype (for example through alteration 
of the balance between differentiation and stem cell expansion, or through differential 
secretion of pro-inflammatory/pro-angiogenic cytokines). 
The results of the analysis here additionally suggest predictive roles for more common 
variables which generally are not restricted to a particular MPN subtype, including 
9pUPD, MPL, CALR, TET2 and DNMT3A. For these variables, the associated increase in 
risk may be lower, but their frequency means that they still have an important effect 
population-wide, and are therefore likely to be useful to still include in a model. 
Analysis of the effect of clone size on risk suggests that for most genes, whether a 
mutation in a given gene is clonal or subclonal does not substantially affect its impact on 
clinical outcome. This suggests that in the MPNs, the major determinant of clinical 
outcome is likely to be affected more by most aggressive subclone a patient has, rather 
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than specifically the genomic changes of the dominant clone. One exception in this 
analysis was ASXL1, however this observation would require further validation given the 
relatively weak strength of association and the multiple hypothesis testing. 
Although the multi-stage model performs well, and has a number of advantages over 
existing scoring systems, there are a number of further steps that should or could be taken 
before it could be used for clinical practice. Firstly, the risk of over-fitting is always a 
concern. Even though internal cross-validation was used, and validation was carried out 
on an external cohort, the external cohort had only limited genomic characterisation. 
Therefore it is important to validate this model in other cohorts of patients. However, the 
model itself might be improved in a number of ways. Beyond validation, data from a 
wider pool of patients could be used to expand the knowledge bank from which the 
models are built, thereby refining the co-efficients used and improving the power to detect 
smaller effects. Secondly, the variables used could be expanded to include factors such as 
other genomic variables (e.g. chromosomal translocations or the clone sizes for detected 
mutations), degree of bone marrow fibrosis or other histopathological variables, blood 
count parameters (e.g. blast count, neutrophil count or red cell distribution width245), 
germ-line variants (e.g. JAK2 haplotype or rs11104870) or co-morbidities (e.g. 
cardiovascular risk factors). Finally, the modelling process might be improved, for 
example by including selected interaction terms or through transformation or the use of 
splines for selected variables244. For example, the effect of platelet count is modelled 
linearly, but one might expect poorer outcomes to be associated with very high or very low 
platelet counts. 
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6 Role of inflammatory cytokines in MPNs 
6.1 Introduction 
Haematopoietic stem and progenitor properties such as quiescence, self-renewal and 
differentiation are tightly regulated by micro-environmental factors. There is increasing 
evidence that there is dysregulation of these processes in myeloproliferative neoplasms 
(MPNs)246. 
As discussed in Section 1.10, stromal secretion of cytokines such as IL-6 or TNF-alpha 
may give a competitive advantage to the tumour which can further be supported through 
remodelling of the microenvironment induced by the tumour clone itself. Secretion of 
soluble mediators by the clone itself, or induced by the clone, may also drive fibrosis and 
angiogenesis as well as promoting DNA damage. 
In general, across the MPN subtypes MF has been associated with the highest levels of IL-
1RA, -2R, -6, -8, -10, -12,-15 TNFa, IP-10, HGF and VEGF. Of these, the levels of IP-10, 
IL-2R, -8, -12 and -15 are associated with an adverse prognosis247, and IL-8 with 
increased microvascular density (a feature of MF)248. Overall therefore, it appears that pro-
inflammatory signals may play a valuable role in MPN development and disease 
progression, and therefore a more comprehensive description of cytokine secretion across 
the MPN subtypes may offer insights into their biology as well as offer predictive 
biomarkers or therapeutic targets. 
In order to investigate these possibilities, we quantified the levels of pro-inflammatory 
mediators in serum samples from over 400 patients with MPNs, as well as comparator 
samples from healthy controls. 
6.2 Clinical and Genomic correlates of cytokine levels 
6.2.1 Discovery 32-plex panel 
Cytokine concentrations for 38 cytokines were assessed in an initial cohort of 199 patients 
and controls (100 patients with ET, 32 with PV, 53 with MF and 14 healthy controls) to 
identify those that were most discriminatory for MPN subtype. 
Surprisingly, few cytokines were significantly different when concentrations were 
compared between control and MPN cases as a whole, after correction for age and sex: 
GRO-alpha (CXCL1) and EGF were most significant (p-values 0.01 and 0.03 
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respectively). However, IP-10, TNF-alpha, GRO, TGF-alpha, EGF, Eotaxin, IL-1RA, IL-
8, IL-3 varied significantly across MPN subtypes (p<0.005 in all cases). 
A discriminatory role for IP-10, TNF-alpha, GRO, TGF-alpha, EGF, Eotaxin, IL-1RA and 
IL-8 was confirmed upon multivariate analysis taking into account patient age and sex. 
Furthermore, these same factors contributed the most in random forest analyses predictive 
of diagnosis. IL-6 and IFN-! were also taken forward for further analysis given previous 
evidence for their role in MPN pathogenesis, resulting in a total of 10 candidate cytokines 
subsequently measured using a 10-plex assays (Table 10). 
 
Table 10: Rankings for variable importance in 2 random forest analyses classifying 
patients into diagnostic group (one with control patients, and one restricted to MPN 
patients alone. Ranking according to Gini and mean decrease in accuracy. Significance 
levels : .<0.1, *<0.05, **<0.001, ***<0.0001  
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IP.10 1 1 1 1 *** *** .
TGF.a 2 2 2 2 ** **
GRO 3 4 3 4 * ** *
EGF 6 3 6 5 * ** *
IL.1Ra 7 6 4 3
Eotaxin 4 5 5 7 *** **
TNF.a 5 7 9 10 **
IL.12.p40 12 10 7 6 * *
sCD40L 9 12 10 14 . .
IL.8 8 8 27 9
IFN.a2 15 9 22 8 ** **
G.CSF 14 11 15 15 . ** *
IL.6 11 13 18 17
IL.10 21 16 17 12 .
IL.3 19 26 8 19 . ***
Fractalkine 16 19 20 20 .
GM.CSF 20 22 24 28 *
MDC 18 14 33 37 . .
IL.9 28 29 30 16 * .
IL.12.p70 29 33 16 32 **
IFN.y 26 25 34 31
IL.17 24 21 38 34 .
FGF2 27 32 26 36 *
IL.4 37 36 32 25 * .
Flt3L 35 34 37 35 . **
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6.2.2 Validation of selected candidate cytokines 
Results from the 10-plex assay were compared to those from the original 38-plex and 
found to be concordant (data not shown, r2 values>0.9). Initial findings were then 
validated using an additional 110 patients (46 with ET, 19 with MF, and 41 with PV – a 
total of 305 patients across both cohorts). A subset of samples were repeated across plates, 
to allow correction for inter-plate variation, and additionally 25 patients had samples from 
2 timepoints and 9 from 3 timepoints. 
In order to account for the effect of inter-plate and inter-patient variation, sampling time 
relative to diagnosis, and the confounding effect of blood counts, age and sex, when 
identifying an association between cytokine levels and MPN subtype, mixed effects 
modelling was used. Here, diagnosis and sex were modelled as fixed effects but age, time 
from diagnosis, plate, and blood counts were modelled as random effects. The effect of 
diagnosis on a cytokine’s levels was therefore assessed through comparison of models that 
did or did not include diagnosis as a variable, which allowed p-values for this comparison 
to be generated. 
 
Figure 30: Levels of IP-10, TNF-alpha, TGF-alpha, IL-1Ra, EGF, Eotaxin and GRO-
alpha according to MPN subtype. 
Overall, the results of these analyses are in keeping with the concept that a continuum of 
increasing pro-inflammatory cytokine concentrations exists from ET to PV to MF: 
Levels of TGF-a and IL-1Ra in patients with ET were lower than those in both PV and MF 
(p<0.001 in all cases) but did not show significant differences between PV and MF cases, 
Levels of IL-6 and IL-8 were significantly lower in ET than in MF (and did not differ 
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between PV and MF) in univariate analyses but did not meet the threshold for statistical 
significance in multivariate, mixed-effects analysis (data not shown). Levels of IP.10 and 
TNF-alpha showed a clear continuum, increasing significantly from ET to PV to MF 
(Figure 30). 
In contrast, GRO-alpha levels were markedly raised in ET patients compared to PV, MF 
and control cases (p<0.001) while EGF and eotaxin were higher in chronic phase cases 
than MF cases (p<0.001). 
6.2.3 Genomic associations 
Samples from a final cohort of patients were analysed from the 10-plex assay to test an 
additional set of hypotheses regarding genomic associations and the predictive value of 
cytokine measurement (Section 5.3). This cohort comprised 126 patients with ET from the 
PT-1 multicentre trial (see Section 2.1), who had undergone targeted genome sequencing 
as described in sections 3 and 4 and for whom long-term follow-up data was available. 
There thus was an intersection of 241 patients who both underwent targeted genome 
sequencing as described in sections 3 and 4, and who underwent quantification of serum 
cytokines using the 10-plex panel. This allowed us to model the effect of somatic 
mutations on the concentrations of the 10 measured cytokines, since certain mutations 
may be associated with differential cytokine secretion, or conversely, different mutant 
clones may have a selective advantage under certain micro-environmental conditions. 
After correction for diagnosis, age and sex, there were surprisingly few differences in 
cytokine profiles across patient genotypes. One exception was IP-10 (Figure 31), which 
was 1.5-fold higher in JAK2-mutated patients (p-value<0.001), 1.9-fold higher in JAK2-
mutated patients with 9pUPD compared to those without (p-value=0.002), 2-fold higher 
when JAK2-mutations were found in combination with TET2-mutations (p-value=0.005) 
and correlated with JAK2 allele burden (r2=0.46, p<0.001). A similar pattern of IP-10 
secretion was also seen in JAK2 transgenic mice and those cross-bred with TET2-knock 
out mice (work done by Dr Juan Li, Miriam Belmonte and Dr David Kent). 
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Figure 31: Correlates of IP-10 levels. (left) IP-10 concentrations across different genomic 
groups. JAK2 het=heterozygosity alone, JAK2hom=JAK2 homozygosity alone, JAK2 
other includes JAK2 mutated patients with additional TET2 or DNMT3A, Other includes 
the TP53 and chromatin-spliceosome groups. (right) correlation of IP-10 levels with JAK2 
burden. 
6.3 Prognostic correlates of pro-inflammatory cytokines in MPNs 
6.3.1 Diagnostic cytokine levels 
Previous studies have highlighted a prognostic role for a number of pro-inflammatory 
cytokines in MF. Outcome data was available for 182 of the original cohort and therefore 
this question could be evaluated both for MF and chronic phase patients. Unfortunately, 
this cohort had only 8 documented transformation events and 25 deaths. Cox proportional 
hazards modelling, incorporating clinical and demographic variables, suggested a 
prognostic role for GRO-alpha as a predictor for an increased risk of transformation from 
chronic phase to myelofibrosis or AML (p=0.002), although there were only a small 
number of events 
The prognostic role for GRO-alpha was therefore evaluated in the 126-patient PT-1 
cohort, in whom genomic variables could also be taken into account. This cohort had a 
median follow-up of 11.7 years (with a range of 2 months to 43 years from diagnosis) and 
was enriched for transformation events, with 26 AML transformations, 30 myelofibrotic 
transformations and 69 deaths. In this analysis samples were diluted 1:5 as it was noted 
that in some cases GRO-alpha levels exceeded the range covered by the standard curve. 
Overall, the addition of cytokine quantification to clinical and genomic data improved the 
concordance of predictive models for overall survival and progression (Figure 32). GRO-
alpha, as well as IL-8 and IP-10 in particular, were selected (using variable selection 
methods described previously) as predictive of progression (p-values 0.007, 0.007 and 
0.01 respectively). 
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Figure 32: Comparison of concordances for Cox proportional hazards modelling assess 
for the addition of cytokine and genomic data to a baseline model using age and sex 
alone, for overall survival, myelofibrotic transformation and AML transformation 
predictions. 
6.3.2 Longitudinal measurement of cytokine levels 
As well as evaluating the predictive value of cytokine measurement at diagnosis, the value 
of longitudinal sampling was also assessed in 81 patients who had multiple samples and 
clinical follow-up. The rate of change in EGF strikingly correlated with transformation 
risk (p-value 0.008 in Cox proportional hazards modelling including age, sex and disease 
subtype), with the majority of transformations (~80%) observed in patients whose EGF 
levels decreased over time (Figure 33, stability defined as an absolute rate of change of 
<4pg/ml per year).  Compared to patients with stable or increasing EGF levels, there was a 
4.3-fold (95% confidence interval 1.7 - 10.9) increased likelihood of transformation to MF 
or AML if EGF levels dropped over the course of the longitudinal sampling, strongly 
indicating the utility of monitoring EGF levels during the course of disease. 
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Figure 33: Rate of change of EGF and outcome. (A) EGF levels over time. Change in 
concentration denoted by thick line joining the two sampling time-points, length of faded 
line indicates subsequent follow-up period until censoring or event. Square marker 
denotes time of MF transformation, Triangle denotes time of AML transformation. (B) 
Kaplan Meier analysis showing progression free survival, according to rate of change of 
EGF. 
6.4  Functional evaluation of MPN-associated cytokines 
Although a number of the correlations between cytokine levels and clinical phenotype are 
quite convincing, the pathophysiology underlying them is not entirely clear. It is possible 
that the differences in cytokine levels are directly due to secretion by cells arising from the 
tumour clone (e.g. monocytes or macrophages) or they may be triggered indirectly by the 
effects of the tumour clone upon non-tumour cells in the bone marrow niche (whether 
stromal cells, or cells of the immune system). Conversely, particular micro-environmental 
conditions, existing independent of the tumour clone itself may promote expansion of the 
MPN clone, or influence the MPN phenotype, such that the same clone arising under two 
separate conditions would manifest as two separate phenotypes. It is also not clear to what 
extent the differences in cytokine profiles actually play a role in disease pathogenesis or 
simply are surrogate markers of the underlying myeloproliferation or, in other words are 
simply epiphenomena. 
The 38-plex panel was used to measure the levels of the selected cytokines from 
supernatant from a megakaryocytic-differentiated induced pluripotent stem cell (IPSC)-
derived cell line (supplied by Dr Thorsten Klampfl) demonstrate that these cells secrete 
EGF, IL-17, IL-1, IL-3, IL-8, IP-10, MIP-1a, MIP-1b, TNF-a, and GRO-alpha (at 10- to 
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100-fold higher levels than these other cytokines). 
Work carried out by Dr Nina Friesgaard Øbro and Dr Miriam Belmonte using flow 
cytometric intra-cytoplasmic cytokine measurement indicates that stimulated CD14+ 
monocytes are the primary source of IP-10 in patients with ET and healthy controls, but 
that IP-10 production is additionally seen by populations of CD56+ monocytes, 
granulocytes and T cells in patients with PV and MF, with flow cytometric quantification 
of IP-10 correlating well serum levels measured with the 10- or 38-plex assays. T cells 
were found to be the main producers of IFN-! and TNF-a, suggesting this was not direct 
secretion by the MPN clone, but potentially a reaction to it. 
6.5 Discussion and Future work 
The work presented here demonstrates that cytokine profiles differ significantly between 
patients with ET, PV and MF. Overall they form a continuum of increasing pro-
inflammatory cytokines (including IP-10, TGF-alpha and TNF-alpha in particular), but 
patients with MF were found to have lower levels of GRO-alpha (which was highest in 
patients with ET), EGF and Eotaxin. 
Further work is required to establish whether these correlations exist because of (a) 
cytokine secretion directly by the tumour clone, (b) secretion by non-tumour cells in 
response to the clone, (c) secretion by non-tumour cells independent but permitting or 
promoting tumour clone expansion, (d) secretion independent of the tumour clone but with 
other effects on disease pathogenesis (e.g. induction of fibrosis or angiogenesis) or (e) 
some combination of these. If secretion is by the tumour clone or in response to it, it also 
remains to be determined which cells or tissues are the targets and how this influences 
disease maintenance or progression, if at all. 
The evidence presented here indirectly suggests IP-10 may be secreted by mutant 
monocytes, since IP-10 levels correlate closely with JAK2 clonal burden and the presence 
of homozygosity, while TNF-alpha and IFN-!  are more likely to be produced by T cells 
and therefore less likely to derive from the tumour clone itself. A number of cytokines, 
GRO-alpha in particular, were shown to be secreted by a megakaryocytic cell line, which 
is in keeping with the correlation between ET and high GRO-alpha levels. It is therefore 
likely that GRO-alpha levels are acting as a surrogate for megakaryocytic activity, 
although no clear correlation with platelet count was seen, and it is possible that this 
underlies the correlation seen between high GRO-alpha levels and risk of myelofibrotic 
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transformation. As GRO-alpha acts as a neutrophil chemo-attractant and has a role in 
angiogenesis, it is possible that it may stimulate fibrosis via other mechanisms. 
Previous studies have suggested that the secretion IL-6, TNF-alpha and TGF-beta may 
provide a selective advantage to the mutant clone, while inhibiting normal haematopoiesis. 
Work done in the Kent lab suggests a similar role for IFN-!  (unpublished data), with 
increased colony growth seen with IFN-!  treated colonies from patients with MF, but 
inhibited growth in samples from patients with ET. Surprisingly, other than IP-10, none of 
the cytokines measured correlated significantly with tumour burden or the underlying 
mutational profile, which would appear to argue against secretion by tumour-derived cells 
themselves and potentially for a model in which cytokine secretion serves to permit or 
encourage expansion of the clone relative to wild type cells. 
The mechanisms by which these cytokines may contribute to disease are difficult to 
determine and further in vitro and in vivo work is required to elucidate this. It is, for 
example, difficult to hypothesise why MF is associated with increased TGF-alpha levels 
but lower EGF levels (which here are shown to predict for MF progression) since both 
molecules have similar functions and act on the same receptor (epidermal growth factor 
receptor, EGFR). Further work might include comparing secretion profiles of tumour-
derived megakaryocytes and monocytes to wild-type controls, assessing the effect of these 
cytokines on colony growth and differentiation, and assessing their effect on fibroblast 
function, including collagen production. Finally, the contribution of these cytokines to 
disease establishment and progression could be assessed in vivo through the use of 
cytokine-knockout mouse models along with transplant experiments using established 
JAK2 or CALR transgenic models of MPN. 
Therefore, although much work remains to be done in order to understand the role of the 
micro-environment in MPN pathogenesis, the work presented here should hopefully form 
a strong basis for this through the identification of a number of candidate cytokines, and 
additionally identifies a number of candidate biomarkers for disease progression which 
could be validated in future studies. 
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7 Discussion 
7.1 Introduction 
The Philadelphia-negative myeloproliferative neoplasms offer a promising disease model 
for understanding how haematological malignancies originate and develop. They are 
relatively genomically simple, with few mutations per patient, and the majority of patients 
harbour JAK2, CALR or MPL mutations. Genomically, however, they overlap not only 
with each other but also with MDS and AML, and also with otherwise healthy patients 
who can be found to harbour expanded clones carrying JAK2 or other mutations 
(CHIP/ARCH). Clinically, patients can transition between these disease states: CHIP to an 
MPN, ET or PV to MF, MPN to MDS and MPN or MDS to AML. 
It is therefore remains a challenge to determine which variables, genomic or otherwise, 
determine which clinical phenotype a patient may have (if any at all) and their risk of 
progression into another disease state. 
7.2 The Genomic Landscape of MPNs 
7.2.1 Overview of somatic genomic variation in MPNs 
The results of this large sequencing study are consistent with previous sequencing studies 
in MPNs, with recurrent mutations seen across genes implicated in cell signalling, 
epigenetic and transcriptional regulation and mRNA splicing. As well as JAK2, CALR, 
MPL, CBL and SH2B3, which are well understood to be involved in cellular responses to 
Epo, Tpo and G-CSF with down-stream JAK-STAT signalling, mutations in GNAS and 
GNB1 were also seen, the latter restricted to the K57 hot-spot. Mutations in G proteins are 
only recently described in a small number of cases of myeloid and lymphoid malignancies 
as well as in cases with clonal haematopoiesis249,250, and have been associated with 
resistance to oncogenic kinase inhibition. Although only a small number of cases were 
seen in this cohort, there did appear to be an association with poorer outcomes, and 
therefore this may represent a clinically important pathway, disrupted in a subset of 
patients. 
 
Mutations in TET2, DNMT3A, ASXL1, EZH2 were frequently found, as were mutations 
in splicing components, SRSF2, ZRSR2, U2AF1 and SF3B1 in a smaller number. SF3B1, 
however, appears to have a different functional role in MPNs than the other mutated 
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spliceosome genes which tend to occur later, are associated with increasing age and 
disease burdens, as well as with significant cytopenias and poor risk disease across both 
chronic phase and myelofibrotic disease. This is not the cases for SF3B1, which generally 
occurs early, and is associated with anaemia alone, but not with as significant a risk of 
disease transformation. This may reflect the predominant effects of SF3B1 on iron 
homeostasis and erythropoiesis, in contrast to the more significant disruption of stem cell 
function seen in mouse models with the other spliceosomal components. 
 
Mutations of TP53 were recurrent, as previously reported, but PPM1D, a negative 
regulator of TP53, was also shown to be mutated, with mutations showing a similar 
pattern to those seen in other cancers221,251. Although previous reports have hypothesised 
that these mutations represent germ-line mosaicism, evidence is presented here supporting 
their somatic nature. They are demonstrated here to be late events, often occuring 
secondary to JAK2 or CALR mutations, but also seen in a small number of cases as being 
isolated events. Although occurring together with TP53 or 17p UPD/deletions in a small 
number of cases, no statistically significant enrichment was seen, and these mutations 
were not significant predictors for AML transformation, unlike those in TP53 (or 5q/17p 
changes). These mutations appear to be enriched in patients with chemotherapy exposure, 
as demonstrated both here in relation to hydroxycarbamide exposure and other studies, 
and may be associated with resistance to therapy252. However, their presence at diagnosis 
or early in disease, prior to any cytotoxic exposure, is seen in a subset of patients here. It 
may be that screening for these mutations may be helpful in predicting treatment 
responses, something that could be examined in future clinical trials. 
 
Frameshift/nonsense MLL3 mutations, previously reported only in a very small number of 
AML cases224, are here demonstrated to be recurrent in MPNs, with no clear phenotypic or 
prognostic associations. These mutations however are enriched in triple-negative patients, 
and can occur in isolation, suggesting they may be sufficient to cause clonal expansion 
and disease, a hypothesis that needs to be tested in vitro, as well as screened for in a wider, 
triple-negative population. Although a number of other putative candidates were suggested 
by these data, there were no clear novel phenotypic drivers discovered in this cohort. 
 
Recurrent chromosomal changes were also seen across 14 chromosomes, most commonly 
on 9p, associated with JAK2 mutations, leading to their homozygosity. UPD or copy-
number changes on chromosomes 1, 4, 7, 11, 12, 17 and 19 were also seen recurrently and 
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strongly associated with mutations in MPL (including one non-canonical variant), TET2, 
EZH2 (although also seen independently), CBL, SH2B3, TP53, and CALR, leading to loss 
of heterozygosity for these mutations. UPD was also seen affecting chromosomes 13, 14 
and 18, with no associated mutations detected, and no recurrent SNPs (although relatively 
few were genotyped in this study). Further work is required to determine whether UPD on 
these chromosomes is associated with unrecognised somatic mutations and/or with loss of 
heterozygosity for functionally relevant germ-line SNPs, as well as the functional 
consequences of 5q and 20q deletions and trisomy 8. 
7.2.2 Sufficiency of phenotypic driver mutations for MPN development 
Previous studies of mouse models of MPNs have suggested that while JAK2 and CALR 
mutations are sufficient to give rise to a myeloproliferative phenotype, they do not 
necessarily provide a stem cell advantage, leading in some cases to a failure to give rise to 
sustainable disease in competitive transplant experiments. Furthermore, JAK2 mutations 
are found in a proportion of the general public in the absence of any overt haematological 
abnormality. In the proportion that do progress to develop an MPN, there is often a lag-
time of many years. One hypothesis is that mutations in other genes are required to 
provide a sufficient competitive advantage and to initiate disease. It is notable that many 
of the additional mutations seen in this and other studies, including TET2, DNMT3A, 
ASXL1 and EZH2, are associated with expansion of the stem cell pool, and therefore are 
likely to offer a relative clonal advantage to the mutant clone. 
The data presented here do not support this hypothesis, since ~50% of JAK2, CALR or 
MPL-mutated cases were not found to have mutations in other genes, or to have 
chromosomal abnormalities. However, this study is limited in that only a targeted set of 
genes were sequenced, and only their coding regions. and it is therefore possible that 
mutations crucial for MPN development are present, but not captured by this study. 
A number of pro-inflammatory cytokines were found in this and other studies, to be raised 
in MPNs, particularly in cases of MF. These include TNF-alpha and IL-6 which have been 
found to promote the expansion of JAK2-mutant clones while inhibiting normal 
haematopoiesis, and unpublished data suggests interferon-gamma may also preferentially 
support the growth of mutant clones. These cytokines may in some cases be produced or 
induced by the tumour clone, but are also associated with ageing, and also with a large 
number of inflammatory conditions. It is therefore feasible that the probability of a JAK2 
clone expanding and giving rise to disease is influenced by changes in the bone marrow 
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micro-environment induced by the clone itself, by the ageing process or by other 
inflammatory processes, as well as differences in the relative fitness of the wild-type 
clones. These differences may relate to the genetic background of the patient, including 
JAK2 haplotype in particular, to other disease processes, or toxin exposure, e.g. smoking 
(rates of which are higher in patients with PV than unaffected controls) or chemotherapy 
exposure. It is possible that the threshold required for an increase in 
erythropoiesis/thrombopoiesis to reach clinically detectable levels will depend on other 
factors (concurrent iron deficiency, smoking or alcohol use, or germ-line variation in 
baseline haemoglobin or platelet counts) that vary between patients. 
Given the heterogeneity of mutations and cytokine profiles observed, rates of progression 
to MPN and age of presentation, it is reasonable therefore to hypothesise that multiple 
paths exist leading from JAK2-mutated CHIP to MPN, such that additional mutations or 
stimulation from pro-inflammatory signals are needed to overcome reduced fitness in 
some contexts but not in others. While attractive, this model is not entirely borne out by 
the data here. For example, MPL mutations, which have not been reported in the general 
population and therefore are likely to carry a high probability of resulting in an MPN 
phenotype, tend to be associated with a higher mutation burden than JAK2 and CALR 
mutations. Furthermore, increasing mutation burden and pro-inflammatory states, rather 
appearing to exist as alternative pathways to MPN tend to co-occur, each correlating with 
increasing age and with myelofibrosis. 
This highlights the need for additional studies addressing in detail the differences in germ-
line variants, somatic mutation rates, inflammatory signals and chemical/radiation 
exposure between patients with MPNs and those with CHIP/ARCH. 
7.3 Determinants of phenotype in JAK2-mutated chronic phase patients 
The comprehensive clinical and genomic description of this cohorts allows us to examine 
the factors influencing the development of PV rather than ET in patients with JAK2 
V617F mutations. 
7.3.1 Demographic, Micro-environmental and Genomic factors 
Male sex and increasing age were associated with PV phenotype. The association with 
male sex may reflect intrinsic germ-line differences affecting stem cell function, but may 
also be a function of differences in hormones, iron stores, inflammatory signals or 
environmental factors (e.g. toxin exposure). The correlation with increasing age supports 
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the hypothesis that age-related changes in the bone marrow may lead to selection of 
different stem/progenitor populations, and may be supporting the expansion of JAK2 
clones, in keeping with multiple lines of evidence showing an association between JAK2 
burden/dosage and erythrocytosis. Indeed, a number of pro-inflammatory cytokines, 
several of which are implicated in supporting JAK2-mutant clone growth, were higher in 
patients with PV than those with ET, including TNF-alpha, TGF-alpha, IP-10, and to a 
lesser extent IL-6 and IL-8. Differences in IP-10 secretion are particularly of interest, 
since they correlate closely with JAK2 burden, and also because of previous work 
implicating differences in interferon signalling seen between patients with ET and PV45. 
Conversely, much higher GRO-alpha levels are associated with ET. However, further work 
is required to investigate causality here, since high JAK2 burden disease may be 
responsible for higher pro-inflammatory cytokine levels rather than the other way around, 
and GRO-alpha levels may be a surrogate for increased megakaryocytic activity rather 
than themselves causing thrombocytosis (or lower haemoglobin concentrations). 
 
The type of JAK2 mutation also appears to correlate with phenotype, most significantly 
with exon 12 mutations, however a number of non-canonical JAK2 mutations also appear 
to be restricted to particular phenotypes. This may reflect differences in EPOR or MPL 
binding or the strength of signalling, with different degrees of JAK2, STAT or ERK 
phosphorylation. 
 
NFE2 mutations were also enriched in patients with PV, as were STAG2 mutations in a 
small number, and tended to co-occur with 9pUPD. As noted previously, this is in keeping 
with previous studies showing an association between NFE2 mutations and expanded 
erythropoiesis114.  The expression of NFE2 is regulated by pro-inflammatory signals, 
including IL-1beta, and in turn its expression (increased either due to these signals, or 
mutation) is associated with increased IL-8 production, potentially causing a feedback 
loop, sustaining disease253. Another genomic variable strongly associated with MPN 
phenotype in JAK2-mutated cases was rs11042125, which has been associated with 
haemoglobin concentrations in the general population205, suggesting germ-line 
determinants of haematological parameters also further modify the phenotype in patients 
with MPNs. 
7.3.2 JAK2 mutation order and V617F homozygosity 
The data presented here confirm a strong correlation between JAK2 clone size and JAK2 
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homozygosity with PV phenotype, with detectable 9pUPD a rare event in ET patients. 
They also confirm the association between the order of JAK2 mutation acquisition and 
ET/PV phenotype in the ~50% of patients who carry mutations in addition to those of 
JAK2. Earlier acquisition of JAK2 mutations (“JAK2 first”), and therefore their presence 
in the dominant clone, was shown to associate with a greater incidence of 9pUPD and 
with a PV phenotype. This relationship was the case even in cases lacking detectable 
9pUPD, suggesting this was not the sole determinant, and appeared to hold regardless of 
partner mutation (TET2, DNMT3A or other mutations). The possible mechanisms 
underlying this have been discussed in earlier sections, but it is again tempting to 
hypothesise a role for micro-environmental changes in determining these phenotypic 
differences, with an earlier and large JAK2 clone leading to a longer period of bone 
marrow modelling and cytokine secretion supporting out-growth of the JAK2 clone 
7.3.3  JAK2 haplotype and V617F homozygosity 
A significant association between the JAK2 46/1 haplotype and the presence of 9pUPD 
and PV phenotype was also seen in this study. This is an intriguing finding which raises a 
number of questions about MPN pathogenesis. It is consistent with previous reports from 
other groups that reported associations between PV and SNPs in linkage dysequilibrium 
with 46/1 haplotype SNPs140,147and showing more rapid increases in JAK2 allele burden 
over time in those carrying the 46/1 haplotype144,145,160. There are number of possible 
explanations for these associations which are not necessarily mutually exclusive. The 
presence of the 46/1 haplotype may be associated with greater regional instability, as has 
been previously suggested230, leading to a greater probability of both JAK2 mutation and 
mitotic recombination leading to 9pUPD (or increasing the possibility of bi-allelic JAK2 
mutations); an additional competitive advantage may be imparted to the JAK2-mutant 
clone, when the mutation is acquired on the 46/1 background (although changes in JAK2 
expression or splicing have not been demonstrated in previous studies141), and outgrowth 
of the clone increases the probability of 9pUPD occurring; and acquired homozygosity for 
the 46/1 haplotype as a result of 9pUPD may itself offer an additional clonal advantage. 
 
A clonal advantage for the JAK2 46/1 haplotype in its own right is supported here by the 
demonstration that the haplotype is not just enriched in cases with JAK2 mutations, but 
also in cases with MPL, and to a lesser extent, CALR mutations. Previous studies have 
also demonstrated a small number of cases where acquired homozygosity for 9pUPD 
occurred prior to the acquisition of the JAK2 mutation7,254, suggesting that acquired 
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homozygosity for germ-line variants (with 46/1 haplotype as one reasonable candidate) 
may offer an advantage to the clone. 
 
Furthermore, as well as its association with MPN-related mutations, the JAK2 46/1 
haplotype has been shown to be enriched in patients with Crohn’s disease, and associated 
with increased rates of DNA damage in these patients255–257. It has also been shown to be 
associated with normal karyotype acute myelomonocytic leukaemia and with adverse 
outcomes overall in normal karyotype AML258overall suggesting that the haplotype may 
be associated with abnormal myelomonocytic activation and aberrant immune 
responses259, and presenting another pathway for germ-line – environmental interaction. 
 
7.3.4  9pUPD and other genes on 9p 
 
Additionally, a number of SNPs implicated in variation in haematological parameters 
including rs409801 and rs385893, associated with platelet counts, are also located on 9p. 
It is possible that homozygosity for 9pUPD, leading to acquired homozygosity for these 
variants, in turn contributing to further skewing of blood counts and alteration of the 
resultant MPN phenotype. NF-IB is also located on 9p, centromeric to JAK2 (Figure 16 
(C)). Earlier reports of 9pUPD demonstrated markedly increased expression of NF-IB in 
patients with 9pUPD and hypothesised that this offers a protective advantage to the clone 
from the inhibitory effects of TGF-beta7. 
 
Intriguingly, a cluster of interferon genes is also present on 9p21.3 (Figure 16 (D)). This is 
a locus that has been implicated in cardiovascular risk (coronary artery and aortic disease) 
across a large number of studies and in particular, rs4977574, an intergenic SNP 
associated with CDKN2A and CDKN2B has been identified as a significant predictor of 
risk260,261. Unfortunately, SNPs in this region were not covered by the bait sets used in this 
study, but this would be worth following up in future studies, particularly because of the 
variation seen in thrombotic risk in MPN patients and the need for risk stratification, as 
well as the differential interferon responses noted in patients with ET or PV45. Preliminary 
data presented here also suggest that the length of chromosome 9p involved in 9pUPD 
varies between patients with ET and PV. It is possible that differences in involved genes 
and functional SNPs affected by 9pUPD underlie some of the differences in interferon 
response and phenotype. 
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Finally, PD-L1 (CD274, Figure 16 (B)) lies adjacent to JAK2. It is of particular interest in 
haematological malignancies as its expression has been shown to be increased in 
lymphoma in conjunction with gains/amplification of 9p, offering a mechanism for 
immune evasion. It therefore is another candidate gene affected by 9pUPD, and indeed 
recent data show increased PD-L1 expression in JAK2-mutants (although the mechanism 
underlying this is unknown), associated with immune evasion in cell line and murine 
models. 
In summary therefore, the phenotypic differences seen among patients with JAK2-mutated 
chronic phase disease appear to depend on a number of factors including (a) age and sex, 
(b) JAK2 allele burden, (c) the presence of 9pUPD, (d)  46/1 haplotype +/- acquired 
homozygosity due to 9pUPD (e) other genomic variation on 9pUPD +/- acquired 
homozygosity due to 9pUPD, (f) genomic variation at other sites (e.g. rs11042125), (g) 
additional somatic mutations (potentially in NFE2 and STAG2) and (h) levels of pro-
inflammatory cytokines. Further comprehesive analyses examining candidate SNPs along 
9p and elsewhere in conjunction with the presence of 9pUPD and other somatic changes 
are required to fully elucidate these interactions. 
7.4 Pathogenesis of Myelofibrosis and Blast Transformation 
7.4.1 Myelofibrosis and recurrent somatic mutations 
A recurring feature of the analyses presented in this thesis is the cluster of genes including 
ASXL1, EZH2, SRSF2 and U2AF1. ASXL1 mutation is often seen in EZH2, SRSF2 or 
U2AF1-mutated cases, but these mutations are not seen together. This family of mutations 
was identified by clustering using a Dirichlet-process based Bayesian clustering algorithm, 
and was also identified using this method when the data was combined with an 
independent dataset from patients with MDS, and also is associated with mutations in 
ZRSR2, IDH1/2, NRAS, CBL and GNAS, as well as 7q  deletions/UPD. 
This cluster is strongly enriched in patients with MF, as well as in patients with chronic 
phase disease subsequently transforming to MF. It is possible that mutations in these genes 
present alternative pathways for the development of MF, but the mutual exclusivity of 
EZH2, U2AF1 and SRSF2 both in this cohort and others points to functional redundancy 
and the existence of common mechanisms, as do the similarity in mutation partners for 
these mutations (ASXL1 in particular). 
The mechanisms that may underlie this have been discussed in previous sections, but 
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common to these mutations appear to be the following features: an association with 
anaemia +/- thrombocytopenia in keeping with their association with dysplasia and 
ineffective haematopoiesis; expansion of the stem cell pool in murine models, often with 
maturation arrest; dysregulation of H3K27 methylation; dysregulation of genes regulating 
stem cell quiescence and differentiation, including genes of the  HOXA cluster; the 
development of bone marrow fibrosis; poor risk disease in both chronic phase and 
myelofibrosis, with an increased risk of AML transformation. 
Unfortunately, no correlation was seen between mutations in this set of genes and cytokine 
secretion, after correction for MPN subtype, going against the hypotheses that either these 
mutations lead to a pro-inflammatory/pro-fibrotic environment or that such an 
environment is supportive for the expansion of these mutant clones. However, these 
hypotheses cannot be discounted altogether as these same mechanisms may be present in 
other cases of MF in the absence of these mutations, obscuring a possible correlation. 
The effects of this cluster of mutations appear to transcend the background on which they 
occur (whether in JAK2-, CALR- or MPL-mutated or triple negative disease) as well as 
the MPN subtype they are found in, justifying the proposal that they exist as an entitity in 
their own right. As noted above, this group of mutations is also frequently seen in MDS 
and AML, where it is also associated with poorer outcomes189,214. 
7.4.2 Determinants of blast transformation 
Overlap was seen between the predictors of AML transformation from CP and MF. 
Ultimately these two cohorts were combined for the prediction of AML transformation in 
the final multi-stage model. 
ASXL1, EZH2, U2AF1 and SRSF2 are also strongly correlated with risk of AML 
transformation. Other predictors include TET2 and DNMT3A, which are also associated 
with expansion of the stem cell pool in mouse models. Although the associated risk carried 
by these mutations is small, it is likely to be clinically relevant as they occur at a greater 
frequency than other mutations. GNAS, NRAS, RUNX1 and trisomy 9 are also associated 
with an increased risk of transformation, although the mechanisms underlying this are less 
clear. 
TP53 mutations carry the strongest risk of AML transformation, and are commonly found 
with 5q and 17p changes, themselves associated with increased AML risk. This set of 
changes also was found to define a separate cluster in Bayesian clustering analysis. Again, 
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the phenotypic consequences of this group (with a >10-fold increased risk of AML 
transformation) transcend both the background on which these mutations occur, and the 
MPN subtype the patient has been classified into. Furthermore, the size of the TP53 clone 
at the time of sampling (near to diagnosis in the majority of cases) does not appear to 
correlate with the risk of transformation, suggesting its presence alone is sufficient to mark 
the patient as being at high risk and suggesting either that these clones expand over time, 
regardless of their size at MPN diagnosis, or that AML clones may arise even from small 
TP53 clones, gaining an advantage over the dominant clone. 
7.5 Ontological status of MPN entities 
There has been much debate regarding the diagnostic criteria for ET, PV and primary MF. 
Controversies include the correct thresholds for determining a raised red cell mass, 
whether haemoglobin or haematocrit should be used, whether ET and PV are distinct 
biological entities or sit on a continuum, and whether a continuum exists between ET and 
MF, or between MF and a pre-fibrotic state (pre-fibrotic MF). These issues are 
complicated by confounding variables (such as plasma volume or gender) and inter-
observer variability when defining histological grading or subgroups192,262–264. 
The analyses reported above present a complex picture of the myeloproliferative 
neoplasms, with numerous lines of evidence suggesting that the traditional division into 
ET, PV and MF is an over-simplification that does not necessarily respect the underlying 
biological features of these conditions. 
The Bayesian clustering algorithm defines a number of genomically defined entities, 
based on genomic data alone. The examples given above, of the spliceosome-chromatin 
and TP53-17p-5q groups demonstrate that these entities transcend clinical MPN entities 
but also are strongly correlated with the risk of disease transformation and with overall 
survival, with a classification based solely on these entities showing better predictive 
ability (assessed using concordance) than one using the MPN subtype alone. Furthermore, 
in multivariate, multi-stage modelling, the removal of the distinction between ET or PV 
did not significantly worsen the performance of the model, once genomic, demographic 
and clinical data are taken into account. 
Furthermore, the since the spliceosome-chromatin group is enriched both in patients with 
MF and those that subsequently transform to MF and in both cases with poor outcomes, it 
appears arbitrary to classify these patients into two separate diagnostic entities based on 
the disease state in which they present, and furthermore to classify the subgroup of ET 
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patients with spliceosome-chromatin group mutations (and high risk of transformation and 
poor OS) into the same classification as ET patients with an isolated JAK2 mutation or no 
detectable mutations, for example. The division of remaining groups, defined 
predominantly by the presence of JAK2, JAK2 homozygosity, CALR or MPL, identifies 
patients with more benign disease, and as previously shown, correlates with differences in 
haematological variables and thrombotic risk42,265. 
 
A genomic classification, such as this one, offers the advantages of objectivity and 
reproducibility, and, for the reasons described above, may improve the ability to make 
predictions about possible outcome based on diagnostic classification alone. Furthermore, 
given it is based on the genomic lesions that are present, may aid the targeting of 
therapeutic agents by identifying specific targets or identifying specific patient groups that 
may or not benefit from specific treatments. This classification also identifies entities that 
may transcend the boundaries between MPN, MDS, MPN/MDS overlap syndromes and 
AML, and it may be more appropriate for a patient’s management to be targeted according 
to genomic boundaries rather than specifically on criteria such as thrombocytosis, 
dysplasia or bone marrow fibrosis that may results in patients with a similar biological 
process (e.g. SRSF2 and ASXL1 mutated disease) being classified into separate diagnostic 
categories and being treated in different ways as a result. Conversely, this genomic 
classification also picks out a class of patients with no detectable mutations, who carry a 
low risk of adverse outcomes, and therefore again should not necessarily be grouped 
together, and treated the same as, a cohort of patients with confirmed clonal disease. 
 
However, it is evident from the analyses presented above that both these genomic entities 
and existing clinical entities do not fully account for the phenotypic heterogeneity seen in 
patients with MPNs. As argued here, and in a previous review262, it may be more accurate 
to view individual patients as sitting within a continuum (or phase space) with their 
phenotype depending on many variables such as age, sex, somatic mutations, the ordering 
and clonal composition of these mutations, chromosomal changes, germ-line SNPs (and 
the acquisition of homozygosity for these SNPs in some cases), levels of pro-
inflammatory cytokines, iron stores, among others. 
 
These variables then determine factors fundamental to the disease phenotype and 
behaviour, such as the degree of erythrocytosis (with early JAK2 mutations, NFE2 or 
JAK2 exon 12 mutations, 46/1 haplotype, 9p UPD at one end, late JAK2, CALR or MPL 
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mutations, rs11042125 genotype, spliceosomal or chromatin mutations at the other); the 
degree of stem cell expansion or dysplasia (including age, inflammatory states, DNMT3A, 
TET2, TP53, spliceosomal or chromatin mutations) and the degree of fibrosis (including 
age, inflammatory states, spliceosomal or chromatin mutations). These variables also 
determine a patients of moving within this phase space, for example towards a more 
myelofibrotic phenotype, or to AML. 
 
This model therefore argues for both a clinical and genomic assessment, leading to an 
individualised approach to both disease classification and risk assessment. However, a 
wider study that includes patients with overlap syndromes, MDS, AML and CHIP/ARCH 
is required in order to fully understand the biological differences that underlie these 
phenotypic entities and determine a patients transition between states. 
7.6 Prognostic utility of genomic data  
A number of predictive scores for myelofibrosis are validated in this study, including 
HMR, IPSS, DIPSS and the use of CALR/ASXL1 alone, and here we show that they can, 
in some cases, be extrapolated to chronic phase patients. Presently available prognostic 
scoring systems have a number of advantages including their ease of use and the 
requirement for only a few known variables, however they have a number of limitations 
and flaws, which include: 
•! The lack of existing prognostic modelling for patients with chronic phase disease. 
Prognostication in these patients carries an additional dimension as they can 
transform to myelofibrosis. 
•! These models work by assigning scores of 0-2 for each variable, either for 
presence/absence or by dichotomising a continuous variable. This results in loss of 
available information - e.g. for a cut-off of 65 years, assuming all else is equal, a 
patient of 20 is assumed to have the same risk as one of 64, and one of 66 as one of 
90, while the 64 and 66 year olds are treated as having different risks. Furthermore 
the standardisation of each variable to single integer value of 1 or 2 also may not 
accurately reflect the risk associated with each variable. Potential information is 
lost further when patients with different totals are grouped together. 
•! Previous studies generally chose a small number of variables, generally selected 
from a relatively small initial pool of variables. While using a score with only few 
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variables improves simplicity of the model, variable selection again leads to loss of 
information and then to overestimation of the effect sizes of the selected variables 
when models are re-built using only the selected variables. 
•! Cytogenetic analyses are used to detect chromosomal amplifications/losses, but 
copy-number neutral events are not included in any analyses. 
•! These analysis generally classify patients into 3 or 4 risk groups. Predictions are 
not specific to a given individual, and therefore comparisons between patients 
within a risk group cannot be further refined, and predictions for a particular 
disease outcome (e.g. AML transformation vs. non-AML death) or particular time-
point cannot be made (or need to be inferred from the behaviour of the risk group 
as a whole). In other words, while modelling is used to select variables, a 
predictive model in its own right is not created, but rather patients are assumed to 
have a similar risk to that of those in the relevant prognostic category. 
On this basis, we have presented here an integrated prognostic model that encorporates 
data from patients with both CP and MF, using demographic, clinical and genomic data, 
accounting for transitions between disease states and that enables predictions to be 
provided for specific outcomes for specific time-points. These predictions are therefore 
amenable to direct comparison against actual outcomes. An additional benefit of this 
approach is that risk groups are not defined a priori, but rather continuous predictions are 
given, which allows the model to be tailored as required if categorisation into risk groups 
is required. In Appendix 5 we provide estimates of the number of patients needed to test 
using this model to define patients groups meeting particular thresholds. Analyses such as 
this may then inform clinical trial design (e.g. identifying a target high-risk cohort for a 
trial of a novel treatment) or day-to-day patient management (e.g. identifying a very low 
risk cohort that do not require regular clinic follow-up or intervention). 
We have shown that these models perform well when compared to those lacking full 
genomic characterisation and to models designed using variable selection methods. They 
also perform at least as well at risk stratifying patients. Even if not adopted, they also 
inform the selection of variables for more simplified scoring systems. For example, it is 
clear that the inclusion of a number of more rare variables, such as TP53 or NRAS, may 
result in significantly different predictions being made in individual cases. 
As discussed in an earlier section, there are a number of ways in which the modelling 
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presented here could be improved, including a larger knowledge bank, inclusion of 
additional variables, and alterations in model fitting. Given the data presented regarding 
GRO-alpha and EGF trends, it may be that cytokine profiling can offer an additional and 
dynamic means of prognostication that could be built into existing models. 
7.7  Conclusion 
The majority of myeloproliferative neoplasms display a narrow repertoire of mutations in 
genes involved in erythropoietin or thrombopoietin signalling with a long tail of less 
frequent mutations. Despite this, we have shown here that a better understanding of the 
additional somatic events (mutations or chromosomal changes) and germ-line genomic 
background can inform our understanding of the processes giving rise to the 
myeloproliferative phenotypes in these patients, and can help us to accurately predict the 
risk of disease transformation. Striking differences in cytokine profiles are also seen They 
also argue for a personalised medical approach, where these variables, together with 
clinical and demographic variables, allow for better characterisation of the disease 
phenotype and associated risk, rather than assigning an individual to a broad diagnostic 
group or risk category. 
Further work examining the role of somatic and germ-line variation, the interaction 
between the two, and the contribution of micro-environmental factors will be required in 
order to understand the phenotypic heterogeneity of these conditions and their relationship 
to other related clonal haematopoietic disorders. 
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ppendix 2: R
 code used in statistical analysis. 
 library(C
oxH
D
); library(survival); library(D
T); library(htm
lw
idgets); library(IR
display); library(repr); library(m
sSurv); library(R
cpp); library(H
ilbertV
is); 
library(rm
s); library(data.table); library(hdp); library(ggplot2); library(lsr); library(B
radleyTerry2); library(qvcalc); library(tidyr); library(survA
U
C
) 
setw
d("/U
sers/jg23/data") 
 # B
radley terry m
odelling perform
ed using separate file tabulating "w
ins/losses" for each com
bo of genes 
btz<-read.table("btz.csv",sep=",",header=TR
U
E) 
btm
<- B
Tm
(cbind(w
in1, w
in2), Var1, Var2, ~ Var, id = "Var", data=btz,br=TR
U
E,refcat="V
617F") 
# refcat is arbitrary 
qv<-qvcalc(B
Tabilities(btm
)) 
sink("TG
S_output.txt",append=TR
U
E) 
cat("B
radley Terry estim
ates for abilities, w
ith quasi variances \n") 
qv; sink() 
 raw
D
ata <- read.table("TG
SZ.csv", header=T, sep=",", fill=T, na.strings=c("N
A
","na")) 
TG
SZ<-raw
D
ata 
TG
SZ$D
eathC
[w
hich(TG
SZ$A
M
LTC
==1)]<-1 
TG
SZcut<-subset(TG
SZ,D
eath>=0) 
 ###D
escriptive Stats 
sink("TG
S_output.txt",append=TR
U
E) 
cat("D
escriptive stats by diagnosis \n") 
cat("H
b, W
C
C
, Pl, A
ge by D
iag \n") 
aggregate(TG
SZ[,c("H
b","W
C
C
","Pl","A
ge")],by=list(TG
SZ$D
iag),FU
N
=m
edian,na.rm
=TR
U
E) 
cat("Sex and C
ohort by D
iag \n") 
table(TG
SZ$Sex,TG
SZ$D
iag) 
table(TG
SZ$C
ohort,TG
SZ$D
iag) 
cat("C
ounts for each m
utation \n") 
aggregate(TG
SZ[,c("JA
K
2", "C
A
LR
", "M
PL", "JA
K
2e12", "TET2", "A
SX
L1", "D
N
M
T3A
", "PPM
1D
", "EZH
2", "N
F1", "N
FE2", "SF3B
1", "SR
SF2", 
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"TP53", "U
2A
F1", "C
B
L", "M
LL3", "ZR
SR
2", "G
N
A
S", "K
R
A
S", "SH
2B
3", "ID
H
2", "PTPN
11", "K
IT", "R
B
1", "B
C
O
R
", "N
R
A
S", "C
U
X
1", "STA
G
2", 
"ID
H
1", "R
U
N
X
1", "PH
F6", "G
ATA
2", "G
N
B
1","C
1p", "C
1q", "C
4", "C
5", "C
7", "C
8", "C
9U
", "C
9g", "C
11", "C
12", "C
13", "C
14", "C
17", "C
18", "C
19", 
"C
20")],by=list(TG
SZ$D
iag),FU
N
=sum
,na.rm
=TR
U
E) 
cat("Linear regression for H
b \n") 
sum
m
ary(glm
(H
b~JA
K
2+C
A
LR
+M
PL+JA
K
2e12+TET2+A
SX
L1+D
N
M
T3A
+PPM
1D
+EZH
2+N
F1+N
FE2+SF3B
1+SR
SF2+TP53+U
2A
F1+C
B
L+M
LL3+
ZR
SR
2+G
N
A
S+K
R
A
S+SH
2B
3+ID
H
2+PTPN
11+K
IT+R
B
1+B
C
O
R
+N
R
A
S+C
U
X
1+STA
G
2+ID
H
1+R
U
N
X
1+PH
F6+G
ATA
2+G
N
B
1+C
1p+C
1q+C
4+C
5+
C
7+C
8+C
9U
+C
9g+C
11+C
12+C
13+C
14+C
17+C
18+C
19+C
20+A
ge+Sex+D
iag,data=TG
SZ)) 
cat("Linear regression for W
C
C
 \n") 
sum
m
ary(glm
(W
C
C
~JA
K
2+C
A
LR
+M
PL+JA
K
2e12+TET2+A
SX
L1+D
N
M
T3A
+PPM
1D
+EZH
2+N
F1+N
FE2+SF3B
1+SR
SF2+TP53+U
2A
F1+C
B
L+M
LL
3+ZR
SR
2+G
N
A
S+K
R
A
S+SH
2B
3+ID
H
2+PTPN
11+K
IT+R
B
1+B
C
O
R
+N
R
A
S+C
U
X
1+STA
G
2+ID
H
1+R
U
N
X
1+PH
F6+G
ATA
2+G
N
B
1+C
1p+C
1q+C
4+C
5+C
7+C
8+C
9U
+C
9g+C
11+C
12+C
13+C
14+C
17+C
18+C
19+C
20+A
ge+Sex+D
iag,data=TG
SZ)) 
cat("Linear regression for Platelet count \n") 
sum
m
ary(glm
(Pl~JA
K
2+C
A
LR
+M
PL+JA
K
2e12+TET2+A
SX
L1+D
N
M
T3A
+PPM
1D
+EZH
2+N
F1+N
FE2+SF3B
1+SR
SF2+TP53+U
2A
F1+C
B
L+M
LL3+
ZR
SR
2+G
N
A
S+K
R
A
S+SH
2B
3+ID
H
2+PTPN
11+K
IT+R
B
1+B
C
O
R
+N
R
A
S+C
U
X
1+STA
G
2+ID
H
1+R
U
N
X
1+PH
F6+G
ATA
2+G
N
B
1+C
1p+C
1q+C
4+C
5+
C
7+C
8+C
9U
+C
9g+C
11+C
12+C
13+C
14+C
17+C
18+C
19+C
20+A
ge+Sex+D
iag,data=TG
SZ)) 
sink() 
 ##O
R
 
 a<-TG
SZ[,c("ET","M
F","PV
","JA
K
2", "C
A
LR
", "M
PL", "JA
K
2e12", "TET2", "A
SX
L1", "D
N
M
T3A
", "PPM
1D
", "EZH
2", "N
F1", "N
FE2", "SF3B
1", 
"SR
SF2", "TP53", "U
2A
F1", "C
B
L", "M
LL3", "ZR
SR
2", "G
N
A
S", "K
R
A
S", "SH
2B
3", "ID
H
2", "PTPN
11", "K
IT", "R
B
1", "B
C
O
R
", "N
R
A
S", "C
U
X
1", 
"STA
G
2", "ID
H
1", "R
U
N
X
1", "PH
F6", "G
ATA
2", "G
N
B
1","C
1p", "C
1q", "C
4", "C
5", "C
7", "C
8", "C
9U
", "C
9g", "C
11", "C
12", "C
13", "C
14", "C
17", 
"C
18", "C
19", "C
20")] 
a<-as.m
atrix(a) 
 a<-t(a)%
*%
a; counts<-apply(a,1,m
ax); b<-counts-a; c<-t(b); d<-nrow
(TG
SZ)-a-b-c 
 O
R
<-(a*d)/(b*c) 
R
R
<-(a/(a+b))/(c/(c+d)) 
SE<-sqrt(1/a+1/b+1/c+1/d) 
U
L<-2^(log(O
R
,2)+1.96*SE) 
LL<- 2^(log(O
R
,2)-1.96*SE) 
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SER
<-sqrt(b/(a*(a+b))+d/(c*(c+d))) 
U
LR
<-2^(log(R
R
,2)+1.96*SER
) 
LLR
<- 2^(log(R
R
,22)-1.96*SER
) 
new
<-cbind(as.vector(a),as.vector(b),as.vector(c),as.vector(d)) 
chis<-function(dataset,a,b,c,d){ 
A
<-0 
g<-1 
w
hile(g<=nrow
(dataset)){ 
if(is.na(dataset[g,c])){ 
A
[g]<-N
A
 
g<-g+1 
}else{ 
A
[g]<-fisher.test(m
atrix(c(dataset[g,a],dataset[g,b],dataset[g,c],dataset[g,d]), nrow
=2, ncol=2))$p.value 
g<-g+1}} 
return(A
)} 
chi<-chis(new
,1,2,3,4) 
size<-length(a) 
 chi<-m
atrix(chi,ncol=nrow
(a),nrow
=nrow
(a)) 
 ps<-chi 
 ps[low
er.tri(ps,diag=TR
U
E)]<-N
A
 
 ps2<-p.adjust(ps,m
ethod="B
H
") 
ps3<-ps2 
sigs<-gather(data.fram
e(O
R
),gene,O
R
,factor_key=TR
U
E) 
sigs$gene2<-colnam
es(O
R
) 
sigs$U
L<-m
atrix(U
L,ncol=1) 
sigs$LL<-m
atrix(LL,ncol=1) 
sigs$pvalue<-ps3 
sigs<-sigs[w
hich(ps3<0.05),] 
sink("TG
S_output.txt",append=TR
U
E) 
cat("Significant associations \n") 
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sigs 
sink() 
 ps2<-m
atrix(ps2,ncol=nrow
(a),nrow
=nrow
(a)) 
 w
rite.table(ps2,file="Zps2.csv",sep=",") 
 w
rite.table(O
R
,file="ZO
R
.csv",sep=",") 
w
rite.table(a,file="Za.csv",sep=",") 
w
rite.table(chi,file="Zchi.csv",sep=",") 
w
rite.table(U
L,file="ZU
L.csv",sep=",") 
w
rite.table(LL,file="ZLL.csv",sep=",") 
 G
W
A
S<-read.table("G
W
A
S_Z.csv",sep=",",header=TR
U
E) 
a<-G
W
A
S[,c(7:83,91:105,108:143)] 
a<-as.m
atrix(a) 
a<-t(a)%
*%
a 
 counts<-apply(a,1,m
ax) 
 b<-counts-a 
 c<-t(b) 
d<-nrow
(G
W
A
S)-a-b-c 
 O
R
<-(a*d)/(b*c) 
R
R
<-(a/(a+b))/(c/(c+d)) 
SE<-sqrt(1/a+1/b+1/c+1/d) 
U
L<-2^(log(O
R
,2)+1.96*SE) 
LL<- 2^(log(O
R
,2)-1.96*SE) 
SER
<-sqrt(b/(a*(a+b))+d/(c*(c+d))) 
U
LR
<-2^(log(R
R
,2)+1.96*SER
) 
LLR
<- 2^(log(R
R
,22)-1.96*SER
) 
new
<-cbind(as.vector(a),as.vector(b),as.vector(c),as.vector(d)); chis<-function(dataset,a,b,c,d){ 
A
<-0 
g<-1 
w
hile(g<=nrow
(dataset)){ 
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if(is.na(dataset[g,c])){ 
A
[g]<-N
A
 
g<-g+1 
}else{ 
A
[g]<-fisher.test(m
atrix(c(dataset[g,a],dataset[g,b],dataset[g,c],dataset[g,d]), nrow
=2, ncol=2))$p.value 
g<-g+1}} 
return(A
)} 
chi<-chis(new
,1,2,3,4) 
size<-length(a) 
 chi<-m
atrix(chi,ncol=nrow
(a),nrow
=nrow
(a)) 
 ps<-chi 
 ps[low
er.tri(ps,diag=TR
U
E)]<-N
A
 
 ps2<-p.adjust(ps,m
ethod="B
H
") 
ps3<-ps2 
sigs<-gather(data.fram
e(O
R
),gene,O
R
,factor_key=TR
U
E) 
sigs$gene2<-colnam
es(O
R
) 
sigs$U
L<-m
atrix(U
L,ncol=1) 
sigs$LL<-m
atrix(LL,ncol=1) 
sigs$pvalue<-ps3 
sigs<-sigs[w
hich(ps3<0.05),] 
sink("TG
S_output.txt",append=TR
U
E) 
cat("Significant associations \n") 
sigs 
sink() 
 ps2<-m
atrix(ps2,ncol=nrow
(a),nrow
=nrow
(a)) 
 w
rite.table(ps2,file="G
ps2.csv",sep=",") 
 w
rite.table(O
R
,file="G
O
R
.csv",sep=",") 
w
rite.table(a,file="G
a.csv",sep=",") 
w
rite.table(chi,file="G
chi.csv",sep=",") 
w
rite.table(U
L,file="G
U
L.csv",sep=",") 
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w
rite.table(LL,file="G
LL.csv",sep=",") 
 JEP<-subset(G
W
A
S,JA
K
2==1&
(ET==1|PV
==1)) 
a<-JEP[,c(7:83,91:105,108:143)] 
a<-as.m
atrix(a) 
a<-t(a)%
*%
a 
 counts<-apply(a,1,m
ax) 
 b<-counts-a 
 c<-t(b) 
d<-nrow
(JEP)-a-b-c 
 O
R
<-(a*d)/(b*c) 
R
R
<-(a/(a+b))/(c/(c+d)) 
SE<-sqrt(1/a+1/b+1/c+1/d) 
U
L<-2^(log(O
R
,2)+1.96*SE) 
LL<- 2^(log(O
R
,2)-1.96*SE) 
SER
<-sqrt(b/(a*(a+b))+d/(c*(c+d))) 
U
LR
<-2^(log(R
R
,2)+1.96*SER
) 
LLR
<- 2^(log(R
R
,22)-1.96*SER
) 
new
<-cbind(as.vector(a),as.vector(b),as.vector(c),as.vector(d)) 
chis<-function(dataset,a,b,c,d){ 
A
<-0 
g<-1 
w
hile(g<=nrow
(dataset)){ 
if(is.na(dataset[g,c])){ 
A
[g]<-N
A
 
g<-g+1 
}else{ 
A
[g]<-fisher.test(m
atrix(c(dataset[g,a],dataset[g,b],dataset[g,c],dataset[g,d]), nrow
=2, ncol=2))$p.value 
g<-g+1}} 
return(A
)} 
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chi<-chis(new
,1,2,3,4) 
size<-length(a) 
 chi<-m
atrix(chi,ncol=nrow
(a),nrow
=nrow
(a)) 
 ps<-chi 
 ps[low
er.tri(ps,diag=TR
U
E)]<-N
A
 
 ps2<-p.adjust(ps,m
ethod="B
H
") 
ps3<-ps2 
sigs<-gather(data.fram
e(O
R
),gene,O
R
,factor_key=TR
U
E) 
sigs$gene2<-colnam
es(O
R
) 
sigs$U
L<-m
atrix(U
L,ncol=1) 
sigs$LL<-m
atrix(LL,ncol=1) 
sigs$pvalue<-ps3 
sigs<-sigs[w
hich(ps3<0.05),] 
sink("TG
S_output.txt",append=TR
U
E) 
cat("Significant associations \n") 
sigs 
cat("Logistic regression results \n") 
sum
m
ary(glm
(PV
~N
FE2+C
9+V
617FH
igh+rs409801+rs2867932+rs2236496+rs12340895+rs11042125+rs10974900+rs10758658+A
ge+Sex,fam
ily=binom
i
al(link='logit'),data=JEP)) 
sink() 
  ps2<-m
atrix(ps2,ncol=nrow
(a),nrow
=nrow
(a)) 
 w
rite.table(ps2,file="Jps2.csv",sep=",") 
 w
rite.table(O
R
,file="JO
R
.csv",sep=",") 
w
rite.table(a,file="Ja.csv",sep=",") 
w
rite.table(chi,file="Jchi.csv",sep=",") 
w
rite.table(U
L,file="JU
L.csv",sep=",") 
w
rite.table(LL,file="JLL.csv",sep=",") 
 # ggplot(subset(FP,gene2=="PV
"),aes(x=O
R
,y=O
rder,label=pval))+geom
_point()+scale_x_log10()+scale_y_discrete(lim
its=c("rs2236496 (C
)","rs409801 
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(C
)", "rs11042125 (T)","rs10758658 (A
)","M
ale sex","A
ge >60","rs12340895 (G
)","N
FE2","JA
K
2 clone 
>50%
","9p"))+geom
_errorbarh(aes(xm
ax=U
L,xm
in=LL,height=0.1))+geom
_text(nudge_y=-0.25,nudge_x=0.2,cex=2)+them
e_bw
()+xlab("O
dds ratio for 
Polycythem
ia vera")+ylab("")+coord_fixed(ratio = 0.1) 
 #ggplot(subset(FP,gene2=="M
F"),aes(x=O
R
,y=O
rder,label=pval))+geom
_point()+scale_x_log10()+scale_y_discrete(lim
its=c("rs13219787 
(A
)","rs11104870 (T)","M
ale sex","A
ge >60","9p","JA
K
2 clone 
>50%
","1p","C
B
L","A
SX
L1","EZH
2","SR
SF2","U
2A
F1","7q","ZR
SR
2","N
R
A
S"))+geom
_errorbarh(aes(xm
ax=U
L,xm
in=LL,height=0.1))+geom
_text(nu
dge_y=-0.25,nudge_x=0.2,cex=2)+them
e_bw
()+xlab("O
dds ratio for M
yelofibrosis")+ylab("")+coord_fixed(ratio = 0.1) 
  ## D
irichlet analysis 
genotypes<-TG
SZ[,c("Jhet", "Jhom
","C
A
LR
", "M
PL", "JA
K
2e12", "TET2", "A
SX
L1", "D
N
M
T3A
", "PPM
1D
", "EZH
2", "N
F1", "N
FE2", "SF3B
1", 
"SR
SF2", "TP53", "U
2A
F1", "C
B
L", "M
LL3", "ZR
SR
2", "G
N
A
S", "K
R
A
S", "SH
2B
3", "ID
H
2", "PTPN
11", "K
IT", "R
B
1", "B
C
O
R
", "N
R
A
S", "C
U
X
1", 
"STA
G
2", "ID
H
1", "R
U
N
X
1", "PH
F6", "G
ATA
2", "G
N
B
1","C
1p", "C
1q", "C
4", "C
5", "C
7", "C
8", "C
11", "C
12", "C
13", "C
14", "C
17", "C
18", "C
19", 
"C
20")] 
n <- ncol(genotypes) 
shape <- 5 
invscale <- 5 
hdp <- hdp_init(ppindex=0, #index of the parent D
P for initial D
P 
        cpindex=1, #index of alphaa and alphab for initial D
P 
        hh=rep(1/n,n), #param
s for base distn (uniform
 D
irichlet) 
        alphaa=shape, 
        alphab=invscale) 
hdp <- hdp_adddp(hdp, 
        num
dp=nrow
(genotypes), # one D
P for every sam
ple in that cancer type 
        ppindex=1, # parent D
P for group i is the i-th+1 overall D
P because of the grandparent at position 1 
        cpindex=1) # index of alphaa and alphab for each D
P 
 # A
ssign the data from
 each patient to a child D
P 
hdp <- hdp_setdata(hdp = hdp, dpindex=1:nrow
(genotypes)+1, data=genotypes) 
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 # A
ctivate the D
Ps w
ith specified num
ber of classes (signatures) 
hdp <- dp_activate(hdp, 1:(nrow
(genotypes)+1), initcc=5, seed=42) 
 burnin <- 500 
postsam
ples <- 1000 
spacebw
 <- 20 
cpsam
ples <- 10 
set.seed(42) 
hdpC
hain <- hdp_posterior(hdp, #activated hdp structure 
        burnin=burnin, 
        n=postsam
ples, 
        space=spacebw
, 
        cpiter=cpsam
ples) 
 hdpM
erged <- hdp_extract_com
ponents(hdpC
hain, cos.m
erge=0.95) 
 posteriorSam
ples <- aperm
(array(unlist(hdpM
erged@
com
p_categ_counts), dim
=c(dim
(hdpM
erged@
com
p_categ_counts[[1]]), 
length(hdpM
erged@
com
p_categ_counts))), c(2,3,1))  
row
nam
es(posteriorSam
ples) <- colnam
es(genotypes) 
colnam
es(posteriorSam
ples) <- paste("C
lass", 1:ncol(posteriorSam
ples) -1) 
posteriorM
eans <- row
M
eans(posteriorSam
ples, dim
=2) 
posteriorQ
uantiles <- apply(posteriorSam
ples, 1:2, quantile, c(0.025,.5,0.975), type=1) 
posteriorM
ode <- apply(posteriorSam
ples, 1:2, function(x) {t <- table(x); as.num
eric(nam
es(t)[w
hich.m
ax(t)])}) 
sink("TG
S_output.txt",append=TR
U
E) 
cat("G
enes by H
D
P group \n") 
data.table(data.fram
e(Lesion=colnam
es(posteriorQ
uantiles), posteriorQ
uantiles[2,,])) 
sink() 
 ## K
M
s for H
D
P groups 
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pdf("H
D
P_K
M
.pdf") 
par(m
frow
=c(7,2), m
ar=c(2,2,2,1)) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="TP53")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="TP53")),conf.int=FA
LSE,xlim
=c(0,25),lty=2) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="TP53")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="TP53")),conf.int=FA
LSE,xlim
=c(0,25),lty=2);lines(survfit(Surv(M
FT/365.25,M
FTC
)~1,data=subset(TG
SZ,
M
F==0&
H
D
P=="TP53")),conf.int=FA
LSE,xlim
=c(0,25),lty=3) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="A
dv")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="A
dv")),conf.int=FA
LSE,xlim
=c(0,25),lty=2) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="A
dv")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="A
dv")),conf.int=FA
LSE,xlim
=c(0,25),lty=2);lines(survfit(Surv(M
FT/365.25,M
FTC
)~1,data=subset(TG
SZ,
M
F==0&
H
D
P=="A
dv")),conf.int=FA
LSE,xlim
=c(0,25),lty=3) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="C
A
LR
")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,
A
M
LTC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="C
A
LR
")),conf.int=FA
LSE,xlim
=c(0,25),lty=2) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="C
A
LR
")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,
A
M
LTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="C
A
LR
")),conf.int=FA
LSE,xlim
=c(0,25),lty=2);lines(survfit(Surv(M
FT/365.25,M
FTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="C
A
LR
")),conf.int=FA
LSE,xlim
=c(0,25),lty=3) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="M
PL")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="M
PL")),conf.int=FA
LSE,xlim
=c(0,25),lty=2) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="M
PL")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="M
PL")),conf.int=FA
LSE,xlim
=c(0,25),lty=2);lines(survfit(Surv(M
FT/365.25,M
FTC
)~1,data=subset(TG
SZ,
M
F==0&
H
D
P=="M
PL")),conf.int=FA
LSE,xlim
=c(0,25),lty=3) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="Jhom
")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="Jhom
")),conf.int=FA
LSE,xlim
=c(0,25),lty=2) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="Jhom
")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="Jhom
")),conf.int=FA
LSE,xlim
=c(0,25),lty=2);lines(survfit(Surv(M
FT/365.25,M
FTC
)~1,data=subset(TG
SZ,
M
F==0&
H
D
P=="Jhom
")),conf.int=FA
LSE,xlim
=c(0,25),lty=3) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="Jhet")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="Jhet")),conf.int=FA
LSE,xlim
=c(0,25),lty=2) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="Jhet")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
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M
LTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="Jhet")),conf.int=FA
LSE,xlim
=c(0,25),lty=2);lines(survfit(Surv(M
FT/365.25,M
FTC
)~1,data=subset(TG
SZ,
M
F==0&
H
D
P=="Jhet")),conf.int=FA
LSE,xlim
=c(0,25),lty=3) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="N
il")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==1&
H
D
P=="N
il")),conf.int=FA
LSE,xlim
=c(0,25),lty=2) 
plot(survfit(Surv(D
eath/365.25,D
eathC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="N
il")),conf.int=FA
LSE,xlim
=c(0,25));lines(survfit(Surv(A
M
LT/365.25,A
M
LTC
)~1,data=subset(TG
SZ,M
F==0&
H
D
P=="N
il")),conf.int=FA
LSE,xlim
=c(0,25),lty=2);lines(survfit(Surv(M
FT/365.25,M
FTC
)~1,data=subset(TG
SZ,M
F
==0&
H
D
P=="N
il")),conf.int=FA
LSE,xlim
=c(0,25),lty=3) 
dev.off() 
 ##p-values, m
edian survival and 10-yr outcom
es for H
D
P groups 
TG
SZ$H
D
P<-relevel(TG
SZ$H
D
P,ref="Jhet") 
sink("TG
S_output.txt",append=TR
U
E) 
coxph(Surv(D
eath,D
eathC
)~H
D
P,subset(TG
SZ,M
F==0)) 
coxph(Surv(D
eath,D
eathC
)~H
D
P,subset(TG
SZ,M
F==1)) 
coxph(Surv(M
FT,M
FTC
)~H
D
P,subset(TG
SZ,M
F==0)) 
coxph(Surv(EFS,EFSC
)~H
D
P,subset(TG
SZ,M
F==0)) 
coxph(Surv(A
M
LT,A
M
LTC
)~H
D
P,subset(TG
SZ,M
F==0)) 
coxph(Surv(A
M
LT,A
M
LTC
)~H
D
P,subset(TG
SZ,M
F==1)) 
 survfit(Surv(D
eath,D
eathC
)~H
D
P,subset(TG
SZ,M
F==0)) 
survfit(Surv(D
eath,D
eathC
)~H
D
P,subset(TG
SZ,M
F==1)) 
survfit(Surv(M
FT,M
FTC
)~H
D
P,subset(TG
SZ,M
F==0)) 
survfit(Surv(EFS,EFSC
)~H
D
P,subset(TG
SZ,M
F==0)) 
survfit(Surv(A
M
LT,A
M
LTC
)~H
D
P,subset(TG
SZ,M
F==0)) 
survfit(Surv(A
M
LT,A
M
LTC
)~H
D
P,subset(TG
SZ,M
F==1)) 
 data.fram
e(levels(TG
SZ$H
D
P),sum
m
ary(survfit(Surv(D
eath,D
eathC
)~H
D
P,subset(TG
SZ,M
F==0)),tim
es=c(10*365.25))$surv) 
data.fram
e(levels(TG
SZ$H
D
P),sum
m
ary(survfit(Surv(D
eath,D
eathC
)~H
D
P,subset(TG
SZ,M
F==1)),tim
es=c(10*365.25))$surv) 
data.fram
e(levels(TG
SZ$H
D
P),sum
m
ary(survfit(Surv(M
FT,M
FTC
)~H
D
P,subset(TG
SZ,M
F==0)),tim
es=c(10*365.25))$surv) 
data.fram
e(levels(TG
SZ$H
D
P),sum
m
ary(survfit(Surv(EFS,EFSC
)~H
D
P,subset(TG
SZ,M
F==0)),tim
es=c(10*365.25))$surv) 
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data.fram
e(levels(TG
SZ$H
D
P),sum
m
ary(survfit(Surv(A
M
LT,A
M
LTC
)~H
D
P,subset(TG
SZ,M
F==0)),tim
es=c(10*365.25))$surv) 
data.fram
e(levels(TG
SZ$H
D
P),sum
m
ary(survfit(Surv(A
M
LT,A
M
LTC
)~H
D
P,subset(TG
SZ,M
F==1)),tim
es=c(10*365.25))$surv) 
sink() 
 ###D
escriptive Stats by H
D
P 
sink("TG
S_output.txt",append=TR
U
E) 
cat("D
escriptive stats by H
D
P \n") 
cat("H
b, W
C
C
, Pl, A
ge by H
D
P \n") 
aggregate(TG
SZ[,c("H
b","W
C
C
","Pl","A
ge")],by=list(TG
SZ$H
D
P),FU
N
=m
edian,na.rm
=TR
U
E) 
cat("Sex and C
ohort by H
D
P \n") 
table(TG
SZ$Sex,TG
SZ$H
D
P) 
table(TG
SZ$C
ohort,TG
SZ$H
D
P) 
table(TG
SZ$D
iag,TG
SZ$H
D
P) 
cat("C
ounts for each m
utation \n") 
aggregate(TG
SZ[,c("JA
K
2", "C
A
LR
", "M
PL", "JA
K
2e12", "TET2", "A
SX
L1", "D
N
M
T3A
", "PPM
1D
", "EZH
2", "N
F1", "N
FE2", "SF3B
1", "SR
SF2", 
"TP53", "U
2A
F1", "C
B
L", "M
LL3", "ZR
SR
2", "G
N
A
S", "K
R
A
S", "SH
2B
3", "ID
H
2", "PTPN
11", "K
IT", "R
B
1", "B
C
O
R
", "N
R
A
S", "C
U
X
1", "STA
G
2", 
"ID
H
1", "R
U
N
X
1", "PH
F6", "G
ATA
2", "G
N
B
1","C
1p", "C
1q", "C
4", "C
5", "C
7", "C
8", "C
9U
", "C
9g", "C
11", "C
12", "C
13", "C
14", "C
17", "C
18", "C
19", 
"C
20")],by=list(TG
SZ$H
D
P),FU
N
=sum
,na.rm
=TR
U
E) 
sum
m
ary(glm
(H
b~H
D
P+A
ge+Sex+D
iag,data=TG
SZ)) 
sum
m
ary(glm
(H
b~H
D
P+A
ge+Sex,data=subset(TG
SZ,ET==1))) 
sum
m
ary(glm
(H
b~H
D
P+A
ge+Sex,data=subset(TG
SZ,PV
==1))) 
sum
m
ary(glm
(H
b~H
D
P+A
ge+Sex,data=subset(TG
SZ,M
F==1))) 
sum
m
ary(glm
(W
C
C
~H
D
P+A
ge+Sex+D
iag,data=TG
SZ)) 
sum
m
ary(glm
(W
C
C
~H
D
P+A
ge+Sex,data=subset(TG
SZ,ET==1))) 
sum
m
ary(glm
(W
C
C
~H
D
P+A
ge+Sex,data=subset(TG
SZ,PV
==1))) 
sum
m
ary(glm
(W
C
C
~H
D
P+A
ge+Sex,data=subset(TG
SZ,M
F==1))) 
sum
m
ary(glm
(Pl~H
D
P+A
ge+Sex+D
iag,data=TG
SZ)) 
sum
m
ary(glm
(Pl~H
D
P+A
ge+Sex,data=subset(TG
SZ,ET==1))) 
sum
m
ary(glm
(Pl~H
D
P+A
ge+Sex,data=subset(TG
SZ,PV
==1))) 
sum
m
ary(glm
(Pl~H
D
P+A
ge+Sex,data=subset(TG
SZ,M
F==1))) 
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sink() 
 ## D
ata prep for individual m
odels 
raw
D
ata$M
FT[raw
D
ata$M
FTC
==0 | is.na(raw
D
ata$M
FTC
)] <- N
A
 
raw
D
ata$A
M
LT[raw
D
ata$A
M
LTC
==0 | is.na(raw
D
ata$A
M
LTC
)] <- N
A
 
raw
D
ata$C
PT <- raw
D
ata$Lcen 
# This takes into account patients that start in M
F 
raw
D
ata$M
FT[raw
D
ata$M
F==1] <- raw
D
ata$Lcen[raw
D
ata$M
F==1]  
raw
D
ata$C
PT[raw
D
ata$M
F==1] <- N
A
 
 raw
D
ata$D
iagnosis <- rep(0, nrow
(raw
D
ata)) 
# C
hange gender to an integer 
row
nam
es(raw
D
ata) <- raw
D
ata$U
PN
 
C
ohorts <- M
akeInteger(raw
D
ata$C
ohort) 
raw
D
ata[colnam
es(C
ohorts)] <- C
ohorts 
raw
D
ata$C
ohort <- N
U
LL 
raw
D
ata$Sex <- as.integer(raw
D
ata$Sex) 
splitPatients <- function(progsTim
es, Z){ 
        Zdup <- lapply(1:nrow
(progsTim
es), function(i){ 
                id <- progsTim
es[i,]$id 
                patient_data <- unlist(Z[row
nam
es(Z) == id,]) 
                return(patient_data) 
        }) 
        return(as.data.fram
e(do.call("rbind",Zdup))) 
} progressionTim
es <- function(data, startN
am
e, endN
am
e, transN
am
es, outcom
eN
am
e){ 
        progress_data <- N
U
LL 
        for (i in c(1:nrow
(data))){ 
                t <- c(as.num
eric(data[i,c(transN
am
es,endN
am
e)]) - as.num
eric(data[i,startN
am
e])) 
                order_idx <- order(t, na.last=N
A
) 
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                ordered_t <- c(0,t[order_idx]) 
                start_t <- ordered_t[-length(ordered_t)] 
                end_t <- ordered_t[-1] 
                trans_group <- m
atrix(0, length(order_idx), length(c(startN
am
e, transN
am
es))) 
                for (r in 1:length(order_idx)) 
                        trans_group[r, c(1,order_idx+1)[r]] <- 1 
                colnam
es(trans_group) <- c(startN
am
e, transN
am
es) 
                outcom
e <- rep(0, length(start_t)) 
                outcom
e[length(outcom
e)] <- data[i,outcom
eN
am
e] 
                s <- data.fram
e(id = row
nam
es(data)[i], trans_group, start.tim
e = start_t, end.tim
e = end_t, outcom
e=outcom
e) 
                progress_data <- rbind(progress_data, s) 
        } 
        return(progress_data) 
} dataG
roups <- list( 
    G
enetics = c("JA
K
2", "C
A
LR
1","C
A
LR
2", "M
PL", "JA
K
2e12", "TET2", "A
SX
L1", "D
N
M
T3A
", "PPM
1D
", "EZH
2", "N
F1", "N
FE2", "SF3B
1", 
"SR
SF2", "TP53", "U
2A
F1", "C
B
L", "M
LL3", "ZR
SR
2", "G
N
A
S", "K
R
A
S", "SH
2B
3", "ID
H
2", "PTPN
11", "K
IT", "R
B
1", "B
C
O
R
", "N
R
A
S", "C
U
X
1", 
"STA
G
2", "ID
H
1", "R
U
N
X
1", "PH
F6", "G
ATA
2", "G
N
B
1"), 
    C
ytogenetics = c("C
1p", "C
1q", "C
4", "C
5", "C
7", "C
8", "C
9U
", "C
9g", "C
11", "C
14", "C
17", "C
18", "C
19", "C
20"), 
    D
em
ographics = c("A
ge", "Sex"), 
    C
linical = c("Splen", "H
b", "W
C
C
", "Pl", "PV
", "ET","M
F","PriorThrom
"), 
N
uisance = c(colnam
es(C
ohorts)) 
)  mustH
aveC
ols <- c("D
eath","D
eathC
") 
for (col in m
ustH
aveC
ols) 
    raw
D
ata <- raw
D
ata[!is.na(raw
D
ata[[col]]),] 
 am
l_corrections <- !is.na(raw
D
ata$A
M
LTC
) &
 raw
D
ata$A
M
LTC
 &
 (raw
D
ata$D
eath - raw
D
ata$A
M
LT) < 1 &
 !is.na(raw
D
ata$A
M
LT) 
raw
D
ata$D
eath[am
l_corrections] <- raw
D
ata$A
M
LT[am
l_corrections] + 1 
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m
f_corrections <- !is.na(raw
D
ata$M
FTC
) &
 raw
D
ata$M
FTC
 &
 (raw
D
ata$D
eath - raw
D
ata$M
FT) < 1 &
 !is.na(raw
D
ata$M
FT) 
raw
D
ata$D
eath[m
f_corrections] <- raw
D
ata$M
FT[m
f_corrections] + 1 
tim
e_m
f_cp <- raw
D
ata$M
FT[raw
D
ata$M
F == 0]/365 
tim
e_am
l_cp <- raw
D
ata$A
M
LT[raw
D
ata$M
F == 0]/365 
tim
e_death_cp <- pm
in(raw
D
ata$D
eath[raw
D
ata$M
F == 0]/365, tim
e_am
l_cp, na.rm
 = T) 
outcom
e_from
_cp <- as.integer(raw
D
ata$D
eathC
[raw
D
ata$M
F == 0] | raw
D
ata$A
M
LTC
[raw
D
ata$M
F == 0]) 
tim
e_m
f_m
f <- raw
D
ata$M
FT[raw
D
ata$M
F != 0]/365 
tim
e_am
l_m
f <- raw
D
ata$A
M
LT[raw
D
ata$M
F != 0]/365 
tim
e_death_m
f <- pm
in(raw
D
ata$D
eath[raw
D
ata$M
F != 0]/365, tim
e_am
l_m
f, na.rm
 = T) 
outcom
e_from
_m
f <- as.integer(raw
D
ata$D
eathC
[raw
D
ata$M
F != 0] | raw
D
ata$A
M
LTC
[raw
D
ata$M
F != 0]) 
tim
eStage <- progressionTim
es(raw
D
ata, "D
iagnosis", "D
eath", c("C
PT", "M
FT", "A
M
LT"), "D
eathC
") 
raw
Z <- raw
D
ata[unlist(dataG
roups)] 
ZStdize <- StandardizeM
agnitude(raw
Z) 
colnam
es(ZStdize) <- colnam
es(raw
Z) 
poorM
ansIm
pute <- function(x) {x[is.na(x)] <- m
ean(x, na.rm
=TR
U
E); return(x)} 
ZIm
pute <- as.data.fram
e(sapply(ZStdize, poorM
ansIm
pute)) 
row
nam
es(ZIm
pute) <- row
nam
es(ZStdize) 
Zdup <- splitPatients(tim
eStage, ZIm
pute) 
all_data <-list(id=tim
eStage$id, 
        start.tim
e=tim
eStage$start.tim
e/365, 
        end.tim
e=tim
eStage$end.tim
e/365, 
        outcom
e=tim
eStage$outcom
e, 
        progression=tim
eStage[c("D
iagnosis", c("C
PT", "M
FT", "A
M
LT"))], 
        Z=Zdup) 
w
hich.m
u <- c() 
new
_split_patient <- w
hich(all_data$progression$D
iagnosis == 1) 
split_patient_diagnosis <- c() 
cp_or_m
f <- "C
P" 
for (i in (1:nrow
(all_data$progression))) { 
    if (i %
in%
 new
_split_patient) { 
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        if (as.integer(all_data$progression[i+1,]$C
PT) == 1){ 
            cp_or_m
f <- "C
P" 
        } 
        if (as.integer(all_data$progression[i+1,]$M
FT) == 1){ 
            cp_or_m
f <- "M
F" 
        } 
    } 
    split_patient_diagnosis <- c(split_patient_diagnosis, cp_or_m
f) 
} wpresam
pling <- w
hich(all_data$progression$D
iagnosis == 1) 
all_data$sam
pling.tim
e <- all_data$start.tim
e[w
presam
pling+1] - all_data$start.tim
e[w
presam
pling] 
# R
em
ove follow
ing line if you w
ant the start tim
e to go from
 sam
pling 
all_data$start.tim
e[w
presam
pling+1] <- all_data$start.tim
e[w
presam
pling] 
### 
all_data$Z <- all_data$Z[-w
presam
pling,] 
all_data$id <- all_data$id[-w
presam
pling] 
all_data$progression <- all_data$progression[-w
presam
pling,] 
all_data$start.tim
e <- all_data$start.tim
e[-w
presam
pling] 
all_data$end.tim
e <- all_data$end.tim
e[-w
presam
pling] 
all_data$outcom
e <- all_data$outcom
e[-w
presam
pling] 
all_data$split_patient_diagnosis <- all_data$split_patient_diagnosis[-w
presam
pling] 
split_patient_diagnosis <- split_patient_diagnosis[-w
presam
pling] 
m
f_data <-list(id=all_data$id[split_patient_diagnosis=="M
F"], 
    start.tim
e=all_data$start.tim
e[split_patient_diagnosis=="M
F"], 
    end.tim
e=all_data$end.tim
e[split_patient_diagnosis=="M
F"], 
    outcom
e=all_data$outcom
e[split_patient_diagnosis=="M
F"], 
    progression=all_data$progression[split_patient_diagnosis=="M
F",], 
    Z=all_data$Z[split_patient_diagnosis=="M
F",]) 
cp_data <-list(id=all_data$id[split_patient_diagnosis=="C
P"], 
    start.tim
e=all_data$start.tim
e[split_patient_diagnosis=="C
P"], 
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    end.tim
e=all_data$end.tim
e[split_patient_diagnosis=="C
P"], 
    outcom
e=all_data$outcom
e[split_patient_diagnosis=="C
P"], 
    progression=all_data$progression[split_patient_diagnosis=="C
P",], 
    Z=all_data$Z[split_patient_diagnosis=="C
P",]) 
dataList <- list( 
    G
enetics = all_data$Z[,dataG
roups$G
enetics], 
    C
ytogenetics = all_data$Z[,dataG
roups$C
ytogenetics], 
    D
em
ographics = all_data$Z[,dataG
roups$D
em
ographics], 
    C
linical = all_data$Z[,dataG
roups$C
linical], 
    N
uisance = all_data$Z[,dataG
roups$N
uisance] 
) groups <- unlist(sapply(nam
es(dataList), function(x) rep(x, ncol(dataList[[x]])))) 
groups <- factor(groups) 
nam
es(groups) <- colnam
es(all_data$Z) 
table(groups) 
w
cp <- w
hich(cp_data$progression$C
PT == 1) # Sub patients that are in C
P 
w
cpam
l <- intersect(w
cp+1, w
hich(cp_data$progression$A
M
LT == 1)) # Sub patients that have progressed to A
M
L from
 C
P 
w
cpm
f <- w
hich(cp_data$progression$M
FT == 1) # Sub patients that have progressed to M
F from
 C
P 
w
cpm
fam
l <- intersect(w
cpm
f+1, w
hich(cp_data$progression$A
M
LT == 1)) # Sub patients that have progressed to A
M
L from
 Secondary M
F 
length(w
cp) 
length(w
cpam
l) 
length(w
cpm
f) 
length(w
cpm
fam
l) 
w
m
f <- w
hich(m
f_data$progression$M
FT == 1) # Sub patients that are in M
F 
w
m
fam
l <- intersect(w
m
f+1, w
hich(m
f_data$progression$A
M
LT == 1)) # Sub patients that have progressed to A
M
L from
 prim
ary M
F 
length(w
m
f) 
length(w
m
fam
l) 
test_os <- Surv(cp_data$start.tim
e[w
cp], tim
e_death_cp, outcom
e_from
_cp) 
cp_or_m
f <- union(w
cp, w
cpm
f) 
o <- order(cp_or_m
f) 
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cp_or_m
f <- cp_or_m
f[o] 
os_from
_cp <- Surv(cp_data$start.tim
e[cp_or_m
f], cp_data$end.tim
e[cp_or_m
f], as.integer(cp_data$outcom
e[cp_or_m
f] | 
cp_data$progression$A
M
LT[cp_or_m
f+1]==1)) 
#os_from
_cp <- Surv(cp_data$end.tim
e[cp_or_m
f] - cp_data$start.tim
e[cp_or_m
f], as.integer(cp_data$outcom
e[cp_or_m
f] | 
cp_data$progression$A
M
LT[cp_or_m
f+1]==1)) 
 plot(survfit(os_from
_cp~1), xlim
=c(0, 25), xlab="Y
rs") 
lines(survfit(test_os~1), col="red") 
surv_cp <- Surv(cp_data$start.tim
e, cp_data$end.tim
e, cp_data$outcom
e)[w
cp,] 
#surv_cp <- Surv(cp_data$end.tim
e - cp_data$start.tim
e, cp_data$outcom
e)[w
cp,] 
 param
s_used_cp <- colSum
s(cp_data$Z[w
cp,])!=0 
cp_fit <- C
oxR
FX
(cp_data$Z[w
cp, param
s_used_cp], surv_cp, groups=groups[param
s_used_cp], w
hich.m
u=w
hich.m
u, nu=1, sigm
a0=0.01, m
ax.iter=200) 
o <- rep(0,length(cp_data$outcom
e)) 
o[intersect(w
cp,w
cpam
l-1)] <- 1 
cp_to_am
l_surv <- Surv(cp_data$start.tim
e, cp_data$end.tim
e, o)[w
cp,] 
#cp_to_am
l_surv <- Surv(cp_data$end.tim
e - cp_data$start.tim
e, o)[w
cp,] 
param
s_used_cp_to_am
l <- colSum
s(cp_data$Z[w
cp,])!=0 
cp_to_am
l_fit <- C
oxR
FX
(cp_data$Z[w
cp, param
s_used_cp_to_am
l], cp_to_am
l_surv, groups=groups[param
s_used_cp_to_am
l], w
hich.m
u=w
hich.m
u, 
nu=1, sigm
a0=0.01, m
ax.iter=200) 
o <- rep(0,length(cp_data$outcom
e)) 
o[intersect(w
cp,w
cpm
f-1)] <- 1 
cp_to_m
f_surv <- Surv(cp_data$start.tim
e, cp_data$end.tim
e, o)[w
cp,] 
#cp_to_m
f_surv <- Surv(cp_data$end.tim
e - cp_data$start.tim
e, o)[w
cp,] 
param
s_used_cp_to_m
f <- colSum
s(cp_data$Z[w
cp,])!=0 
cp_to_m
f_fit <- C
oxR
FX
(cp_data$Z[w
cp, param
s_used_cp_to_m
f], cp_to_m
f_surv, groups=groups[param
s_used_cp_to_m
f], w
hich.m
u=w
hich.m
u, nu=1, 
sigm
a0=0.01, m
ax.iter=200) 
com
bined_Z <- rbind(cp_data$Z[w
cpm
f,], m
f_data$Z[w
m
f,]) 
com
bined_Z$A
M
L_from
_M
F_Secondary <- c(rep(0, length(w
cpm
f)), rep(1, length(w
m
f))) 
#dataG
roups$N
uisance <- c(dataG
roups$N
uisance, "A
M
L_from
_M
F_Secondary") 
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#dataList$N
uisance <- com
bined_Z[,dataG
roups$N
uisance] 
dataG
roups$C
linical <- c(dataG
roups$C
linical, "A
M
L_from
_M
F_Secondary") 
dataList$C
linical <- com
bined_Z[,dataG
roups$C
linical] 
com
bined_groups <- unlist(sapply(nam
es(dataList), function(x) rep(x, ncol(dataList[[x]])))) 
com
bined_groups <- factor(com
bined_groups) 
nam
es(com
bined_groups) <- colnam
es(com
bined_Z) 
rebase_start_tim
e <- c(rep(0, length(cp_data$start.tim
e[w
cpm
f])), m
f_data$start.tim
e[w
m
f]) 
rebase_end_tim
e <- c((cp_data$end.tim
e[w
cpm
f] - cp_data$start.tim
e[w
cpm
f]), m
f_data$end.tim
e[w
m
f]) 
surv_m
f <- Surv(rebase_start_tim
e, rebase_end_tim
e, c(cp_data$outcom
e[w
cpm
f], m
f_data$outcom
e[w
m
f])) 
#surv_m
f <- Surv(rebase_end_tim
e - rebase_start_tim
e, c(cp_data$outcom
e[w
cpm
f], m
f_data$outcom
e[w
m
f])) 
param
s_used_m
f <- colSum
s(com
bined_Z)!=0 
com
bined_groups[param
s_used_m
f] 
m
f_fit <- C
oxR
FX
(com
bined_Z[param
s_used_m
f], surv_m
f, groups=com
bined_groups[param
s_used_m
f], w
hich.m
u=w
hich.m
u, nu=1, sigm
a0=0.01, 
m
ax.iter=200) 
rebase_start_tim
e <- c(rep(0, length(cp_data$start.tim
e[w
cpm
f])), m
f_data$start.tim
e[w
m
f]) 
rebase_end_tim
e <- c(cp_data$end.tim
e[w
cpm
f] - cp_data$start.tim
e[w
cpm
f], m
f_data$end.tim
e[w
m
f]) 
o_cp <- rep(0,length(cp_data$outcom
e)) 
o_cp[intersect(w
cpm
f,w
cpm
fam
l-1)] <- 1 
o_m
f <- rep(0,length(m
f_data$outcom
e)) 
o_m
f[intersect(w
m
f,w
m
fam
l-1)] <- 1 
o <- c(o_cp[w
cpm
f], o_m
f[w
m
f]) 
m
f_to_am
l_surv <- Surv(rebase_start_tim
e, rebase_end_tim
e, o) 
#m
f_to_am
l_surv <- Surv(rebase_end_tim
e - rebase_start_tim
e, o) 
param
s_used_m
f_to_am
l <- colSum
s(com
bined_Z)!=0 
m
f_to_am
l_fit <- C
oxR
FX
(com
bined_Z[param
s_used_m
f_to_am
l], m
f_to_am
l_surv, groups=com
bined_groups[param
s_used_m
f_to_am
l], 
w
hich.m
u=w
hich.m
u, nu=1, sigm
a0=0.01, m
ax.iter=200) 
o <- rep(0,length(cp_data$outcom
e)+length(m
f_data$outcom
e)) 
o[intersect(w
cp,w
cpam
l-1)] <- 1 
o[length(cp_data$outcom
e)+intersect(w
m
f,w
m
fam
l-1)] <- 1 
o[intersect(w
cp,w
cpm
fam
l-2)] <- 1 
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cporm
f<-c(w
cp,length(cp_data$outcom
e)+w
m
f) 
am
l_start_tim
e<-c(cp_data$start.tim
e,m
f_data$start.tim
e) 
am
l_end_tim
e<-c(cp_data$end.tim
e,m
f_data$end.tim
e) 
am
l_end_tim
e[intersect(w
cp,w
cpm
fam
l-2)]<-am
l_end_tim
e[w
cpm
fam
l] 
com
binedam
l_surv <- Surv(am
l_start_tim
e, am
l_end_tim
e, o)[cporm
f,] 
am
l_fit <- C
oxR
FX
(rbind(cp_data$Z,m
f_data$Z)[cporm
f,], com
binedam
l_surv, groups=groups, w
hich.m
u=w
hich.m
u, nu=1, sigm
a0=0.01, m
ax.iter=200) 
d <- sapply(1:length(w
cp), function(i){ 
            i <<- i 
            t <- c(tim
e_m
f_cp[i], tim
e_death_cp[i]) - cp_data$start.tim
e[w
cp][i] 
            o <- order(t, na.last=N
A
) 
            stages <- c(1:2,0) 
            r <- stages[c(1, o+1)] 
            if(outcom
e_from
_cp[i] &
 is.na(tim
e_am
l_cp[i])) 
                r[length(r)] <- r[length(r)-1] +2 
            if(!is.na(tim
e_am
l_cp[i])) 
                r[length(r)] <- r[length(r)-1] +4 
            tt <- c(cp_data$start.tim
e[w
cp][i],t[o]+cp_data$start.tim
e[w
cp][i]) 
            if(length(o)==0) 
                return(c(rep(N
A
,7),i)) 
            s <- cbind(id=i, start=tt[-length(tt)],  stop=tt[-1], start.stage=r[-length(r)], end.stage=r[-1])[diff(tt)!=0,] 
            # s <- cbind(tim
e1 = tt[-length(tt)], tim
e2=tt[-1], death=c(rep(0, length(o)-1), clinicalD
ata$Status[i]), outer(0:(length(o)-1), r[-3], `>=`)+0, 
i=i)[diff(tt)!=0,] 
            return(s) 
        }) 
d <- as.data.fram
e(do.call("rbind",d)) 
nodes <- as.character(1:6) 
edges <- list(`1`=list(edges=c("2","3","5")), `2`=list(edges=c("4","6")), `3`=list(edges=N
U
LL), `4`=list(edges=N
U
LL), 
`5`=list(edges=N
U
LL),`6`=list(edges=N
U
LL)) 
struct <-  new
("graphN
EL", nodes = nodes, edgeL = edges, edgem
ode = "directed") 
m
surv <- m
sSurv(d, struct, bs = FA
LSE, LT=TR
U
E) 
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y <- t(apply(cbind(1,-m
surv@
ps[,c(3:6, 2:1)]),1,cum
sum
)) 
par(m
ar=c(3,3,1,1), bty="n", m
gp=c(2,.5,0), las=1) 
plot(m
surv@
et, y[,1], ylim
=c(0,1), type="s",lty=0, xlab="Tim
e after diagnosis (years)", ylab="Fraction of patients", xlim
=c(0,25), xaxs="i", yaxs="i") 
steps <- function(x, type="s") rep(x, each=2)[if(type=="s") -1 else -2*length(x)] 
x <- steps(m
surv@
et, type="S") 
for(i in 1:6) 
    polygon(c(x, rev(x)), c(steps(y[,i]), rev(steps(y[,i+1])) ), col=c(brew
er.pal(5,"Pastel1")[c(1,2,3,4,5)],"#D
D
D
D
D
D
")[i], border=N
A
) 
abline(h=seq(0,1,.2), col='w
hite', lty=3) 
abline(v=seq(0,25,1), col='w
hite', lty=3) 
#plot(survfit(os_from
_cp ~ 1), xlim
=c(0, 25), ylim
=c(00, 1)) 
lines(x, steps(y[,5]), lw
d=2, col="black") 
#lines(survfit(test2_surv ~ 1), col="green") 
w
 <- w
hich.m
in(abs(m
surv@
et-25)) 
text(x=par("usr")[2], y= y[w
,-7]+diff(y[w
,])/2, labels=c(c("D
eath in post M
F A
M
L","D
eath in post C
P A
M
L","D
eath in M
F","D
eath in C
P")[4:1],"A
live in 
M
F","A
live in C
P"), pos=2) 
length(cp_or_m
f) 
M
ultiR
FX
5 <- function(coxR
FX
cpd, coxR
FX
am
ld, coxR
FX
m
f, coxR
FX
pm
fd, coxR
FX
pm
fam
ld, data, x =365, tdM
fB
aseline = rep(1, ceiling(m
ax(x))+1), 
tdM
fA
m
lB
aseline = rep(1, ceiling(m
ax(x))+1), tdPrm
B
aseline = rep(1, ceiling(m
ax(x))+1), tdO
sB
aseline = rep(1, ceiling(m
ax(x))+1), ciType="analytical",  
stage0="C
P"){ 
    cppFunction('N
um
ericVector com
puteH
ierarchicalSurvival(N
um
ericVector x, N
um
ericVector diffS0, N
um
ericVector S1Static, N
um
ericVector 
haz1Tim
eD
ep) { 
                    int xLen = x.size(); 
                    double h; 
                    N
um
ericVector overallSurvival(xLen); 
                    for(int i = 0; i < xLen; ++i) overallSurvival[i] = 1; 
                    for(int j = 1; j < xLen; ++j) if(diffS0[j-1] != 0){ 
                    h = haz1Tim
eD
ep[j-1]; 
                    for(int i = j; i < xLen; ++i){ 
                    overallSurvival[i] += diffS0[j-1] * (1-pow
(S1Static[i-j], h)); 
                    } 
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                    } 
                    return overallSurvival; 
                    }') 
    ## Step 1: C
om
pute K
M
 survival curves and log hazard 
    getS <- function(coxR
FX
, data, m
ax.x=5000) {         
        if(!is.null(coxR
FX
$na.action)) coxR
FX
$Z <- coxR
FX
$Z[-coxR
FX
$na.action,] 
        data <- as.m
atrix(data[,m
atch(colnam
es(coxR
FX
$Z),colnam
es(data)), drop=FA
LSE]) 
        r <- PredictR
iskM
issing(coxR
FX
, data, var="var2") 
        H
0 <- basehaz(coxR
FX
, centered = FA
LSE) 
        hazardD
ist <- splinefun(H
0$tim
e, H
0$hazard, m
ethod="m
onoH
.FC
") 
        x <- c(0:ceiling(m
ax.x/25))*25/365 
        S <- exp(-hazardD
ist(x)) 
        return(list(S=S, r=r, x=x, hazardD
ist=hazardD
ist, r0 = coxR
FX
$m
eans %
*%
 coef(coxR
FX
))) 
    } 
    km
M
f <- getS(coxR
FX
 = coxR
FX
m
f, data = data, m
ax.x=m
ax(x)) 
    km
C
pd <- getS(coxR
FX
 = coxR
FX
cpd, data = data, m
ax.x=m
ax(x)) 
    km
A
m
ld <- getS(coxR
FX
 = coxR
FX
am
ld, data = data, m
ax.x=m
ax(x)) 
    data$A
M
L_from
_M
F_Secondary <- rep(ifelse(stage0=="C
P", 1, 0), nrow
(data)) 
    km
Pm
fd <- getS(coxR
FX
 = coxR
FX
pm
fd, data = data, m
ax.x=m
ax(x)) 
    km
Pm
fam
ld <- getS(coxR
FX
 = coxR
FX
pm
fam
ld, data = data, m
ax.x=m
ax(x)) 
    xx <- 0:ceiling(m
ax(x)/25) 
    sapply(1:nrow
(data), function(i){ 
                # A
djust curves for com
peting risks, accounting for hazard 
                # C
P D
eath <-------- C
P --------> A
M
L D
eath 
                #                     | 
                #                     | 
                #                     | 
                #                     | 
                #                     V
 
                # M
F D
eath <-------- M
F --------> A
M
L D
eath 
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                m
fpA
bs <-  cum
sum
(c(1,diff(km
M
f$S^exp(km
M
f$r[i,1]))) * (km
C
pd$S ^ exp(km
C
pd$r[i,1])) * (km
A
m
ld$S ^ exp(km
A
m
ld$r[i,1]))) 
                cpdA
bs  <- cum
sum
(c(1,diff(km
C
pd$S^exp(km
C
pd$r[i,1]))) * (km
A
m
ld$S ^ exp(km
A
m
ld$r[i,1])) * (km
M
f$S ^ exp(km
M
f$r[i,1]))) ## array 
tim
es x nrow
(data) 
                am
ldA
bs  <- cum
sum
(c(1,diff(km
A
m
ld$S^exp(km
A
m
ld$r[i,1]))) * (km
M
f$S ^ exp(km
M
f$r[i,1])) * (km
C
pd$S ^ exp(km
C
pd$r[i,1]))) 
                m
fdA
bs <- cum
sum
(c(1,diff(km
Pm
fd$S^exp(km
Pm
fd$r[i,1]))) * (km
Pm
fam
ld$S ^ exp(km
Pm
fam
ld$r[i,1]))) 
                m
fam
ldA
bs <- cum
sum
(c(1,diff(km
Pm
fam
ld$S^exp(km
Pm
fam
ld$r[i,1]))) * (km
Pm
fd$S ^ exp(km
Pm
fd$r[i,1]))) ## array tim
es x nrow
(data) 
                ### O
verall survival from
 cronic phase 
                m
fam
ldC
p <- com
puteH
ierarchicalSurvival(x = xx, diffS0 = diff(m
fpA
bs), S1Static = m
fam
ldA
bs, haz1Tim
eD
ep = tdM
fA
m
lB
aseline) 
                m
fdC
p <- com
puteH
ierarchicalSurvival(x = xx, diffS0 = diff(m
fpA
bs), S1Static = m
fdA
bs, haz1Tim
eD
ep = tdM
fB
aseline) 
                ### O
verall survival from
 starting in M
F 
                m
fam
ldM
f <- m
fam
ldA
bs 
                m
fdM
f <- m
fdA
bs 
                cbind( 
                  deathInC
pFrom
C
p=1 - cpdA
bs, 
                  deathInM
fFrom
C
p=1 - m
fdC
p, 
                  deathInA
m
lFrom
C
p=1 - am
ldA
bs, 
                  deathInM
fam
lFrom
C
p=1 - m
fam
ldC
p, 
                  aliveInM
fFrom
C
p=1 - m
fpA
bs - (1 - m
fdC
p) - (1 - m
fam
ldC
p), 
                  deathInM
fFrom
M
F=1 - m
fdM
f, 
                  deathInA
m
lFrom
M
F=1 - m
fam
ldM
f 
                ) 
            }, sim
plify='array') 
}  save(all_data, cp_data, m
f_data, groups, M
ultiR
FX
5, dataG
roups, dataList, file="loo.R
D
ata") 
sm
f <- m
f_fit$surv 
coxphM
f <- coxph(sm
f[1:length(w
cpm
f)] ~ pspline(tim
e0, df=3) + I(offset), data=data.fram
e(tim
e0=cp_data$start.tim
e[w
cpm
f] - cp_data$start.tim
e[w
cpm
f 
- 1], offset=m
f_fit$linear.predictors[1:length(w
cpm
f)])) 
tdM
fB
aseline <- pm
in(50,pm
ax(0.1,exp(predict(coxphM
f, new
data=data.fram
e(tim
e0=seq(0,25,25/365), 
offset=m
ean(m
f_fit$linear.predictors[1:length(w
cpm
f)])))))) 
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plot(seq(0,25,25/365),tdM
fB
aseline, log="y") 
 # sam
l <- m
f_to_am
l_fit$surv 
# coxphM
fA
m
l <- coxph(sam
l[1:length(w
cpm
f)] ~ pspline(tim
e0, df=3) + I(offset), data=data.fram
e(tim
e0=cp_data$start.tim
e[w
cpm
f] - 
cp_data$start.tim
e[w
cpm
f - 1], offset=m
f_to_am
l_fit$linear.predictors[1:length(w
cpm
f)])) 
# tdM
fA
m
lB
aseline <-  pm
in(10,pm
ax(0.1,exp(predict(coxphM
fA
m
l, new
data=data.fram
e(tim
e0=seq(0,25,25/365), 
offset=m
ean(m
f_to_am
l_fit$linear.predictors[1:length(w
cpm
f)])))))) 
# plot(seq(0,25,25/365),tdM
fA
m
lB
aseline, log="y") 
fiveStagePredictedC
P <- M
ultiR
FX
5(cp_fit, am
l_fit, cp_to_m
f_fit, m
f_fit, am
l_fit, cp_data$Z[w
cp,], x=365*25)#, tdM
fB
aseline=tdM
fB
aseline, 
tdM
fA
m
lB
aseline=tdM
fA
m
lB
aseline) 
fiveStagePredictedM
F <- M
ultiR
FX
5(cp_fit, cp_to_am
l_fit, cp_to_m
f_fit, m
f_fit, m
f_to_am
l_fit, m
f_data$Z[w
m
f,], x=365*25)#, 
tdM
fB
aseline=tdM
fB
aseline, tdM
fA
m
lB
aseline=tdM
fA
m
lB
aseline) 
 sedim
entPlot <- function(Y, x=1:nrow
(Y
)*25/365, y0=0, y1=N
U
LL, col=1:ncol(Y
), ...){ 
    Z <- cbind(t(apply(cbind(y0,Y
),1,cum
sum
)),y1) 
    plot(x,Z[,1], xlim
=range(x), ylim
=range(Z), lty=0, pch=N
A
,...) 
    for(i in 2:ncol(Z)) 
        polygon(c(x,rev(x)), c(Z[,i-1],rev(Z[,i])), border=N
A
, col=col[i-1]) 
} lineStageC
P <- function(m
f_date, D
ate_LF, ER
D
ate, am
l_date, Status, y=0, col=1:5, pch.trans=19, pch.end=19, ...){ 
    xpd <- par("xpd") 
    par(xpd=N
A
) 
    t <- as.num
eric(c(m
f_date, D
ate_LF) - ER
D
ate ) 
    w
 <- !is.na(t) 
    o <- order(t) 
    to <- pm
in(t[o], par("usr")[2]) 
    l <- length(to) 
    segm
ents(c(0,to[-l]), rep(y,l), to, rep(y,l), col=col, lend=1, ...) 
    status <- 1 
    if(!is.na(m
f_date)) 
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        status <- status + 1 
    if(Status==1 &
 is.na(am
l_date)) 
        status <- status + 2 
    if(!is.na(am
l_date)) 
        status <- status + 4 
    x <- ifelse(t <= par("usr")[2], t, N
A
) 
    points(x, rep(y, length(t)), pch=c(pch.trans, if(Status | !is.na(am
l_date)) pch.end else N
A
), col=col[c(2,status)]) 
    par(xpd=xpd) 
} lineStageM
F <- function(D
ate_LF, ER
D
ate, am
l_date, Status, y=0, col=1:5, pch.trans=19, pch.end=19, ...){ 
    xpd <- par("xpd") 
    par(xpd=N
A
) 
    t <- as.num
eric(D
ate_LF - ER
D
ate ) 
    to <- pm
in(t, par("usr")[2]) 
    l <- length(to) 
    segm
ents(0, y, to, y, col=col, lend=1, ...) 
    status <- 1 
    if (is.na(am
l_date) &
 Status==1) 
      status <- 2 
    else if (!is.na(am
l_date)) 
      status <- 3 
    x <- ifelse(t <= par("usr")[2], t, N
A
) 
    points(x, y, pch=c(if(Status | !is.na(am
l_date)) pch.end else N
A
), col=col[status]) 
    par(xpd=xpd) 
} pastel1 <- brew
er.pal(9, "Pastel1") 
par(m
frow
=c(1,1), m
ar=c(3,3,1,1), cex=1) 
sedim
entPlot(-row
M
eans(fiveStagePredictedC
P[,1:5,], dim
s=2), y0=1, y1=0,  col=c(pastel1[c(1,2,3,4,5)], "#D
D
D
D
D
D
")) 
lines(survfit(os_from
_cp ~ 1)) 
legend('bottom
left', bty='n', col=c("red", "blue", "green", "purple", "orange", "grey"), legend=c("D
eath in C
P", "D
eath in M
F", "D
eath in A
M
L post C
P", 
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"D
eath in A
M
L post M
F", "A
live in M
F", "A
live in C
P"), lty=1) 
nStars <- 32; set.seed(42) 
os_cp_start <- Surv(cp_data$start.tim
e[w
cp], tim
e_death_cp, outcom
e_from
_cp) 
#os_cp_start <- Surv(tim
e_death_cp - cp_data$start.tim
e[w
cp], outcom
e_from
_cp) 
 cO
s_cp_start <- C
oxR
FX
(cp_data$Z[w
cp,], os_cp_start, groups=groups, w
hich.m
u = w
hich.m
u, nu=1, sigm
a0=0.01) 
 s_term
 <- sam
ple(w
hich(outcom
e_from
_cp==1)) 
s_cens <- sam
ple(w
hich(outcom
e_from
_cp==0),nStars^2 - length(s_term
)) 
s <- c(s_term
, s_cens) 
l <- "cO
s_cp_start" 
t <- os_cp_start 
p <- PartialR
isk(get(l),  new
Z=cp_data$Z[w
cp, colnam
es(get(l)$Z)]) 
p <- p[,colnam
es(p)!="N
uisance"] 
locations <- hilbertC
urve(log2(nStars))+1  
m
at <- m
atrix(order(locations[,1], locations[,2]), ncol=nStars) 
h <- hclust(dist(t(fiveStagePredictedC
P[5*365/25,,s])))#hclust(dist(p[s,])) 
o <- h$order # seq_along(h$order)# 
##Tiles graph 
pdf("tiles.pdf") 
layout(m
at[nStars:1,]) 
par(m
ar=c(0,0,0,0),+.5, bty="n") 
for(i in 1:nStars^2){ # Fitted predictions 
    sedim
entPlot(-fiveStagePredictedC
P[seq(1,301,30),1:5,s[o[i]]], x=seq(1,301,30),y0=1, y1=0,  col=c(pastel1[c(1,2,3,4,5)], "#D
D
D
D
D
D
"), 
xlab="tim
e",ylab="fraction", xaxt="n", yaxt="n") 
    lines(x=seq(1,301,30), y=1-row
Sum
s(fiveStagePredictedC
P[seq(1,301,30),1:4,s[o[i]]]), lw
d=1) 
    i <- s[o[i]] 
    lineStageC
P(tim
e_m
f_cp[i]*365/25, tim
e_death_cp[i]*365/25, cp_data$start.tim
e[w
cp][i]*365/25, tim
e_am
l_cp[i]*365/25, outcom
e_from
_cp[i], 
col=c('#999999','#ddcc00','#990000','#000099','#009900','#990099'), lw
d=2, pch.trans=N
A
, y=0.05)     
    #text(x=c(150), y=c(0.2), labels=c(i)) 
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} dev.off() 
survC
oncordance(cp_fit$surv ~ predict(cp_fit)) 
survC
oncordance(m
f_fit$surv ~ predict(m
f_fit)) 
survC
oncordance(cp_to_m
f_fit$surv ~ predict(cp_to_m
f_fit)) 
survC
oncordance(cp_to_am
l_fit$surv ~ predict(cp_to_am
l_fit)) 
survC
oncordance(m
f_to_am
l_fit$surv ~ predict(m
f_to_am
l_fit)) 
survC
oncordance(am
l_fit$surv ~ predict(am
l_fit)) 
# print(survC
oncordance(os_cp_start ~ colSum
s(fiveStagePredictedC
P[5*365/25,1:4,]))) 
# print(survC
oncordance(os_cp_start ~ colSum
s(fiveStagePredictedC
P[10*365/25,1:4,]))) 
# print(survC
oncordance(os_cp_start ~ colSum
s(fiveStagePredictedC
P[15*365/25,1:4,]))) 
# print(survC
oncordance(os_cp_start ~ colSum
s(fiveStagePredictedC
P[20*365/25,1:4,]))) 
# print(survC
oncordance(os_cp_start ~ colSum
s(fiveStagePredictedC
P[25*365/25,1:4,]))) 
sink("TG
S_output.txt",append=TR
U
E) 
cat("Variance contributions and H
R
s for each variable") 
cbind(colSum
s(cov(as.m
atrix(all_data$Z[,nam
es(am
l_fit$coeff)])%
*%
diag(am
l_fit$coeff))),exp(am
l_fit$coeff)) 
cbind(colSum
s(cov(as.m
atrix(cp_data$Z[,nam
es(cp_fit$coeff)])%
*%
diag(cp_fit$coeff))),exp(cp_fit$coeff)) 
cbind(colSum
s(cov(as.m
atrix(m
f_data$Z[,nam
es(m
f_fit$coeff[1:61])])%
*%
diag(m
f_fit$coeff[1:61]))),exp(m
f_fit$coeff)[1:61]) 
cbind(colSum
s(cov(as.m
atrix(cp_data$Z[,nam
es(cp_to_m
f_fit$coeff)])%
*%
diag(cp_to_m
f_fit$coeff))),exp(cp_to_m
f_fit$coeff)) 
sink() 
###R
un LO
O
 first, then 
TG
SZcut_pred<- sapply(lapply(c(1:nrow
(TG
SZcut)), function(i){ 
e <- new
.env() 
if (i %
in%
 (c(1:20)*100)) 
print(paste("D
one",i,"out of",nrow
(TG
SZcut))) 
t <- try(load(paste0("../data/loo/",TG
SZcut$U
PN
[i],".R
D
ata"), env=e)) 
if(class(t)=="try-error") rep(N
A
, length(tim
es)) 
else e$fiveStagePredicted[,,1] 
}), I, sim
plify="array") 
##O
therw
ise: TG
SZcut_pred<-M
ultiR
FX
5(cp_fit, am
l_fit, cp_to_m
f_fit, m
f_fit, am
l_fit, TG
SZcut, x=365*25) 
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new
dataplot<- 
function(new
data,ET=new
data$ET,PV
=new
data$PV,M
F=new
data$M
F){ 
pastel2<-c("#B
FFFFF","#A
3D
8D
1","#FFB
FC
9","#FF7387","#D
1C
299","#A
3D
8D
1","#FF7387") 
new
data$M
F==M
F;new
data$PV
==PV;new
data$ET==ET 
m
ultistate<-M
ultiR
FX
5(cp_fit, am
l_fit, cp_to_m
f_fit, m
f_fit, am
l_fit, new
data, x=365*25) 
if (M
F==0) { 
sedim
entPlot(-m
ultistate[seq(1,361,30),1:5,1], x=seq(1,361,30),y0=1, y1=0,  col=c(pastel2[c(1,2,3,4,5)], "#D
6E3D
E"), xlab="Tim
e from
 diagnosis 
(years)",ylab="Proportion of patients", xaxt="n",yaxt="n") 
    lines(x=seq(1,361,30), y=1-row
Sum
s(m
ultistate[seq(1,361,30),1:4,1]), lw
d=1) 
segm
ents(x0=0,y0=0.5,x1=new
data$D
eath/25,y1=0.5) 
points(x=new
data$D
eath/25,y=0.5,cex=new
data$D
eathC
,pch=19);points(x=new
data$D
eath/25,y=0.5,cex=new
data$D
eathC
*0.85,pch=19,col="#B
FFFFF") 
if(new
data$D
eathC
==1&
new
data$M
FTC
==1&
new
data$A
M
LTC
==0){points(x=new
data$D
eath/25,y=0.5,cex=0.9,pch=19,col="#A
3D
8D
1")} 
if(new
data$D
eathC
==1&
new
data$M
FTC
==1&
new
data$A
M
LTC
==1){points(x=new
data$D
eath/25,y=0.5,cex=0.9,pch=19,col="#FF7387")} 
if(new
data$D
eathC
==1&
new
data$M
FTC
==0&
new
data$A
M
LTC
==1){points(x=new
data$D
eath/25,y=0.5,cex=0.9,pch=19,col="#FFB
FC
9")} 
points(x=new
data$M
FT/25,y=0.5,cex=new
data$M
FTC
*0.5,pch=18) 
} else { 
sedim
entPlot(-m
ultistate[seq(1,361,30),6:7,1], x=seq(1,361,30),y0=1, y1=0,  col=c(pastel2[c(6,7)], "#D
1C
299"), xlab="Tim
e from
 diagnosis 
(years)",ylab="Proportion of patients", xaxt="n",yaxt="n") 
    lines(x=seq(1,361,30), y=1-row
Sum
s(m
ultistate[seq(1,361,30),6:7,1]), lw
d=1) 
segm
ents(x0=0,y0=0.5,x1=new
data$D
eath/25,y1=0.5);points(x=new
data$D
eath/25,y=0.5,cex=new
data$D
eathC
,pch=19);points(x=new
data$D
eath/25,y=0.5
,cex=new
data$A
M
LTC
*0.85,pch=19,col="#FF7387") 
} } new
dataplotLO
O
<- 
function(new
data,m
ultistate,i){ 
pastel2<-c("#B
FFFFF","#A
3D
8D
1","#FFB
FC
9","#FF7387","#D
1C
299","#A
3D
8D
1","#FF7387") 
new
data<-new
data[i,];M
F<-new
data$M
F;PV
<-new
data$PV;ET<-new
data$ET 
if (M
F==0) { 
sedim
entPlot(-m
ultistate[seq(1,361,30),1:5,i], x=seq(1,361,30),y0=1, y1=0,  col=c(pastel2[c(1,2,3,4,5)], "#D
6E3D
E"), xlab="Tim
e from
 diagnosis 
(years)",ylab="Proportion of patients", xaxt="n",yaxt="n") 
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    lines(x=seq(1,361,30), y=1-row
Sum
s(m
ultistate[seq(1,361,30),1:4,i]), lw
d=1) 
segm
ents(x0=0,y0=0.5,x1=new
data$D
eath/25,y1=0.5) 
points(x=new
data$D
eath/25,y=0.5,cex=new
data$D
eathC
*2,pch=19);points(x=new
data$D
eath/25,y=0.5,cex=new
data$D
eathC
*1.8,pch=19,col="#B
FFFFF") 
if(new
data$D
eathC
==1&
new
data$M
FTC
==1&
new
data$A
M
LTC
==0){points(x=new
data$D
eath/25,y=0.5,cex=1.8,pch=19,col="#A
3D
8D
1")} 
if(new
data$D
eathC
==1&
new
data$M
FTC
==1&
new
data$A
M
LTC
==1){points(x=new
data$D
eath/25,y=0.5,cex=1.8,pch=19,col="#FF7387")} 
if(new
data$D
eathC
==1&
new
data$M
FTC
==0&
new
data$A
M
LTC
==1){points(x=new
data$D
eath/25,y=0.5,cex=1.8,pch=19,col="#FFB
FC
9")} 
points(x=new
data$M
FT/25,y=0.5,cex=new
data$M
FTC
,pch=4) 
} else { 
sedim
entPlot(-m
ultistate[seq(1,361,30),6:7,i], x=seq(1,361,30),y0=1, y1=0,  col=c(pastel2[c(6,7)], "#D
1C
299"), xlab="Tim
e from
 diagnosis 
(years)",ylab="Proportion of patients", xaxt="n",yaxt="n") 
    lines(x=seq(1,361,30), y=1-row
Sum
s(m
ultistate[seq(1,361,30),6:7,i]), lw
d=1) 
segm
ents(x0=0,y0=0.5,x1=new
data$D
eath/25,y1=0.5);points(x=new
data$D
eath/25,y=0.5,cex=new
data$D
eathC
*2,pch=19);points(x=new
data$D
eath/25,y=
0.5,cex=new
data$D
eathC
*1.8,pch=19,col="#A
3D
8D
1");points(x=new
data$D
eath/25,y=0.5,cex=new
data$A
M
LTC
*1.8,pch=19,col="#FF7387") 
} } ape2<-function (x, tim
e,censor, tim
epoint, censored = "conditional")  
{     surv<-Surv(tim
e,censor) 
    status <- survStatus(surv, tim
epoint, censored = censored) 
    p<-length(w
hich(status==1))/length(censor);unc<-p*(1-p) 
    err <- c(unc=unc, brier = m
ean((x-status)^2, na.rm
 = TR
U
E),brier0=m
ean((rep(0,length(censor))-status)^2,na.rm
=TR
U
E), 
brier1=m
ean((rep(1,length(censor))-status)^2,na.rm
=TR
U
E), brierp=m
ean((rep(p,length(censor))-status)^2,na.rm
=TR
U
E), abs = m
ean(abs(x-status),  
        na.rm
 = TR
U
E)) 
    return(err) 
} sink("TG
S_output.txt",append=TR
U
E) 
cat("C
oncordances for full m
ultistate m
odel") 
for(i in c(5,10,15,20)){ 
cat("O
S concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$M
F==0)]))$
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concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$M
F==0)]))$
std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("M
F transform
ation concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$M
F==0)]
))$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$M
F==0)]
))$std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L transform
ation concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,c(3,4),w
hich(TG
SZcut$M
F==0
)]))$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,c(3,4),w
hich(TG
SZcut$M
F==0
)]))$std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("EFS concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0)]))$co
ncordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0)]))$std.
err,"\n") 
}  for(i in c(5,10,15,20)){ 
cat("O
S concordance for ET, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$ET==1)]))$c
oncordance, " stderr: ", 
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survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$ET==1)]))$s
td.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("M
F transform
ation concordance for ET, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$ET==1)])
)$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$ET==1)])
)$std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L transform
ation concordance for ET, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,c(3,4),w
hich(TG
SZcut$ET==1)
]))$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,c(3,4),w
hich(TG
SZcut$ET==1)
]))$std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("EFS concordance for ET, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$ET==1)]))$con
cordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$ET==1)]~colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$ET==1)]))$std.e
rr,"\n") 
}  for(i in c(5,10,15,20)){ 
cat("EFS concordance for M
F, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==1)]~colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1)]))$co
ncordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==1)]~colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1)]))$std.
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err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L concordance for M
F, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut_pred[i*365/25,7,w
hich(TG
SZcut$M
F==1)])$concordan
ce, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut_pred[i*365/25,7,w
hich(TG
SZcut$M
F==1)])$std.err,"\n"
) } cat("Prediction uncertainty, B
rier score, A
PE for full m
ultistate m
odel") 
for(i in c(5,10,15,20)){ 
cat("O
S in C
P at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$M
F==0)]),TG
SZcut$D
eath[w
hich(TG
SZcut$M
F==0)],TG
SZcut$D
eathC
[w
hich(TG
SZcut$M
F==0)]
,i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("M
F transform
ation in C
P at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$M
F==0)]),TG
SZcut$M
FT[w
hich(TG
SZcut$M
F==0)],TG
SZcut$M
FTC
[w
hich(TG
SZcut$M
F==
0)],i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L transform
ation in C
P at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,c(3,4),w
hich(TG
SZcut$M
F==0)]),TG
SZcut$A
M
LT[w
hich(TG
SZcut$M
F==0)],TG
SZcut$A
M
LTC
[w
hich(TG
SZcut$M
F
==0)],i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("EFS in C
P at",i,"yrs", 
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ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0)]),TG
SZcut$EFS[w
hich(TG
SZcut$M
F==0)],TG
SZcut$EFSC
[w
hich(TG
SZcut$M
F==0)],i*
365.25),"\n") 
}  cat("Prediction uncertainty, B
rier score, A
PE for full m
ultistate m
odel") 
for(i in c(5,10,15,20)){ 
cat("O
S in ET at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$ET==1)]),TG
SZcut$D
eath[w
hich(TG
SZcut$ET==1)],TG
SZcut$D
eathC
[w
hich(TG
SZcut$ET==1)],i
*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("M
F transform
ation in ET at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$ET==1)]),TG
SZcut$M
FT[w
hich(TG
SZcut$ET==1)],TG
SZcut$M
FTC
[w
hich(TG
SZcut$ET==1
)],i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L transform
ation in ET at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,c(3,4),w
hich(TG
SZcut$ET==1)]),TG
SZcut$A
M
LT[w
hich(TG
SZcut$ET==1)],TG
SZcut$A
M
LTC
[w
hich(TG
SZcut$ET==
1)],i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("EFS in ET at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$ET==1)]),TG
SZcut$EFS[w
hich(TG
SZcut$ET==1)],TG
SZcut$EFSC
[w
hich(TG
SZcut$ET==1)],i*36
5.25),"\n") 
} 
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 for(i in c(5,10,15,20)){ 
cat("EFS in M
F at",i,"yrs", 
ape2(1-
colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1)]),TG
SZcut$EFS[w
hich(TG
SZcut$M
F==1)],TG
SZcut$EFSC
[w
hich(TG
SZcut$M
F==1)],i*
365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L transform
ation in M
F at",i,"yrs", 
ape2(1-
TG
SZcut_pred[i*365/25,7,w
hich(TG
SZcut$M
F==1)],TG
SZcut$A
M
LT[w
hich(TG
SZcut$M
F==1)],TG
SZcut$A
M
LTC
[w
hich(TG
SZcut$M
F==1)],i*365.25)
,"\n") 
}  cat("O
ther m
odels:") 
cat("O
S concordance for C
P, using H
M
R
: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$concordance, " stderr: 
", survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("M
F transform
ation concordance for H
M
R
: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("A
M
L transform
ation concordance for H
M
R
: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$concordance, " 
stderr: ", survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("EFS concordance for C
P, using H
M
R
. C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
 cat("O
S concordance for C
P, using A
ge/throm
bosis: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$concordance, " stderr: 
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", survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("M
F transform
ation concordance for A
ge/Throm
bosis: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("A
M
L transform
ation concordance for A
ge/throm
bosis: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$concordance, " 
stderr: ", survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("EFS concordance for C
P, using A
ge/Throm
bosis: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
 cat("O
S concordance for C
P, using IPSET: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$concordance, " stderr: 
", survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$std.err,"\n") 
cat("M
F transform
ation concordance for IPSET: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$std.err,"\n") 
cat("A
M
L transform
ation concordance for IPSET: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$concordance, " 
stderr: ", survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$std.err,"\n") 
cat("EFS concordance for C
P, using IPSET. C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$concordance, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$ET==1)]~TG
SZcut$IPSET[w
hich(TG
SZcut$ET==1)])$std.err,"\n") 
 cat("O
S concordance for C
P, using C
A
LR
A
SX
L1: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$concordance, 
" stderr: ", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("M
F transform
ation concordance in C
P for C
A
LR
A
SX
L1: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$concordance, " 
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stderr: ", 
survC
oncordance(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("A
M
L transform
ation concordance in C
P for C
A
LR
A
SX
L1: C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$concordanc
e, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
cat("EFS concordance for C
P, using C
A
LR
A
SX
L1. C
oncordance:", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$concordance, " 
stderr: ", 
survC
oncordance(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==0)])$std.err,"\n") 
 cat("EFS concordance for H
M
R
 in M
F: ", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==1)])$concordance, " stderr: 
", survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==1)])$std.err,"\n") 
cat("A
M
L transform
ation concordance for H
M
R
 in M
F: ", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==1)])$concordance, " 
stderr: ", survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$H
M
R
[w
hich(TG
SZcut$M
F==1)])$std.err,"\n") 
 cat("EFS concordance for PT60 in M
F: ", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==1)])$concordance, " stderr: 
", survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==1)])$std.err,"\n") 
cat("A
M
L transform
ation concordance for PT60 in M
F: ", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==1)])$concordance, " 
stderr: ", survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$PT60[w
hich(TG
SZcut$M
F==1)])$std.err,"\n") 
 cat("EFS concordance for C
A
LR
A
SX
L1 in M
F: ", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==1)])$concordance, 
" stderr: ", 
survC
oncordance(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==1)])$std.err,"\n") 
cat("A
M
L transform
ation concordance for C
A
LR
A
SX
L1 in M
F: ", 
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survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==1)])$concordanc
e, " stderr: ", 
survC
oncordance(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1)]~TG
SZcut$C
A
LR
A
SX
L1[w
hich(TG
SZcut$M
F==1)])$std.err,"\n") 
 for(i in c(5,10,15,20)){ 
print(cbind(aggregate(1-colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0)]),by=list(quantileC
ut(1-
colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0)]),20)),FU
N
=m
edian),sum
m
ary(survfit(Surv(EFS/365.25,EFSC
)[w
hich(TG
SZcut$M
F==0)]
~quantileC
ut(1-
colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0)]),20),data=TG
SZcut),tim
es=c(i),extend=TR
U
E)$surv,sum
m
ary(survfit(Surv(EFS/365.25,E
FSC
)[w
hich(TG
SZcut$M
F==0)]~quantileC
ut(1-
colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0)]),20),data=TG
SZcut),tim
es=c(i),extend=TR
U
E)$std.err)) 
}  for(i in c(5,10,15,20)){ 
print(cbind(aggregate(1-colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1)]),by=list(quantileC
ut(1-
colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1)]),15)),FU
N
=m
edian),sum
m
ary(survfit(Surv(D
eath/365.25,D
eathC
)[w
hich(TG
SZcut$M
F==
1)]~quantileC
ut(1-
colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1)]),15),data=TG
SZcut),tim
es=c(i),extend=TR
U
E)$surv,sum
m
ary(survfit(Surv(D
eath/365.25,
D
eathC
)[w
hich(TG
SZcut$M
F==1)]~quantileC
ut(1-
colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1)]),15),data=TG
SZcut),tim
es=c(i),extend=TR
U
E)$std.err)) 
}    sink() 
 ## External validation cohort 
florM
F<-read.table("florM
F2.csv",sep=",",header=TR
U
E) 
florM
F$D
eathC
[w
hich(florM
F$A
M
LTC
==1)]<-1 
florM
F_pred<-M
ultiR
FX
5(cp_fit, am
l_fit, cp_to_m
f_fit, m
f_fit, am
l_fit, florM
F, x=365*25) 
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 sink("TG
S_output.txt",append=TR
U
E) 
cat("A
nalysis of external M
F cohort") 
for(i in c(5,10,15,20)){ 
cat("EFS concordance for M
F, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1)]))$concordan
ce, " stderr: ", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1)]))$std.err,"\n
") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L concordance for M
F, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F_pred[i*365/25,7,w
hich(florM
F$M
F==1)])$concordance, " 
stderr: ", survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F_pred[i*365/25,7,w
hich(florM
F$M
F==1)])$std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("EFS in M
F at",i,"yrs", 
ape2(1-
colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1)]),florM
F$D
eath[w
hich(florM
F$M
F==1)],florM
F$D
eathC
[w
hich(florM
F$M
F==1)],i*365.25),"
\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L transform
ation in M
F at",i,"yrs", 
ape2(1-
florM
F_pred[i*365/25,7,w
hich(florM
F$M
F==1)],florM
F$A
M
LT[w
hich(florM
F$M
F==1)],florM
F$A
M
LTC
[w
hich(florM
F$M
F==1)],i*365.25),"\n") 
}  cat("EFS concordance for M
F using D
IPSS: C
oncordance:", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~florM
F$D
IPSS)$concordance, " stderr: ", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~florM
F$D
IPSS)$std.err,"\n") 
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 cat("A
M
L concordance for M
F using D
IPSS: C
oncordance:", 
survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F$D
IPSS)$concordance, " stderr: ", 
survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F$D
IPSS)$std.err,"\n") 
 cat("EFS concordance for M
F using IPSS: C
oncordance:", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~florM
F$IPSS)$concordance, " stderr: ", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~florM
F$IPSS)$std.err,"\n") 
 cat("A
M
L concordance for M
F using IPSS: C
oncordance:", 
survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F$IPSS)$concordance, " stderr: ", 
survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F$IPSS)$std.err,"\n") 
 cat("EFS concordance for M
F using H
M
R
: C
oncordance:", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~florM
F$H
M
R
)$concordance, " stderr: ", 
survC
oncordance(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1)]~florM
F$H
M
R
)$std.err,"\n") 
 cat("A
M
L concordance for M
F using H
M
R
: C
oncordance:", 
survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F$H
M
R
)$concordance, " stderr: ", 
survC
oncordance(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1)]~florM
F$H
M
R
)$std.err,"\n") 
 for(i in c(5,10,15,20)){ 
print(cbind(aggregate(1-colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1)]),by=list(quantileC
ut(1-
colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1)]),10)),FU
N
=m
edian),sum
m
ary(survfit(Surv(D
eath/365.25,D
eathC
)[w
hich(florM
F$M
F==1)]~q
uantileC
ut(1-
colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1)]),10),data=florM
F),tim
es=c(i),extend=TR
U
E)$surv,sum
m
ary(survfit(Surv(D
eath/365.25,D
eath
C
)[w
hich(florM
F$M
F==1)]~quantileC
ut(1-
colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1)]),10),data=florM
F),tim
es=c(i),extend=TR
U
E)$std.err)) 
}  
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cat("\n External C
P cohort") 
florC
P<-read.table("florC
P_backup.csv",sep=",",header=TR
U
E) 
florC
P<-florC
P[w
hich(florC
P$O
LD
==0),] 
florC
P$D
eathC
[w
hich(florC
P$A
M
LTC
==1)]<-1 
florC
P_pred<-M
ultiR
FX
5(cp_fit, am
l_fit, cp_to_m
f_fit, m
f_fit, am
l_fit, florC
P, x=365*25) 
  for(i in c(5,10,15,20)){ 
cat("O
S concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(florC
P$D
eath,florC
P$D
eathC
)~colSum
s(florC
P_pred[i*365/25,1:4,]))$concordance, " stderr: ", 
survC
oncordance(Surv(florC
P$D
eath,florC
P$D
eathC
)~colSum
s(florC
P_pred[i*365/25,1:4,]))$std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("A
M
L concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(florC
P$A
M
LT,florC
P$A
M
LTC
)~colSum
s(florC
P_pred[i*365/25,3:4,]))$concordance, " stderr: ", 
survC
oncordance(Surv(florC
P$A
M
LT,florC
P$A
M
LTC
)~colSum
s(florC
P_pred[i*365/25,3:4,]))$std.err,"\n") 
}  for(i in c(5,10,15,20)){ 
cat("M
FT concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(florC
P$M
FT,florC
P$M
FTC
)~colSum
s(florC
P_pred[i*365/25,c(2,4,5),]))$concordance, " stderr: ", 
survC
oncordance(Surv(florC
P$M
FT,florC
P$M
FTC
)~colSum
s(florC
P_pred[i*365/25,c(2,4,5),]))$std.err,"\n") 
} for(i in c(5,10,15,20)){ 
cat("EFS concordance for C
P, using",i, "yr predictions: C
oncordance:", 
survC
oncordance(Surv(florC
P$EFS,florC
P$EFSC
)~colSum
s(florC
P_pred[i*365/25,1:5,]))$concordance, " stderr: ", 
survC
oncordance(Surv(florC
P$EFS,florC
P$EFSC
)~colSum
s(florC
P_pred[i*365/25,1:5,]))$std.err,"\n") 
}   
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for(i in c(5,10,15,20)){ 
print(cbind(aggregate(1-colSum
s(florC
P_pred[i*365/25,1:5,]),by=list(quantileC
ut(1-
colSum
s(florC
P_pred[i*365/25,1:5,]),10)),FU
N
=m
edian),sum
m
ary(survfit(Surv(EFS/365.25,EFSC
)~quantileC
ut(1-
colSum
s(florC
P_pred[i*365/25,1:5,]),10),data=florC
P),tim
es=c(i),extend=TR
U
E)$surv,sum
m
ary(survfit(Surv(EFS/365.25,EFSC
)~quantileC
ut(1-
colSum
s(florC
P_pred[i*365/25,1:5,]),10),data=florC
P),tim
es=c(i),extend=TR
U
E)$std.err)) 
}  for(i in c(5,10,15,20)){ 
cat("U
nc/B
riar/A
pe. O
S in C
P at",i,"yrs", 
ape2(1-colSum
s(florC
P_pred[i*365/25,1:4,]),florC
P$D
eath,florC
P$D
eathC
,i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("U
nc/B
riar/A
pe. A
M
LT in C
P at",i,"yrs", 
ape2(1-colSum
s(florC
P_pred[i*365/25,3:4,]),florC
P$A
M
LT,florC
P$A
M
LTC
,i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("U
nc/B
riar/A
pe. M
FT in C
P at",i,"yrs", 
ape2(1-colSum
s(florC
P_pred[i*365/25,c(2,4,5),]),florC
P$M
FT,florC
P$M
FTC
,i*365.25),"\n") 
} for(i in c(5,10,15,20)){ 
cat("U
nc/B
riar/A
pe. EFS in C
P at",i,"yrs", 
ape2(1-colSum
s(florC
P_pred[i*365/25,1:5,]),florC
P$EFS,florC
P$EFSC
,i*365.25),"\n") 
}    ##A
U
C
.uno 
 for(i in c(5,10,15,20)){ 
cat("U
no. O
S in C
P at",i,"yrs", 
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A
U
C
.uno(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0&
TG
SZcut$D
eathC
>=0)],Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==0&
TG
SZcut$D
eathC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$M
F==0&
TG
SZcut$D
eathC
>=0)]),seq(100,365*25,50))$iau
c, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. M
FT in C
P at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$M
F==0&
TG
SZcut$M
FTC
>=0)],Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZc
ut$M
F==0&
TG
SZcut$M
FTC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$M
F==0&
TG
SZcut$M
FTC
>=0)]),seq(100,365*25,50))$iauc
, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. A
M
L in C
P at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==0&
TG
SZcut$A
M
LTC
>=0)],Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich
(TG
SZcut$M
F==0&
TG
SZcut$A
M
LTC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,3:4,w
hich(TG
SZcut$M
F==0&
TG
SZcut$A
M
LTC
>=0)]),seq(100,365*25,50
))$iauc, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. EFS in C
P at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$M
F==0&
TG
SZcut$EFSC
>=0)],Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$
M
F==0&
TG
SZcut$EFSC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$M
F==0&
TG
SZcut$EFSC
>=0)]),seq(100,365*25,50))$iauc, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. O
S in ET at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$ET==1&
TG
SZcut$D
eathC
>=0)],Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$ET==1&
TG
SZcut$D
eathC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,1:4,w
hich(TG
SZcut$ET==1&
TG
SZcut$D
eathC
>=0)]),seq(100,365*25,50))$iauc
, "\n") 
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}  for(i in c(5,10,15,20)){ 
cat("U
no. M
FT in ET at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZcut$ET==1&
TG
SZcut$M
FTC
>=0)],Surv(TG
SZcut$M
FT,TG
SZcut$M
FTC
)[w
hich(TG
SZc
ut$ET==1&
TG
SZcut$M
FTC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,c(2,4,5),w
hich(TG
SZcut$ET==1&
TG
SZcut$M
FTC
>=0)]),seq(100,365*25,50))$iauc, 
"\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. A
M
L in ET at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$ET==1&
TG
SZcut$A
M
LTC
>=0)],Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich
(TG
SZcut$ET==1&
TG
SZcut$A
M
LTC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,3:4,w
hich(TG
SZcut$ET==1&
TG
SZcut$A
M
LTC
>=0)]),seq(100,365*25,50)
)$iauc, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. EFS in ET at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$ET==1&
TG
SZcut$EFSC
>=0)],Surv(TG
SZcut$EFS,TG
SZcut$EFSC
)[w
hich(TG
SZcut$E
T==1&
TG
SZcut$EFSC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,1:5,w
hich(TG
SZcut$ET==1&
TG
SZcut$EFSC
>=0)]),seq(100,365*25,50))$iauc, "\n") 
}   for(i in c(5,10,15,20)){ 
cat("U
no. EFS in M
F at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1&
TG
SZcut$D
eathC
>=0)],Surv(TG
SZcut$D
eath,TG
SZcut$D
eathC
)[w
hich(TG
SZcut$M
F==1&
TG
SZcut$D
eathC
>=0)],colSum
s(TG
SZcut_pred[i*365/25,6:7,w
hich(TG
SZcut$M
F==1&
TG
SZcut$D
eathC
>=0)]),seq(100,365*25,50))$iau
c, "\n") 
}  
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for(i in c(5,10,15,20)){ 
cat("U
no. A
M
L in M
F at",i,"yrs", 
A
U
C
.uno(Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich(TG
SZcut$M
F==1&
TG
SZcut$A
M
LTC
>=0)],Surv(TG
SZcut$A
M
LT,TG
SZcut$A
M
LTC
)[w
hich
(TG
SZcut$M
F==1&
TG
SZcut$A
M
LTC
>=0)],TG
SZcut_pred[i*365/25,7,w
hich(TG
SZcut$M
F==1&
TG
SZcut$A
M
LTC
>=0)],seq(100,365*25,50))$iauc, 
"\n") 
}   for(i in c(5,10,15,20)){ 
cat("U
no. O
S in external C
P at",i,"yrs", 
A
U
C
.uno(Surv(florC
P$D
eath,florC
P$D
eathC
)[w
hich(florC
P$M
F==0&
florC
P$D
eathC
>=0)],Surv(florC
P$D
eath,florC
P$D
eathC
)[w
hich(florC
P$M
F==0&
fl
orC
P$D
eathC
>=0)],colSum
s(florC
P_pred[i*365/25,1:4,w
hich(florC
P$M
F==0&
florC
P$D
eathC
>=0)]),seq(100,365*25,50))$iauc, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. M
FT in external C
P at",i,"yrs", 
A
U
C
.uno(Surv(florC
P$M
FT,florC
P$M
FTC
)[w
hich(florC
P$M
F==0&
florC
P$M
FTC
>=0)],Surv(florC
P$M
FT,florC
P$M
FTC
)[w
hich(florC
P$M
F==0&
florC
P$M
FTC
>=0)],colSum
s(florC
P_pred[i*365/25,c(2,4,5),w
hich(florC
P$M
F==0&
florC
P$M
FTC
>=0)]),seq(100,365*25,50))$iauc, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. A
M
L in external C
P at",i,"yrs", 
A
U
C
.uno(Surv(florC
P$A
M
LT,florC
P$A
M
LTC
)[w
hich(florC
P$M
F==0&
florC
P$A
M
LTC
>=0)],Surv(florC
P$A
M
LT,florC
P$A
M
LTC
)[w
hich(florC
P$M
F==
0&
florC
P$A
M
LTC
>=0)],colSum
s(florC
P_pred[i*365/25,3:4,w
hich(florC
P$M
F==0&
florC
P$A
M
LTC
>=0)]),seq(100,365*25,50))$iauc, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. EFS in external C
P at",i,"yrs", 
A
U
C
.uno(Surv(florC
P$EFS,florC
P$EFSC
)[w
hich(florC
P$M
F==0&
florC
P$EFSC
>=0)],Surv(florC
P$EFS,florC
P$EFSC
)[w
hich(florC
P$M
F==0&
florC
P$E
FSC
>=0)],colSum
s(florC
P_pred[i*365/25,1:5,w
hich(florC
P$M
F==0&
florC
P$EFSC
>=0)]),seq(100,365*25,50))$iauc, "\n") 
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}  for(i in c(5,10,15,20)){ 
cat("U
no. A
M
L in M
F at",i,"yrs", 
A
U
C
.uno(Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1&
florM
F$A
M
LTC
>=0)],Surv(florM
F$A
M
LT,florM
F$A
M
LTC
)[w
hich(florM
F$M
F==1&
florM
F$A
M
LTC
>=0)],florM
F_pred[i*365/25,7,w
hich(florM
F$M
F==1&
florM
F$A
M
LTC
>=0)],seq(100,365*25,50))$iauc, "\n") 
}  for(i in c(5,10,15,20)){ 
cat("U
no. EFS in M
F at",i,"yrs", 
A
U
C
.uno(Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==1&
florM
F$D
eathC
>=0)],Surv(florM
F$D
eath,florM
F$D
eathC
)[w
hich(florM
F$M
F==
1&
florM
F$D
eathC
>=0)],colSum
s(florM
F_pred[i*365/25,6:7,w
hich(florM
F$M
F==1&
florM
F$D
eathC
>=0)]),seq(100,365*25,50))$iauc, "\n") 
}  sink() 
   #Sedim
ents plots 
#R
estrict to only patients w
ho had event or sufficiently long FU
 to assess m
odel 
#B
est and w
orst 
 TG
SZC
P<-TG
SZcut[w
hich(TG
SZcut$M
F==0&
(TG
SZcut$EFSC
==1|TG
SZcut$D
eath>=3650)),] 
TG
SZC
Ppred<-TG
SZcut_pred[,,w
hich(TG
SZcut$M
F==0&
(TG
SZcut$EFSC
==1|TG
SZcut$D
eath>=3650))] 
TG
SZM
F<-TG
SZcut[w
hich(TG
SZcut$M
F==1&
(TG
SZcut$EFSC
==1|TG
SZcut$D
eath>=5*365)),] 
TG
SZM
Fpred<-TG
SZcut_pred[,,w
hich(TG
SZcut$M
F==1&
(TG
SZcut$EFSC
==1|TG
SZcut$D
eath>=5*365))] 
 pdf("C
P_O
S_top30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZC
Ppred[10*365/25,1:4,]))[(nrow
(TG
SZC
P)-29):nrow
(TG
SZC
P)]){new
dataplotLO
O
(TG
SZC
P,TG
SZC
Ppred,i)} 
 
193 
dev.off() 
pdf("C
P_A
M
L_top30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZC
Ppred[10*365/25,3:4,]))[(nrow
(TG
SZC
P)-29):nrow
(TG
SZC
P)]){new
dataplotLO
O
(TG
SZC
P,TG
SZC
Ppred,i)} 
dev.off() 
pdf("C
P_M
F_top30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZC
Ppred[10*365/25,c(2,4,5),]))[(nrow
(TG
SZC
P)-29):nrow
(TG
SZC
P)]){new
dataplotLO
O
(TG
SZC
P,TG
SZC
Ppred,i)} 
dev.off() 
pdf("C
P_EFS_top30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZC
Ppred[10*365/25,1:5,]))[(nrow
(TG
SZC
P)-29):nrow
(TG
SZC
P)]){new
dataplotLO
O
(TG
SZC
P,TG
SZC
Ppred,i)} 
dev.off() 
pdf("C
P_EFS_best30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZC
Ppred[20*365/25,1:5,]))[1:30]){new
dataplotLO
O
(TG
SZC
P,TG
SZC
Ppred,i)} 
dev.off() 
pdf("C
P_transdeaths_top30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZC
Ppred[10*365/25,2:4,]))[(nrow
(TG
SZC
P)-29):nrow
(TG
SZC
P)]){new
dataplotLO
O
(TG
SZC
P,TG
SZC
Ppred,i)} 
dev.off() 
pdf("M
F_O
S_top30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZM
Fpred[10*365/25,6:7,]))[(nrow
(TG
SZM
F)-29):nrow
(TG
SZM
F)]){new
dataplotLO
O
(TG
SZM
F,TG
SZM
Fpred,i)} 
dev.off() 
pdf("M
F_A
M
L_top30.pdf",w
idth=2) 
par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(TG
SZM
Fpred[10*365/25,7,])[(nrow
(TG
SZM
F)-29):nrow
(TG
SZM
F)]){new
dataplotLO
O
(TG
SZM
F,TG
SZM
Fpred,i)} 
dev.off() 
pdf("M
F_O
S_best30.pdf",w
idth=2) 
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par(m
frow
=c(10,3), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZM
Fpred[10*365/25,6:7,]))[1:30]){new
dataplotLO
O
(TG
SZM
F,TG
SZM
Fpred,i)} 
dev.off() 
 # Flor M
F sedim
ent plots by H
M
R
 
   0   1   2   3  
 43  89 109  57  
 pdf("D
IPSS0.pdf",w
idth=5) 
par(m
frow
=c(9,5), m
ar=c(0,0,0,0)) 
for(i in 
order(colSum
s(florM
F_pred[10*365/25,6:7,w
hich(florM
F$D
IPSS==0)]))){new
dataplotLO
O
(florM
F[w
hich(florM
F$D
IPSS==0),],florM
F_pred[,,w
hich(flor
M
F$D
IPSS==0)],i)} 
dev.off() 
 pdf("D
IPSS1.pdf",w
idth=10) 
par(m
frow
=c(9,10), m
ar=c(0,0,0,0)) 
for(i in 
order(colSum
s(florM
F_pred[10*365/25,6:7,w
hich(florM
F$D
IPSS==1)]))){new
dataplotLO
O
(florM
F[w
hich(florM
F$D
IPSS==1),],florM
F_pred[,,w
hich(flor
M
F$D
IPSS==1)],i)} 
dev.off() 
 pdf("D
IPSS2.pdf",w
idth=12) 
par(m
frow
=c(9,12), m
ar=c(0,0,0,0)) 
for(i in 
order(colSum
s(florM
F_pred[10*365/25,6:7,w
hich(florM
F$D
IPSS==2)]))){new
dataplotLO
O
(florM
F[w
hich(florM
F$D
IPSS==2),],florM
F_pred[,,w
hich(flor
M
F$D
IPSS==2)],i)} 
dev.off() 
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pdf("D
IPSS3.pdf",w
idth=7) 
par(m
frow
=c(9,7), m
ar=c(0,0,0,0)) 
for(i in 
order(colSum
s(florM
F_pred[10*365/25,6:7,w
hich(florM
F$D
IPSS==3)]))){new
dataplotLO
O
(florM
F[w
hich(florM
F$D
IPSS==3),],florM
F_pred[,,w
hich(flor
M
F$D
IPSS==3)],i)} 
dev.off() 
 #Sedim
ent plots 
# 30 equally spread 
 pdf("C
P_EFS_range.pdf",w
idth=3) 
par(m
frow
=c(10,4), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZC
Ppred[20*365/25,1:5,]))[seq(1,857,length.out=50)]){new
dataplotLO
O
(TG
SZC
P,TG
SZC
Ppred,i)} 
dev.off() 
 pdf("M
F_EFS_range40.pdf",w
idth=3) 
par(m
frow
=c(10,4), m
ar=c(0,0,0,0)) 
for(i in order(colSum
s(TG
SZM
Fpred[10*365/25,6:7,]))[seq(1,210,length.out=40)]){new
dataplotLO
O
(TG
SZM
F,TG
SZM
Fpred,i)} 
dev.off() 
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Appendix(3:(M
utational(profiles(of(2035(M
PN(patients(
(
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203 
165"
ET"
ASXL1"
20"
31023092"
_"
delC"
p.N
859fs*8"
0.44"
fram
eshift"(+1bp)"
CALR"
B"
166"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
167"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
168"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
169"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
170"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
171"
ET"
KRAS"
12"
25380256"
T"
A"
p.R68W
"
0.07"
M
issense"
JAK2V617F"
B"
172"
ET"
TET2"
4"
106190905"
G"
A"
p.?"
0.14"
Splice"
CALR"
B"
172"
ET"
TP53"
17"
7578388"
C"
T"
p.R181H"
0.23"
M
issense"
CALR"
B"
172"
ET"
ASXL1"
20"
31022844"
G"
T"
p.E777*"
0.19"
N
onsense"
CALR"
B"
173"
ET"
N
F1"
17"
29654554"
G"
A"
p.R1769Q
"
0.56"
M
issense"
CALR"
B"
173"
ET"
PPM
1D"
17"
58740559"
_"
delT"
p.S489fs*2"
0.05"
fram
eshift"(+1bp)"
CALR"
B"
173"
ET"
PPM
1D"
17"
58740376"
G"
A"
p.W
427*"
0.4"
N
onsense"
CALR"
B"
174"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
175"
ET"
DN
M
T3A"
2"
25467083"
G"
A"
p.R598*"
0.34"
N
onsense"
JAK2V617F"
B"
175"
ET"
TET2"
4"
106164020"
T"
G"
p.I1177S"
0.36"
M
issense"
JAK2V617F"
B"
176"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
177"
ET"
TET2"
4"
106156439"
_"
delG"
p.E448fs*2"
0.45"
fram
eshift"(+1bp)"
JAK2V617F"
B"
177"
ET"
TET2"
4"
106193931"
C"
T"
p.R1465*"
0.11"
N
onsense"
JAK2V617F"
B"
177"
ET"
ASXL1"
20"
31022937"
_"
delCC"
p.P808fs*13"
0.17"
fram
eshift"(+2bp)"
JAK2V617F"
B"
178"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
179"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
180"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.34"
M
issense"
JAK2V617F"
B"
180"
ET"
TET2"
4"
106157326"
_"
insA"
p.Q
744fs*10"
0.11"
fram
eshift"(+2bp)"
JAK2V617F"
B"
181"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
182"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
 
204 
183"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
184"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
185"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
186"
ET"
SF3B1"
2"
198266518"
A"
C"
p.L773R"
0.14"
M
issense"
JAK2V617F"
B"
187"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
188"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
189"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.32"
M
issense"
JAK2V617F"
B"
190"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
191"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
192"
ET"
TET2"
4"
106196762"
C"
T"
p.Q
1699*"
0.49"
N
onsense"
JAK2V617F"
Chr9,14"
192"
ET"
CBL"
11"
119149239"
G"
C"
p.C416S"
0.06"
M
issense"
JAK2V617F"
Chr9,14"
192"
ET"
ZRSR2"
X"
15833805"
C"
A"
p.S188*"
0.92"
N
onsense"
JAK2V617F"
Chr9,14"
193"
ET"
N
FE2"
12"
54686441"
G"
T"
p.A280D"
0.16"
M
issense"
B"
B"
194"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
195"
ET"
PPM
1D"
17"
58740536"
_"
delG"
p.A481fs*2"
0.08"
fram
eshift"(+1bp)"
CALR"
Chr5,17,20"
195"
ET"
PPM
1D"
17"
58740542"
_"
insAC"
p.R485fs*1"
0.06"
fram
eshift"(+1bp)"
CALR"
Chr5,17,20"
195"
ET"
TP53"
17"
7577120"
C"
T"
p.R273H"
0.5"
M
issense"
CALR"
Chr5,17,20"
196"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
197"
ET"
ASXL1"
20"
31022937"
_"
delC"
p.P808fs*10"
0.03"
fram
eshift"(+1bp)"
CALR"
Chr20"
198"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.31"
M
issense"
JAK2V617F"
B"
198"
ET"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.4"
M
issense"
JAK2V617F"
B"
198"
ET"
GATA2"
3"
128200729"
A"
G"
p.L359S"
0.2"
M
issense"
JAK2V617F"
B"
199"
ET"
PPM
1D"
17"
58740508"
_"
delA"
p.E472fs*11"
0.01"
fram
eshift"(+1bp)"
CALR"
B"
199"
ET"
PPM
1D"
17"
58740546"
T"
G"
p.L484*"
0.16"
N
onsense"
CALR"
B"
199"
ET"
PPM
1D"
17"
58740691"
_"
delA"
p.N
533fs*6"
0.05"
fram
eshift"(+1bp)"
CALR"
B"
200"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
 
205 
201"
ET"
ASXL1"
20"
31022899"
_"
delC"
p.W
796fs*22"
0.36"
fram
eshift"(+1bp)"
JAK2V617F"
Chr12"
202"
ET"
TET2"
4"
106164079"
A"
G"
p.K1197E"
0.12"
M
issense"
JAK2V617F"
Chr9"
202"
ET"
CBL"
11"
119149245"
T"
C"
p.F418S"
0.06"
M
issense"
JAK2V617F"
Chr9"
203"
ET"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.43"
M
issense"
JAK2V617F"
Chr9"
204"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
205"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
206"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
207"
ET"
EZH2"
7"
148506401"
C"
T"
p.?"
0.07"
Splice"
JAK2V617F"
B"
208"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.33"
M
issense"
JAK2V617F"
B"
209"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
210"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F,CALR"
B"
211"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
212"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
213"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
214"
ET"
TP53"
17"
7578503"
C"
T"
p.V143M
"
0.05"
M
issense"
CALR"
B"
215"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
216"
ET"
TET2"
4"
106182915"
_"
delG"
p.?"
0.16"
Splice"
CALR"
B"
216"
ET"
TET2"
4"
106156359"
_"
delA"
p.E421fs*6"
0.03"
fram
eshift"(+1bp)"
CALR"
B"
216"
ET"
N
FE2"
12"
54687087"
_"
delA"
p.Y65fs*46"
0.18"
fram
eshift"(+1bp)"
CALR"
B"
217"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
218"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
219"
ET"
TET2"
4"
106158055"
G"
T"
p.G986*"
0.05"
N
onsense"
CALR"
B"
220"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
221"
ET"
DN
M
T3A"
2"
25466836"
_"
delA"
p.Y623fs*28"
0.08"
fram
eshift"(+1bp)"
CALR"
B"
222"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.24"
M
issense"
CALR"
B"
223"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
 
206 
224"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
225"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
226"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
227"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
228"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr14"
229"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
230"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
231"
ET"
PPM
1D"
17"
58740836"
C"
T"
p.R581*"
0.18"
N
onsense"
CALR"
B"
232"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
233"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
234"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
235"
ET"
DN
M
T3A"
2"
25457243"
G"
A"
p.R882C"
0.39"
M
issense"
CALR"
B"
235"
ET"
TET2"
4"
106156540"
C"
T"
p.Q
481*"
0.07"
N
onsense"
CALR"
B"
236"
ET"
TET2"
4"
106196650"
T"
G"
p.Y1661*"
0.32"
N
onsense"
JAK2V617F"
Chr9"
237"
ET"
U
2AF1"
21"
44524456"
G"
T"
p.S34Y"
0.14"
M
issense"
M
PLW
515"
B"
238"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
239"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
240"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
241"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
242"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F,M
PLW
515"
B"
243"
ET"
CBL"
11"
119149239"
G"
C"
p.C416S"
0.05"
M
issense"
JAK2V617F"
B"
244"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
245"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
246"
ET"
M
PL"
1"
43818306"
T"
G"
p.Y591D"
0.35"
M
issense"
M
PLW
515"
B"
247"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
248"
ET"
PPM
1D"
17"
58740528"
_"
delGC"
p.A479fs*1"
0.13"
fram
eshift"(+2bp)"
CALR"
B"
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249"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.35"
M
issense"
JAK2V617F"
B"
249"
ET"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.38"
M
issense"
JAK2V617F"
B"
250"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
251"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
252"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
Chr1p"
253"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr19"
254"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
255"
ET"
N
F1"
17"
29664383"
C"
T"
p.?"
0.5"
Splice"
JAK2V617F"
B"
256"
ET"
TET2"
4"
106156819"
C"
T"
p.Q
574*"
0.3"
N
onsense"
JAK2V617F,CALR"
B"
256"
ET"
PPM
1D"
17"
58740498"
C"
G"
p.S468*"
0.31"
N
onsense"
JAK2V617F,CALR"
B"
257"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
258"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
259"
ET"
TET2"
4"
106183003"
C"
A"
p.Q
1348K"
0.3"
M
issense"
JAK2V617F"
B"
260"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
261"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
262"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
263"
ET"
DN
M
T3A"
2"
25457243"
G"
A"
p.R882C"
0.25"
M
issense"
JAK2V617F"
B"
264"
ET"
PPM
1D"
17"
58740836"
C"
T"
p.R581*"
0.06"
N
onsense"
B"
B"
265"
ET"
N
FE2"
12"
54686495"
_"
delCTCT"
p.E261fs*3"
0.23"
fram
eshift"(+1bp)"
CALR"
B"
266"
ET"
PPM
1D"
17"
58740507"
_"
delCA"
p.P471fs*4"
0.11"
fram
eshift"(+2bp)"
CALR"
B"
267"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
268"
ET"
SF3B1"
2"
198267360"
T"
G"
p.K666T"
0.38"
M
issense"
JAK2V617F"
B"
268"
ET"
ASXL1"
20"
31022937"
_"
insC"
p.A809fs*13"
0.09"
fram
eshift"(+2bp)"
JAK2V617F"
B"
268"
ET"
ASXL1"
20"
31023272"
_"
delACCATCTGTTG"
p.P920fs*24"
0.01"
fram
eshift"(+2bp)"
JAK2V617F"
B"
269"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
270"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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271"
ET"
SF3B1"
2"
198267489"
T"
C"
p.Y623C"
0.46"
M
issense"
CALR"
B"
271"
ET"
KRAS"
12"
25398262"
C"
G"
p.L19F"
0.31"
M
issense"
CALR"
B"
272"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
273"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
274"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
275"
ET"
TET2"
4"
106180784"
_"
insG"
p.C1271fs*29"
0.07"
fram
eshift"(+2bp)"
JAK2V617F"
B"
276"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
277"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
278"
ET"
PPM
1D"
17"
58740691"
_"
delA"
p.N
533fs*6"
0.24"
fram
eshift"(+1bp)"
B"
B"
279"
ET"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.34"
fram
eshift"(+2bp)"
CALR"
B"
280"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
281"
ET"
GN
AS"
20"
57415346"
G"
A"
p.R62Q
"
0.39"
M
issense"
CALR"
B"
282"
ET"
N
FE2"
12"
54686495"
_"
delCTCT"
p.E261fs*3"
0.33"
fram
eshift"(+1bp)"
M
PLW
515"
Chr1p"
283"
ET"
DN
M
T3A"
2"
25463556"
G"
C"
p.P709R"
0.05"
M
issense"
JAK2V617F"
B"
284"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
285"
ET"
ASXL1"
20"
31022287"
_"
insA"
p.Y591fs*1"
0.06"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
285"
ET"
ZRSR2"
X"
15836766"
G"
A"
p.?"
0.45"
Splice"
JAK2V617F"
Chr9"
286"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
287"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
288"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
289"
ET"
TET2"
4"
106193892"
C"
T"
p.R1452*"
0.05"
N
onsense"
CALR"
B"
290"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
291"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
292"
ET"
DN
M
T3A"
2"
25470516"
G"
A"
p.R320*"
0.47"
N
onsense"
CALR"
B"
292"
ET"
TET2"
4"
106158339"
_"
delTT"
p.L1081fs*22"
0.22"
fram
eshift"(+2bp)"
CALR"
B"
292"
ET"
KRAS"
12"
25378562"
C"
T"
p.A146T"
0.09"
M
issense"
CALR"
B"
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292"
ET"
N
F1"
17"
29588850"
T"
G"
p.S1567A"
0.07"
M
issense"
CALR"
B"
293"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
294"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
Chr20"
295"
ET"
TET2"
4"
106180784"
_"
insG"
p.C1271fs*29"
0.11"
fram
eshift"(+2bp)"
CALR"
B"
295"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
296"
ET"
PPM
1D"
17"
58740691"
_"
delA"
p.N
533fs*6"
0.03"
fram
eshift"(+1bp)"
M
PLW
515"
Chr1p,14"
297"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
298"
ET"
TET2"
4"
106180784"
_"
insG"
p.C1271fs*29"
0.03"
fram
eshift"(+2bp)"
JAK2V617F"
B"
298"
ET"
TET2"
4"
106157603"
C"
G"
p.S835*"
0.05"
N
onsense"
JAK2V617F"
B"
299"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
300"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
301"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
302"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
303"
ET"
TET2"
4"
106196347"
T"
G"
p.Y1560*"
0.24"
N
onsense"
CALR"
B"
304"
ET"
TET2"
4"
106197235"
_"
insT"
p.P1857fs*2"
0.32"
fram
eshift"(+2bp)"
JAK2V617F,M
PLW
515"
B"
305"
ET"
M
PL"
1"
43815011"
C"
G"
p.Q
516E"
0.26"
M
issense"
M
PLW
515"
B"
305"
ET"
TET2"
4"
106157020"
_"
delG"
p.Q
642fs*58"
0.01"
fram
eshift"(+1bp)"
M
PLW
515"
B"
306"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
307"
ET"
IDH1"
2"
209113112"
C"
T"
p.R132H"
0.09"
M
issense"
CALR"
B"
308"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
309"
ET"
TET2"
4"
106156157"
_"
delG"
p.C353fs*19"
0.07"
fram
eshift"(+1bp)"
JAK2V617F"
B"
309"
ET"
ASXL1"
20"
31022418"
G"
T"
p.E635*"
0.09"
N
onsense"
JAK2V617F"
B"
310"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
311"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
312"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
313"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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314"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
315"
ET"
TET2"
4"
106156701"
_"
delAAAC"
p.N
535fs*6"
0.35"
fram
eshift"(+1bp)"
JAK2V617F"
B"
316"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
317"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
318"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
319"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
320"
ET"
M
LL3"
7"
151882660"
_"
delC"
p.E1689fs*28"
0.07"
fram
eshift"(+1bp)"
B"
B"
321"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
322"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
323"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
324"
ET"
TET2"
4"
106162499"
_"
delA"
p.I1139fs*13"
0.05"
fram
eshift"(+1bp)"
CALR"
B"
325"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
326"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
327"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
328"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
329"
ET"
PPM
1D"
17"
58740357"
C"
G"
p.S421*"
0.18"
N
onsense"
JAK2V617F"
B"
329"
ET"
ASXL1"
20"
31023231"
_"
delG"
p.E906fs*2"
0.07"
fram
eshift"(+1bp)"
JAK2V617F"
B"
330"
ET"
TET2"
4"
106197317"
A"
G"
p.T1884A"
0.27"
M
issense"
JAK2V617F"
B"
331"
ET"
TET2"
4"
106197285"
T"
C"
p.I1873T"
0.36"
M
issense"
JAK2V617F"
B"
331"
ET"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.31"
M
issense"
JAK2V617F"
B"
331"
ET"
RU
N
X1"
21"
36259156"
A"
T"
p.L112Q
"
0.34"
M
issense"
JAK2V617F"
B"
332"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
333"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
334"
ET"
TET2"
4"
106164778"
C"
T"
p.R1216*"
0.45"
N
onsense"
JAK2V617F"
B"
335"
ET"
N
FE2"
12"
54686511"
_"
delA"
p.Y257fs*3"
0.23"
fram
eshift"(+1bp)"
M
PLW
515"
B"
335"
ET"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.26"
M
issense"
M
PLW
515"
B"
 
211 
336"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
337"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
338"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
339"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
340"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
341"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
342"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr9"
343"
ET"
TET2"
4"
106155427"
A"
T"
p.K110*"
0.14"
N
onsense"
B"
B"
344"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
345"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr19"
346"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
347"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
348"
ET"
DN
M
T3A"
2"
25470484"
C"
T"
p.W
330*"
0.36"
N
onsense"
CALR"
B"
349"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
350"
ET"
TET2"
4"
106158041"
_"
insT"
p.K982fs*1"
0.39"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
350"
ET"
M
LL3"
7"
151882660"
_"
delC"
p.E1689fs*28"
0.06"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
351"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
352"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
353"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
354"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
355"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
356"
ET"
GN
B1"
1"
1747229"
T"
C"
p.K57E"
0.43"
M
issense"
JAK2V617F"
B"
356"
ET"
SH2B3"
12"
111885289"
C"
T"
p.Q
393*"
0.06"
N
onsense"
JAK2V617F"
B"
357"
ET"
SF3B1"
2"
198266834"
T"
C"
p.K700E"
0.44"
M
issense"
JAK2V617F"
Chr1q,9"
357"
ET"
TET2"
4"
106158489"
_"
insC"
p.S1132fs*10"
0.07"
fram
eshift"(+2bp)"
JAK2V617F"
Chr1q,9"
358"
ET"
GN
B1"
1"
1747229"
T"
C"
p.K57E"
0.05"
M
issense"
JAK2V617F"
B"
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359"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
360"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
361"
ET"
M
PL"
1"
43814967"
T"
C"
p.V501A"
0.63"
M
issense"
M
PLS505N
"
Chr1p"
362"
ET"
TET2"
4"
106157002"
C"
T"
p.Q
635*"
0.46"
N
onsense"
CALR"
Chr9,19"
362"
ET"
N
FE2"
12"
54686562"
_"
insC"
p.D240fs*10"
0.44"
fram
eshift"(+2bp)"
CALR"
Chr9,19"
363"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
364"
ET"
TET2"
4"
106157345"
_"
delAAATA"
p.I750fs*2"
0.46"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
365"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
366"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
367"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
368"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
369"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
370"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
371"
ET"
ASXL1"
20"
31021348"
C"
G"
p.Y449*"
0.31"
N
onsense"
B"
B"
372"
ET"
DN
M
T3A"
2"
25463247"
C"
T"
p.R749H"
0.39"
M
issense"
JAK2V617F"
B"
373"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
374"
ET"
PTPN
11"
12"
112924336"
G"
A"
p.V428M
"
0.14"
M
issense"
CALR"
B"
375"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
376"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
377"
ET"
TET2"
4"
106197317"
A"
G"
p.T1884A"
0.17"
M
issense"
CALR"
B"
378"
ET"
TET2"
4"
106156336"
_"
delC"
p.P413fs*14"
0.29"
fram
eshift"(+1bp)"
JAK2V617F"
B"
378"
ET"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.29"
fram
eshift"(+2bp)"
JAK2V617F"
B"
379"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
380"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
381"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
382"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
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383"
ET"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.1"
M
issense"
B"
B"
384"
ET"
DN
M
T3A"
2"
25470497"
C"
T"
p.R326H"
0.34"
M
issense"
JAK2V617F"
B"
384"
ET"
TET2"
4"
106197285"
T"
C"
p.I1873T"
0.32"
M
issense"
JAK2V617F"
B"
384"
ET"
TET2"
4"
106196657"
C"
T"
p.Q
1664*"
0.05"
N
onsense"
JAK2V617F"
B"
385"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
386"
ET"
TET2"
4"
106157761"
C"
T"
p.Q
888*"
0.31"
N
onsense"
JAK2V617F"
B"
387"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
389"
ET"
B"
B"
B"
_"
B"
B"
B"
B"
JAK2V617F"
B"
390"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
391"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
392"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
393"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
394"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
395"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
396"
ET"
TET2"
4"
106196329"
_"
insA"
p.E1555fs*23"
0.06"
fram
eshift"(+2bp)"
JAK2V617F"
B"
396"
ET"
TET2"
4"
106164778"
C"
T"
p.R1216*"
0.32"
N
onsense"
JAK2V617F"
B"
397"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
398"
ET"
SH2B3"
12"
111885522"
_"
insG"
p.V434fs*22"
0.11"
fram
eshift"(+2bp)"
JAK2V617F"
B"
399"
ET"
ASXL1"
20"
31024148"
_"
delCTCC"
p.L1213fs*3"
0.02"
fram
eshift"(+1bp)"
CALR"
B"
400"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR,M
PLW
515"
B"
401"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
402"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
403"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
404"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.41"
M
issense"
JAK2V617F"
B"
404"
ET"
SF3B1"
2"
198266834"
T"
C"
p.K700E"
0.19"
M
issense"
JAK2V617F"
B"
405"
ET"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.04"
fram
eshift"(+2bp)"
JAK2V617F"
B"
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406"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
407"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
408"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
409"
ET"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.16"
M
issense"
CALR"
B"
410"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
411"
ET"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.34"
M
issense"
B"
B"
412"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr20"
413"
ET"
SF3B1"
2"
198267361"
T"
G"
p.K666Q
"
0.38"
M
issense"
JAK2V617F"
B"
414"
ET"
M
LL3"
7"
151927007"
C"
G"
p.?"
0.06"
Splice"
CALR"
B"
415"
ET"
DN
M
T3A"
2"
25458595"
A"
G"
p.W
860R"
0.23"
M
issense"
JAK2V617F"
B"
416"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
417"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
418"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
419"
ET"
PPM
1D"
17"
58740526"
_"
delT"
p.C478fs*5"
0.17"
fram
eshift"(+1bp)"
CALR"
B"
420"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
421"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
422"
ET"
TP53"
17"
7578406"
C"
T"
p.R175H"
0.13"
M
issense"
JAK2V617F"
B"
423"
ET"
TET2"
4"
106158218"
T"
A"
p.L1040*"
0.32"
N
onsense"
M
PLW
515"
Chr1p"
423"
ET"
TET2"
4"
106197355"
G"
T"
p.R1896S"
0.06"
M
issense"
M
PLW
515"
Chr1p"
424"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
425"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
426"
ET"
TET2"
4"
106158478"
C"
T"
p.Q
1127*"
0.1"
N
onsense"
JAK2V617F"
B"
426"
ET"
TET2"
4"
106156991"
C"
A"
p.S631*"
0.07"
N
onsense"
JAK2V617F"
B"
427"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
428"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
429"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
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430"
ET"
M
LL3"
7"
151970896"
A"
T"
p.C302*"
0.04"
N
onsense"
JAK2V617F,CALR"
B"
431"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
432"
ET"
PPM
1D"
17"
58740653"
C"
T"
p.Q
520*"
0.05"
N
onsense"
B"
B"
433"
ET"
M
LL3"
7"
151962122"
C"
T"
p.?"
0.07"
Splice"
B"
B"
434"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
435"
ET"
RB1"
13"
49039230"
C"
T"
p.Q
770*"
0.17"
N
onsense"
CALR"
B"
436"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
437"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
438"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
439"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
440"
ET"
DN
M
T3A"
2"
25458619"
T"
C"
p.M
852V"
0.05"
M
issense"
B"
B"
441"
ET"
ASXL1"
20"
31022238"
C"
T"
p.Q
575*"
0.43"
N
onsense"
JAK2V617F"
B"
442"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
443"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
444"
ET"
TET2"
4"
106193719"
A"
G"
p.?"
0.29"
Splice"
JAK2V617F"
B"
444"
ET"
ASXL1"
20"
31021730"
_"
insTGTT"
p.?"
0.35"
Splice"
JAK2V617F"
B"
445"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
446"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
447"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
448"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
449"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
450"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
451"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
452"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
453"
ET"
DN
M
T3A"
2"
25463248"
G"
A"
p.R749C"
0.35"
M
issense"
M
PLW
515"
Chr1p"
453"
ET"
TET2"
4"
106157371"
C"
T"
p.Q
758*"
0.13"
N
onsense"
M
PLW
515"
Chr1p"
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453"
ET"
EZH2"
7"
148511175"
C"
T"
p.C576Y"
0.09"
M
issense"
M
PLW
515"
Chr1p"
453"
ET"
EZH2"
7"
148523590"
C"
T"
p.R288Q
"
0.28"
M
issense"
M
PLW
515"
Chr1p"
454"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
455"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
456"
ET"
DN
M
T3A"
2"
25463563"
C"
T"
p.G707S"
0.14"
M
issense"
CALR"
B"
456"
ET"
TET2"
4"
106190858"
C"
T"
p.A1379V"
0.14"
M
issense"
CALR"
B"
457"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
458"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
459"
ET"
M
BD1"
18"
47803325"
G"
A"
p.S90L"
0.05"
M
issense"
B"
B"
460"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
461"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
462"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr19"
463"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
464"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
465"
ET"
DN
M
T3A"
2"
25463229"
A"
G"
p.F755S"
0.05"
M
issense"
JAK2V617F"
B"
465"
ET"
SF3B1"
2"
198266834"
T"
C"
p.K700E"
0.05"
M
issense"
JAK2V617F"
B"
466"
ET"
TET2"
4"
106193748"
C"
T"
p.R1404*"
0.06"
N
onsense"
JAK2V617F"
B"
467"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
468"
ET"
SH2B3"
12"
111856361"
_"
insT"
p.R139fs*33"
0.06"
fram
eshift"(+2bp)"
JAK2V617F"
B"
469"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
470"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
471"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.18"
M
issense"
JAK2V617F"
B"
471"
ET"
TP53"
17"
7577545"
T"
C"
p.M
246V"
0.19"
M
issense"
JAK2V617F"
B"
472"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
473"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
474"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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475"
ET"
TET2"
4"
106158341"
T"
A"
p.L1081*"
0.29"
N
onsense"
JAK2V617F"
B"
476"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
477"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
478"
ET"
DN
M
T3A"
2"
25463298"
_"
delAAG"
p.F732delF"
0.37"
Infram
e"
JAK2V617F"
B"
479"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
480"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
481"
ET"
TET2"
4"
106158265"
_"
delG"
p.V1056fs*10"
0.23"
fram
eshift"(+1bp)"
CALR"
Chr20"
482"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
483"
ET"
TET2"
4"
106157970"
_"
insA"
p.Q
958fs*14"
0.25"
fram
eshift"(+2bp)"
JAK2V617F"
B"
484"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
485"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
486"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
487"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
488"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
489"
ET"
EZH2"
7"
148544338"
C"
T"
p.R18H"
0.48"
M
issense"
CALR"
Chr14"
490"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
491"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
492"
ET"
TP53"
17"
7577061"
C"
A"
p.G293W
"
0.46"
M
issense"
JAK2V617F"
Chr17"
493"
ET"
ASXL1"
20"
31023630"
C"
T"
p.Q
1039*"
0.14"
N
onsense"
JAK2V617F"
B"
494"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
495"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
496"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
497"
ET"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.42"
M
issense"
M
PLS505N
"
B"
497"
ET"
SRSF2"
17"
74732959"
G"
C"
p.P95R"
0.44"
M
issense"
M
PLS505N
"
B"
498"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
499"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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500"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
501"
ET"
DN
M
T3A"
2"
25462004"
C"
T"
p.M
801I"
0.06"
M
issense"
CALR"
B"
502"
ET"
DN
M
T3A"
2"
25468177"
_"
delAGGC"
p.S499fs*151"
0.23"
fram
eshift"(+1bp)"
JAK2V617F"
B"
503"
ET"
DN
M
T3A"
2"
25464460"
C"
T"
p.G685R"
0.14"
M
issense"
JAK2V617F"
B"
504"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
505"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
506"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F,CALR"
B"
507"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
508"
ET"
M
PL"
1"
43818310"
G"
A"
p.R592Q
"
0.11"
M
issense"
JAK2V617F"
B"
509"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
510"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
511"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
512"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
513"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
514"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
515"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
516"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
517"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
518"
ET"
TET2"
4"
106196424"
C"
G"
p.S1586*"
0.17"
N
onsense"
JAK2V617F"
B"
519"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
520"
ET"
TET2"
4"
106196886"
T"
G"
p.L1740*"
0.13"
N
onsense"
JAK2V617F"
B"
521"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
522"
ET"
TET2"
4"
106190894"
G"
T"
p.G1391V"
0.25"
M
issense"
JAK2V617F"
B"
523"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
524"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLS204P"
Chr1p"
525"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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526"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
527"
ET"
TET2"
4"
106193723"
_"
insA"
p.C1396fs*5"
0.43"
fram
eshift"(+2bp)"
JAK2V617F"
B"
528"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
529"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
530"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
531"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
532"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
533"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
534"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
535"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
536"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
537"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
538"
ET"
KIT"
4"
55594198"
G"
A"
p.R634Q
"
0.56"
M
issense"
JAK2V617F"
B"
539"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr20"
540"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
541"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
542"
ET"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.4"
M
issense"
JAK2V617F"
B"
543"
ET"
PPM
1D"
17"
58740522"
_"
delA"
p.N
477fs*6"
0.1"
fram
eshift"(+1bp)"
JAK2V617F"
B"
543"
ET"
PPM
1D"
17"
58740642"
C"
A"
p.S516*"
0.19"
N
onsense"
JAK2V617F"
B"
544"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
545"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
546"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
547"
ET"
TP53"
17"
7578413"
C"
T"
p.V173M
"
0.06"
M
issense"
JAK2V617F"
Chr17"
548"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
549"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
550"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
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551"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
552"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
553"
ET"
M
LL3"
7"
151927096"
_"
delC"
p.C963fs*68"
0.09"
fram
eshift"(+1bp)"
B"
B"
554"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F,CALR"
B"
555"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
556"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
557"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
558"
ET"
TP53"
17"
7577509"
C"
T"
p.E258K"
0.37"
M
issense"
CALR"
Chr17"
558"
ET"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.18"
M
issense"
CALR"
Chr17"
559"
ET"
TET2"
4"
106197082"
_"
delC"
p.H1806fs*14"
0.14"
fram
eshift"(+1bp)"
M
PLW
515"
B"
560"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
561"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
562"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.44"
M
issense"
JAK2V617F"
B"
563"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
564"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
565"
ET"
EZH2"
7"
148526906"
T"
C"
p.Y133C"
0.13"
M
issense"
CALR"
B"
565"
ET"
CEBPA"
19"
33792303"
C"
T"
p.G340S"
0.51"
M
issense"
CALR"
B"
566"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
567"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
568"
ET"
IDH2"
15"
90631934"
C"
A"
p.R140L"
0.38"
M
issense"
CALR"
Chr18"
568"
ET"
SRSF2"
17"
74732959"
G"
A"
p.P95L"
0.35"
M
issense"
CALR"
Chr18"
569"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
570"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
571"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
572"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
573"
ET"
M
LL3"
7"
151970872"
A"
T"
p.C310*"
0.05"
N
onsense"
B"
B"
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574"
ET"
TET2"
4"
106190785"
GC"
AT"
p.A1355I"
0.05"
M
issense"
JAK2V617F"
B"
574"
ET"
TET2"
4"
106193731"
_"
insT"
p.T1399fs*2"
0.04"
fram
eshift"(+2bp)"
JAK2V617F"
B"
575"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
576"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
577"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
578"
ET"
PPM
1D"
17"
58740665"
C"
T"
p.Q
524*"
0.1"
N
onsense"
JAK2V617F"
B"
579"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
580"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
581"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
582"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
583"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
584"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
585"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
586"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
587"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F,M
PLW
515"
B"
588"
ET"
TET2"
4"
106155921"
_"
delC"
p.N
275fs*18"
0.5"
fram
eshift"(+1bp)"
CALR"
B"
589"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
590"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F,CALR"
B"
591"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
592"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
593"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr17"
594"
ET"
TET2"
4"
106196382"
G"
A"
p.R1572Q
"
0.49"
M
issense"
JAK2V617F"
B"
595"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr14"
596"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
597"
ET"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.18"
M
issense"
JAK2V617F"
B"
597"
ET"
TET2"
4"
106196631"
_"
delCGATGGAT"
p.M
1656fs*2"
0.16"
fram
eshift"(+2bp)"
JAK2V617F"
B"
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598"
ET"
DN
M
T3A"
2"
25467083"
G"
A"
p.R598*"
0.1"
N
onsense"
CALR"
B"
599"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
600"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
601"
ET"
DN
M
T3A"
2"
25463212"
T"
C"
p.M
761V"
0.41"
M
issense"
JAK2V617F"
B"
602"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
Chr1p"
603"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
604"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
605"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
606"
ET"
ASXL1"
20"
31022899"
_"
delC"
p.W
796fs*22"
0.01"
fram
eshift"(+1bp)"
CALR"
B"
607"
ET"
TP53"
17"
7579599"
G"
A"
p.?"
0.43"
Splice"
JAK2V617F"
B"
608"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
609"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
610"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
611"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
612"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
613"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
614"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
615"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
616"
ET"
M
PL"
1"
43818306"
T"
G"
p.Y591D"
0.44"
M
issense"
JAK2V617F"
B"
617"
ET"
DN
M
T3A"
2"
25458593"
C"
T"
p.W
860*"
0.2"
N
onsense"
JAK2V617F"
B"
618"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
619"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
620"
ET"
TET2"
4"
106182959"
T"
A"
p.M
1333K"
0.11"
M
issense"
CALR"
Chr20"
620"
ET"
N
FE2"
12"
54686478"
_"
delG"
p.R268fs*34"
0.31"
fram
eshift"(+1bp)"
CALR"
Chr20"
621"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
622"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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623"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
624"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.32"
M
issense"
JAK2V617F"
B"
625"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
626"
ET"
TET2"
4"
106197373"
C"
G"
p.Y1902*"
0.25"
N
onsense"
JAK2V617F"
B"
626"
ET"
SRSF2"
17"
74732959"
G"
C"
p.P95R"
0.31"
M
issense"
JAK2V617F"
B"
627"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
628"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
629"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
630"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
631"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
632"
ET"
IDH1"
2"
209113112"
C"
T"
p.R132H"
0.21"
M
issense"
JAK2V617F"
Chr9"
633"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
634"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
635"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
636"
ET"
IDH1"
2"
209113112"
C"
T"
p.R132H"
0.4"
M
issense"
JAK2V617F"
B"
636"
ET"
ASXL1"
20"
31021543"
_"
delTG"
p.V515fs*13"
0.45"
fram
eshift"(+2bp)"
JAK2V617F"
B"
637"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
638"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
639"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
640"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
641"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
642"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
643"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
644"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
645"
ET"
PHF6"
X"
133511696"
_"
delTGTGGCT"
p.C17fs*14"
0.41"
fram
eshift"(+1bp)"
JAK2V617F"
B"
646"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
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647"
ET"
N
FE2"
12"
54686317"
_"
delG"
p.M
322fs*5"
0.17"
fram
eshift"(+1bp)"
JAK2V617F"
B"
648"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
649"
ET"
DN
M
T3A"
2"
25463593"
C"
A"
p.E697*"
0.46"
N
onsense"
JAK2V617F"
B"
650"
ET"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.29"
fram
eshift"(+2bp)"
JAK2V617F"
B"
651"
ET"
DN
M
T3A"
2"
25462020"
C"
T"
p.G796D"
0.35"
M
issense"
JAK2V617F,CALR"
B"
652"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
653"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
654"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
655"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
656"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
657"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
658"
ET"
TET2"
4"
106164741"
C"
G"
p.S1203R"
0.48"
M
issense"
CALR"
B"
659"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLS204P"
Chr18"
660"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
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ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
662"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
663"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
664"
ET"
DN
M
T3A"
2"
25457161"
A"
C"
p.F909C"
0.16"
M
issense"
JAK2V617F"
B"
664"
ET"
TET2"
4"
106156747"
C"
T"
p.R550*"
0.16"
N
onsense"
JAK2V617F"
B"
665"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
666"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
667"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
668"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
669"
ET"
DN
M
T3A"
2"
25457243"
G"
A"
p.R882C"
0.37"
M
issense"
M
PLW
515"
B"
670"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
671"
ET"
N
F1"
17"
29654554"
G"
A"
p.R1769Q
"
0.46"
M
issense"
CALR"
B"
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672"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
673"
ET"
PPM
1D"
17"
58740559"
_"
delTTCT"
p.S489fs*1"
0.02"
fram
eshift"(+1bp)"
JAK2V617F"
B"
673"
ET"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.27"
fram
eshift"(+2bp)"
JAK2V617F"
B"
674"
ET"
TET2"
4"
106196575"
_"
delC"
p.L1637fs*58"
0.03"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
675"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
676"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
677"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
678"
ET"
DN
M
T3A"
2"
25457259"
G"
T"
p.D876E"
0.05"
M
issense"
JAK2V617F"
Chr17"
678"
ET"
SH2B3"
12"
111885301"
C"
T"
p.R397W
"
0.52"
M
issense"
JAK2V617F"
Chr17"
679"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
680"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
681"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
682"
ET"
TET2"
4"
106155580"
_"
insA"
p.D162fs*9"
0.21"
fram
eshift"(+2bp)"
CALR"
B"
683"
ET"
TET2"
4"
106164071"
C"
G"
p.P1194R"
0.21"
M
issense"
JAK2V617F"
B"
684"
ET"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.33"
M
issense"
JAK2V617F"
B"
684"
ET"
ASXL1"
20"
31021250"
C"
T"
p.R417*"
0.38"
N
onsense"
JAK2V617F"
B"
685"
ET"
TET2"
4"
106156304"
C"
G"
p.S402*"
0.27"
N
onsense"
JAK2V617F"
B"
686"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
687"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
688"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
689"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
690"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
691"
ET"
N
FE2"
12"
54686495"
_"
delCTCT"
p.E261fs*3"
0.14"
fram
eshift"(+1bp)"
JAK2V617F"
B"
692"
ET"
N
FE2"
12"
54686575"
_"
delA"
p.P236fs*12"
0.07"
fram
eshift"(+1bp)"
CALR"
B"
692"
ET"
PPM
1D"
17"
58740540"
_"
delT"
p.L482fs*3"
0.14"
fram
eshift"(+1bp)"
CALR"
B"
693"
ET"
GN
B1"
1"
1747229"
T"
C"
p.K57E"
0.29"
M
issense"
CALR"
B"
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694"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
695"
ET"
TET2"
4"
106157023"
C"
T"
p.Q
642*"
0.08"
N
onsense"
JAK2V617F"
Chr9"
696"
ET"
TET2"
4"
106155195"
_"
delA"
p.K33fs*16"
0.03"
fram
eshift"(+1bp)"
JAK2V617F"
B"
697"
ET"
DN
M
T3A"
2"
25467448"
C"
T"
p.G543D"
0.29"
M
issense"
JAK2V617F"
B"
697"
ET"
DN
M
T3A"
2"
25467433"
A"
G"
p.M
548T"
0.31"
M
issense"
JAK2V617F"
B"
697"
ET"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.26"
M
issense"
JAK2V617F"
B"
698"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLS505N
"
B"
699"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
700"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
701"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
702"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
703"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
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ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
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ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
706"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
707"
ET"
DN
M
T3A"
2"
25469028"
C"
T"
p.?"
0.29"
Splice"
JAK2V617F"
B"
708"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
709"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
710"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
711"
ET"
DN
M
T3A"
2"
25464544"
C"
T"
p.V657M
"
0.08"
M
issense"
JAK2V617F"
B"
712"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
713"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
714"
ET"
TET2"
4"
106164020"
T"
A"
p.I1177N
"
0.2"
M
issense"
JAK2V617F"
B"
715"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLS204P"
B"
716"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
717"
ET"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.1"
M
issense"
CALR"
B"
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718"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
719"
ET"
TP53"
17"
7578190"
T"
C"
p.Y220C"
0.55"
M
issense"
B"
Chr17"
720"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
721"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
722"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
723"
ET"
ASXL1"
20"
31023272"
_"
insA"
p.P920fs*4"
0.29"
fram
eshift"(+2bp)"
CALR"
B"
724"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
725"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
726"
ET"
TET2"
4"
106197309"
A"
G"
p.H1881R"
0.11"
M
issense"
JAK2V617F"
B"
727"
ET"
TET2"
4"
106196497"
_"
delT"
p.S1611fs*5"
0.16"
fram
eshift"(+1bp)"
M
PLW
515"
B"
728"
ET"
DN
M
T3A"
2"
25470464"
G"
T"
p.S337*"
0.23"
N
onsense"
JAK2V617F"
B"
729"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
730"
ET"
JAK2"
9"
5077468"
A"
C"
p.E627A"
0.43"
M
issense"
B"
B"
731"
ET"
TET2"
4"
106196705"
C"
T"
p.Q
1680*"
0.06"
N
onsense"
JAK2V617F"
B"
731"
ET"
ASXL1"
20"
31022411"
C"
A"
p.C632*"
0.36"
N
onsense"
JAK2V617F"
B"
732"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
733"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
734"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
736"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
737"
ET"
ASXL1"
20"
31022650"
_"
delC"
p.M
713fs*12"
0.13"
fram
eshift"(+1bp)"
JAK2V617F"
B"
738"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
739"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
740"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
741"
ET"
CU
X1"
7"
101840530"
_"
delC"
p.L614fs*25"
0.4"
fram
eshift"(+1bp)"
JAK2V617F"
Chr14"
741"
ET"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.44"
M
issense"
JAK2V617F"
Chr14"
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742"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr13"
743"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
744"
ET"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.38"
M
issense"
M
PLW
515"
B"
745"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
746"
ET"
TET2"
4"
106164791"
_"
delC"
p.C1221fs*5"
0.47"
fram
eshift"(+1bp)"
M
PLW
515"
B"
747"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
748"
ET"
TET2"
4"
106157946"
_"
delTGCTG"
p.A950fs*20"
0.13"
fram
eshift"(+2bp)"
JAK2V617F"
B"
749"
ET"
ASXL1"
20"
31022484"
G"
T"
p.E657*"
0.38"
N
onsense"
JAK2V617F"
B"
750"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
752"
ET"
M
LL3"
7"
151970884"
A"
C"
p.Y306*"
0.05"
N
onsense"
JAK2V617F"
B"
753"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
754"
ET"
B"
B"
B"
B"
B"
B"
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B"
755"
ET"
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B"
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B"
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B"
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B"
757"
ET"
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B"
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B"
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B"
CALR"
B"
758"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr20"
759"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
760"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
761"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
762"
ET"
TET2"
4"
106190798"
G"
T"
p.R1359L"
0.32"
M
issense"
JAK2V617F"
B"
762"
ET"
TET2"
4"
106158248"
C"
A"
p.S1050*"
0.29"
N
onsense"
JAK2V617F"
B"
762"
ET"
ASXL1"
20"
31023356"
_"
insG"
p.E948fs*7"
0.37"
fram
eshift"(+2bp)"
JAK2V617F"
B"
763"
ET"
TET2"
4"
106164940"
G"
A"
p.?"
0.37"
Splice"
JAK2V617F"
B"
763"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
764"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
765"
ET"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.08"
M
issense"
JAK2V617F"
B"
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766"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
767"
ET"
SH2B3"
12"
111884663"
G"
A"
p.?"
0.5"
Splice"
CALR"
B"
768"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
769"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
770"
ET"
TET2"
4"
106162494"
_"
delAG"
p.?"
0.41"
Splice"
JAK2V617F"
B"
771"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
772"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
773"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
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B"
1265"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1266"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1267"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1268"
ET"
KIT"
4"
55602733"
G"
A"
p.V852I"
0.46"
M
issense"
JAK2V617F"
B"
1269"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1270"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1271"
ET"
ASXL1"
20"
31023153"
_"
insA"
p.T880fs*2"
0.3"
fram
eshift"(+2bp)"
CALR"
B"
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1272"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1273"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1274"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLS505N
"
B"
1275"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1276"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1277"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1278"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1279"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1280"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
B"
1281"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1282"
ET"
M
PL"
1"
43812147"
G"
C"
p.E338Q
"
0.48"
M
issense"
B"
B"
1283"
ET"
TET2"
4"
106157769"
_"
insA"
p.Q
891fs*10"
0.16"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1284"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1285"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1286"
ET"
M
LL3"
7"
151970896"
A"
T"
p.C302*"
0.04"
N
onsense"
CALR"
B"
1287"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1288"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1289"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1290"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1291"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1292"
ET"
CBL"
11"
119148978"
A"
T"
p.M
400L"
0.51"
M
issense"
CALR"
B"
1293"
ET"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.47"
M
issense"
JAK2V617F"
Chr9"
1294"
ET"
EZH2"
7"
148508788"
C"
T"
p.V626M
"
0.38"
M
issense"
JAK2V617F"
B"
1294"
ET"
TP53"
17"
7577563"
T"
C"
p.S240G"
0.23"
M
issense"
JAK2V617F"
B"
1295"
ET"
EZH2"
7"
148506443"
C"
T"
p.R690H"
0.41"
M
issense"
JAK2V617F"
B"
1295"
ET"
PPM
1D"
17"
58740460"
_"
delG"
p.I456fs*1"
0.08"
fram
eshift"(+1bp)"
JAK2V617F"
B"
 
251 
1295"
ET"
PPM
1D"
17"
58740642"
C"
G"
p.S516*"
0.14"
N
onsense"
JAK2V617F"
B"
1296"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1297"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1298"
ET"
DN
M
T3A"
2"
25469541"
C"
T"
p.W
409*"
0.17"
N
onsense"
JAK2V617F"
B"
1299"
ET"
DN
M
T3A"
2"
25463302"
A"
C"
p.F731V"
0.44"
M
issense"
M
PLW
515"
B"
1299"
ET"
ASXL1"
20"
31023437"
C"
G"
p.Y974*"
0.39"
N
onsense"
M
PLW
515"
B"
1300"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1301"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1302"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1303"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1304"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1305"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1306"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1307"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1308"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1309"
ET"
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FE2"
12"
54687044"
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delG"
p.P79fs*32"
0.17"
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eshift"(+1bp)"
JAK2V617F"
B"
1310"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1311"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1312"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1313"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1314"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1315"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1316"
ET"
M
LL3"
7"
151882660"
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delC"
p.E1689fs*28"
0.05"
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eshift"(+1bp)"
CALR"
B"
1317"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1318"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1319"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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1320"
ET"
N
FE2"
12"
54686495"
_"
delCTCT"
p.E261fs*3"
0.24"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1321"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1322"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr20"
1323"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1324"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1325"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1326"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1327"
ET"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1328"
M
F"
TET2"
4"
106157244"
_"
delCT"
p.S716fs*6"
0.22"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1328"
M
F"
EZH2"
7"
148507433"
A"
G"
p.L674S"
0.27"
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issense"
JAK2V617F"
B"
1328"
M
F"
KRAS"
12"
25378562"
C"
G"
p.A146P"
0.16"
M
issense"
JAK2V617F"
B"
1328"
M
F"
ZRSR2"
X"
15827338"
_"
delA"
p.T152fs*13"
0.52"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1329"
M
F"
TET2"
4"
106156153"
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delT"
p.F352fs*20"
0.41"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1329"
M
F"
TET2"
4"
106197353"
A"
G"
p.R1896G"
0.48"
M
issense"
JAK2V617F"
Chr9"
1329"
M
F"
CBL"
11"
119148922"
G"
A"
p.C381Y"
0.3"
M
issense"
JAK2V617F"
Chr9"
1329"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.14"
M
issense"
JAK2V617F"
Chr9"
1329"
M
F"
ASXL1"
20"
31022614"
_"
insGAG"
p.Y700delins*"
0.2"
N
onsense"
JAK2V617F"
Chr9"
1330"
M
F"
TET2"
4"
106197285"
T"
A"
p.I1873N
"
0.97"
M
issense"
M
PLW
515"
Chr1p,4"
1330"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.48"
M
issense"
M
PLW
515"
Chr1p,4"
1331"
M
F"
TP53"
17"
7578212"
G"
A"
p.R213*"
0.61"
N
onsense"
CALR"
Chr17"
1331"
M
F"
ASXL1"
20"
31022782"
_"
delACCAG<15>CCCCT"
p.Q
757fs*7"
0.33"
fram
eshift"(+1bp)"
CALR"
Chr17"
1331"
M
F"
ASXL1"
20"
31022592"
C"
T"
p.R693*"
0.1"
N
onsense"
CALR"
Chr17"
1332"
M
F"
TET2"
4"
106190861"
A"
C"
p.H1380P"
0.49"
M
issense"
JAK2V617F"
Chr9,14"
1333"
M
F"
M
PL"
1"
43818405"
C"
G"
p.H624D"
0.32"
M
issense"
JAK2V617F"
B"
1333"
M
F"
TET2"
4"
106158419"
C"
A"
p.S1107*"
0.33"
N
onsense"
JAK2V617F"
B"
1333"
M
F"
CU
X1"
7"
101459338"
C"
T"
p.Q
10*"
0.38"
N
onsense"
JAK2V617F"
B"
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1333"
M
F"
PTPN
11"
12"
112888172"
A"
G"
p.Y63C"
0.24"
M
issense"
JAK2V617F"
B"
1333"
M
F"
ASXL1"
20"
31022983"
T"
A"
p.L823*"
0.26"
N
onsense"
JAK2V617F"
B"
1333"
M
F"
U
2AF1"
21"
44514770"
_"
insCTCATA"
p.E159_M
160insYE"
0.21"
Infram
e"
JAK2V617F"
B"
1334"
M
F"
ASXL1"
20"
31023591"
G"
T"
p.G1026*"
0.05"
N
onsense"
JAK2V617F,CALR"
Chr20"
1335"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1336"
M
F"
N
FE2"
12"
54686495"
_"
delCTCT"
p.E261fs*3"
0.16"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9,20"
1337"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1338"
M
F"
SETBP1"
18"
42531919"
G"
C"
p.G872R"
0.08"
M
issense"
M
PLW
515"
Chr1p"
1338"
M
F"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.08"
fram
eshift"(+2bp)"
M
PLW
515"
Chr1p"
1338"
M
F"
ASXL1"
20"
31023717"
C"
T"
p.R1068*"
0.17"
N
onsense"
M
PLW
515"
Chr1p"
1338"
M
F"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.48"
M
issense"
M
PLW
515"
Chr1p"
1339"
M
F"
GN
AS"
20"
57484421"
G"
A"
p."R201H"
0.46"
M
issense"
JAK2V617F"
Chr9"
1339"
M
F"
ZRSR2"
X"
15809095"
_"
delG"
p.R27fs*11"
0.71"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1340"
M
F"
TET2"
4"
106155778"
G"
T"
p.E227*"
0.44"
N
onsense"
JAK2V617F"
Chr9"
1340"
M
F"
M
LL3"
7"
151970896"
A"
T"
p.C302*"
0.06"
N
onsense"
JAK2V617F"
Chr9"
1341"
M
F"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.08"
M
issense"
JAK2V617F"
Chr9"
1342"
M
F"
N
RAS"
1"
115258747"
C"
T"
p.G12D"
0.1"
M
issense"
JAK2V617F"
Chr9"
1342"
M
F"
EZH2"
7"
148506444"
G"
T"
p.R690S"
0.47"
M
issense"
JAK2V617F"
Chr9"
1342"
M
F"
PPM
1D"
17"
58740691"
_"
delA"
p.N
533fs*6"
0.48"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1342"
M
F"
ASXL1"
20"
31022550"
G"
T"
p.G679*"
0.41"
N
onsense"
JAK2V617F"
Chr9"
1342"
M
F"
ASXL1"
20"
31022817"
C"
T"
p.Q
768*"
0.15"
N
onsense"
JAK2V617F"
Chr9"
1342"
M
F"
ZRSR2"
X"
15827389"
C"
T"
p.R169*"
0.97"
N
onsense"
JAK2V617F"
Chr9"
1343"
M
F"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.12"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9,13,14"
1344"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1345"
M
F"
TET2"
4"
106197357"
T"
G"
p.I1897S"
0.09"
M
issense"
JAK2V617F"
B"
1345"
M
F"
ASXL1"
20"
31022288"
C"
G"
p.Y591*"
0.45"
N
onsense"
JAK2V617F"
B"
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1345"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.27"
M
issense"
JAK2V617F"
B"
1346"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr19"
1347"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1348"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1349"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1350"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1351"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLW
515"
Chr1p"
1352"
M
F"
TP53"
17"
7578535"
T"
C"
p.K132R"
0.38"
M
issense"
JAK2V617F"
Chr5,9,17,20"
1352"
M
F"
GN
AS"
20"
57484597"
G"
T"
p.Q
227H"
0.45"
M
issense"
JAK2V617F"
Chr5,9,17,20"
1353"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
Chr7"
1354"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.25"
M
issense"
JAK2V617F"
B"
1355"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1356"
M
F"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.46"
M
issense"
JAK2V617F"
B"
1356"
M
F"
TET2"
4"
106156306"
C"
T"
p.Q
403*"
0.47"
N
onsense"
JAK2V617F"
B"
1357"
M
F"
TET2"
4"
106196684"
_"
delC"
p.P1673fs*22"
0.94"
fram
eshift"(+1bp)"
JAK2V617F"
Chr4,7,9"
1358"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1359"
M
F"
ASXL1"
20"
31022258"
_"
delACCCTGGGTGGTTA"
p.P582fs*32"
0.13"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1360"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1361"
M
F"
TET2"
4"
106155526"
G"
A"
p.D143N
"
0.52"
M
issense"
JAK2V617F"
B"
1361"
M
F"
TET2"
4"
106158427"
A"
T"
p.K1110*"
0.61"
N
onsense"
JAK2V617F"
B"
1361"
M
F"
TET2"
4"
106196217"
_"
insT"
p.S1518fs*60"
0.33"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1362"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1363"
M
F"
SF3B1"
2"
198266834"
T"
C"
p.K700E"
0.41"
M
issense"
CALR,M
PLS204P"
B"
1363"
M
F"
CBL"
11"
119148931"
G"
A"
p.C384Y"
0.3"
M
issense"
CALR,M
PLS204P"
B"
1364"
M
F"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.41"
M
issense"
CALR"
B"
1365"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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1366"
M
F"
DN
M
T3A"
2"
25463533"
_"
delTGACGATGGAG"
p.S714fs*16"
0.3"
fram
eshift"(+2bp)"
CALR"
B"
1367"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
M
PLS204P"
Chr1p"
1368"
M
F"
N
RAS"
1"
115258747"
C"
T"
p.G12D"
0.39"
M
issense"
CALR"
B"
1368"
M
F"
ASXL1"
20"
31022847"
C"
T"
p.Q
778*"
0.48"
N
onsense"
CALR"
B"
1369"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1370"
M
F"
TET2"
4"
106164913"
C"
T"
p.R1261C"
0.34"
M
issense"
CALR"
B"
1370"
M
F"
ASXL1"
20"
31022937"
_"
delC"
p.P808fs*10"
0.4"
fram
eshift"(+1bp)"
CALR"
B"
1371"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1372"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1373"
M
F"
EZH2"
7"
148506172"
A"
G"
p.F729S"
0.42"
M
issense"
CALR"
Chr7"
1374"
M
F"
ASXL1"
20"
31022697"
G"
T"
p.E728*"
0.47"
N
onsense"
M
PLW
515"
B"
1375"
M
F"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.2"
fram
eshift"(+2bp)"
CALR"
B"
1375"
M
F"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.74"
M
issense"
CALR"
B"
1376"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1377"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1378"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1379"
M
F"
TET2"
4"
106155471"
_"
insA"
p.N
124fs*12"
0.38"
fram
eshift"(+2bp)"
CALR"
B"
1379"
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F"
N
FE2"
12"
54686430"
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p.R284C"
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CALR"
B"
1380"
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F"
EZH2"
7"
148507475"
C"
T"
p.G660E"
0.24"
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PLW
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Chr1p"
1380"
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F"
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20"
31024148"
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0.49"
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F"
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2"
25457242"
C"
T"
p.R882H"
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B"
1381"
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F"
SF3B1"
2"
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T"
C"
p.K700E"
0.49"
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B"
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F"
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0.47"
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B"
1382"
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F"
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F1"
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T"
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CALR"
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F"
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eshift"(+2bp)"
CALR"
Chr1p"
1383"
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F"
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20"
31022592"
C"
T"
p.R693*"
0.29"
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B"
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M
F"
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36252849"
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CALR"
Chr7"
1387"
M
F"
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X"
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C"
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B"
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PPM
1D"
17"
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4"
106193885"
_"
delT"
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F"
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F"
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T"
p.G12S"
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B"
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T"
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0.52"
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Chr20"
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p.P95H"
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Chr9"
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B"
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C"
T"
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T"
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Chr7"
1405"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
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B"
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Chr9"
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F"
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p.G245S"
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17"
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p.P95R"
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F"
SF3B1"
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p.K666N
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F"
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p.G12R"
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B"
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T"
p.G12D"
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B"
1427"
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F"
TET2"
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p.R1516*"
0.45"
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1427"
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F"
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p.S1898F"
0.41"
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B"
1427"
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p.Y591fs*1"
0.48"
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1428"
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0.19"
M
issense"
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F"
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209113112"
C"
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p.R132H"
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1428"
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31022592"
C"
T"
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B"
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C"
A"
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1431"
M
F"
CBL"
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0.24"
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B"
1431"
M
F"
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20"
31021211"
C"
T"
p.R404*"
0.32"
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JAK2V617F"
B"
1432"
M
F"
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M
T3A"
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25457243"
G"
A"
p.R882C"
0.48"
M
issense"
B"
B"
1432"
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F"
EZH2"
7"
148506443"
C"
T"
p.R690H"
0.27"
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issense"
B"
B"
1432"
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F"
U
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21"
44524456"
G"
A"
p.S34F"
0.25"
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issense"
B"
B"
1432"
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F"
STAG2"
X"
123220440"
C"
T"
p.R1033*"
0.14"
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1433"
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F"
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198257839"
C"
T"
p.E1205K"
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1433"
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C"
G"
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T"
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F"
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T"
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157P"
0.45"
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1435"
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F"
TET2"
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C"
T"
p.R1216*"
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N
onsense"
JAK2V617F"
B"
1435"
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F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
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B"
1436"
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G"
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p.R749S"
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p.A1071G"
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p.P95H"
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74732960"
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0.47"
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Chr9"
1442"
M
F"
TET2"
4"
106180782"
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insT"
p.C1271fs*29"
0.12"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1443"
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F"
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21"
36252877"
C"
T"
p.R162K"
0.23"
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issense"
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B"
1443"
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F"
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36231859"
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eshift"(+1bp)"
JAK2V617F"
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B"
1445"
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F"
TET2"
4"
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p.G1564fs*17"
0.2"
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eshift"(+2bp)"
JAK2V617F"
B"
1445"
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F"
TET2"
4"
106158123"
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eshift"(+2bp)"
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B"
1446"
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25457243"
G"
A"
p.R882C"
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CALR"
B"
1447"
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F"
EZH2"
7"
148507425"
C"
G"
p.D677H"
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Chr7"
1447"
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F"
ASXL1"
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p.Y591fs*1"
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Chr7"
1448"
M
F"
ZRSR2"
X"
15827389"
C"
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p.R169*"
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1448"
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F"
ASXL1"
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A"
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0.31"
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B"
1451"
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F"
SF3B1"
2"
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T"
C"
p.K700E"
0.54"
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TET2"
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M
F"
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G"
A"
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CALR"
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1451"
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p.G245D"
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G"
A"
p.E602K"
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CALR"
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Chr9"
1453"
M
F"
TET2"
4"
106180865"
G"
A"
p.C1298Y"
0.51"
M
issense"
JAK2V617F"
B"
1454"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1455"
M
F"
SF3B1"
2"
198267359"
C"
G"
p.K666N
"
0.5"
M
issense"
JAK2V617F"
B"
1456"
M
F"
CBL"
11"
119149217"
C"
T"
p.?"
0.26"
Splice"
B"
B"
1456"
M
F"
TP53"
17"
7576593"
G"
T"
p.?"
0.16"
Splice"
B"
B"
1457"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
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Chr17"
1458"
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SRSF2"
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G"
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p.P95R"
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p.P95L"
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1460"
M
F"
ASXL1"
20"
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0.42"
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CALR"
B"
1468"
M
F"
ASXL1"
20"
31022902"
G"
A"
p.W
796*"
0.56"
N
onsense"
CALR"
B"
1468"
M
F"
GN
AS"
20"
57484421"
G"
A"
p.R201H"
0.43"
M
issense"
CALR"
B"
1468"
M
F"
ZRSR2"
X"
15833814"
_"
delAT"
p.H191fs*12"
0.73"
fram
eshift"(+2bp)"
CALR"
B"
1469"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1470"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.8"
M
issense"
JAK2V617F"
B"
1471"
M
F"
N
RAS"
1"
115258747"
C"
T"
p.G12D"
0.6"
M
issense"
JAK2V617F"
B"
1471"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.38"
M
issense"
JAK2V617F"
B"
1472"
M
F"
CBL"
11"
119148973"
A"
G"
p.H398R"
0.23"
M
issense"
M
PLW
515"
Chr1p"
1472"
M
F"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.57"
M
issense"
M
PLW
515"
Chr1p"
1472"
M
F"
ASXL1"
20"
31022988"
A"
T"
p.K825*"
0.49"
N
onsense"
M
PLW
515"
Chr1p"
1473"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1474"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1475"
M
F"
N
RAS"
1"
115258747"
C"
T"
p.G12D"
0.39"
M
issense"
B"
B"
1475"
M
F"
TET2"
4"
106157968"
_"
delTT"
p.L957fs*14"
0.5"
fram
eshift"(+2bp)"
B"
B"
1475"
M
F"
GN
AS"
20"
57484420"
C"
T"
p.R201C"
0.44"
M
issense"
B"
B"
1476"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1477"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1478"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1479"
M
F"
TET2"
4"
106197387"
T"
C"
p.M
1907T"
0.11"
M
issense"
JAK2V617F"
Chr9"
1480"
M
F"
N
F1"
17"
29661945"
C"
T"
p.R1968*"
0.14"
N
onsense"
B"
B"
1481"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.57"
M
issense"
JAK2V617F"
B"
1482"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1483"
M
F"
PTPN
11"
12"
112888301"
A"
C"
p.D106A"
0.42"
M
issense"
JAK2V617F"
Chr9"
1484"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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1485"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1486"
M
F"
N
RAS"
1"
115258747"
C"
T"
p.G12D"
0.4"
M
issense"
B"
B"
1486"
M
F"
GATA2"
3"
128200137"
T"
C"
p.K390E"
0.58"
M
issense"
B"
B"
1486"
M
F"
GN
AS"
20"
57484421"
G"
A"
p.R201H"
0.41"
M
issense"
B"
B"
1487"
M
F"
ASXL1"
20"
31022624"
_"
delT"
p.N
703fs*22"
0.29"
fram
eshift"(+1bp)"
CALR"
B"
1488"
M
F"
RB1"
13"
48942685"
C"
T"
p.R358*"
0.39"
N
onsense"
B"
B"
1488"
M
F"
RB1"
13"
49039374"
C"
T"
p.R787*"
0.45"
N
onsense"
B"
B"
1488"
M
F"
ASXL1"
20"
31022319"
G"
T"
p.E602*"
0.53"
N
onsense"
B"
B"
1489"
M
F"
PTPN
11"
12"
112915532"
A"
G"
p.M
311V"
0.39"
M
issense"
JAK2V617F"
Chr9,14"
1489"
M
F"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.4"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9,14"
1490"
M
F"
TP53"
17"
7579353"
C"
T"
p.G112S"
0.38"
M
issense"
JAK2V617F"
Chr9,18"
1491"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1492"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1493"
M
F"
SF3B1"
2"
198266834"
T"
C"
p.K700E"
0.17"
M
issense"
JAK2V617F"
B"
1494"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1495"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1496"
M
F"
KRAS"
12"
25398285"
C"
T"
p.G12S"
0.38"
M
issense"
JAK2V617F"
B"
1496"
M
F"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.28"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1497"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1498"
M
F"
SRSF2"
17"
74732959"
G"
A"
p.P95L"
0.77"
M
issense"
JAK2V617F"
B"
1499"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr20"
1500"
M
F"
IDH1"
2"
209103945"
G"
A"
p.A335V"
0.22"
M
issense"
JAK2V617F"
B"
1500"
M
F"
U
2AF1"
21"
44524456"
G"
A"
p.S34F"
0.14"
M
issense"
JAK2V617F"
B"
1501"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1502"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1503"
M
F"
N
RAS"
1"
115258747"
C"
T"
p.G12D"
0.42"
M
issense"
B"
B"
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1503"
M
F"
TET2"
4"
106164914"
G"
C"
p.R1261P"
0.47"
M
issense"
B"
B"
1503"
M
F"
TET2"
4"
106157302"
_"
delAGTTCACA"
p.S736fs*15"
0.32"
fram
eshift"(+2bp)"
B"
B"
1503"
M
F"
EZH2"
7"
148526820"
C"
T"
p.E162K"
0.37"
M
issense"
B"
B"
1504"
M
F"
ZRSR2"
X"
15840988"
_"
delG"
p.K359fs*>130"
0.25"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1505"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1506"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1507"
M
F"
TET2"
4"
106193885"
_"
delTT"
p.F1450fs*27"
0.57"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1507"
M
F"
TET2"
4"
106156069"
C"
T"
p.Q
324*"
0.53"
N
onsense"
JAK2V617F"
B"
1507"
M
F"
CBL"
11"
119149248"
G"
A"
p.C419Y"
0.42"
M
issense"
JAK2V617F"
B"
1507"
M
F"
CBL"
11"
119148958"
T"
C"
p.I393T"
0.16"
M
issense"
JAK2V617F"
B"
1507"
M
F"
CBL"
11"
119155763"
C"
T"
p.R506*"
0.21"
N
onsense"
JAK2V617F"
B"
1507"
M
F"
ASXL1"
20"
31023077"
_"
delTGAT"
p.D855fs*11"
0.38"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1508"
M
F"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.51"
M
issense"
JAK2V617F"
B"
1509"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1510"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1511"
M
F"
RU
N
X1"
21"
36231774"
G"
A"
p.R204*"
0.41"
N
onsense"
CALR"
Chr7"
1512"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1513"
M
F"
N
RAS"
1"
115258747"
C"
T"
p.G12D"
0.38"
M
issense"
B"
B"
1513"
M
F"
STAG2"
X"
123224609"
_"
delT"
p.Y1155fs*5"
0.96"
fram
eshift"(+1bp)"
B"
B"
1514"
M
F"
ASXL1"
20"
31022712"
C"
T"
p.Q
733*"
0.13"
N
onsense"
JAK2V617F"
B"
1514"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.15"
M
issense"
JAK2V617F"
B"
1515"
M
F"
IDH1"
2"
209113112"
C"
T"
p.R132H"
0.33"
M
issense"
JAK2V617F,CALR"
Chr20"
1516"
M
F"
TET2"
4"
106164862"
_"
delCT"
p.Y1245fs*22"
0.04"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1517"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1518"
M
F"
EZH2"
7"
148523590"
C"
T"
p.R288Q
"
0.29"
M
issense"
JAK2V617F"
Chr8,9"
1518"
M
F"
ASXL1"
20"
31021250"
C"
T"
p.R417*"
0.51"
N
onsense"
JAK2V617F"
Chr8,9"
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1519"
M
F"
ASXL1"
20"
31023379"
_"
delG"
p.S955fs*29"
0.35"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1519"
M
F"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.49"
M
issense"
JAK2V617F"
B"
1519"
M
F"
ZRSR2"
X"
15833942"
C"
T"
p.Q
234*"
0.86"
N
onsense"
JAK2V617F"
B"
1520"
M
F"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.06"
M
issense"
JAK2V617F"
B"
1520"
M
F"
DN
M
T3A"
2"
25463184"
G"
A"
p.S770L"
0.14"
M
issense"
JAK2V617F"
B"
1521"
M
F"
GATA2"
3"
128200131"
_"
delATGAAGAAGGAAins
TTC"
p.M
388_E391delinF"
0.23"
Infram
e"
JAK2V617F"
Chr1q,9"
1522"
M
F"
N
F1"
17"
29556918"
_"
insCTA"
p.L972_D973ins*"
0.05"
N
onsense"
JAK2V617F"
B"
1523"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1524"
M
F"
ASXL1"
20"
31022662"
_"
delC"
p.A716fs*9"
0.06"
fram
eshift"(+1bp)"
CALR"
B"
1524"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.4"
M
issense"
CALR"
B"
1525"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.38"
M
issense"
JAK2V617F"
Chr9"
1526"
M
F"
TET2"
4"
106197285"
T"
C"
p.I1873T"
0.49"
M
issense"
JAK2V617F"
B"
1526"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.5"
M
issense"
JAK2V617F"
B"
1526"
M
F"
ASXL1"
20"
31023261"
A"
T"
p.R916*"
0.44"
N
onsense"
JAK2V617F"
B"
1527"
M
F"
TET2"
4"
106182906"
C"
G"
p.?"
0.47"
Splice"
JAK2V617F"
B"
1527"
M
F"
CBL"
11"
119148990"
T"
C"
p.C404R"
0.28"
M
issense"
JAK2V617F"
B"
1527"
M
F"
CBL"
11"
119103370"
_"
delA"
p.E138fs*14"
0.29"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1527"
M
F"
ASXL1"
20"
31023408"
C"
T"
p.R965*"
0.38"
N
onsense"
JAK2V617F"
B"
1527"
M
F"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.51"
M
issense"
JAK2V617F"
B"
1527"
M
F"
ZRSR2"
X"
15838385"
C"
T"
p.R295*"
0.99"
N
onsense"
JAK2V617F"
B"
1528"
M
F"
ASXL1"
20"
31022277"
C"
T"
p.Q
588*"
0.37"
N
onsense"
JAK2V617F"
B"
1528"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.29"
M
issense"
JAK2V617F"
B"
1529"
M
F"
IDH1"
2"
209113112"
C"
T"
p.R132H"
0.51"
M
issense"
JAK2V617F"
Chr9"
1529"
M
F"
TP53"
17"
7578406"
C"
T"
p.R175H"
0.22"
M
issense"
JAK2V617F"
Chr9"
1529"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.46"
M
issense"
JAK2V617F"
Chr9"
1530"
M
F"
CBL"
11"
119148919"
T"
C"
p.L380P"
0.88"
M
issense"
JAK2V617F"
Chr7,11"
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1530"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.55"
M
issense"
JAK2V617F"
Chr7,11"
1530"
M
F"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.39"
fram
eshift"(+2bp)"
JAK2V617F"
Chr7,11"
1531"
M
F"
M
BD1"
18"
47803329"
G"
T"
p.P89T"
0.2"
M
issense"
JAK2V617F"
B"
1532"
M
F"
ASXL1"
20"
31022937"
_"
delC"
p.P808fs*10"
0.31"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1532"
M
F"
U
2AF1"
21"
44514777"
T"
G"
p.Q
157P"
0.43"
M
issense"
JAK2V617F"
B"
1533"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1534"
M
F"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.5"
M
issense"
JAK2V617F"
Chr9"
1535"
M
F"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.34"
M
issense"
JAK2V617F"
Chr9"
1535"
M
F"
SRSF2"
17"
74732959"
G"
A"
p.P95L"
0.33"
M
issense"
JAK2V617F"
Chr9"
1536"
M
F"
ZRSR2"
X"
15833838"
_"
delC"
p.L200fs*38"
0.27"
fram
eshift"(+1bp)"
CALR"
B"
1537"
M
F"
TET2"
4"
106158491"
_"
insTTTCC"
p.P1131fs*8"
0.33"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1537"
M
F"
TET2"
4"
106196964"
_"
delACAGT<7>CGGGC"
p.S1767fs*16"
0.44"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1538"
M
F"
SF3B1"
2"
198266834"
T"
C"
p.K700E"
0.41"
M
issense"
CALR"
Chr20"
1539"
M
F"
ASXL1"
20"
31024339"
C"
G"
p.S1275*"
0.41"
N
onsense"
CALR"
B"
1540"
M
F"
TET2"
4"
106196347"
_"
delT"
p.S1561fs*10"
0.42"
fram
eshift"(+1bp)"
CALR"
B"
1541"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1542"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1543"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1544"
M
F"
TP53"
17"
7577114"
C"
T"
p.C275Y"
0.22"
M
issense"
JAK2V617F"
B"
1545"
M
F"
TET2"
4"
106158463"
_"
insCT"
p.P1123fs*15"
0.17"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1546"
M
F"
DN
M
T3A"
2"
25467518"
_"
delA"
p.C520fs*131"
0.3"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1546"
M
F"
DN
M
T3A"
2"
25463184"
G"
A"
p.S770L"
0.31"
M
issense"
JAK2V617F"
Chr9"
1546"
M
F"
TET2"
4"
106197285"
T"
C"
p.I1873T"
0.13"
M
issense"
JAK2V617F"
Chr9"
1546"
M
F"
EZH2"
7"
148507485"
C"
G"
p.D657H"
0.34"
M
issense"
JAK2V617F"
Chr9"
1547"
M
F"
TET2"
4"
106180824"
_"
delCTT"
p.F1285delF"
0.3"
Infram
e"
M
PLW
515"
B"
1548"
M
F"
DN
M
T3A"
2"
25457242"
C"
T"
p.R882H"
0.46"
M
issense"
JAK2V617F"
Chr9"
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1549"
M
F"
DN
M
T3A"
2"
25457272"
_"
insTATAGTGG"
p.D876fs*8"
0.28"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1549"
M
F"
ASXL1"
20"
31022600"
_"
insACTAC"
p.L697fs*8"
0.06"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1549"
M
F"
ASXL1"
20"
31023269"
_"
delCATAC"
p.P920fs*2"
0.08"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1549"
M
F"
ASXL1"
20"
31023153"
_"
insTA"
p.T880fs*1"
0.05"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1549"
M
F"
U
2AF1"
21"
44514777"
T"
C"
p.Q
157R"
0.47"
M
issense"
JAK2V617F"
B"
1550"
M
F"
EZH2"
7"
148515067"
_"
insT"
p.D382fs*5"
0.29"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1550"
M
F"
ASXL1"
20"
31022402"
_"
delTC"
p.H630fs*4"
0.47"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1551"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1552"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1553"
M
F"
SRSF2"
17"
74732959"
G"
C"
p.P95R"
0.41"
M
issense"
JAK2V617F"
Chr9"
1554"
M
F"
U
2AF1"
21"
44524456"
G"
T"
p.S34Y"
0.34"
M
issense"
JAK2V617F"
Chr14"
1555"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1556"
M
F"
PHF6"
X"
133511698"
T"
A"
p.C17*"
0.96"
N
onsense"
JAK2V617F"
Chr9"
1557"
M
F"
GATA2"
3"
128204753"
G"
A"
p.R230C"
0.23"
M
issense"
M
PLW
515"
Chr1p"
1558"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1559"
M
F"
TET2"
4"
106182958"
_"
insA"
p.M
1333fs*6"
0.59"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1559"
M
F"
ZRSR2"
X"
15841123"
_"
delA"
p.R403fs*>86"
0.75"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1560"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9,14"
1561"
M
F"
TET2"
4"
106156569"
_"
insA"
p.Q
491fs*13"
0.45"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1561"
M
F"
SRSF2"
17"
74732959"
G"
T"
p.P95H"
0.52"
M
issense"
JAK2V617F"
Chr9"
1562"
M
F"
TET2"
4"
106156035"
_"
insA"
p.T313fs*18"
0.32"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1563"
M
F"
EZH2"
7"
148506443"
C"
T"
p.R690H"
0.14"
M
issense"
CALR"
B"
1563"
M
F"
RB1"
13"
48955389"
_"
delC"
p.T502fs*17"
0.42"
fram
eshift"(+1bp)"
CALR"
B"
1563"
M
F"
ASXL1"
20"
31022712"
C"
T"
p.Q
733*"
0.47"
N
onsense"
CALR"
B"
1564"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1565"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr18"
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1566"
M
F"
TET2"
4"
106180784"
G"
C"
p.C1271S"
0.15"
M
issense"
JAK2V617F"
B"
1566"
M
F"
TET2"
4"
106197003"
_"
delC"
p.L1780fs*40"
0.35"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1566"
M
F"
TET2"
4"
106156594"
_"
delC"
p.P499fs*34"
0.05"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1566"
M
F"
CBL"
11"
119142478"
_"
delC"
p.H160fs*6"
0.17"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1567"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1568"
M
F"
IDH1"
2"
209104604"
G"
A"
p.T325M
"
0.14"
M
issense"
JAK2V617F"
Chr9"
1568"
M
F"
TET2"
4"
106180784"
G"
A"
p.C1271Y"
0.1"
M
issense"
JAK2V617F"
Chr9"
1568"
M
F"
TET2"
4"
106164913"
C"
T"
p.R1261C"
0.63"
M
issense"
JAK2V617F"
Chr9"
1568"
M
F"
SRSF2"
17"
74732959"
G"
A"
p.P95L"
0.29"
M
issense"
JAK2V617F"
Chr9"
1568"
M
F"
ASXL1"
20"
31021439"
G"
T"
p.E480*"
0.39"
N
onsense"
JAK2V617F"
Chr9"
1569"
M
F"
SRSF2"
17"
74732959"
G"
C"
p.P95R"
0.35"
M
issense"
B"
B"
1569"
M
F"
ASXL1"
20"
31022839"
T"
G"
p.L775*"
0.5"
N
onsense"
B"
B"
1570"
M
F"
TP53"
17"
7578389"
G"
A"
p.R181C"
0.17"
M
issense"
JAK2V617F"
Chr5"
1571"
M
F"
TET2"
4"
106164061"
C"
T"
p.Q
1191*"
0.42"
N
onsense"
JAK2V617F"
B"
1571"
M
F"
CU
X1"
7"
101848438"
_"
delTG"
p.V1041fs*17"
0.31"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1571"
M
F"
SRSF2"
17"
74732959"
G"
C"
p.P95R"
0.55"
M
issense"
JAK2V617F"
B"
1571"
M
F"
ASXL1"
20"
31023479"
_"
delCT"
p.S989fs*1"
0.35"
fram
eshift"(+2bp)"
JAK2V617F"
B"
1572"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1573"
M
F"
DN
M
T3A"
2"
25470925"
_"
delTC"
p.D279fs*1"
1"
fram
eshift"(+2bp)"
CALR"
Chr7,12,19"
1573"
M
F"
TET2"
4"
106197020"
A"
T"
p.K1785*"
0.5"
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onsense"
CALR"
Chr7,12,19"
1574"
M
F"
N
FE2"
12"
54686430"
G"
A"
p.R284C"
0.13"
M
issense"
JAK2V617F"
Chr9"
1575"
M
F"
ASXL1"
20"
31023608"
_"
delG"
p.D1032fs*15"
0.29"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1576"
M
F"
JAK2"
9"
5081734"
_"
delTAT"
p.L816delL"
0.36"
Infram
e"
JAK2V617F"
B"
1577"
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F"
B"
B"
B"
B"
B"
B"
B"
B"
CALR"
B"
1578"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
B"
B"
1579"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
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1580"
M
F"
SF3B1"
2"
198267359"
C"
A"
p.K666N
"
0.39"
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issense"
JAK2V617F"
B"
1581"
M
F"
B"
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B"
B"
B"
B"
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B"
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Chr9"
1582"
M
F"
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B"
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B"
1583"
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F"
TET2"
4"
106197061"
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p.K1799fs*21"
0.5"
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eshift"(+1bp)"
JAK2V617F"
Chr9"
1584"
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F"
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B"
CALR"
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B"
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CALR"
B"
1586"
M
F"
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B"
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B"
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B"
JAK2V617F"
Chr8,9"
1587"
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F"
N
FE2"
12"
54686469"
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delG"
p.R271fs*31"
0.12"
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eshift"(+1bp)"
JAK2V617F"
B"
1588"
M
F"
TET2"
4"
106164941"
T"
A"
p.?"
0.94"
Splice"
JAK2V617F"
Chr9"
1589"
M
F"
DN
M
T3A"
2"
25463596"
_"
delG"
p.Q
696fs*9"
0.41"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1589"
M
F"
N
FE2"
12"
54686495"
_"
delCTCT"
p.E261fs*3"
0.02"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1590"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1591"
M
F"
KRAS"
12"
25398242"
T"
A"
p.N
26I"
0.54"
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issense"
JAK2V617F"
Chr7,9"
1591"
M
F"
RU
N
X1"
21"
36252940"
G"
T"
p.S141*"
0.44"
N
onsense"
JAK2V617F"
Chr7,9"
1592"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1593"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1594"
M
F"
ASXL1"
20"
31023717"
C"
T"
p.R1068*"
0.18"
N
onsense"
JAK2V617F"
Chr9"
1595"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9,14"
1596"
M
F"
SRSF2"
17"
74732959"
G"
C"
p.P95R"
0.33"
M
issense"
JAK2V617F"
B"
1597"
M
F"
TET2"
4"
106155535"
G"
T"
p.D146Y"
0.21"
M
issense"
JAK2V617F"
B"
1597"
M
F"
M
LL3"
7"
151945328"
C"
A"
p.E731*"
0.54"
N
onsense"
JAK2V617F"
B"
1597"
M
F"
FLT3"
13"
28608260"
T"
A"
p.Y599F"
0.25"
M
issense"
JAK2V617F"
B"
1598"
M
F"
TET2"
4"
106156701"
_"
delAAAC"
p.N
535fs*6"
0.28"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1598"
M
F"
IDH2"
15"
90631934"
C"
T"
p.R140Q
"
0.16"
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issense"
JAK2V617F"
Chr9"
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F"
B"
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B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1600"
M
F"
TET2"
4"
106156767"
_"
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p.Q
557fs*10"
0.51"
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eshift"(+2bp)"
JAK2V617F"
Chr9"
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1601"
M
F"
B"
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B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1602"
M
F"
B"
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B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1603"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1604"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
B"
1605"
M
F"
TET2"
4"
106196684"
_"
delC"
p.P1673fs*22"
0.03"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1606"
M
F"
N
FE2"
12"
54687087"
_"
insA"
p.Y65fs*20"
0.52"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1607"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1608"
M
F"
PPM
1D"
17"
58740602"
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insCAACAdelGTTG"
p.S503fs*2"
0.08"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1609"
M
F"
TET2"
4"
106196703"
_"
insT"
p.Y1679fs*8"
0.41"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1609"
M
F"
CBL"
11"
119169244"
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delACA"
p.T811delT"
0.7"
Infram
e"
JAK2V617F"
Chr9"
1609"
M
F"
N
FE2"
12"
54686380"
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delCCGCTCCAGCTC"
p.E297_R300delELER"
0.5"
Infram
e"
JAK2V617F"
Chr9"
1610"
M
F"
TP53"
17"
7577551"
C"
A"
p.G244C"
0.81"
M
issense"
JAK2V617F"
Chr5,9,17"
1610"
M
F"
U
2AF1"
21"
44514770"
_"
delCTCATA"
p.Y158_E159delYE"
0.36"
Infram
e"
JAK2V617F"
Chr5,9,17"
1611"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1612"
M
F"
TET2"
4"
106156747"
C"
T"
p.R550*"
0.41"
N
onsense"
JAK2V617F"
B"
1612"
M
F"
N
FE2"
12"
54687044"
_"
delG"
p.P79fs*32"
0.28"
fram
eshift"(+1bp)"
JAK2V617F"
B"
1613"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1614"
M
F"
N
FE2"
12"
54686654"
G"
T"
p.S209*"
0.2"
N
onsense"
JAK2V617F"
Chr9,20"
1615"
M
F"
DN
M
T3A"
2"
25463286"
C"
A"
p.R736L"
0.2"
M
issense"
JAK2V617F"
Chr9"
1616"
M
F"
DN
M
T3A"
2"
25457243"
G"
A"
p.R882C"
0.52"
M
issense"
JAK2V617F"
B"
1617"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1618"
M
F"
ASXL1"
20"
31022839"
T"
A"
p.L775*"
0.21"
N
onsense"
JAK2V617F"
Chr9"
1619"
M
F"
TET2"
4"
106156706"
_"
insT"
p.K536fs*31"
0.05"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1620"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1621"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1622"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
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1623"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
JAK2V617F"
Chr9"
1624"
M
F"
EZH2"
7"
148507443"
G"
C"
p.L671V"
0.13"
M
issense"
JAK2V617F"
Chr9"
1624"
M
F"
EZH2"
7"
148506167"
A"
C"
p.Y731D"
0.2"
M
issense"
JAK2V617F"
Chr9"
1624"
M
F"
ASXL1"
20"
31022403"
_"
delCACCA<13>GCGGC"
p.E635fs*15"
0.15"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1624"
M
F"
ASXL1"
20"
31022289"
C"
T"
p.Q
592*"
0.17"
N
onsense"
JAK2V617F"
Chr9"
1625"
M
F"
TET2"
4"
106164860"
A"
G"
p.K1243R"
0.48"
M
issense"
JAK2V617F"
Chr9"
1625"
M
F"
SH2B3"
12"
111885596"
T"
C"
p.L458P"
0.5"
M
issense"
JAK2V617F"
Chr9"
1626"
M
F"
ASXL1"
20"
31021630"
_"
delAGATCGTC"
p.D544fs*4"
0.07"
fram
eshift"(+2bp)"
JAK2V617F"
Chr9"
1627"
M
F"
N
RAS"
1"
115256535"
G"
T"
p.A59D"
0.33"
M
issense"
JAK2V617F"
B"
1627"
M
F"
TET2"
4"
106164775"
G"
T"
p.E1215*"
0.4"
N
onsense"
JAK2V617F"
B"
1627"
M
F"
TET2"
4"
106196705"
C"
T"
p.Q
1680*"
0.45"
N
onsense"
JAK2V617F"
B"
1627"
M
F"
PHF6"
X"
133551230"
C"
A"
p.T289N
"
0.47"
M
issense"
JAK2V617F"
B"
1628"
M
F"
B"
B"
B"
B"
B"
B"
B"
B"
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Chr9"
1629"
M
F"
TET2"
4"
106158248"
C"
A"
p.S1050*"
0.09"
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onsense"
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B"
1629"
M
F"
TP53"
17"
7577535"
C"
A"
p.R249M
"
0.13"
M
issense"
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B"
1629"
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F"
ASXL1"
20"
31022656"
_"
delC"
p.R715fs*10"
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eshift"(+1bp)"
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B"
1629"
M
F"
ASXL1"
20"
31022287"
_"
insA"
p.Y591fs*1"
0.22"
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eshift"(+2bp)"
JAK2V617F"
B"
1630"
M
F"
B"
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B"
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B"
B"
JAK2V617F"
B"
1631"
M
F"
TET2"
4"
106158455"
T"
G"
p.L1119*"
0.38"
N
onsense"
JAK2V617F"
B"
1632"
M
F"
KRAS"
12"
25398285"
C"
T"
p.G12S"
0.21"
M
issense"
JAK2V617F"
Chr9"
1632"
M
F"
ASXL1"
20"
31022784"
C"
T"
p.Q
757*"
0.41"
N
onsense"
JAK2V617F"
Chr9"
1633"
M
F"
TET2"
4"
106180838"
_"
delG"
p.C1289fs*74"
0.78"
fram
eshift"(+1bp)"
JAK2V617F"
Chr9"
1634"
M
F"
PTPN
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12"
112888210"
G"
C"
p.E76Q
"
0.14"
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issense"
JAK2V617F"
Chr9"
1635"
M
F"
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B"
B"
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B"
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Chr9"
1636"
M
F"
BCO
R"
X"
39933295"
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delTC"
p.D435fs*4"
0.31"
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eshift"(+2bp)"
JAK2V617F"
B"
1637"
M
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_u"
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M
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25457242"
C"
T"
p.R882H"
0.38"
M
issense"
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17"
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0.34"
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106157814"
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B"
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20"
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p.E635fs*15"
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 Appendix 4: Accuracy'of'the'multivariate'multistate'model'in'patients'with'MF''
Accuracy'of'the'multivariate'multistate'model'was'assessed'using'several'statistical'parameters.'
Results' of' Brier' score' (“Brier”)' and' concordance' (“Uno' C”)' statistics' are' shown' using' the'
multivariate'multistate'model' (“full'model”)' applied' to' the' training' cohort' using' leave@one@out'
cross@validation'(“Training@Xval”),'as'well'as'to'the'external'cohort'(“External”).'Also'shown'is'the'
concordance'statistic'obtained'using'currently'available'prognostic'schemas'(High'Molecular'Risk,'
“HMR”;' ' international' prognostic' scoring' system' (“IPSS”);' Dynamic' IPSS' (“DIPSS”).' Outcomes'
assessed'using'overall'survival'(“OS”)'and'AML'transformation'(“AML”).'
'
Diagnosis' Cohort' Model' Outcome'
Time'
(yrs)' Brier'
Absolute'Prediction'
Error' Stderr'
Uno'
C' Uncertainty'
MF'
Training@
Xval' Full'model' OS' 5' 0.15' 0.31' 0.03' 0.85' 0.25'
MF'
Training@
Xval' Full'model' OS' 10' 0.13' 0.29' 0.03' 0.85' 0.14'
MF'
Training@
Xval' Full'model' OS' 15' 0.09' 0.23' 0.03' 0.86' 0.06'
MF'
Training@
Xval' HMR' OS' @' @' @' 0.02' 0.65' @'
MF'
Training@
Xval' Full'model' AMLT' 5' 0.08' 0.14' 0.06' 0.85' 0.25'
MF'
Training@
Xval' Full'model' AMLT' 10' 0.09' 0.16' 0.06' 0.84' 0.17'
MF'
Training@
Xval' Full'model' AMLT' 15' 0.08' 0.17' 0.06' 0.76' 0.06'
MF'
Training@
Xval' HMR' AMLT' @' @' @' 0.04' 0.64' @'
MF' External'
Limited'genomic'
data' OS' 5' 0.12' 0.28' 0.03' 0.81' 0.24'
MF' External'
Limited'genomic'
data' OS' 10' 0.1' 0.24' 0.03' 0.78' 0.12'
MF' External'
Limited'genomic'
data' OS' 15' 0.06' 0.18' 0.03' 0.7' 0.04'
MF' External' HMR' OS' @' @' @' 0.03' @' @'
MF' External' IPSS' OS' @' @' @' 0.03' 0.82' @'
MF' External' DIPSS' OS' @' @' @' 0.03' 0.68' @'
MF' External'
Limited'genomic'
data' AMLT' 5' 0.08' 0.16' 0.06' 0.85' 0.25'
MF' External'
Limited'genomic'
data' AMLT' 10' 0.08' 0.18' 0.06' 0.84' 0.14'
MF' External'
Limited'genomic'
data' AMLT' 15' 0.08' 0.2' 0.06' 0.81' 0.07'
MF' External' HMR' AMLT' @' @' @' 0.05' @' @'
MF' External' IPSS' AMLT' @' @' @' 0.05' 0.74' @'
MF' External' DIPSS' AMLT' @' @' @' 0.05' 0.76' @'
'
'
'
' '
 Appendix'5'
Assessment'of'performance'of'multistate'model'in'chronic'phase'(CP)'patients'
Results' of' Brier' score' (“Brier”)' and' concordance' (“Uno' C”)' statistics' are' shown' using' the'
multivariate'multistate'model' (“full'model”)' applied' to' the' training' cohort' using' leave@one@out'
cross@validation' (“Training' (Xval)”),' as' well' as' to' the' external' cohort' (“External”).' These' are'
compared'to'the'concordance'obtained'using'the'International'Prognostic'Score'in'ET'(IPSET)'for'
patients'with'ET.'Outcomes'are'overall'and'event'free'survival'(OS'and'EFS),'and'transformation'
to'myelofibrosis'(MFT)'or'acute'myeloid'leukemia'(AMLT).'Also'shown'is'the'concordance'statistic'
obtained' using' currently' available' prognostic' schemas' (High' Molecular' Risk,' “HMR”;''
international' prognostic' scoring' system' (“IPSS”);' Dynamic' IPSS' (“DIPSS”).' Outcomes' assessed'
using'overall'survival'(“OS”)'and'AML'transformation'(“AML”).'
'
Diagnosi
s' Cohort' Model'
Outcom
e'
Time'
(yrs)'
Brie
r'
Absolute'Prediction'
Error'
Stder
r'
Un
o'C'
Uncertaint
y'
CP'
Training@
Xval' Full'model' OS' 5' 0.05' 0.11' 0.02'
0.8
6' 0.18'
CP'
Training@
Xval' Full'model' OS' 10' 0.09' 0.2' 0.02'
0.8
6' 0.24'
CP'
Training@
Xval' Full'model' OS' 15' 0.09' 0.23' 0.02'
0.8
6' 0.11'
CP'
Training@
Xval' Full'model' AMLT' 5' 0.01' 0.02' 0.05'
0.7
8' 0.18'
CP'
Training@
Xval' Full'model' AMLT' 10' 0.01' 0.03' 0.06'
0.7
8' 0.24'
CP'
Training@
Xval' Full'model' AMLT' 15' 0.03' 0.06' 0.06'
0.7
4' 0.11'
CP'
Training@
Xval' Full'model' MFT' 5' 0.01' 0.02' 0.06'
0.6
8' 0.2'
CP'
Training@
Xval' Full'model' MFT' 10' 0.02' 0.04' 0.06'
0.6
7' 0.24'
CP'
Training@
Xval' Full'model' MFT' 15' 0.03' 0.06' 0.06'
0.6
3' 0.11'
CP'
Training@
Xval' Full'model' EFS' 5' 0.06' 0.13' 0.02'
0.8
4' 0.2'
CP'
Training@
Xval' Full'model' EFS' 10' 0.1' 0.21' 0.02'
0.8
4' 0.23'
CP'
Training@
Xval' Full'model' EFS' 15' 0.1' 0.24' 0.02'
0.8
4' 0.1'
ET'
Training@
Xval' Full'model' OS' 5' 0.06' 0.12' 0.02'
0.8
6' 0.17'
ET'
Training@
Xval' Full'model' OS' 10' 0.1' 0.21' 0.02'
0.8
6' 0.24'
ET'
Training@
Xval' Full'model' OS' 15' 0.09' 0.24' 0.02'
0.8
6' 0.1'
ET'
Training@
Xval' IPSET' OS' @' @' @' 0.02'
0.7
2' @'
ET'
Training@
Xval' Full'model' AMLT' 5' 0.01' 0.02' 0.05'
0.7
7' 0.17'
ET'
Training@
Xval' Full'model' AMLT' 10' 0.02' 0.03' 0.05'
0.7
6' 0.24'
ET'
Training@
Xval' Full'model' AMLT' 15' 0.03' 0.07' 0.05'
0.7
1' 0.1'
ET'
Training@
Xval' IPSET' AMLT' @' @' @' 0.05'
0.5
7' @'
ET'
Training@
Xval' Full'model' MFT' 5' 0.01' 0.02' 0.05'
0.6
5' 0.17'
ET'
Training@
Xval' Full'model' MFT' 10' 0.02' 0.04' 0.05'
0.6
4' 0.24'
ET'
Training@
Xval' Full'model' MFT' 15' 0.03' 0.06' 0.05'
0.6
1' 0.1'
 ET'
Training@
Xval' IPSET' MFT' @' @' @' 0.05' 0.6' @'
ET'
Training@
Xval' Full'model' EFS' 5' 0.07' 0.14' 0.02'
0.8
3' 0.18'
ET'
Training@
Xval' Full'model' EFS' 10' 0.1' 0.23' 0.02'
0.8
4' 0.24'
ET'
Training@
Xval' Full'model' EFS' 15' 0.1' 0.25' 0.02'
0.8
4' 0.09'
ET'
Training@
Xval' IPSET' EFS' @' @' @' 0.02' @' @'
CP' External'
Limited'genomic'
data' OS' 5' 0.06' 0.11' 0.03'
0.8
3' 0.07'
CP' External'
Limited'genomic'
data' OS' 10' 0.09' 0.2' 0.03'
0.8
4' 0.21'
CP' External'
Limited'genomic'
data' OS' 15' 0.13' 0.3' 0.03'
0.8
4' 0.23'
CP' External'
Limited'genomic'
data' AMLT' 5' 0.01' 0.04' 0.09'
0.8
1' 0.07'
CP' External'
Limited'genomic'
data' AMLT' 10' 0.2' 0.08' 0.09'
0.8
1' 0.21'
CP' External'
Limited'genomic'
data' AMLT' 15' 0.06' 0.19' 0.09'
0.8
1' 0.24'
CP' External'
Limited'genomic'
data' MFT' 5' 0.03' 0.06' 0.04'
0.5
8' 0.09'
CP' External'
Limited'genomic'
data' MFT' 10' 0.08' 0.13' 0.04'
0.5
8' 0.23'
CP' External'
Limited'genomic'
data' MFT' 15' 0.13' 0.23' 0.04'
0.5
6' 0.21'
CP' External'
Limited'genomic'
data' EFS' 5' 0.08' 0.15' 0.03' 0.7' 0.09'
CP' External'
Limited'genomic'
data' EFS' 10' 0.14' 0.27' 0.03'
0.7
2' 0.23'
CP' External'
Limited'genomic'
data' EFS' 15' 0.17' 0.35' 0.03'
0.7
2' 0.21'
'
 Appendix'6:'Numbers'needed'to'test'using'multistage'model'to'detect'one'patient'meeting'
required'criteria'(probability'greater'than'threshold'x%)'
'
''
Group Subgroup Outcome Timepoint1(yrs) Threshold1(x%) NNT
ET/PV All AML1transformation 10 10 43
ET/PV All AML1transformation 15 10 8
ET/PV All AML1transformation 15 20 33
ET/PV All AML1transformation 15 30 77
ET/PV Under160yrs AML1transformation 15 10 10
ET/PV Under160yrs AML1transformation 15 20 45
ET/PV All AML/MF1transformation1or1Death 5 10 5
ET/PV All AML/MF1transformation1or1Death 5 20 10
ET/PV All AML/MF1transformation1or1Death 5 30 22
ET/PV All AML/MF1transformation1or1Death 5 40 54
ET/PV All AML/MF1transformation1or1Death 10 10 2
ET/PV All AML/MF1transformation1or1Death 10 20 3
ET/PV All AML/MF1transformation1or1Death 10 30 5
ET/PV All AML/MF1transformation1or1Death 10 40 6
ET/PV All AML/MF1transformation1or1Death 10 50 9
ET/PV All AML/MF1transformation1or1Death 15 30 2
ET/PV All AML/MF1transformation1or1Death 15 40 3
ET/PV All AML/MF1transformation1or1Death 15 50 3
ET/PV Under160yrs AML/MF1transformation1or1Death 5 10 73
ET/PV Under160yrs AML/MF1transformation1or1Death 10 10 4
ET/PV Under160yrs AML/MF1transformation1or1Death 10 20 21
ET/PV Under160yrs AML/MF1transformation1or1Death 15 10 2
ET/PV Under160yrs AML/MF1transformation1or1Death 15 20 3
ET/PV Under160yrs AML/MF1transformation1or1Death 15 30 4
ET/PV Under160yrs AML/MF1transformation1or1Death 15 40 6
ET/PV Under160yrs AML/MF1transformation1or1Death 15 50 19
ET/PV All MF1transformation 10 10 49
ET/PV All MF1transformation 15 10 10
ET/PV All MF1transformation 15 20 60
ET/PV Under160yrs MF1transformation 10 10 86
ET/PV Under160yrs MF1transformation 15 10 12
ET/PV Under160yrs MF1transformation 15 20 63
MF All AML1transformation 5 10 4
MF All AML1transformation 5 20 9
MF All AML1transformation 5 30 17
MF All AML1transformation 5 40 28
MF All AML1transformation 5 50 56
MF All AML1transformation 10 10 3
MF All AML1transformation 10 20 6
MF All AML1transformation 10 30 10
MF All AML1transformation 10 40 17
MF All AML1transformation 10 50 35
MF Under160yrs AML1transformation 5 10 13
MF Under160yrs AML1transformation 5 20 22
MF Under160yrs AML1transformation 5 30 55
MF Under160yrs AML1transformation 10 10 7
MF Under160yrs AML1transformation 10 20 13
MF Under160yrs AML1transformation 10 30 22
MF Under160yrs AML1transformation 10 40 37
MF All AML1transformation1or1death 5 20 2
MF All AML1transformation1or1death 5 30 3
MF All AML1transformation1or1death 5 40 3
MF All AML1transformation1or1death 5 50 4
MF All AML1transformation1or1death 10 50 2
MF Under160yrs AML1transformation1or1death 5 10 2
MF Under160yrs AML1transformation1or1death 5 20 6
MF Under160yrs AML1transformation1or1death 5 30 10
MF Under160yrs AML1transformation1or1death 5 40 22
MF Under160yrs AML1transformation1or1death 5 50 55
MF Under160yrs AML1transformation1or1death 10 20 2
MF Under160yrs AML1transformation1or1death 10 30 3
MF Under160yrs AML1transformation1or1death 10 40 6
MF Under160yrs AML1transformation1or1death 10 50 8
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BACKGROUND
Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythe-
mia, and myelofibrosis, are chronic hematologic cancers with varied progression 
rates. The genomic characterization of patients with myeloproliferative neoplasms 
offers the potential for personalized diagnosis, risk stratification, and treatment.
METHODS
We sequenced coding exons from 69 myeloid cancer genes in patients with myelo-
proliferative neoplasms, comprehensively annotating driver mutations and copy-
number changes. We developed a genomic classification for myeloproliferative 
neoplasms and multistage prognostic models for predicting outcomes in individual 
patients. Classification and prognostic models were validated in an external cohort.
RESULTS
A total of 2035 patients were included in the analysis. A total of 33 genes had 
driver mutations in at least 5 patients, with mutations in JAK2, CALR, or MPL being 
the sole abnormality in 45% of the patients. The numbers of driver mutations in-
creased with age and advanced disease. Driver mutations, germline polymor-
phisms, and demographic variables independently predicted whether patients re-
ceived a diagnosis of essential thrombocythemia as compared with polycythemia 
vera or a diagnosis of chronic-phase disease as compared with myelofibrosis. We 
defined eight genomic subgroups that showed distinct clinical phenotypes, includ-
ing blood counts, risk of leukemic transformation, and event-free survival. Inte-
grating 63 clinical and genomic variables, we created prognostic models capable 
of generating personally tailored predictions of clinical outcomes in patients with 
chronic-phase myeloproliferative neoplasms and myelofibrosis. The predicted and 
observed outcomes correlated well in internal cross-validation of a training cohort 
and in an independent external cohort. Even within individual categories of exist-
ing prognostic schemas, our models substantially improved predictive accuracy.
CONCLUSIONS
Comprehensive genomic characterization identified distinct genetic subgroups and 
provided a classification of myeloproliferative neoplasms on the basis of causal 
biologic mechanisms. Integration of genomic data with clinical variables enabled 
the personalized predictions of patients’ outcomes and may support the treatment 
of patients with myeloproliferative neoplasms. (Funded by the Wellcome Trust and 
others.)
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in Myeloproliferative Neoplasms
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Classification and Prognosis in Myeloprolifer ative Neoplasms
Myeloproliferative neoplasms are clonal hematopoietic disorders compris-ing polycythemia vera, which is charac-
terized by red-cell overproduction; essential throm-
bocythemia, which involves elevated platelet 
counts; and myelofibrosis, which is defined by 
bone marrow fibrosis.1 Polycythemia vera and 
essential thrombocythemia are chronic-phase my-
eloproliferative neoplasms, whereas myelofibrosis 
represents advanced disease that is diagnosed 
either initially or after the diagnosis of essential 
thrombocythemia or polycythemia vera. Current 
classification schemes distinguish among the sub-
types of myeloproliferative neoplasms according 
to clinical and laboratory features,2-5 but uncer-
tainty clouds where and how to draw dividing 
lines among them.6,7
Biologically, the development of myeloprolifer-
ative neoplasms is driven by mutations in JAK2, 
CALR, or MPL. Many patients have additional 
drivers that span a wide range of cancer genes, 
with patient-to-patient variation in the genetic 
and clonal landscape.8,9 Driver mutations correlate 
with phenotype and prognosis,10-12 and mutation 
order can also influence phenotype.13,14 This com-
plex genetic landscape probably contributes to 
heterogeneity in diagnostic features and outcomes 
in patients with myeloproliferative neoplasms.
In blood cancers, a progressive shift is under 
way, from clinical and morphologic classification 
schemes to those that are based on genomics.15 
Driver mutations are increasingly important in 
predicting clinical outcomes, but large, well-
characterized cohorts are necessary for accurate 
prognostic models.16 Studies have suggested that 
this promise extends to myeloproliferative neo-
plasms,10,17 but larger cohorts and comprehensive 
gene sequencing are needed in order to provide 
definitive answers.
Me thods
Study Samples
We analyzed samples that were obtained from 
patients after they provided written informed 
consent and after ethics approval from relevant 
authorities was obtained. Details regarding the 
cohort, disease classification, and diagnostic re-
view are provided in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org. Tumor DNA was derived from blood 
granulocytes, bone marrow mononuclear cells, 
or whole blood. The majority of patients did not 
have matched germline samples sequenced. We 
use the term “myelofibrosis” to encompass both 
primary myelofibrosis and myelofibrosis that 
evolved from essential thrombocythemia or poly-
cythemia vera.
No commercial support was involved in this 
study. See the Supplementary Appendix for de-
tails regarding patient cohorts and samples.
Sequencing and Analyses
We designed custom RNA baits to capture the 
full coding sequence of 69 genes, single-nucleo-
tide polymorphisms for copy number profiling, 
and germline loci that have been associated with 
myeloproliferative neoplasms (Tables S1 and S2 
in the Supplementary Appendix).18-20 Additional 
patients underwent whole-exome sequencing, as 
reported previously.8
Clinical Variables
Laboratory and clinical data from diagnosis were 
incorporated into prognostic models. The median 
duration between diagnosis and sample acquisi-
tion was 49 days. The median follow-up was 
93.8 months (range, <1 to 523) from diagnosis 
and 72.0 months (range, <1 to 360) from DNA 
sampling.
Statistical Analysis
We estimated the timing of mutation acquisition 
using Bradley–Terry models of pairwise compari-
sons of clonal fractions.13 We used a Bayesian 
network analysis and Dirichlet processes to iden-
tify genetic associations and subgroups. Random-
effects Cox proportional-hazards multistate 
modeling was used for outcome predictions (see 
the Supplementary Appendix).
R esult s
Spectrum of Genomic Changes  
in Myeloproliferative Neoplasms
Targeted sequencing for the full coding sequence 
of 69 genes and genomewide copy-number infor-
mation was undertaken in 1887 patients, and 148 
patients underwent whole-exome sequencing, as 
reported previously.8 The cohort of 2035 patients 
included 1321 patients with essential thrombo-
cythemia, 356 with polycythemia vera, 309 with 
myelofibrosis, and 49 with other diagnoses of 
myeloproliferative neoplasms (Table S3 in the 
Supplementary Appendix). A total of 33 genes 
had driver mutations in at least 5 patients (Fig. 1A, 
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and Tables S4 and S5 in the Supplementary Ap-
pendix). Mutations in JAK2, MPL, and CALR ac-
counted for 1831 driver mutations and were the 
sole abnormality in 45% of the patients. A total 
of 1075 driver mutations were identified across 
other genes. Loss of heterozygosity was frequent 
for JAK2 V617F, especially in patients with poly-
cythemia vera, but was infrequent for CALR and 
MPL (Fig. S1 in the Supplementary Appendix).
We identified 45 truncating mutations in the 
terminal exon of PPM1D in 38 patients within 
the cohort (1.9%) (Fig. 1B); thus, PPM1D was the 
eighth most commonly mutated gene in myelo-
proliferative neoplasms. These mutations have also 
been detected in solid tumors, blood samples ob-
tained from healthy persons, and patients with 
breast or ovarian tumors, often after chemother-
apy.21,22 In our cohort, 10 patients had PPM1D 
mutations that were detectable only in a later 
sample obtained during treatment with hydroxy-
urea. However, PPM1D mutations were also de-
tected at or within 1 month after diagnosis in 20 
patients. Analysis of single-cell–derived hemato-
poietic colonies identified mutated PPM1D in a 
patient with triple-negative essential thrombocy-
themia (i.e., nonmutated JAK2, CALR, or MPL) but 
also identified mutated PPM1D that was sub-
clonal to JAK2 V617F in a patient with polycythe-
mia vera (Fig. 1C). These data confirm that 
PPM1D mutations can occur within the myelo-
proliferative neoplasm clone and be present at 
diagnosis; thus, their presence does not always 
indicate age-related clonal hematopoiesis or 
therapy-related disease evolution.
Mutations in MLL3 were detected in 20 patients 
(1.0%) and were predominantly nonsense or 
frameshift, as has been reported in patients with 
acute myeloid leukemia (Fig. 1A, and Table S4 in 
the Supplementary Appendix).23 Among these 20 
patients, 7 patients had triple-negative myelopro-
liferative neoplasms, which suggests that MLL3 
could be an important tumor-suppressor gene in 
these patients.
Whether mutations in JAK2 and MPL outside 
the known hot spots could be relevant to patients 
with myeloproliferative neoplasms has been un-
clear.24,25 We identified noncanonical variants in 
JAK2 and MPL in 16 patients with triple-negative 
essential thrombocythemia and in 1 patient with 
triple-negative myelofibrosis (Fig. 1D). Of these, 
three groups of variants were likely to be rele-
vant to disease pathogenesis: JAK2 R683G and 
JAK2 E627A in 2 patients with essential throm-
bocythemia (reported in acute lymphoblastic leu-
kemia in which they activate JAK226-28); JAK2 
R867 in 2 patients with essential thrombocythemia 
(associated with familial thrombocythemia29); 
and MPL S505N and MPL S204P in 4 and 5 pa-
tients, respectively, with essential thrombocythe-
mia.24 MPL S204P co-occurred with loss of hetero-
zygosity (LOH) at chromosome 1p, which suggests 
Figure 1 (facing page). Genomic Landscape  
of Myeloproliferative Neoplasms.
Panel A shows the frequency of recurrently mutated 
genes and chromosomal abnormalities in the cohort  
of 2035 patients. Mutations were stratified according 
to type (missense, nonsense, affecting a splice site,  
or other [e.g., stop, gain, or loss]). Insertions and dele-
tions (del) were categorized according to whether they 
resulted in a shift in the codon reading frame (by either 
1 or 2 base pairs [bp]) or were in frame. Chromosomes 
are indicated by Chr plus a numeral (e.g., Chr9 denotes 
chromosome 9). Chromosomal gains include whole-
chromosome gains (trisomy) and subchromosomal 
amplifications. Chromosomal losses include whole-
chromosome deletions (monosomy) and subchromo-
somal deletions. Loss of heterozygosity (LOH) was 
predominantly copy-number neutral, but in some cases, 
chromosome losses could not be ruled out. Panel B 
shows the site within the gene and protein consequence 
of PPM1D mutations. Colored shapes represent the 
characteristics of the patient who had the specific mu-
tation (shapes indicate the subtype of myeloproliferative 
neoplasm, and colors the phenotypic driver). A triple-
negative finding indicates nonmutated JAK2, CALR, 
and MPL. The term aa denotes amino acid, ET essen-
tial thrombocythemia, fs frameshift, MF myelofibrosis, 
PP2C protein phosphatase 2C domain, and PV poly-
cythemia vera. Panel C shows clonal structures of two 
patients with PPM1D mutations determined by geno-
typing of hematopoietic colonies derived from periph-
eral-blood mononuclear cells. Each circle represents a 
group of hematopoietic colonies that share the same 
genotype: wild type (white), other driver mutations 
(black), and PPM1D mutated (yellow). Wild-type colo-
nies are represented at the top of each diagram, with 
subsequent mutant subclones shown below. Somatic 
mutations acquired in each subclone are indicated be-
side respective nodes and represent those that were 
acquired in addition to mutations present in earlier sub-
clones. The term hom denotes homozygous. Panel D 
shows the site within the gene and protein consequence 
of noncanonical mutations of JAK2 and MPL. The V617F 
and exon 12 mutations in JAK2 and W515 mutations in 
MPL are not shown. Mutations highlighted in red are 
likely to be relevant to disease pathogenesis, with previ-
ous studies having shown somatic acquisition, familial 
inheritance, or functional consequences for the specific 
variants (see box of abbreviations). FERM denotes the 
4.1–ezrin–radixin–moesin domain, SH2 Src homology 2, 
Sig signal, and TM transmembrane.
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a clonal advantage to acquired homozygosity for 
this variant.
Factors Influencing Classification  
into Disease Subtypes
Currently, patients with myeloproliferative neo-
plasms are classified as having essential throm-
bocythemia, polycythemia vera, or myelofibrosis 
on the basis of clinical and laboratory criteria,2-5 
but the biologic factors underlying these distinc-
tions are incompletely understood. The number 
of driver mutations per patient was higher in 
those with myelofibrosis than in those with 
polycythemia vera or essential thrombocythemia 
(Fig. 2A), as previously reported,8 and increased 
according to the age of the patient (Fig. 2B).
The distinction between JAK2 V617F–mutated 
essential thrombocythemia and polycythemia vera 
rests on whether the red-cell mass or hematocrit 
is elevated. We found that acquired driver muta-
tions correlated with hematologic variables (Fig. 
S2 in the Supplementary Appendix) and were the 
strongest determinants of a patient with JAK2 
V617F–mutated chronic-phase disease receiving 
a diagnosis of essential thrombocythemia as com-
pared with polycythemia vera, although germline 
genetic background and demographic factors also 
contributed (Fig. 2C, and Fig. S2 in the Supple-
mentary Appendix). LOH at chromosome 9p 
(9pLOH), causing JAK2 V617F homozygosity, or a 
high JAK2 V617F allele burden correlated with poly-
cythemia vera, as did mutated NFE2, a transcrip-
tion factor critical to erythroid differentiation.
Germline polymorphisms that have been asso-
ciated with red-cell variables in the general popu-
lation were distributed unevenly, with alleles as-
sociated with lower hemoglobin level and higher 
platelet counts being enriched in patients with 
essential thrombocythemia (Fig. 2C). Further-
more, the JAK2 46/1 haplotype, which is known 
to increase the predisposition to myeloprolifera-
tive neoplasms,18 correlated with polycythemia vera 
(odds ratio, 2.3; 95% confidence interval [CI], 
1.7 to 3.3; P = 0.004), possibly through increasing 
odds of JAK2 V617F homozygosity by 9pLOH 
(odds ratio, 2.7; 95% CI, 2.0 to 3.9; P<0.001). 
Older age and male sex also increased the odds 
of polycythemia vera. These data show that the 
location of any chronic-phase disease on the he-
moglobin and red-cell mass continuum is influ-
enced by many factors and that any arbitrary 
threshold to label patients’ disease as being one 
subtype or the other will not distinguish among 
patients with different underlying biologic factors.
Mutations in spliceosome components, epi-
genetic regulators, and the RAS pathway were 
strongly associated with accelerated phase (myelo-
fibrosis), as compared with chronic-phase dis-
ease (essential thrombocythemia or polycythe-
mia vera), as were male sex, older age, and 
germline loci associated with platelet count and 
red-cell variables (Fig. 2D).
The order in which mutations are acquired in 
myeloproliferative neoplasms has previously been 
shown to influence disease phenotype.1314 CALR 
and MPL mutations occurred more commonly 
early in disease, whereas mutations in NRAS, 
TP53, PPM1D, and NFE2 were acquired signifi-
cantly later in disease (Fig. 2E, and Fig. S3 in the 
Supplementary Appendix). Some of the earlier-
occurring mutations in genes such as SF3B1 and 
Figure 2 (facing page). Factors Affecting Disease 
 Classification at Presentation and Timing of Somatic 
Mutations.
Histograms show the frequency of driver mutations  
or chromosomal changes (gains, losses, or LOH) that 
were identified in different molecular subtypes of myelo-
proliferative neoplasm (MPN) (excluding 24 patients 
with >1 detectable phenotypic driver mutation) (Panel A) 
and according to the age of the patient at diagnosis 
(Panel B). Forest plots showing the associations between 
genetic or demographic features and presentation with 
essential thrombocythemia (ET) as compared with poly-
cythemia vera (PV) in patients with JAK2 V617F muta-
tions (Panel C) and the presentation in chronic-phase 
(CP) disease as compared with MF across patients with 
JAK2, CALR, or MPL mutations (Panel D). Significant 
associations from univariate analyses after correction 
for multiple hypothesis testing are shown. P values 
were derived from logistic-regression modeling, identi-
fying independent associations. Causes of reductions 
in the hemoglobin (Hb) level, mean corpuscular hemo-
globin (MCH) level, mean corpuscular volume (MCV), 
and platelet (Plt) count are indicated. Of 671 patients 
who had more than one somatic mutation, the order  
of mutation acquisition of at least one pair of mutations 
was determined in 271 patients (40%) (Panel E). These 
ordered pairings were used to determine the relative 
probabilities of a gene occurring first or second for a 
given pairing with the use of Bradley–Terry modeling, 
which provided an estimate of the overall timing of 
mutation acquisition. The horizontal axis shows the log 
odds of a gene occurring second in a gene pair. For ex-
ample, as compared with JAK2, PPM1D mutations have 
a log odds of 1.45 and therefore are e1.45, or 4.3, times 
more likely to occur second in the pair. Any pair of genes 
can be assessed in this manner by calculating the exponen-
tial of the difference in log odds for gene A and gene B. 
The error bars indicate 95% confidence intervals.
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DNMT3A are also associated with age-related 
clonal hematopoiesis,30,31 which suggests that 
some myeloproliferative neoplasms could arise 
from an antecedent asymptomatic clone. In pa-
tients with multiple mutations, JAK2 V617F was 
more commonly a secondary event in patients 
with essential thrombocythemia and an earlier 
event in those with polycythemia vera or myelo-
fibrosis (Figs. S4 and S5 in the Supplementary 
Appendix), a finding that confirms and general-
izes observations that had previously been shown 
for JAK2 relative to TET2 or DNMT3A.13,14
Genomic Subgroups in Myeloproliferative 
Neoplasms
Hematologic cancers may be subclassified accord-
ing to driver mutations that distinguish sub-
groups of patients,32,33,34 with the use of patterns 
of mutually exclusive or co-mutated genes. In our 
cohort, driver mutations showed complex patterns 
of assortment (Fig. S6 in the Supplementary Ap-
pendix). We used Bayesian modeling to identify 
genomic subgroups of myeloproliferative neo-
plasms with maximum within-group similarity 
and maximum between-group discrimination.
We identified eight genomic subgroups in 
myeloproliferative neoplasms, defined according 
to simple rules (Fig. 3, and Fig. S7 in the Supple-
mentary Appendix). TP53 mutations, often co-
occurring with aberrations at chromosome 17p, 
and deletions at chromosome 5q identified the 
first subgroup. TP53 mutations often occur later 
in disease (Fig. 2E) but dominate the genomic 
and clinical features of these patients regardless 
of the initial driver of the myeloproliferative 
neoplasm. As in patients with other blood can-
cers with TP53 mutations,32,35 these patients have 
a dismal prognosis with a high risk of transfor-
mation to acute myeloid leukemia (hazard ratio 
vs. the JAK2-heterozygous subgroup, 15.5; 95% 
CI, 7.5 to 31.4; P<0.001) and early death (hazard 
ratio, 2.4; 95% CI, 1.6 to 3.6; P<0.001).
The second subgroup was defined by the 
presence of one or more mutations in 16 myeloid 
cancer genes, especially chromatin and spliceo-
some regulators, LOH at chromosome 4q, and 
aberrations in chromosomes 7 and 7q. This sub-
group was enriched for patients with myelofibro-
sis (odds ratio, 6.5; 95% CI, 4.9 to 8.7; P<0.001) 
and myelodysplastic–myeloproliferative neoplasms 
(including all seven patients with chronic myelo-
monocytic leukemia or atypical chronic myeloid 
leukemia) but also included 8.4% of patients 
with essential thrombocythemia and 11.5% of 
those with polycythemia vera. Patients were at 
increased risk for transformation to myelofibro-
sis (hazard ratio vs. the JAK2-heterozygous sub-
group, 5.4; 95% CI, 2.7 to 11.0; P<0.001) and 
shorter event-free survival, regardless of mye-
loproliferative neoplasm subtype or phenotypic 
driver mutation (hazard ratio for disease progres-
sion or death, 2.6; 95% CI, 2.1 to 3.2; P<0.001).
Patients who were not identified in the above 
two subgroups were classified according to their 
dominant myeloproliferative neoplasm pheno-
typic driver mutation. Patients with CALR muta-
tions, which co-occurred with LOH at chromo-
some 19p and with deletion at chromosome 20q, 
or those with MPL mutations all presented with 
essential thrombocythemia or myelofibrosis. Pa-
tients with MPL-mutated myelofibrosis had an 
elevated rate of acute myeloid leukemia transfor-
mation (hazard ratio vs. the JAK2-heterozygous 
subgroup, 8.6; 95% CI, 1.4 to 49.1; P = 0.02), but 
otherwise the two subgroups had a clinical 
course that was similar to that in the JAK2 sub-
groups. Patients with JAK2 V617F heterozygos-
ity constituted most of the patients with JAK2-
Figure 3 (facing page). Genomic Subgroups in MPN 
and Phenotypic Characteristics.
According to a Bayesian clustering algorithm (Dirichlet 
process), patients could be classified into six distinct 
subgroups on the basis of the presence or absence of 
mutations and chromosomal abnormalities. The remaining 
patients either had no detectable genomic changes or 
had clonal markers that were not defining for one of the 
six groups. The flowchart shows the logic that allows pa-
tients to be classified into the total of eight groups. Pro-
portions of patients with essential thrombocythemia 
(ET), polycythemia vera (PV), myelofibrosis (MF, either 
primary or after chronic-phase disease), or other MPN 
diagnoses are shown, as are rates of overall survival and 
myelofibrotic or leukemic transformation among patients 
in the individual subgroups. The 18 genetic aberrations 
involved EZH2, IDH1, IDH2, ASXL1, PHF6, CUX1, ZRSR2, 
SRSF2, U2AF1, KRAS, NRAS, GNAS, CBL, Chr7/7qLOH, 
Chr4qLOH, RUNX1, STAG2, and BCOR. Patients who had 
more than one mutation across JAK2, CALR, and MPL 
and deletion at chromosome 20q could belong to more 
than one classification. In patients who had myelopro-
liferation with other driver mutations, other diagnoses 
should be considered, depending on the nature of the 
genetic aberration. Chromo some 9pLOH was judged 
to be present if detectable at a 10% clonal fraction. 
The number of asterisks indicates the P value (*P<0.05, 
**P<0.01, and ***P<0.001) for the comparison with pa-
tients with MPN with heterozygous JAK2 mutation.
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mutated essential thrombocythemia but also 
some of the patients with polycythemia vera or 
myelofibrosis; these patients had generally favor-
able outcomes. The subgroup of patients with 
JAK2 homozygosity was enriched for patients 
with NFE2 mutations and for patients with poly-
cythemia vera. Myelofibrosis transformations oc-
curred more frequently in this subgroup (hazard 
ratio vs. the JAK2-heterozygous subgroup, 3.0; 
95% CI, 1.3 to 6.6; P = 0.007).
A seventh subgroup (36 patients [1.8%]) had 
identifiable driver mutations but none of the 
class-defining drivers identified above. This in-
cluded patients with mutations in genes such as 
TET2 and DNMT3A that are not disease-specific 
or with mutations in genes that have been as-
sociated with other myeloid cancers (such as KIT 
in systemic mastocytosis). The eighth subgroup 
(192 patients [9.4%]) had no detectable driver 
mutations and may have included patients with 
either reactive thrombocythemia or myeloprolif-
erative neoplasms with unidentified drivers. Pa-
tients were typically young and female and had 
received a diagnosis of essential thrombocythe-
mia. This subgroup had particularly benign out-
comes; only 1 patient (0.5%) had myelofibrosis 
transformation and 2 (1%) had acute myeloid 
leukemia transformation during a median follow-
up of 8.0 years (hazard ratio for disease progres-
sion or death vs. the JAK2-heterozygous subgroup, 
0.56; 95% CI, 0.38 to 0.78; P = 0.005).
We applied our proposed classification scheme 
to an external cohort of 270 patients with myelo-
proliferative neoplasms (137 patients with essential 
thrombocythemia, 14 with polycythemia vera, and 
119 with myelofibrosis) that had sufficient ge-
nomic characterization so that our f lowchart 
could be applied. The subgroup proportions were 
similar in the two cohorts (Fig. S7 in the Supple-
mentary Appendix).
Factors Influencing Disease Progression
A key determinant of the treatment of patients 
with myeloproliferative neoplasms is the predict-
ed prognosis. For example, patients who are ex-
pected to have a benign future clinical course 
would probably benefit from treatments that are 
aimed at minimizing thrombotic risk, and those 
who are expected to have progression to leuke-
mia or myelofibrotic bone marrow failure could 
be candidates for intensive therapy or clinical 
trials of new agents. We developed multivariate 
statistical models, incorporating 63 clinical and 
genomic variables, that estimated a patient’s prob-
ability of transition between stages of disease 
— namely, chronic-phase disease (essential throm-
bocythemia or polycythemia vera), advanced-
phase disease (myelofibrosis), acute myeloid leu-
kemia, and death.
We determined the fraction of explained varia-
tion for each outcome that was attributable to 
different prognostic factors (Fig. 4A). Death in 
Figure 4 (facing page). Modeling Outcome in Patients.
Panel A shows the transition states during a patient’s 
disease and the factors contributing to the risk of each 
transition. Patients may have presented with either 
chronic-phase disease (polycythemia vera, essential 
thrombocythemia, or unclassifiable MPN) or myelofi-
brosis (MF), as represented by the two central, rounded 
rectangles. The patient may have subsequently remained 
alive in these disease states or, alternatively, could have 
transitioned to one of four states: death in chronic-phase 
disease, death in MF, MF transformation of chronic-
phase disease, and acute myeloid leukemia (AML) trans-
formation of either chronic-phase disease or MF. Individual 
models were created for each of these four disease-state 
transitions and combined into a  single multistate model 
allowing for the prediction of probability of being in each 
disease state occurring at any time point in the future 
(up to 25 years after diagnosis), as calculated on an in-
dividual patient basis. Pie charts show the variables that 
contributed most to the predicted risk for each of the 
four transitions. These show the effect on disease tran-
sitions of both rare variables with a strong effect and 
common variables with a milder  effect. Variables with 
a hazard ratio of more than 2.0 are shown in blue type. 
The numbers of patients with chronic-phase disease or 
MF are shown alongside the numbers of patients who 
transitioned to other states. Patients may have transi-
tioned more than once during their clinical course (e.g., 
from chronic-phase disease to MF and then to AML). 
The risk of AML transformation was highest among pa-
tients with MF. WCC denotes white-cell count; the arrows 
by the clinical variables indicate whether the value in-
creased (up arrow) or decreased (down arrow). Panel B 
shows the model predictions, as compared with the 
actual event-free survival (EFS), among patients. Com-
parisons of the actual EFS with the predicted EFS derived 
from multistate random-effects Cox proportional-hazards 
modeling for patients with chronic-phase disease and 
MF, for both the training cross-validation cohort and 
the external validation cohort, are shown. Each cohort 
was split into equally sized subgroups of patients, and 
each subgroup is represented by a data point plotted 
according to the observed and predicted EFS. Overall, 
the models show good correlation between predicted 
and actual outcomes for both the training and external 
validation cohorts at several time points (brown indi-
cates the EFS at 5 years, blue at 10 years, and red at 20 
years). The dashed line indicates points at which pre-
dicted outcomes perfectly match observed outcomes.
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B Actual vs. Predicted Event-free Survival (EFS) among Patients with Chronic-Phase Disease or with Myelofibrosis
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the chronic phase was influenced predominantly 
by age, with genomic features having little pre-
dictive power — a finding that suggests that 
once cytoreduction has achieved adequate con-
trol of blood counts, causes of death are domi-
nated by those that would also occur in the gen-
eral population.36 These would, therefore, not be 
well predicted by the specific genomic features 
of the myeloproliferative neoplasm.
By contrast, genomic features played a sub-
stantial role in predicting progression from 
chronic-phase disease to myelofibrosis and to 
acute leukemia transformation (Fig. 4A). CALR 
mutations were independently associated with an 
increased risk of myelofibrotic transformation, 
as previously reported.37 Mutations in epigenetic 
regulators, splicing factors, and RAS signaling 
were all associated with myelofibrotic and leuke-
mic transformation — some of these associa-
tions have been identified previously.10-12 Whether 
mutations were clonal or subclonal had little 
effect on prognosis (see the Supplementary Ap-
pendix). Clinical features of the disease, such as 
anemia, splenomegaly, or thrombocytosis, still 
retained independent predictive power for trans-
formation events, which suggests that these vari-
ables reflect important features of the disease 
state that are not captured in the genomic land-
scape. Outcomes in patients with myelofibrosis 
did not significantly differ on the basis of 
whether the myelofibrosis was primary or oc-
curred after essential thrombocythemia or poly-
cythemia vera.
Personally Tailored Prognosis
Current prognostic models for myeloprolifera-
tive neoplasms, which are focused on myelofi-
brosis, use simple scoring systems and group 
patients into broad prognostic categories. Many 
factors influence clinical outcomes, with a wide 
range of effect sizes, which means that current 
schemes discard information that is relevant to 
prognosis. We explored whether our multivari-
ate, multistate prognostic models could generate 
accurate predictions for individual patients.
The usefulness of personally tailored predic-
tions can be assessed in two ways: do the predic-
tions usefully distinguish among patients ac-
cording to prognosis, and are the predictions 
more informative than conventional schemas? 
Regarding the first question, not only is our 
model able to generate a wide range of specific 
risk predictions (regarding long-term survival, 
death in chronic-phase disease, and myelofi-
brotic and leukemic transformation) but they 
correlate well with observed outcomes (Figs. 4B 
and 5, and Fig. S8 and Tables S6 and S7 in the 
Supplementary Appendix), both in cross-valida-
tion of an internal cohort and in an external 
validation cohort of 515 patients with myelopro-
liferative neoplasms (137 patients with essential 
thrombocythemia, 188 with polycythemia vera, 
and 190 with myelofibrosis).
Internal cross-validation showed concordanc-
es of 76 to 86% for overall survival, event-free 
Figure 5 (facing page). Personalized Predictions  
of Outcomes in Patients.
Panels A and B show example tiles that represent per-
sonalized predicted outcomes in individual patients. 
Panel A shows the predicted outcomes of a 79-year-old 
woman who presented with essential thrombocythemia 
(ET) with a hemoglobin level of 104 g per liter, a white-
cell count of 8400 per cubic millimeter, and a platelet 
count of 2,300,000 per cubic millimeter, and mutated 
CALR, SRSF2, and IDH2 along with LOH in chromosome 
18q. For such a patient presenting with chronic-phase 
(CP) disease (PV or ET), the model incorporates all 
clinical, demographic, laboratory, and genomic variables 
to predict the overall probabilities over time of being 
alive in CP, dying in CP, being alive in myelofibrosis (MF) 
after CP, dying in MF after CP, transitioning to AML from 
CP, and transitioning to AML from MF after CP. The vary-
ing probabilities of each of these transitions can be judged 
from the vertical axis and their respective Kaplan–Meier 
curves over a 25-year period shown along the horizontal 
axis. The black curve shows the predicted Kaplan–Meier 
curve of overall survival. This patient transitioned to MF 
and died within 5 years; this outcome is shown along the 
bottom of the plot, where the length of the horizontal 
black line shows the duration of follow-up and the cause 
of death is indicated by the shading of the circle. For  
a patient who presented with MF, as shown in Panel B, 
the same model predicts the probabilities of being alive 
in MF, dying in MF, and transitioning to AML over a peri-
od of 25 years. Panel B shows the predicted and actual 
outcomes of a 57-year-old man with MF who had a he-
moglobin level of 125 g per liter, a white-cell count of 
27,000 per cubic millimeter, and a platelet count of 
119,000 per cubic millimeter, and mutated TET2, ASXL1, 
CBL, and BCOR along with deletion in chromosomes 
7q and 11q. This patient died in MF within 2 years. All 
patients with chronic-phase disease or MF who had 
 either a disease event (death or disease progression) 
or had more than 10 years of follow-up (>5 years for 
patients with MF) were ranked according to their over-
all predicted EFS. The predicted and actual outcomes 
for 40 individual patients with CP (Panel C) and MF 
(Panel D) showing how patients in the cohort may be 
distinguished in terms of EFS and cause of death.
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survival, and transformation to acute leukemia 
as well as good performance on absolute predic-
tive accuracy (Fig. 4B, and Tables S6 and S7 in the 
Supplementary Appendix). Concordances were 
similar in the external cohort, despite the fact 
that patients in the external cohort received diag-
noses at another center, were evaluated by differ-
ent pathologists who used different diagnostic 
criteria, and underwent sequencing at a different 
facility with the use of a different gene panel 
from the training cohort (Fig. 4B). Thus, the 
model provides considerable discriminatory power 
that accurately generalizes to other real-world 
cohorts. Owing to the existence of different di-
agnostic criteria, the model does not rely heavily 
on the exact classification label of the patient’s 
disease. Indeed, removing the distinction be-
tween polycythemia vera and essential thrombo-
cythemia, but simply retaining the distinction 
between myelofibrosis and chronic-phase disease, 
did not reduce the predictive accuracy of the 
model (Fig. S9 in the Supplementary Appendix).
Our model showed superior performance to 
current major prognostic schemas in clinical use, 
such as the International Prognostic Scoring 
System (IPSS),38 the Dynamic IPSS (DIPSS),39 the 
high molecular risk category for myelofibrosis,10 
and the International Prognostic Score for Essen-
tial Thrombocythemia score40 (Fig. S9 and Ta-
bles S6 and S7 in the Supplementary Appendix). 
Furthermore, we identified substantial heteroge-
neity in disease outcomes within individual prog-
nostic categories of current prognostic schemas 
(shown for DIPSS in Fig. S10 in the Supplemen-
tary Appendix); this was especially prominent for 
intermediate-risk patients and allowed for more 
informative predictions in a group with other-
wise uncertain outcomes. This means that not 
so many patients need be screened before some 
emerge as having an increased risk of poor out-
comes; the numbers needed to test across differ-
ent scenarios are shown in Table S8 in the Sup-
plementary Appendix. The inclusion of mutations 
and chromosomal changes beyond JAK2, CALR, 
and MPL improved the predictive power of prog-
nostic models (Tables S6 and S7 in the Supple-
mentary Appendix).
We have implemented a free, user-friendly on-
line calculator of individualized patient outcomes 
(https://cancer . sanger . ac . uk/ mpn - multistage/ ) that 
enables the exploration of data from patients in 
our cohort, and the generation of new patient 
predictions according to available clinical, labo-
ratory and genomic features. Further validation 
of our model with the use of additional cohorts 
of patients with myeloproliferative neoplasms will 
be important, given the bias toward including 
patients with essential thrombocythemia in this 
study.
Discussion
A major challenge is how we use our under-
standing of the pathogenic complexity of myelo-
proliferative neoplasms to identify groups of pa-
tients with shared causative biologic factors of 
disease, such that existing and new therapies 
can be targeted to the most appropriate patients. 
Current classification of myeloproliferative neo-
plasms is hampered by disease heterogeneity 
within, and clinical overlap between, subtypes. 
A genomic classification has the virtue of iden-
tifying patients with shared causative biologic 
factors, is stable over time, and does not rely on 
blood-count thresholds for assigning particular 
disease labels.
Of the eight subgroups of myeloproliferative 
neoplasms identified, the subgroup with TP53 
mutations was genomically unstable and had 
poor outcomes; this same subgroup, with simi-
lar clinical implications, has been identified in 
acute myeloid leukemia and other hematologic 
cancers.32,35 Likewise, the subgroup of myelopro-
liferative neoplasms with mutations in genes 
regulating chromatin and RNA splicing is mir-
rored in both the myelodysplastic syndrome34 
and acute myeloid leukemia.32 Patients with myelo-
proliferative neoplasms in this group typically 
had myelofibrosis, although some had essential 
thrombocythemia or polycythemia vera, and 
shared a relatively poor prognosis (as seen in 
patients with the myelodysplastic syndrome or 
acute myeloid leukemia). This raises the possi-
bility that these driver mutations define a myeloid 
cancer in older patients that transcends tradi-
tional diagnostic categories.
Our model accurately identified a minority of 
patients with chronic-phase myeloproliferative 
neoplasms who were at substantial risk for dis-
ease progression. Such patients could be consid-
ered for clinical trials of new therapeutic agents, 
since they are the most likely to benefit and the 
trials would be more efficient if higher-risk pa-
tients are preferentially enrolled. Our model also 
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accurately identified the majority of patients 
with chronic-phase disease who seemingly had a 
benign outlook at diagnosis. In such patients, 
experimental therapy would be unnecessary, and 
a conservative treatment strategy that is based on 
cytoreduction and reduction of vascular risk will 
suffice to give long-term, event-free survival. 
Myeloproliferative neoplasms continue to evolve, 
however, and it would be informative to evaluate 
the opportunities offered by serial genomic pro-
filing to update treatment choices if high-risk 
genomic changes emerge or if therapy drives 
further evolution.
Comprehensive gene sequencing of patients 
with blood cancers is becoming increasingly ac-
cessible and routine. The integration of clinical 
data with diagnostic genome profiling may pro-
vide prognostic predictions that are personally 
tailored to individual patients. Regarding patients 
with myeloproliferative neoplasms, such informa-
tion will empower the clinician and support 
complex decisions around the choice and inten-
sity of therapy, recruitment into clinical trials, 
and long-term clinical outlook.
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